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CHAPTER 1 INTRODUCTION: EXPANDING THE ENCODING GENOMES AND 
POST-TRANSLATIONAL MODIFICATION 
(Some of the text in this chapter were reprinted or modified from: “A cell permeable ATP 
analog for kinase-catalyzed biotinylation”. Angew Chem Int. Ed., 2015, 54, 9618)1 
The coding genome (coding DNA) is smaller by two to three fold compared to 
proteomes magnitude (types and numbers of proteins). The reason of the high 
proteome magnitude is the derivatization of proteins by two mechanisms.2 The first is 
pretranslational modification and the second is posttranslational modification. In the 
pretranslational modification, alternative RNA splicing results in protein diversification by 
selective joining of the 5’ and 3’ splicing sites.3 In posttranslational modifications 
(PTMs), proteins are derivatized after translation of RNA. PTMs diversification occur 
either by cleavage of a part of the protein through proteases or by covalent addition of 
certain groups. Examples of covalent PTMs are acetylation, acylation, adenylation, 
glycosylation, methylation, phosphorylation, etc.2 PTMs allow the acquisition of new 
properties of proteins, such as change in protein function or access of modified proteins 
by proteolytic enzymes.2 PTMs can be dynamically installed and removed as a part of 
controlling living cells by regulating a variety of cell signaling pathways in both normal 
and diseased cells.2 Therefore, studying PTMs is important for understanding cell 
signaling and cell biology. 
1.1. Protein phosphorylation 
Protein phosphorylation is a ubiquitous PTM that is catalyzed by protein kinases. 
Protein kinases catalyze phosphorylation of hydroxyl containing amino acids serine, 
threonine and tyrosine,4-7 while dephosphorylation of phosphoproteins is catalyzed by a 
group of proteins called phosphatases (Figure 1).4,5 Kinases utilize Adenosine 5’- 
triphosphate (ATP) as a phosphate donor, where the hydroxyl group of serine, threonine 
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or tyrosine on protein substrates attacks the γ-phosphate of ATP resulting in the 
formation of negatively charged phosphoproteins.8 Phosphorylation and 
dephosphorylation dynamically regulate many cell functions by installing or removing a 
negatively charged phosphate group on proteins instead of neutral hydroxyl group.9-11 
For example, protein kinases regulate metabolism, transcription, cell cycle progression, 
cytoskeletal rearrangement, apoptosis, intracellular communications and 
differentiation.12 Mutations and irregularities of protein kinases play a major role in 
several diseases, such as cancer, Alzheimers, Parkinsons and many others.10,13-16 
Studying kinases and their substrates is essential for drug discovery and understanding 
of pathogenesis of many diseases. 
 
Figure 1. 1: Protein phosphorylation of A) Serine (R=H) and threonine (R=Me), or B) 
tyrosine 
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1.2. The role of protein phosphorylation in cell biology 
Protein phosphorylation regulates many cell signaling pathways that control 
many cell functions through protein kinases. Cell functions regulated by kinase-
catalyzed phosphorylation are broad and diverse, including immunity, signal 
transduction in nervous system, morphogenesis, cell cycle progression, and etc. 
Studying kinase-catalyzed phosphorylation will provide a comprehensive understanding 
of cell biology, which will positively impact drug discovery. 
1.2.1. Kinases and immunity 
Many kinases control defense mechanisms through regulating the innate 
immunity and inflammatory responses.11 For example, Janus (JAK) tyrosine kinases are 
associated with the cytoplasmic domain of cytokine receptor.17 During inflammation, 
cytokines bind to cytokine receptors on cells leading to dimerization of JAKs and their 
activation. Upon activation of JAKs, JAKs phosphorylate several protein substrates, 
such as signal transducers and activators of transcription (STAT) transcription factors. 
STATs phosphorylation lead to their dimerization and migration to nucleus to initiate 
cytokines mediated responses (Figure 1.2).11,18 
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Figure 1.2: Schematic diagram of the effect of cytokines on JAK/STAT pathway. 
Upon cytokine binding to their receptor, receptor dimerization lead to JAK dimerization 
and activation. JAK activation leads to STAT phosphorylation, which translocate to 
nucleus to start an immune response.18 
 
1.2.2. Kinases and nervous system 
Transportation of proteins, lipids, and RNA along the axon of neuronal cells is 
called axonal transport. Axonal transport is regulated by various kinases through 
phosphorylation of motor and adapter proteins or through modification of microtubules. 
For instance, axonal transport from the cell body towards axial tips is mediated by 
kinesin protein and is called anterograde axonal transport. However, axonal transport in 
the opposite direction is called retrograde axonal transport and is mediated by 
cytoplasmic dynein (Figure 3). Protein kinases regulate axonal transport by 
phosphorylation of kinesin and dynein proteins. For example, extracellular signal-
regulated kinase 1 and 2 (ERK1/2) directly phosphorylates kinesin and dynein to 
regulate their association with cargoes. ERK1/2 phosphorylates dynein intermediate 
chain 1 B (DIC1B) and 2C (DIC2C), which results in increasing dynein association with 
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TrkB/Rab7-positive signaling endosomes. The association leads to elevation in 
signaling endosomes quantities moving in the retrograde direction. On the other hand, 
ERK 1/2 phosphorylates the light chain of kinesin (KLC1) at Ser460 resulting in 
unbinding of the motor to amyloid precursor proteins (APP)-labeled vesicles, leading to 
slowdown in the anterograde transport. Other kinases involved in axonal transports are 
GSK3B, JNK, p38 MAPK, AKT, PKA, Cdk5, PKC, and PINK1.19 
Figure 1.3: Schematic diagram representing anterograde and retrograde axonal 
transport. Anterograde transport occurs via kinesin, while retrograde transport undergo 
through cytoplasmic dynein.19 
1.2.3. Kinases and cell signaling pathways 
Cell growth, arrest and apoptosis are regulated by kinase protein. For example, 
cell growth is mediated through PI3K/Akt signaling pathway (Figure 4). Upon activation 
of receptor tyrosine kinase, autoinhibition of PI3K is removed and the enzyme becomes 
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catalytically active. Activated PI3K will catalyze the phosphorylation of 
phosphatidylinisitol diphosphate (PIP2) into phosphatidylinisitol triphosphate (PIP3). 
20PIP3 activates PDK1 by binding to its pleckstrin homology domain. Afterwards, 
activated phosphoinositide-dependent kinase 1 (PDK1) phosphorylates Akt1 at 
Thr308.21 Akt1 is then activated by phosphorylation at Ser473 by mTORC2 resulting in 
signaling events.21 Activated Akt1 phosphorylates its substrates, which prime cell cycle 
progression, survival, migration, and metabolism (Figure 1.4).21 Several reports 
revealed numerous non redundant Akt1 substrates, which are involved in different 
aspects of cell function.22-24 
 
Figure 1.4: Schematic diagram representing PI3K/Akt pathway21 
1.2.4. Phosphorylation and protein-protein interactions 
Phosphorylation plays a crucial role in protein-protein interactions, which regulate 
trafficking in cells. For example, CREB (cyclic adenosine 3’, 5’-monophosphate 
responsive element binding) -CBP (CREB binding protein) interaction is dependent on 
phosphorylation of CREB.25,26 CREB is phosphorylated at serine-133 to yield a 
negatively charged phosphoserine residue. The phosphorylation of CREB induces a 
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hydrogen bond between CREB S-133 and Y-658 on CBP, which induces their 
interactions.25 The CREB-CBP interaction positively induces the transcriptional activity 
of CREB. 
1.3. The role of kinases in formation of diseases 
Kinase enzymes are involved in many diseases such as rheumatoid arthritis,27 
diabetes,28 Parkinsons,29,30 cardiovascular diseases,31,32 and cancer.33 For instance, 
MAPK pathway is hyperactivated by cytokines, such as TNF-α, in rheumatoid arthritis 
patient. Upon activation of the pathway, MAPK kinase kinase phosphorylates MAPK 
kinases (MKK) that consequently phosphorylates MAPK. MAPK includes extracellular 
signal-regulated kinases (ERK) and the p38 kinase (p38) that activate several 
transcriptional factors upon MAPK phosphorylation (Figure 1.5).27  
 
Figure 1.5: Schematic diagram representing the role of several kinases in 
Rhematoid arthritis.27  
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Another example, epidermal growth factor receptor tyrosine kinases (EGFR-TKs) 
is associated with cancer. In normal cells, epidermal growth factor (EGF) binds to cell 
surface receptor of EGFR-TK, which leads to dimerization of the cell surface receptor of 
EGFR-TK (Figure 1.6).33,34 Dimerization of the EGFR-TK receptor triggers the activation 
of signal transduction pathway. In tumor cells, EGFR-TK receptors are elevated or 
hyperactivated due to excess ligand, which leads to higher expression of cell surface 
receptor or mutations and aberrant cell growth and malignancy.33,34 As a third example 
example, BRAF kinase is mutated in 66% of melanomas.35 Mutation of BRAF kinase 
lead to increase of its activity, which increases cancer proliferation.35 Lastly in 
Parkinsons disease, a mutation in leucine rich repeat kinase 2 (LRRK2) increases its 
activity, which elevates phosphorylation of its substrates. 30,36 Therefore, further studies 
are needed to explore the function of LRRK2 and the relation between LRRK2 and 
Parkinsons. In the last few decades, scientists in drug discovery have targeted many 
protein kinases with small molecules or antibodies to treat many diseases.33  
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Figure 1.6: Cell signal pathway for epidermal growth factor tyrosine kinase.34 
Epidermal growth factor (EGF) binds to cell surface receptor of EGFR-TK, which leads 
to dimerization of the cell surface receptor of EGFR-TK. Dimerization of the EGFR-TK 
triggers the activation of RAS protein, which activates downstream signal until it reaches 
the nucleus. 
1.4. Kinase inhibitors 
Phosphorylation/dephosphorylation constitutes the key player in several 
diseases, such as rheumatoid arthritis,27 diabetes,28 Parkinsons,29,30 cardiovascular 
diseases,31,32 and cancer33. Dysregulation of phosphorylation/dephosphorylation 
balance results in the emergence of a disease. Many of these diseases are due to 
hyperactivation or overexpression of kinases that infers an over phosphorylation events. 
The hyperactivated or overexpressed kinase is a candidate target to treat the resulted 
disease. Pharmaceutical companies have developed many drugs targeting kinases; 
some are FDA approved and some still in clinical trials. A list of some FDA approved 
drugs is shown in table 1.1.10,37-39 
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Table 1. 1: List of some of FDA approved drugs and their targeted kinase9,36-38 
Structure of the compounds are shown in figure 1.8 
Inhibitor/ 
Drug 
Disease Targeted kinase Company 
Year 
approved 
by FDA 
Lenvatinib Thyroid cancer VEGFR Eisai Co 2015 
Palbocicnib 
ER-positive and 
HER2-negative 
breast cancer  
CDK4/CDK6 Pfizer 2015 
Afatinib 
Non-small cell 
lung cancer 
EGFR/ErbB2 
Boehringer 
Ingelheim 
2013 
Crizotinib  
NSCLC with 
Alk mutation 
ALK/ROS1  Pfizer  2011 
Dasatinib 
Chronic 
myelogenous 
leukemia 
multiple targets BMS  2006 
Ibrutinib 
Mantle cell 
lymphoma 
BTK Pharmacyclics  2013 
Pazopanib (RCC) VEGFR2/PDGFR/c-kit GlaxoSmithKline 2009 
Ruxolitinib  (Myelofibrosis) JAK Incyte  2011 
Sunitinib RCC & GIST multiple targets SUGEN/ Pfizer 2006 
Vemurafenib Aug Melanoma BRAF Roche 2011 
Axitinib  
Renal cell 
carcinoma 
VEGFR1/VEGFR2/VE
GFR3/PDGFRB/c-KIT 
Pfizer  2012  
Bosutinib 
Chronic 
myelogenous 
leukemia 
Bcr-Abl /SRC Pfizer  2012 
Kinase inhibitors are classified into 2 major groups: reversible or irreversible 
inhibitors. The irreversible inhibitors react with a cysteine residue proximal to the ATP 
binding site, leading to blockage of active site. The reversible inhibitors can be further 
classified into four groups, according to the conformation of the binding pocket and the 
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DFG motif. Type 1 inhibitors are ATP-competitive inhibitors, in which the aspartate 
residue of the DFG motif is pointing into the active site (Figure 1.7). Type 2 inhibitors 
bind to the inactive form of kinases and the aspartate residue of DFG motif is pointing 
out of the ATP binding pocket, which provides accessibility of type 2 inhibitors to 
additional pocket adjacent to the ATP-binding site (Figure 1.7). The third type of 
inhibitors bind non-competitively to an allosteric site adjacent to ATP-binding pocket 
(Figure 1.7). On the other hand, type 4 inhibitors bind to allosteric site non-adjacent to 
ATP-binding pocket (Figure 1.7).37 
 
Figure 1.7: The four types of reversible kinase inhibitors.37 
The kinase active site is represented in orange and the kinase inhibitor is represented in 
blue. Type 1 inhibitors are ATP-competitive inhibitors in which the aspartate residue 
(red) of the DFG motif is pointing into the active site. Type 2 inhibitors bind to the 
inactive form of kinase and the aspartate residue (red) of DFG motif is pointing out of 
the ATP binding pocket. The third type of inhibitors bind non-competitively to an 
allosteric site adjacent to ATP-binding pocket, while type 4 inhibitors bind to allosteric 
site non-adjacent to ATP-binding pocket 
Although there are over 500 kinases, they share a highly conserved active site. 
This similarity results in a challenge in designing kinase inhibitors due to nonspecific 
binding of kinase inhibitors to several kinases.10 The first rationally designed selective 
kinase inhibitor is Gleevec® (Imatinib) (Figure 1.8), which selectively inhibits tyrosine 
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kinase Bcr-Abl, an oncogene for chronic myeloid leukemia. 33,37  Other examples of 
selective kinase inhibitors are Sprycelare®33 (Bcr-Abl kinase inhibitor) and Tykerb®  
(EGFR family members, which blocks the tumorigenic effects of these RTKs).33 In 
addition, there are other FDA non-organic compounds, such as monoclonal antibody 
Herceptin®, which is used against receptor tyrosine kinases (RTKs) to treat breast 
cancer.33 In addition, many natural products, such as staurosporine, are potent inhibitor 
against kinases, which are used in biological assays.33 
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Figure 1.8: Structure of kinase inhibitors in Table 1.1 and discussed in text.  
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1.5. Protein Kinases, mechanism of phosphorylation, and substrate specificity 
There are over 500 protein kinases, which belong to two major classes. The first 
class is tyrosine kinases that catalyze the phosphorylation of tyrosine residues. The 
second class is serine/threonine kinases, which catalyze the phosphorylation of serine 
and threonine residues. Another classification divides human kinases into eight 
subgroups according to sequence similarities in their catalytic sites (Figure 1.9).12 
 
Figure 1.9: Classifcation of Human Kinases.12  
Human kinases are classified into 7 groups: 1) ACG: Containing PKA, PKG, PKC 
families; 2) CAMK: Calcium/calmodulin-dependent protein kinase; 3) CK1: Casein 
kinase 1 family; 4) CMGC: Containing CDK, MAPK, GSK3, CLK families; 5) STE: 
Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; 6) TK: Tyrosine kinase 
family; 7) TKL: Tyrosine kinase-like family. Other: other kinases that do not belong to 
specific group. 
 
Kinase enzymes catalyze the phosphorylation of protein substrates using ATP as 
a phosphate donor.8 Kinases possess two binding sites: one to bind ATP and the other 
to bind protein substrate.6 The ATP-binding pocket is formed between β-sheets (N-
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terminal loop) connected through hinge region to α-helices (C-terminal loop).37,40 The α-
helices contains the substrate binding site, which has specific amino acids that binds 
the substrate (Figure 1.10).6 
 
Figure 1.10: Crystal structure of CK2 downloaded from protein data bank (Pdb ID: 
1DAW). Kinase crystal structure consists of -sheet (N-loop, yellow) and -helices (C-
loop, red) connected with hinge region (green). The image shows binding of ANP 
(phosphoaminophosphonic acid-adenylate ester), which is analogous to ATP. ANP 
binds between N- and C-loop. ANP is color-coded (C = green; H = grey; N = blue; O = 
red; P = orange). For clarity, the atomic radius of Mg2+ was reduced to 0.5 Å. 
 
 The active site is conserved among all protein kinases and contains nine highly 
conserved amino acids in the catalytic site (G52, K72, Q91, D166, N171, D184, G186, 
Q208, and R280, Figure 1.11).41 Therefore, the general mechanism for protein 
phosphorylation is almost the same among the kinase family. The binding site for the 
ATP cosubstrate contains two divalent metal ion, Mg2+ or Mn2+, which stabilize the 
binding of ATP to the enzyme (Figure 1.11).6 The divalent metal acts a bridge between 
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amino acids in the ATP binding site and the ATP cosubstrate. During phosphorylation, 
the hydroxyl group in the protein substrate is deprotonated by an aspartate residue 
(D166, Figure 1.11). Deprotonation of the hydroxyl group will increase its nucleophilicity 
and facilitate the attack on the -phosphate of ATP (Figure 1.11).6 
 
Figure 1.11: Catalytically relevant residues in the active site of PKA kinase and 
their interaction with ATP cosubstrate and protein substrate6,41 
 
There are two theories regarding the mechanism of kinase-catalyzed 
phosphorylation.42,43 The first mechanism is an associative mechanism, in which the 
hydroxyl group of substrate attacks the -phosphate of ATP at the same time the bond 
between the -phosphate and ADP molecule is breaking (Figure 1.12).44 The second 
type is dissociative mechanism. In the dissociative mechanism, the bond between ADP 
and -phosphate breaks, followed by the attack of hydroxyl group of substrate. Recent 
studies suggests that the dissociative mechanism is more accurate.42,43,45 
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Figure 1.12: Associative mechanism versus dissociative mechanism of kinase-
catalyzed phosphorylation. In the associative mechanism, nucleophilic oxygen of 
substrate attacks ATP at the same time as ADP leaves. In the dissociative mechanism, 
ADP leaves before the attack of nucleophilic oxygen of substrate onto ATP. 
 
Kinase substrate phosphorylation is contingent upon recognition of protein or 
peptide substrate by its corresponding kinase. The recognition depends on a certain 
sequence on the substrate called consensus sequence.6 The consensus sequence is a 
sequence of amino acid present in the protein or peptide substrate, including the 
hydroxyl containing amino acid target.  Specifically, the amino acids surrounding the 
hydroxyl containing amino acid plays a crucial role in kinase recognition. Consensus 
sequence may contain acidic, basic, hydrophobic, or proline residues. For instance, 
PKA and Akt1 are serine/threonine kinases and recognize basic consensus 
sequences.46 Representative examples of consensus sequence of selected kinases are 
presented in table 1.2.46-49 
 
 
 
 
 
 
 
 
18 
 
 
Table 1. 2: Consensus sequences of selected kinases.49 X – any residue, Z-
hydrophobic residue, pS is phosphorylated serine, Green/Bold is the site of 
phosphorylation 
Kinase Consensus sequence Nature of amino acids 
Abl I/V/L-Y-X-X-P/F Hydrophobic 
Akt1 R-X-R-X-X-S/T Basic  
PKA R-R-X-S/T-Z Basic  
CK1 pS-X-X-S/T Phosphoserine 
CK2 S/T-D/E-X-D/E Acidic 
CHK 1 R-X-X-S/T Basic 
Aurora A R/K/N-R-X-S/T-B Acidic 
SRC E-E-I-Y-E/G-X-F Acidic 
ERK 2 P-X-S/T-P Proline 
EGFR E-E-E-Y-F Acidic 
 
 
1.6. Kinase substrate identification 
With over 500 kinases and thousands of substrates, kinase-substrate 
identification is a complex process. Kinase-substrate identification is used to reveal the 
molecular details of cell signaling pathway and understanding many diseases. Many 
tools were developed to identify kinase-substrate pairs, including in vitro 
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phosphorylation, pull down assays, yeast two-hybrid systems, and chemical 
approaches, such as ATP analogs. ATP analogs have been used extensively to study 
kinases and their substrates. They were used to identify kinase-substrate pairs and 
kinome profile. However, it is still challenging to determine kinase activities and its 
effectors in cell signaling pathways. Therefore, development of novel methods to 
identify kinase-substrate pairs in a kinase-catalyzed phosphorylation manner will allow a 
better deciphering of cell signaling events. Detailed discussion of current tools to identify 
kinase-substrate pairs is presented in chapter 4 (Section 4.1.3). In addition, we will 
present our latest contribution to develop new tool to identify kinase-substrate pairs 
using novel ATP analogs.  
1.7. Kinase cosubstrate promiscuity 
Enzyme cosubstrate promiscuity were reported for several PTMs.50-59 
Cosubstrate promiscuity occurs when an enzyme utilize a modified cosubstrate similar 
to the natural one. Examples of enzymes that exhibit cosubstrate promiscuity are 
acetyltransferase, transglutaminase, galactosyltransferase, etc. In particularly, kinase 
enzymes also showed cosubstrate promiscuity. ATP is a kinase cosubstrate and it is the 
phosphoryl donor to phosphorylate proteins (Figure 1.13). ATP binds into ATP binding 
pocket of kinases, where adenine moiety binds deep into the active site with the 
triphosphate protruding into the solvent exposed area of the pocket (Figure 1.13). 
Modifications on -phosphate were accepted promiscuously by kinases. 
1.7.1. ATP-S 
The earliest reported -modified ATP analog was ATP -S.60  Protein kinases 
were reported to show promiscuity using ATP -S, producing thiophorylated products 
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(Figure 1.13).60-63 ATP -S was first reported in the context of glycerokinase, 
hexokinase, and pyruvate kinase.64 Indeed, ATP -S was also used with protein kinases 
to produce thiophosphorylated products (Figure 1.13).63 Thiophosphorylation with ATP 
-S was used as a tool to purify and identify kinase substrates (Figure 1.13). The 
purification can be done by several methods. The first example used iodoacetyl-linked 
biotin affinity tags that promote subsequent avidin enrichment (Figure 1.13).65,66 By 
maintaining low pH, thiophosphorylated products are more nucleophilic than other 
amino acid residues, which allows selective purification of thiophosphorylated products. 
In a second method, thiophosphorylated products were reacted iodoacetyl-linked resins 
that capture both thiophosphorylated and cysteine containing products.67-69 However, 
selective elution of thiophosphorylated captured products was done by peroxides. The 
third method includes pretreatment of samples containing thiophosphorylated products 
with a capping reagent.70,71 The capping reagent reacts with cysteines through thiol-ene 
reaction, leaving thiophosphorylated products. The thiophosphorylated products were 
then labeled with iodoacetly BODIPY fluorophore. The fourth method depends on 
capture of thiophosphorylated products via disulfide linkage.72,73 This method captures 
both thiophosphorylated products and cysteine residues. However, thiophosphorylated 
products were selectively eluted via sodium hydroxide. The last method includes 
immunoaffinity purification of thiophosphorylated products.74-76 The sample was first 
treated with p-nitrobenzylmethylate (PNBM) to alkylate all nucleophilic groups, including 
cysteines and thiophosphorylated proucts. Afterwards, alkylated thiophosphorylated 
products were purified by paranitrobenzylthiophosphoryl polyclonal antibodies (IgY and 
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IgG). Interestingly, ATP-S was coupled with the as-kinase strategy to identify specific 
substrate kinase relationship, as discussed in chapter 4 (Section 4.3.1.2).74 
 
Figure 1.13: Methods of purification of thiophosphorylated products. ATP-S was 
incubated with a sample containing kinases and protein substrates to produce 
thiophosphorylated products. The reaction mixture was purified by A) iodoacetyl biotin, 
B) iodoacetyl resin, C) thiol-ene reaction followed by iodoacetyl-BODIPY, D) disulfide 
resin followed by treatment with NaOH, and E) p-nitrobenzylmesylate followed by 
immunoaffinity prurification. 
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1.7.2. ATP-biotin 
Kinase cosubstrate promiscuity was extended by attaching several groups to -
phosphate beyond ATP-S. Attaching a probe or a large group to the -phosphate 
results in the transfer of the -phosphate together with the probe onto protein substrate 
in a kinase-catalyzed reaction (Figure 1.14).77 The group should be attached to the -
phosphate via a linker. The structure activity relationship of the nature and size of both 
the linker and the attached group will be discussed later in chapter 5 (Section 5.1.1). 
Several groups were attached to the -phosphate of ATP. The first example is biotin 
(Figure 1.14, ATP-biotin 1a).77 ATP-biotin was initially tested by Pflum lab for kinase 
promiscuity by incubating with recombinant kinases and peptide substrates. (Figure 
1.14). Three kinases with their corresponding peptide substrates were used: PKA, CK2, 
and Abl. The first two are serine/threonine kinases and the last is tyrosine kinase. The 
biochemical reaction results were assessed by a quantitative mass spectrometric (MS) 
analysis, assuming that the reaction with ATP is providing 100% conversion. ATP-biotin 
was accepted by all three kinases and the percentage conversion is shown in Table 
1.3.77  Afterwards, ATP-biotin was used with full length proteins and recombinant 
kinases. For example, ATP-biotin was incubated with CK2 kinase and β-casein protein 
substrate. The reaction mixture were analyzed by SDS-PAGE gel electrophoresis, 
followed by transferring onto PVDF (polyvinylidene difluoride) membrane. Biotinylation 
was detected on the membrane using SA-HRP (Streptavidin-horseradish peroxidase) 
conjugate.77 In addition, incubation of ATP-biotin with cell lysates resulted in 
biotinylation of protein substrates, which is consistent with that biotinylation as a 
generally kinase-catalyzed phenomenon.77,78 
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Figure 1.14: Kinase-Catalyzed Biotinylation. 
Kinase enzyme catalyzes the phosphoryl biotinylation of protein substrate with ATP-biotin 
To test the generality of biotinylation, the Pflum lab selected 25 kinases 
throughout the kinome tree to test if ATP-biotin is generally accepted by kinases.79 Both 
kinetic analysis and percentage phosphorylation using each kinase with ATP-biotin 
were performed. The efficiency of biotinylation was determined by comparing 
percentage phoshphorylation and Km/Kcat using ATP-biotin to ATP, taking in 
consideration that ATP gives 100% phosphorylation. All 25 kinases accepted ATP-biotin 
with different kinetic efficiencies. The most efficient kinase with highest percentage 
conversion was SCR (96%±7). Also, SCR showed the highest catalytic efficiency, which 
is the most similar to ATP. By analyzing the results using docking studies for selective 
kinases, we found that the most efficient kinases positioned the -phosphate of ATP-
biotin proximal to catalytic lysine as ATP.79 With generality of biotinylation with protein 
kinases, ATP-biotin can be used with cell lysates to study dynamic 
phosphoproteomics.80,81   
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Table 1.3: Quantitative mass spectrometry of the kinase-catalyzed 
phosphorylation using previously reported ATP analogs77,82,83 
 PKA CK2 Abl 
ATP-biotin 79% 56% 80% 
ATP-dansyl 91% 81% 87% 
ATP-Ar-N3 86% 51% 78% 
 
1.7.3. ATP-dansyl 
After establishing kinase-catalyzed biotinylation, kinase cosubstrate promiscuity 
was shown by other commercially available ATP analogs. Specifically, commercially 
available ATP-dansyl (Figure 1.15) was incubated with selected kinases (Abl, PKA, and 
CK2) with their corresponding peptides. The reaction mixtures were analyzed by 
quantitative mass spectrometry (MS) (Table 1.3). The results showed that ATP-dansyl 
was also accepted with diverse kinases. Subsequently, kinetic analysis was performed 
using an absorbance assay in presence of PKA and either ATP-dansyl or ATP. ATP-
dansyl and ATP exhibits similar Km (23 µM and 24 µM respectively). However, ATP-
dansyl had 9 fold reduced Kcat than ATP. Reduced Kcat indicates that kinase-catalyzed 
dansylation is slower than phosphorylation reaction using ATP.82 
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Figure 1.15: Kinase-Catalyzed dansylation using ATP-dansyl. 
1.7.4. ATP-Aryl-Azide (ATP-ArN3) 
To expand the applications of ATP analogs, other ATP analogs were developed. 
Interestingly, an ATP analog with a photocrosslinker (ATP-ArN3) was developed by 
Pflum lab to crosslink protein kinase to its substrate in a phosphorylation dependent 
reaction (Figure 1.16). First, ATP-ArN3 was tested for its efficiency as a kinase 
cosubstrate using three kinases (PKA, CK2, and Abl) with their corresponding peptides 
using quantitative MS/MS assay (Table 1.3). MS/MS analysis revealed that ATP-ArN3 
can act as a kinase cosubstrate with different efficiency from one enzyme to another 
(Table 1.3). After confirming the ability of ATP-ArN3 to work as a kinase cosubstrate, 
Pflum lab tested the validity of the analog as a kinase-substrate crosslinker. ATP-ArN3 
was incubated with CK2 and its substrate casein in the presence of UV light. The 
reaction mixture was separated by SDS-PAGE analysis, followed by transferring onto 
PVDF membrane to analyze crosslinked complex via western blotting. Western blotting 
analysis showed a higher molecular weight complex equal to the sum of the molecular 
weight of CK2 and casein (Figure 1.16). The higher molecular weight complex was 
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visualized in gel via protein stain and western blot using CK2 antibody. In contrast, no 
crosslinked complex was observed in absence of ATP-ArN3 or UV. All these 
observations suggested that ATP-ArN3 can result into a kinase-dependent 
photocrosslinking of kinases to their substrates. Other ATP-photocrosslinkers are being 
developed and are discussed in chapter 4.83 
 
 
Figure 1.16: Kinase-catalyzed photocrosslinking of CK2 kinase enzyme to casein 
protein substrate using ATP-ArN3.  
The gel electrophoresis showed the presence of higher molecular weight complex or 
bands equal to the sum of molecular weight of CK2 and casein protein, which indicates 
their crosslinking 
1.7.5. ATP-Ferrocene 
ATP-Ferrocene was developed by the Kraatz lab to transfer a ferrocene-
phosphate group onto peptide or protein through a kinase-catalyzed reaction (Figure 
1.17). Ferrocene-phosphate transfer was confirmed by antiferrocene antibodies. 
Interestingly, ATP-ferrocene was used to detect kinase activity by electrochemical 
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monitoring of ferrocene transfer onto protein or peptide substrate. Also, this assay was 
used to identify kinase inhibitors.84,85 
 
Figure 1.17: Kinase-Catalyzed phosphate ferrocene transfer using ATP-ferrocene. 
1.7.6. Manns/Governeau’s ATP analogs 
The Mann and Governeau Labs developed a new generation of  -modified ATP 
analogs with alkynes, azides, and alkenes on the -phosphate (Figure 1.18). These 
analogs are useful for subsequent click chemistry or Staudinger ligation. Mann lab 
utilized cyclin E1/cdk2 kinase to test the cosubstrate promiscuity related to their 
analogs. They incubated their analogs with cyclin E1/cdk2 kinase and protein substrate, 
followed by SDS-PAGE gel analysis and western blotting. Their ATP analogs 
demonstrated successful phosphorylation using western blotting and phosphor 
antibodies. However, the studies of these analogs were limited and Mann lab did not 
use their analogs with click chemistry or Staudinger ligation.86 
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Figure 1.18: Structures of Mann and Governeau’s ATP analogs86 
1.7.7. Clickable ATP-Ferrocene (Fc-CO-Lys-ATP) 
Recently, the Kraatz and Mann labs developed a clickable ATP-Ferrocene 
analog, Fc-CO-Lys-ATP for measuring kinases activity (Figure 1.19). Three kinases 
were used in this study: Sarcoma-related kinase (Src), cyclin-dependent kinase (CDK2), 
or casein kinase II (CK2a). Fc-CO-Lys-ATP was incubated together with the selected 
kinases and its corresponding peptide substrate fixed to gold particles. The kinase-
catalyzed Ferrocen-phosphorylation of peptide gold particle was detected 
electrochemically or with antiferrocene antibodies as in section 1.6.5. Importantly, 
probing the Ferrocene-phosphorylated of peptide gold particle using click chemistry 
allowed visualization of ferrocene-phosphorylation by microscopy (Figure 1.19). The 
latter assay can be used to replace the well-established immunoassay. In conclusion, 
Fc-CO-Lys-ATP can be further applied to multiplex assays.87 
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Figure 1.19: Kinase-catalyzed ferrocyl-phosphorylation using clickable ATP-
Ferrocene (Fc-CO-Lys-ATP) 
 
1.7.8. ATP-acyl-biotin (X-probe) 
-Modified ATP analogs were not only used to label kinase substrates but also 
used to identify and label kinases themselves. For example, ATP-acyl-biotin was utilized 
to identify many kinases.88,89 Generally, kinases have two conserved lysine residues in 
the active site, which are positioned proximal to β- and -phosphate.12,90,91 Interestingly, 
ATP-acyl-biotin binds to the active site of kinase and then the amine group of the lysine 
residue attacks the acyl-phosphate group and releases ATP. This reaction forms a 
covalent bond between the kinase and the acyl-biotin. The biotin tag allows purification 
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of the kinase by streptavidin beads and the kinase can be identified by MS/MS 
analysis.88,89 
 
Figure 1.20: Kinase labeling with ATP-acyl-biotin. 
 
1.8. Thesis projects 
Kinase-catalyzed phosphorylation is critical in regulating cell signaling. With a 
large number of kinases and protein substrates, continuous development of tools to 
study kinase-catalyzed phosphorylation events is needed to decipher the molecular 
details of cell signaling cascades. The Pflum lab and others developed several ATP 
analogs to study kinase-catalyzed phosphorylation. However, ATP analogs applications 
were limited to in vitro usage due to cell impermeability of ATP analogs. In vitro studies 
may be less relevant than in cellulo experiments due to absence of compartments in 
lysates. To utilize our -modified ATP analogs in vitro, we developed two strategies to 
permeablize cells toward ATP analogs. The first one is synthesizing and developing a 
cell permeable ATP analog by attaching a polyamine to ATP analog (Chapter 2). The 
second strategy is the usage of an external polyamino-carbohydrate additive to 
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permeabilize ATP analogs (Chapter 3). Both strategies were successfully applied and 
showed that ATP analogs can pass cell mebrane using polymamines. 
Previously, we developed a kinase cosubstrate photocosslinker, ATP-ArN3 
(Chapter 1. Section 1.7.4). ATP-ArN3 can crosslink kinase enzymes to their protein 
substrates. However, the azide group of ATP-ArN3 is converted to a very reactive 
species that can crosslink with proximal many proteins, which leads to non-specificity. 
Therefore, we developed an affinity-based ATP crosslinking analogs, ATP-acrylamides 
(Chapter 4). ATP-acrylamides have an acrylamide group instead of azide group, which 
crosslink only cysteine containing kinases.  
My last project is a comparative study of the effect of different atoms attached to 
-phosphate on the ability of analog to act as kinase cosubstrate (chapter 5). 
Specifically, we synthesized three -modified ATP analogs with different atom attached 
to  -phosphate. We studied the effect of different atoms on both the kinase cosubstrate 
ability and efficiency. Detailed kinetic studies were performed for all analogs. 
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CHAPTER 2 DEVELOPMENT OF A CELL PERMEABLE ATP ANALOG FOR 
KINASE CATALYZED-BIOTINYLATION 
(Some of the text in this chapter were reprinted or modified from: “A cell permeable ATP 
analog for kinase-catalyzed biotinylation”. Angew. Chem. Int. Ed., 2015, 54, 9618)1 
2.1 Introduction 
In this chapter, we discuss the development of the first cell permeable ATP 
analog for kinase-catalysed labelling. The Pflum lab and others have utilized -
phosphate modified ATP analogs as tools to study kinase-catalysed 
phosphorylation.74,75,78,84-86,92-97  As discussed in chapter 1, ATP-biotin (1) is 
promiscuously accepted as a cosubstrate by protein kinases to phosphorylbiotinylate 
substrates.79,92,95,98  After kinase-catalyzed biotinylation with ATP-biotin, the biotin group 
facilitates analysis of phosphoproteins using various commercial streptavidin-
conjugated reagents.92,99 Unfortunately, due to the impermeability of ATP analogs, ATP-
biotin has been used in vitro only.95 The ability to utilize ATP-biotin in living cells would 
promote the study of protein kinases in more physiologically relevant conditions. Here, 
we describe the first cell permeable ATP-biotin analog for live cell kinase-catalysed 
biotinylation. A summary of methods used to permeabilize phosphate containing 
compounds is also discussed in this chapter 
2.1.1 Cell delivery of ATP analogs 
ATP analogs have been extensively used in studying kinase-catalyzed 
phosphorylation. ATP analogs in kinase-catalyzed phosphorylation studies were 
extensively applied in vitro, with less applications in cellulo due to cell impermeability of 
ATP analogs. The cell impermeability of ATP analogs is a result of the negatively 
charged triphosphates. Several reports documented the usage of permeabilizing 
agents, such as digitonin, to deliver ATP analogs.100 These methods suffer from several 
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drawbacks that limited their applications, which will be discussed extensively in chapter 
3. In this chapter, we are discussing the development of the first intrinsically cell 
permeable ATP analog for kinase-catalyzed labeling studies. The cell permeable ATP 
analog does not require externally added additives, which suffers from several 
drawbacks such as incompatability with growing cell media or the usage of less 
physiologically relevant conditions.     
2.1.2 Methods used to intrinsically permeabilize phosphate-containing 
compounds 
Phosphate-containing compounds, such as ATP and phosphatidylinositol 
triphosphates, are cell impermeable due to the presence of highly polar negative charge 
on phosphates. Several approaches were used to permeabilize phosphate containing 
compounds to be used for different applications. Cell permeabilzation of phosphate-
containing compounds depends on neutralizing the negative charge of phosphate 
groups to promote the cell permeability of compounds.101-103 For example, 
phosphatidylinositol triphosphate (PIP3) (Figure 2.1.A) is a key factor in the EGF/PIP3K 
signaling pathway.101 Studying the effect of PIP3 alteration within a cell is ubiquitous to 
understand its subsequent cell signaling events. Due to cell impermeability of PIP3, 
utilization of PIP3 to alter cellular levels is challenging. One reported approach to 
enhance cell permeability of PIP3 was to develop a membrane permeant derivative 
(PIP3/Ac) by masking the charges of the phosphate groups with acetoxymethyl ester 
(Figure 2.1.A).  Acetoxymethyl esters are bioactive and will be hydrolyzed by cellular 
carboxyhydrolases, liberating free PIP3 (Figure 2.1.A). Also, an additional butyrate 
group was installed on free hydroxyl groups of PIP3 to assist cell permeability, which 
were and then removed by carboxyhydrolases after passing cell membrane. 
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Furthermore, installing an additional phosphate on the protected PIP3 resulted in a 
more potent cell permeable PIP3 alternative (PIP4/Ac) (Figure 2.1.A), which is more 
synthetically feasible.101 This protection/enzyme deprotection strategy was also used to 
enhance the cell permeability of bisphosphonate anticancer drugs and increase their 
potency (Figure 2.1.B).102 
 
Figure 2.1: A) Schematic diagram of conversion of protected phosphatidylinositol 
triphosphates derivatives (PIP3/Ac and PIP4/Ac) to free phosphatidylinositol 
triphosphates (PIP3). B) Schematic diagram of conversion of protected bisphosphonate 
to free bisphosphonate after passing the cell membranes. 
Another alternative to enhance the permeability of phosphate containing 
compounds is the usage of photoactivatable protecting group (Figure 2.2).103 For 
instance, photoactivatable protected PIP3 (PA PIP3) was used to deliver PIP3 into cells. 
After cell delivery of PA PIP3, the photoactivable group was removed to liberate free 
PIP3 (Figure 2.2). PA PIP3 has the advantage of providing a fast release of PIP3 in 
more physiologically relevant quantities that acetoxymethyl esters.103 
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Figure 2.2: Schematic diagram of conversion of photoactivatable protected PIP3 (PA 
PIP3) to free PIP3 
A third example of enhancing the cell permeability of phosphate-containing 
compounds is the usage of polyamines.104 Polyamines are positively charged under 
physiological conditions and can chelate negatively charged phosphates to form cell 
permeable complexes. Aminoglycoside derivatives such as neomycin were incubated 
with PIP3 to form a cell permeable complex (Figure 2.3). In addition, polybasic proteins, 
such as histones, were also used to deliver PIP3.104 
 
Figure 2. 3: Structure of Neomycin-Rhodamine B 
In summary, phosphate-containing compounds are cell impermeable. To develop 
cell permeable phosphate-containing compounds, the negative charges of phosphates 
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should be masked by either protection with bioactive or photoactivatable protecting 
group or by using polyamine deliver agent. These findings guided us through our project 
to develop the first cell permeable ATP analog. 
2.2 Development of cell permeable ATP analog for kinase-catalyzed biotinylation 
In our lab and several other groups, -phosphate modified ATP analogs were 
utilized to study kinase-catalysed phosphorylation.74,75,78,84-86,92-97  An important example 
developed by our lab is ATP-biotin (1, Figure 2.4 B). ATP-biotin  phosphorylbiotinylates 
protein substrates and peptides through a kinase-catalyzed reaction (Figure 2.4 
A).79,92,95,98  Following kinase-catalyzed biotinylation with ATP-biotin, the biotin group 
can facilitate analysis of phosphoproteins using various commercial streptavidin-
conjugated reagents.92,99 Unfortunately, ATP-biotin has been used in vitro only due to 
the cell impermeability of ATP analogs as a result of the presence of highly polar 
negative charged phosphates.95 Permeabilizing cells towards ATP-biotin would promote 
the study of protein kinases in more physiologically relevant conditions. In this chapter, 
we focus on systemic development of the first intrinsic cell permeable ATP-biotin analog 
for live cell kinase-catalyzed biotinylation (2, Figure 2.4).1 Our developing strategy 
depended on previous finding of permeabilizing phosphate containing compounds. 
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Figure 2.4: (A) Kinase-catalyzed phosphorylation of a protein substrate (green) with (B) 
ATP (R = O-) or ATP analogs ATP-biotin (1), or APB (2). 
2.2.1 Results and discussion 
 Building on previous precedents of cell delivering phosphate containing 
compounds, we replaced the PEG linker of ATP-biotin with a polyamine linker to create 
ATP-spermine (Figure 2.4). Polyamines are known cell delivery vehicles for phosphate 
containing compounds.105,106  In the case of ATP-spermine, the polyamine linker will be 
positively charged under physiological conditions to partially neutralize the triphosphate 
charge and promote cell permeability. We chose spermine as the linker because its size 
mimics the original poly ethylene glycol (PEG) linker in ATP-biotin (Figure 2.4).  
To test our hypothesis, ATP-spermine was synthesized according to scheme 2.1. 
Biotin was selectively coupled to one primary amine of commercially available spermine 
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to give Biotin-spermine in 67% yield. Biotin-spermine was then coupled to ATP in a pH 
dependent reaction to afford ATP-spermine in 35% yield (Scheme 2.1). 
Scheme 2. 1:  Synthesis of ATP-spermine. 
 
Before testing the cell permeability of ATP-spermine, We tested its ability to work 
in vitro as a kinase-cosubstrate. We chosed a well stablished system in our lab, where 
the kinase is PKA and the protein substrate is mylein basic protein (MBP). ATP-
spermine was incubated with PKA and MBP, followed by SDS-PAGE analysis and 
protein transfer on PVDF membrane. Kinase-catalyzed biotinylation was then detected 
by streptavdinCy5. Unfortunately, ATP-spermine showed biotinylation in presence and 
abscence of PKA (lane 2 and 4, Figure 2.5), The biotinylation in presence and abscence 
of kniase may be due side reactions of the nucleophilic secondary amines.1  
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Figure 2.5: Kinase-catalyzed biotinylation of MBP with ATP-spermine. MBP was 
incubated with ATP-spermine and PKA in the manufacture provided buffer. The labeled 
mixtures were separated by SDS-PAGE and visualized by SYPRO® Ruby to see total 
proteins (bottom gel) or streptavdin Cy-5 (SA-Cy5, Life Technologies) to detect 
biotinylation (Top gel). 
To solve the problem of non-specficity of ATP-spermine, we redesigned our ATP 
analog. We hyptheized that methylating the secondary nitrogen of spemine linker will 
decrease the reactivity of such nitrogen. To test the validity of the approach, we 
designed a new ATP-biotin with a polyamine linker, ATP-polyamine-biotin (APB). APB 
has a methylated nitrogen on the linker in cotrast to ATP-spermine, which may eliminate 
the non-specfic biotinylation. 
2.2.1.1 Docking Studies of APB with PKA crystal structure. 
Since APB has a methylated linker, which may affect the kinase-cosubstrate 
properties of ATP analogs, we computationally analyzed the kinase compatibility of 
APB. Docking studies with the PKA kinase crystal structure107 were performed using the 
Autodock program.108  Nearly identical PKA binding was observed with of APB (Figure 
2.6 A), ATP-biotin (Figure 2.6 C), and ATP (Figure 2.6 E). The biotin group protrudes 
from the active site, while the triphosphate is positioned in a close proximity to the co-
crystallized peptide.  The -phosphate of APB is 3.8 Å from the catalytic amino acid 
                                  
                                  
 1 2 3 4 
MBP + + + + 
PKA - - + + 
 ATP-biotin  + - + - 
ATP-spermine - + - + 
NHS-biotin  - - - - 
 
SA-Cy5 
SYPRO Ruby 
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K72, as compared to 3.7 and 3.2 Å with ATP or ATP-biotin, respectively (Figure 2.6), 
suggesting that the three ATP molecules bind similarly in the active site.  In contrast, the 
-phosphate of APB is 3.9 Å from K168 (Figure 2.6 B), as compared to 2.4 Å with both 
ATP-biotin and ATP (Figure 2.6 D and F). The docking studies suggest that APB is a 
potential kinase cosubstrate due to the similar active site binding.  However, the long 
distance between the -phosphate of APB and K168 suggests that APB may be a less 
efficient cosubstrate compared to ATP or ATP-biotin.1  
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Figure 2.6: Docking of APB (A), ATP (C), and ATP-biotin (E) into the crystal structure of 
the catalytic active site of PKA kinase co-crystallized with peptide substrate (pdb: 
4DH1)107 using Autodock 4.2.108 The arrow points to the solvent exposed biotin group in 
case of APB and ATP-biotin. Enlarged view of the interaction of APB (B), ATP (D), and 
ATP-biotin (F) with the catalytic Mg2+ metal (yellow orb) and amino acids K72 and K168. 
The -phosphate of APB, ATP, and ATP-biotin is positioned in a close proximity to K168 
while the -phosphate lies near K72.  The APB, ATP, and ATP-biotin atoms are color-
coded (C = green; H = grey; N = blue; O = red; P = orange). For clarity, the atomic 
radius of Mg2+ was reduced to 0.5 Å.   
2.2.1.2 Synthesis of APB with PKA crystal structure. 
To experimentally test APB as a kinase cosubstrate, it was first synthesized from 
commercially available spermine (Scheme 2.2).1 Spermine (3) was protected at the 
primary amines using 2-(t-Butoxycarbonyloxyimino)-2-phenylacetonitrile (BOC-ON) to 
yield protected spermine (4) in 80% yield. Compound 4 was methylated by reductive 
amination at secondary nitrogen using formaldehyde and sodium cyanoborohydride to 
give Boc-protected methylated spermine (5) in 98% yield.109 Compound 5 was 
deprotected by 4M HCl in dioxane to give methylated spermine (6) in 90% yield. After 
deprotection,109 the NHS-ester of biotin was synthesized as reported110 and coupled to 
give polyamine biotin (7) in 40% yield.111 Finally, polyamine-biotin (7) was coupled with 
ATP to obtain APB (2).112 
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Scheme 2. 2:  Synthesis of ATP-polyamine-biotin 2 (APB) 
 
2.2.1.3 In vitro testing of APB. 
To test compatibility with kinase-catalyzed biotinylation, APB was incubated with 
PKA kinase and full-length protein substrate, myelin basic protein (MBP).  As a control, 
we performed the experiment in abscence of PKA or in presence of a panel kinase 
inhibitor, staurosporine. In addition, we treated the reaction mixture with acid after the 
incubation time as another control reaction. The acid should break the phosphoramidate 
bond and remove biotinylation. Biotinylation was visualized after SDS-PAGE gel 
separation, transfer to PVDF membrane, and staining with a streptavidin-Cy5 conjugate 
(Figure 2.7). Biotinylation was observed only in presence of kinase (Figure 2.7, compare 
lanes 3 and 4). In addition, MBP biotinylation was lost in the absence of APB (Figure 
2.7, lane 2), in presence of the kinase inhibitor staursporine (Figure 2.7, compare lanes 
7 and 8) or upon incubation with acid (Figure 2.7, lane 5) due to cleavage of 
phosphoramidate bond (Figure 2.4A). This experiment suggests that APB is a kinase-
cosubstrate and it can be used for a kinase-catalyzed biotinylation reactions. 
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Figure 2.7: Kinase-catalyzed biotinylation of MBP with APB. MBP was incubated with 
APB and PKA in the manufacture provided buffer. As a control, TFA (50%) was added 
after biotinylation labeling to assure biotinylation via an acid-labile phosphoramidate 
bond (lane 5). A kinase inhibitor, Staursporine (STSP) was preincubated with PKA to 
confirm biotinylation via a kinase-catalyzed reaction (lane 8). The labeled mixtures were 
separated by SDS-PAGE and visualized by SYPRO® Ruby to see total proteins (A) or 
streptavdin Cy-5 (SA-Cy5, Life Technologies) to detect biotinylation (B). The images are 
representative of at least three independent trials (Figure A 2.17). 
To further confirm kinase-catalyzed biotinylation by APB, a mass spectrometric 
(MS) study was performed. In this case, the PKA peptide substrate kemptide was 
incubated with APB and PKA before MALDI-TOF MS analysis.  Biotinylated kemptide 
product was observed only in the presence of APB cosubstrate (Figure 2.8, m/z 
1332.490 (M+H)+). The combined gel and MS analyses confirm that APB is a kinase 
cosubstrate.1 
 
 
 
                      
                      
 1 2 3 4 5 6 7 8 
MBP + + + + + + + + 
PKA - + - + + - + + 
ATP - + - - - - - - 
APB - - + + + - + + 
50% TFA - - - - + - - - 
STSP - - - - - - - + 
 
Sypro Ruby 
SA-Cy5 
45 
 
 
 
 
Figure 2.8: MALDI-TOF spectra of a kinase-catalyzed phosphobiotinylation reaction of 
N-acetylated kemptide with PKA in positive ion mode. A) Reaction in the presence of 
APB: ((M+H)+ for C56H107N19O14PS, Calculated: 1332.7698; Observed: 1332.469,; 
(M+K)+ for C56H106KN19O14PS, Calculated: 1371.7151; Observed: 1371.466 B) Reaction 
in the absence of APB showing no product peaks in the same m/z range. The data 
represent at least three repetitive trials (Figure A 2.18). 
2.2.1.4 Determination of APB efficiency as a kinase-cosubstrate. 
To investigate the efficiency of biotinylation using APB, both quantitative 
percentage conversion and kinetic studies were performed. For quantitative conversion 
studies, APB, ATP-biotin, and ATP were separately incubated with MBP and PKA, 
followed by cleavage of the phosphoramidate bond with acid to produce phosphoprotein 
A. 
B. 
1332.469 
1371.466 
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products with all ATP analogs (Figure 2.4), which allowed quantitative comparison. The 
reaction mixtures were then separated by SDS-PAGE with phosphoproteins visualized 
by ProQ diamond stain (Figure 2.9), as previously reported.95 Quantification showed 55 
± 6 % conversion with APB compared to ATP (Figure 2.9, lane 4), while ATP-biotin 
showed 72 ± 7 % conversion compared to ATP (Figure 2.9, lane 3).1  Biotinylation was 
less efficient with APB compared to ATP-biotin, as predicted by the docking studies. 
However, the observed quantitative analysis confirmed that APB is a kinase 
cosubstrate.  
 
Figure 2.9: Quantitative analysis of MBP phosphorylation in presence of PKA with 
either ATP (lane 2), ATP-biotin 1 (lane 3), or APB 2 (lane 4). The reaction mixtures were 
separated by SDS-PAGE and visualized by SYPRO® Ruby stain (top gel) to ensure 
homogeneity of protein loading in all lanes or ProQ diamond stain (bottom gel) to detect 
phosphorylation of MBP. MBP degree of phosphorylation was quantified from the ProQ 
diamond stained gel (bottom gel) and the percentage of phosphorylation was calculated 
by comparison with phosphorylation with ATP (100%). The quantitative analysis is a 
representation of at least three independent trials (Figure A 2.19) 
Next, kinetic studies were performed by incubating APB or ATP (0.5-100 µM) 
with PKA and kemptide peptide substrate. APB revealed a reduced KM (0.87±0.21 µM) 
compared to ATP (2.3±0.6 µM), but ATP showed better kcat (1.2±0.1 s-1) compared to 
APB (0.22±0.01 s-1) (Figure 2.10). In sum, APB exhibited a reduced kcat/KM (0.25 s-1µM-
1) compared to ATP (0.52 s-1µM-1) (Figure 2.10). However, The reduced kcat/KM is 
similar to those observed with other ATP analogs used for kinase studies, including the 
                      APB 55% (±6)                  
                        ATP-biotin 72% (±7) 
 SYPRO Ruby                                   
          ProQ   
 1 2 3 4 
MBP + + + + 
PKA + + + + 
ATP - + - - 
ATP-biotin - - + - 
APB - - - + 
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γ-phosphate modified ATP analog ATP-dansyl,82 or the base-modified analogs N6-
benzyl ATP or N6-(2-phenethyl) ATP.113,114   In total, both quantitative conversion and 
kinetics studies confirm that APB is an efficient kinase cosubstrate with conversions and 
kinetics similar to other known ATP analogs.1 
 
 
 
 
 
Figure 2.10: Michaelis-Menton curve fits for reaction containing ATP (A) or APB (B) as 
the cosubstrate, with kinetic analysis comparison between ATP and APB in the table 
(C). 
 
To analyze the compatibility of APB with cellular kinases, HeLa cell lysates were 
incubated with APB, followed by SDS-PAGE analysis.1 Biotinylation of proteins was 
detected in the APB reaction (Figure 2.11 , lane 4), showing the promiscuity of cellular 
kinases for APB.  Similar levels of labeling were observed comparing APB and ATP-
A B 
934.272 ATP APB 
KM (µM) 2.3 ± 0.6 0.87 ± 0.21 
Vmax (µM/min) 3.5 ± 0.2 0.64 ± 0.02 
kcat (s-1) 1.2± 0.1 0.22± 0.01 
kcat/KM (µM s)-1 0.52 0.25 
 
C 
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biotin (Figure 2.11, lane 4 versus 7).  As a control, heat denatured lysates generated 
low levels of biotinylation with both APB and ATP-biotin (Figure 2.11, lanes 3 and 6), 
which confirmed the kinase-dependence of biotinylation. Acid treatment also reduced 
biotinylation (Figure 2.11, lane 5), which indicated labeling via the phosphoramidate 
bond in APB (Figure 2.4). To assess the quality of biotinylation in the various labeling 
reactions, another control reaction was performed by incubating cell lysates with the 
non-specific biotinylation reagent, NHS-biotin.  Different biotinylated protein bands were 
observed with NHS-biotin treatment compared to kinase-catalyzed reactions with APB 
or ATP-biotin (Figure 2.11, compare lane 2 to lanes 4 and 7), suggesting kinase-
selective biotinylation of lysates. These studies in lysates further establish the 
compatibility of APB with a range of cellular kinases and substrates, similar to ATP-
biotin.92,95 
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Figure 2.11: Kinase-catalyzed biotinylation of HeLa cell lysates (HCL) or heat-
inactivated HeLa cell lysates (HDL) with APB and ATP-biotin. Acid (50% trifluoroacetic 
acid final concentration) was added after biotin labeling to cleave the biotin tag (lane 5). 
NHS-biotin was used to assess nonspecific biotinylation. Reaction mixture were 
separated by SDS-PAGE and visualized with streptavidin-Cy5 (SA-Cy5, top gel) or 
SYPRO® Ruby total protein stain (bottom gels). The gels are representative of at least 
three independent trials (Figre A 2.20). 
2.2.1.5 Evaluation of APB cytotoxicity. 
To assess if APB is cytotoxic to cells or not, a dose-dependent cell viability assay 
was performed.  The cytotoxicity studies will rule out the activation of alternative cell 
signaling pathways due to cell death, which may affect the results gahtered from APB 
biotinylation assays. An increasing concentrations of APB were incubated with HeLa 
cells, followed by washing and staining with trypan blue. Viable cells were counted and 
compared with untreated control cells. APB showed a cytotoxicity EC50 value of 19 ± 1 
mM (Figure 2.12A).  Importantly, 96 ± 1 % cell viability was observed with the 5 mM 
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concentration of APB that we planned to use in the cell labeling assay (Figure 2.12B). 
The cell-based studies show that APB is cell permeable and nontoxic at low mM 
concentrations, with cell penetration and labeling dependent on the polyamine linker.1 
 
 
Concentration (mM) % cell viability 
0.0 100% 
1.0 99 ± 3 % 
5.0 96 ± 1 % 
10 80 ± 4 % 
15 60 ± 6 % 
20 43 ± 3 % 
30 34 ± 2 % 
 
 
Figure 2.12: Cell viability assays with varying concentrations of APB. A) Dose response 
curve of APB with 1, 5, 10, 15, 20, 30 mM final concentrations. The EC50 of APB is 19 ± 
1. B) Table with the percentage viability data plotted in part A.  The concentration of 
APB used in kinase-catalyzed labeling of cells was 5 mM.   
 
 
 
A) 
B) 
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2.2.1.6  Evaluation of APB cell permeability and live cell biotinylation 
Having confirmed the kinase compatibility of APB in vitro and low cytotxicity, we 
next sought to test kinase-catalyzed biotinylation of live cells.  As a first step, 
fluorescence microscopy was used to confirm the cell permeability of APB. Hela cells 
were incubated with APB, followed by washing, fixation, and visualization with 
streptavidin-Cy5 to observe biotin. Cells treated with APB showed fluorescence 
corresponding to the presence of biotin (Figure 2.13). As controls, untreated cells 
(Figure 2.13) or cells incubated with ATP or ATP-biotin showed no biotin signal (Figure 
2.13), which indicated that the polyamine linker in APB was required to promote cell 
permeability.  These microscopy studies confirm that APB is cell permeable and 
validate the use of a polycationic groups to enhance the permeability of ATP analogs.1   
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Figure 2.13: Microscopy studies of ATP-biotin or APB cell permeability. HeLa cells were 
untreated or treated with ATP, ATP-biotin or APB before visualization with the nuclear 
stain DAPI or biotin stain streptavidin-Cy5 (SA-Cy5).  These images are representative 
of three independent trials. One trial is shown here and the rest of trials are shown in 
figure A 2.21. 
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Untreated 
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ATP-
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With the cell permeability of APB confirmed, live cell biotinylation with ABP was 
performed. HeLa cells were incubated with APB, washed to remove excess analog, 
lysed, and then analyzed by SDS-PAGE. Cells incubated with APB showed protein 
biotinylation (Figure 2.14, lane 4), which is consistent with cell permeability. Biotinylation 
was absent with ATP-biotin under the same conditions (Figure 2.14, lane 2), further 
confirming that the polyamine linker is necessary to enhance cell permeability. Also, 
pre-treating cells with the kinase inhibitor staursporine reduced biotinylation (Figure 
2.14, lane 3), indicating that the labeling is kinase-dependent.  Treatment with APB was 
accompanied by a modest loss of total protein (Figure 2.14, lane 3 and 4, bottom gel) 
compared with controls (Figure 2.14, lane 3 and 4, bottom gel), which is similar to the 
levels of protein loss observed in previous cell permeability studies,115,116 including 
experiments with the widely used cationic-based permeabilization reagents.117 This 
experiment confirms that APB is cell permeable and can in cellulo biotinylate protein 
substrates through a kinase-catalyzed reaction. 
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Figure 2.14: In cellulo kinase-catalyzed biotinylation with ATP-biotin or APB in HeLa 
cells. As a control, kinase inhibitor staurosporine (STSP) was pre-incubated with cells to 
prevent kinase catalysis (lane 3). Reaction mixtures (A and C) were separated by SDS-
PAGE and visualized with streptavidin-Cy5 (SA-Cy5, top gel) or SYPRO® Ruby total 
protein stain (bottom gels). The gels are representative of at least three independent 
trials. One trial is shown here and the rest of trials are shown in figure A 2.22. 
2.3 Conclusion and future directions 
In conclusion, we report the first cell permeable ATP analog compatible with 
kinase-catalyzed biotinylation. APB acted as a cosubstrate with protein kinases in vitro 
and in cellulo.  While the percentage conversion and kinetic efficiency was reduced 
compared to ATP or ATP-biotin in vitro, APB was able to label phosphoproteins in live 
cells. Importantly, a comparison of APB labeling reactions in lysates (Figure 2.11, lane 
4) and cells (Figure 2.14, lane 4) revealed different biotinylated protein products, which 
indicated that in cellulo labeling is distinct from labeling in lysates. We speculate that the 
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difference in live cell versus lysates labeling may be due to compartmentalization inside 
the cell, which suggests that in cellulo labeling studies will better interrogate the 
phosphoproteome for cell signaling studies.1 This difference in biotinylated proteins 
argue that labeling in cellulo will better reflect the cellular phosphoproteome.  These 
results lay the foundation for future work using APB and kinase-catalyzed biotinylation 
as tools to identify and isolate phosphoproteins from cells, which will enhance cell 
signaling research. More generally, these studies establish that cationic groups 
attached to ATP analogs promote cell permeability, which provides a general strategy 
for creation of other ATP analogs for live cell labeling studies. 
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2.4 Experimental 
2.4.1 Materials 
Spermine, pyruvate kinase/lactate dehydrogenase, NADH, phosphoenol pyruvic 
acid and alpha-cyano-4-hydroxycinnamic acid were purchased from Sigma Aldrich. ATP 
was purchased from MP Biomedicals.  Dimethyl acetamide (DMAC), 2-(tert-
butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON), 1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDCI), diisopropyl ethyl amine (DIPEA), N-hydroxy 
succinimide (NHS), and N,N,N',N'-Tetramethylethylenediamine for electrophoresis were 
purchased from Acros. The NHS-biotin ester was synthesized according to prior 
literature.110 Sodium cyanoborohydride, formaldehyde, silica, DEAE sephadex A-25, 
and ammonium persulfate (APS) for electrophoresis were bought from Fisher Scientific. 
Dichloromethane (DCM), acetic acid, hydrochloric acid, ammonium hydroxide, and 
HPLC grade acetonitrile were purchased from EMD. Ethanol was obtained from Decon 
lab. 40% Bis-acrylamide (37.5:1) for gel electrophoresis and Bradford reagent were 
purchases from Biorad. Myelin basic protein (MBP), F-12 media and trypan blue were 
bought from Invitrogen. PKA kinase was purchased from New England Biolabs. 
Antibiotic and Dulbecco's Phosphate Buffered Saline (DPBS) for cell culture were 
purchased from HyClone. 3-Hydroxypicolinic acid was bought from Fluka. 
2.4.2 Instruments 
1H NMR, 13C NMR, 31P NMR (Varian Mercury-400), and high resolution mass 
spectra (HRMS) (LCT Premier XT (Waters)) were used to characterize the final APB 
analog. D2O was observed at 4.63 in 1H NMR. The peaks at  1.08 (t) and 3.01 in 1H 
NMR, and  8.29 and 46.59 in 13C NMR of ABP corresponded to the triethylamine 
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counter ion. Absorbance of APB was measure by UV-Vis spectrophotometer (Shimadzu 
2101 PC). A Lyophilizer (VirTis BT 3.3 EL Benchtop) and Speed-vac (ThermoSAVANT, 
SPD131 DDA) were used during synthesis of APB. RP-HPLC was performed with 
Waters 1525 binary HPLC pump, Waters 2998 photodiode array detector, and Reverse 
phase C-18 column (YMC America, INC 250×4.6 mm, 4μm, 8 nm). Bradford assay was 
done using a fluorimeter (GENios Plus Tecan). SDS-PAGE apparatus were bought from 
BioRad (Protean III). Protein transfer was performed using the Mini-Transblot 
Electrophoretic Transfer Cell apparatus from BioRad. SDS gels and PVDF membranes 
were visualized by a Typhoon 9210 scanner (Amersham Biosciences). 
Immunofluorescence images were visualized by Olympus fluorescence microscope (BX 
41). Peptide masses was detected using MTP Plate (Bruker) and MALDI-TOF (Bruker 
Ultraflex). 
2.4.3 Docking Studies 
The crystal structure of PKA was downloaded from RCSB Protein Data Bank 
(pdb ID: 4DH1). The co-crystallized peptide, ATP, and water were deleted using Pymol 
1.5.0.5 (Schrodinger, LLC). All hydrogen atoms, Gasteiger charges and merging non 
polar hydrogen were added by AutoDock Tools 1.5.6, followed by generation of pdbqt 
output file. The charge of Mg was changed from zero to +2 manually. A grid box with a 
spacing of 0.375 Å, size of 74 X 70 X 70, and coordinates for the center of the grid box 
(-9.145, 13.434, -21.018) were used. The grid map files required for docking 
calculations were generated by AutoGrid 4.2. APB was drawn in ChemBioDraw Ultra 
and MM2 energy minimization was done by Chem 3D Pro. AutoDock Tools 1.5.6 was 
used again to add hydrogens, compute Gasteiger charges, merge nonpolar hydrogens, 
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choose torsions, and generate a pdbqt file. All acyclic bonds were rotatable except 
amide bonds. We then used AutoDock 4.2 to run docking calculations using the genetic 
algorithm, and a pdbqt file was generated.  The pdbqt file for PKA was set as a rigid 
macromolecule and the genetic algorithm search parameters were set to 100 GA runs 
with a population size of 150, a maximum number of 2.5 × 105 energy evaluations, a 
maximum number of 2.7 × 104 generations, a mutation rate of 0.2, and a crossover rate 
of 0.8. Default docking parameters were used and the output DLG file was converted to 
pdbqt extension. Image was created using Autodock Tools 1.5.6. 
2.4.4 Synthesis of ATP-polyamine-biotin (ABP) 
 
2.4.4.1 Amine-protection of spermine: Synthesis of di-tert-butyl ((butane-1,4-
diylbis(azanediyl))bis(propane-3,1-diyl))dicarbamate (4) 
Compound 4 was synthesized according to literature, as follows.118 Spermine (3, 
1g, 4.9 mmol) was dissolved in THF (15 mL) at 0 °C. A solution of BOC-ON (2.42 g, 9.8 
mmol) in THF (30 mL) was added drop wise under argon at 0 °C. After stirring at 0 oC 
for 2 minutes, the solution was stirred at room temperature for 1 hour. The reaction was 
quenched with saturated sodium carbonate (45 mL) and extracted with dichloromethane 
(135 mL). The organic layer was evaporated in vacuo and then the residue was purified 
by chromatography using silica and 5% ammonia in ethanol as eluting solvent to obtain 
4 as a white solid (1.7 g, 80% yield). Spectral characterization was consistent with prior 
literature.118 H1NMR (400 MHz, CDCl3): 1.2 (m, 2H), 1.4 (s, 18H), 1.55 (s, 4H), 1.65 (t, 
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4H), 2.6 (m, 8H), 3.1 (m, 4H), 5.3 (s, 2H). C13NMR (100 MHz, CDCl3): 27, 28, 30, 39, 
47, 49, 79, 156. 
 
2.4.4.2 Synthesis of di-tert-butyl ((butane-1,4-diylbis(methylazanediyl)) 
bis(propane-3,1-diyl))dicarbamate (5) 
Compound 5 was synthesized according to literature118. Compound 4 (1.7 g, 3.9 
mmol) was dissolved in ethanol (45 mL) together with a 37% formaldehyde solution 
(17.3 mL, 213.1 mmol). Acetic acid (11.5 mL) was added, followed by sodium 
cyanoborohydride (4.3 g, 68.4 mmol). The reaction was stirred overnight and then 
quenched with saturated sodium carbonate solution until effervescence ceased, 
followed by extraction with dichlormethane (3 times). The organic layer was evaporated 
in vacuo. The residue was purified by chromatography using silica and 5% ammonia in 
ethanol as eluting solvent to obtain 5 as yellowish oil (1.8 mL, 98% yield). The spectral 
characterization was consistent with prior literature.118 ESI (M+H)+ for C22H47N4O4: calc. 
431.6, found 431.6 
 
 
2.4.4.3 Synthesis N1,N1'-(butane-1,4-diyl)bis(N1-methylpropane-1,3-diamine) (6) 
Compound 6 was synthesized according to literature.118 Compound 5 (1.83 g, 4.2 
mmol) was dissolved in 1,4-dioxane (40 mL) at 0 °C, followed by addition of 4N HCl (40 
mL). The reaction was stirred at room temperature for 4 hours and then the solvent was 
evaporated in vacuo. The residue was crystallized with methanol/ethylacetate to give 
white crystals of compound 6 as a chloride salt (1.3 g, 90% yield). The spectral 
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characterization was consistent with prior literature.118 ESI (M+1)+ for C12H31N4: calc. 
231.4, found 231.5  
 
2.4.4.4 Synthesis of polyamine-biotin (using methylated spermine) (7) 
Polyamine-biotin (7) was synthesized according to literature119 with some 
modifications to the procedure. Methylated spermine (6) (0.78 g, 2.5 mmol) was 
dissolved in a mixture of DMAC (25 mL) and DIPEA (3.3 mL) at 0 °C. A solution of NHS 
biotin ester110 (350 mg, 1 mmol) in DMAC (30 mL) was added dropwise over an hour 
under argon and the reaction mixture was stirred overnight at room temperature, 
followed by addition of diethyl ether (30 mL) to precipitate the product. The precipitate 
was filtered and then purified by chromatography using silica and ethanol:THF:DCM: 
ammonia (4:4:2:1) as an eluting solvent. Polyamine-biotin (7) was obtained as oil (0.5 g, 
44%). The spectral data was consistent with literature.119 1H NMR (400 MHz, CD3OD):δ 
1.15-1.19 (m, 6H), 1.39-1.47 (m, 3H), 1.52-1.63 (m, 4H),1.64-1.82 (m, 6H), 2.19-2.34 
(m, 7H), 2.45-2.61 (m,7H), 2.90-2.98 (m, 2H), 3.18-3.30(m, 2H), 4.30-4.48 (t, 1H), 4.49-
4.91 (d, 1H).13C NMR (100 MHz, CD3OD): 23.40, 25.77, 28.47, 28.64, 29.52, 32.66, 
35.66, 38.86, 39.33, 55.87, 59.63, 61.18, 61.48 163.15, 172.22. 
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2.4.4.5 Synthesis of ATP-polyamine-biotin (ABP, 2) 
The disodium salt of ATP (32 mg, 0.059 mmol) was dissolved in water (5 mL) 
and then the pH was adjusted to 7.0 with NaOH (0.5 M). EDCI (452.5 mg, 2.36 mmol) 
was added and the pH was readjusted to 5.6-5.8 with HCl (0.5 M). Polyamine-biotin (7) 
(114 mg, 0.25 mmol) in water (2 mL) was added and the pH was readjusted to 5.6-5.8 
with HCl (0.5 M). The solution was stirred for 3 hours with control of pH at 5.6-5.8. The 
solution was brought to a pH of 8.5 uisng triethylamine and the product was separated 
by anion exchange column (A-25 sephadex, 5 gm) with 0.1-1 M triethyl ammonium 
carbonate buffer (pH 8.5) as eluent. Fractions containing APB were combined, 
lyophilized to dryness, and stored at -80 oC as a white solid (18.9 mg, 36%).  Purity 
(95%) was assessed by RP-HPLC with triethyl ammonium acetate buffer (TEAAB, 
buffer A: 100 mM TEAAB in HPLC water) and acetonitrile (buffer B: 100% acetonitrile) 
using constant 5% buffer B for 10 minutes and then a gradient of 5% to 40% buffer B 
over 40 minutes.  1H NMR (400 MHz, D2O): δ 0.92 (4H, t), 1.24 (6H, t), 1.50-1.53 (3H, 
m), 1.66 (3H, m), 2.05 (1H, t), 2.45 (2H, t), 2.58 (3H, s), 2.71-2.90 (m, 9H), 3.15-3.21 
(6H, q), 4.00 (2H, d), 4.18-4.21 (2H, m), 4.35-4.39 (2H, m), 5.91 (2H, d), 8.07 (1H, s), 
8.37 (1H, s). 13C NMR (100 MHz, D2O): δ 25.1 (2), 25.9, 27.6, 27.9, 35.4 (2), 42.2, 44.7, 
45.3, 45.4, 47.2 (2), 47.9 (2), 48.6 (2), 53.7 (2), 55.3, 60.1 (2), 61.9, 67.4, 86.5, 118.3, 
123.7, 127.7, 139.9, 152.9, 167.6 (2C). 31P NMR (162 MHz, D2O): -1.8 (d), -11.8 (d), -
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23.1 (t). UV/Vis spectroscopy (H2O): 260 nm (ϵ=154000). HRMS: (M-1)- for 
C32H57N11O14P3S: calc. 944.3020, found 944.3046. 
2.4.5 Synthesis of ATP-biotin (1) 
2.4.5.1 Synthesis of biotin amine (1a): 
 
In 250 mL flask, TBTU (828 mg, 2.5 mmol) and biotin (509 mg, 2.08 mmol) were 
added into a mixture of DMF (5 mL) and DCM (15 mL). DIPEA (413 ul, 2.5 mmol) was 
added and the mixture was stirred until a heavy precipitate is formed. The precipitate 
was filtered, suspended in DCM (50 mL) and then added into a solution of PEG amine 
1b (1.14 ml, 5.2 mmol) in DCM (300 mL) portion wise. After stirring overnight, the 
solution was concentrated by evaporation under reduced pressure and purified using 
silica with solvent system of ethanol: DCM: ammonia in ratio 3:1:0.01 to give 1a as 
white solid (600 mg, 80%). 
2.4.5.2 Synthesis of ATP-biotin (1): 
 
ATP (32 mg, 0.059 mmol) was dissolved in 5mL water and then pH was adjusted 
to 7. EDCI (452.5 mg, 2.36 mmol) was added and the pH was readjusted to 5.6-5.8 with 
HCl (0.5 M). Biotin amine (1a) (423 mg, 0.1.18 mmol) in water (2 mL) was added and 
the pH was readjusted to 5.6-5.8 with HCl (0.5 M). The solution was stirred for 3 hours 
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with control of pH at 5.6-5.8. The solution was brought to a pH of 8.5 using one drop 
triethylamine and the product was separated by anion exchange column (A-25 
sephadex, 5 gm) with 0.1-1 M triethyl ammonium carbonate buffer (pH 8.5) as eluent. 
Fractions containing ATP-biotin were combined, lyophilized to dryness, and stored at -
80 oC as a white solid (25 mg, 45%).  H1NMR (D2O): 1.2 (s 2H), 1.6(m, 8H), 2.1 (s, 2H), 
2.6 (d, 2H), 2.8 (m, 5H), 3.1 (s,2H),   3.4 (m, 11H), 4.1 (d, 2H), 4.21(s, 2H), 4.4(s, 2H), 
6.00 (s, 1H), 8.1(s,1H), 8.4 (s, 1H). P31NMr: -1.3(d), -11.6(d), -23.069 (t). MALDI-TOF: 
(M-1)- for C32H58N11O14P3S: calc. 935.2415, found 934.523. 
2.4.6 Preparation of triethyl ammonium carbonate buffer (TEAB) 
To generate TEAB (1M), triethyl amine (139 mL) was mixed with water (861 mL). 
Dry ice was added to the mixture untill pH equaled 8.5 and the buffer was stored at 4 
oC. 
2.4.7 Synthesis of N-acetylated kemptide (AcLRRASLG) 
Acetyl kemptide was synthesized by Fmoc based solid phase peptide solid 
according to literature.82,120 The peptide was purified by RP-HPLC and characterized by 
MALDI-TOF, (M+1)+ for C34H63N13O10+: Calc. 814.4894, found 814.372. 
2.4.8 In vitro kinase-catalyzed biotinylation of MBP with PKA 
Kinase-catalyzed biotinylation was performed by incubating ATP or APB analog 
(5 mM), PKA enzyme (5µg/mL, 500U), and myelin basic protein (MBP) (1 µg/µL) in the 
PKA kinase buffer provided by the manufacturer (1X) (50 mM Tris-HCl, 10 mM MgCl2, 
0.1 mM EDTA, 2 mM DTT, 0.01% Brij 35, pH 7.5 at 25°C). The final volume for the 
reaction was 20 µL. The reaction mixture was incubated at 31 °C for 2 hours. Reactions 
without PKA and/or APB were conducted as control experiments.  Reactions in the 
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presence of the kinase inhibitor staursporine (1 µM final concentration) were also 
performed where inhibitor and PKA were preincubated for 30 minutes before addition of 
APB. Another control experiment was performed by adding TFA (50% final conc.) and 
incubating at 45 °C for 1 hr with shaking at 700 rpm to cleave the phosphoramidate 
bond. TFA was evaporated using speed vac, followed by neutralization of the remaining 
TFA with 1.5 M Tris base (pH=8.8, 10 µL). All reaction mixtures were separated by 16% 
SDS-PAGE and visualized with SYPRO® Ruby or transferred onto a polyvinylidene 
difluoride membrane (Immobilon-P, Milipore) and visualized with streptavidin-Cy5 (Life 
Technologies).  Repetitive trials are shown in Figure 2.7 and A 2.17. 
2.4.9 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The SDS-PAGE gels were prepared as described in Molecular Cloning, 
(Appendix 8.40-8.45) and Chamara Senevirathne’s thesis.121,122 Gels were prepared in 
10% or 16% SDS-PAGE according to the needs of the experiments. 
2.4.10 Visualization of biotinylation 
To transfer proteins separated by SDS-PAGE, we used a polyvinylidene 
difluoride (PVDF) membrane (Immobilon P, Millipore). After wetting the PVDF 
membrane with methanol, a Mini-Transblot Electrophoretic Transfer Cell apparatus 
from BioRad was used to transfer the proteins in CAPS buffer (0.01 M CAPS (N-
cyclohexyl-3-aminopropanesulfonic acid) at pH 10.5, containing 10% methanol). The 
apparatus was set at constant voltage (90 V) for 120 minutes. The membrane was air 
dried after protein transfer and then re-wetted with methanol. The membrane was 
incubated overnight in a blocking buffer (5% (w/v) non-fat milk in PBST (137 mM NaCl, 
2.7mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4 and 0.1% Tween-20) at 4oC. The 
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membrane was rinsed with PBST twice (10 mL each) and then incubated for 1 hour 
with streptavidinCy5 in blocking buffer (1:2000). Membrane was washed with PBST for 
5 minutes twice (10 mL each) and visualized using the Typhoon 9400 scanner at 
650/670 nm excitation and emission, respectively.  
2.4.11 Sypro Ruby staining protocol 
The SDS-polyacrylamide gel was incubated with fixing solution (100 mL, 50% 
methanol and 7% acetic acid in water) with gentle rocking at room temperature for one 
hour. The fixed solution was discarded and Sypro Ruby gel stain (100 mL, Invitrogen) 
was added in dark. The gel was incubated with Sypro Ruby stain at room temperature 
overnight, with gentle rocking and covered from light. The gel stain was removed and 
then destaining solution (10% methanol and 7% acetic acid in water) was added. The 
gel was incubated at room temperature for 30 minutes, followed by washing with 
distilled H2O for 5 minutes to remove excess acid. The stained gel was visualized using 
the Typhoon scanner at an excitation/emission wavelengths of 450 nm and 610 nm 
respectively.  
2.4.12 In vitro MS analysis of kinase-catalyzed biotinylation 
APB analog (5 mM) was incubated with PKA enzyme (20µg/mL, 2000U) and N-
acetylated kemptide (1 mM) in the PKA kinase buffer provided by the manufacturer 
(1X). The final volume for the reaction was 10 µL. The reaction mixture was incubated 
at 31 °C for 2 hours. A reaction without PKA was conducted as a control experiment. 
The reactions were subsequently mixed with an equal volume (10 µL) of a saturated 
solution of a 1:1 mixture of 3-hydroxyalpha picolinic acid and alpha-cyano-4-
hydroxycinnamic acid in 50% acetonitrile, then spotted on a MALDI plate. The spot was 
66 
 
 
left to dry and analyzed by MALDI-TOF (Bruker). Phosphorylbiotinylated peptide 
masses were detected at high laser power.  Repetitive trials are shown in Figure 2.8 
and A 2.18. 
2.4.13 ProQ diamond gold staining protocol 
The SDS-polyacrylamide gel was incubated with fixing solution (100 mL, 50% 
methanol and 10% acetic acid in water) overnight. The solution was discarded, followed 
by rinising the gel with distilled water for 30 minutes, three times. Pro-Q Diamond gel 
stain (100 mL, Invitrogen) was added and incubated with the gel at room temperature 
for 60-90 minutes, with gentle rocking and covered from light. The stain was removed 
and the gel was washed by destaining solution (100 mL, 20% acetonitrile, 50 mM 
sodium acetate pH 4) was added and incubated with the gel at room temperature for 30 
minutes, three times. After removing the destaining solution, the gel was washed with 
distilled water for 5 minutes. The Pro-Q stained gel was visualized using the Typhoon 
scanner at an excitation/emission wavelengths of 532 nm and 555 nm, respectively. 
2.4.14 In vitro quantification of kinase-catalyzed biotinylation of MBP with PKA 
Kinase-catalyzed phosphorylation and biotinylation reactions were performed as 
in section 2.4.8, followed by incubation with TFA (50% final conc.) for 1 hour at 45 oC 
with shaking at 700 rpm. The TFA incubation was necessary to cleave the 
phosphoramidate bond in the ATP-biotin products to create a phosphoprotein for 
quantitative analysis.  TFA was evaporated using speed vac, followed by neutralization 
of the remaining TFA, as described in section 2.4.8. The reaction mixtures were 
separated by SDS-PAGE (16%) gel electrophoresis and visualized by SYPRO® Ruby 
or Pro-Q diamond stain according to the manufacturer’s instructions. Quantification of 
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MBP phosphorylation on the Pro-Q diamond stained gel image was performed with 
ImageQuant 5.2 by drawing the same-sized rectangle on each MBP protein band. The 
MBP phosphorylation signal was background corrected by subtracting the signal after 
kinase reaction by the signal of untreated MBP.  Percentage phosphorylation was 
calculated by dividing the background-corrected MBP phosphorylation signal in ATP-
biotin or APB reactions by the signal in ATP reactions (set as 100% phosphorylation) 
and multiplying by 100. Repetitive trials are shown in Figure 2.9 and A 2.19. 
2.4.15 Kinetic analysis of APB with PKA 
An NADH-dependent coupled assay was used to perform kinetic analysis, as 
previously described7 with some exceptions. The assay was performed using NADH 
(0.5 mM), pyruvate kinase (24 units/mL), lactic acid dehydrogenase (36 units/mL), PKA 
(2.5 µg/mL, 61 nM), ATP or ATP-biotin (final concentrations of 0.5, 1, 3, 10, 30, and 100 
µM), and absorbance at 360 nm taken every 30 second for 60 min. Kaleidagraph 
software (Synergy Software) and non-linear regression analysis was used to obtain KM 
and Vmax values from the Michaelis-Mentor equation (v=Vmax*(S)/(KM + (S)), where v= 
initial rate of the reaction and (S)= substrate concentration). kcat was calculated by 
dividing Vmax by the concentration of PKA enzyme. 
2.4.16 Starting a New Cell Culture  
HeLa cells (HeLa S3 obtained from ATCC (American Type Culture Collection) 
was used. Cell aliquots (1.0 mL, 10 × 106 cells) were stored in cryogenic vials in a liquid 
nitrogen storage tank upon receipt. To start a new cell culture, an aliquot was thawed 
quickly in a 37 °C water bath. The solution of cells was mixed with Ham’s F-12 media 
containing 10% v/v fetal bovine serum (FBS, Invitrogen) (10 mL) and centrifuged at 
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1000 rpm for approximately 5 minutes. The supernatant was removed and cells were 
resuspended into Ham’s F-12 media (10 mL). The cells suspension were added to cell 
culture flask (75 mL, Corning) and grown at 37°C under a 5% CO2 environment with 
95% relative humidity in Hams F12 media containing 10% FSB, penicillin (9 units), and 
streptomycin (9 units). 
2.4.17 Long Term Cell Storage  
After growing cells to 90% confluency, cells (1 × 106 cells per mL) were collected 
by centrifugation at 1000 rpm for 5 minutes. Ham’s F-12 media (1 mL) with 10% v/v 
FBS, containing 10% v/v DMSO was used to suspended cell pellet. The cells were 
slowly cooled in a cryogenic vial (Corning) till the temperature reach -80 oC, followed by 
storing in a liquid nitrogen storage tank (Thermolyne). 
2.4.18 Collection of Cells for Experiment  
Trypsin triple express (5mL) was added to a flask containing HeLa cells at 90% 
confluency to cover the surface and was incubated at 37 °C for 5 minutes. Cells were 
removed and transferred to a centrifuge tube. After centrifugation at 1000 rpm for 5 
minutes, the supernatant was removed and cells were washed with phosphate buffered 
saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and 
centrifuged between washings at 1000 rpm for 5 minutes. The pellets was used or 
stored as needed. 
2.4.19 Bradford Assay  
Bradford assay was used to measure the total protein concentration in cell 
lysates. The procedure was followed according to Chamara Senevirathne’s thesis.122 
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2.4.20 HeLa cells lysis procedure 
HeLa cells (National Cell Culture Center, Biovest) (20 x 106) were lysed in lysis 
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, and 1X 
protease inhibitor cocktail (GenDepot); 1 mL) with rotation for an hour at 4°C. Cell 
debris was removed by centrifugation at 13,200 rpm for 10 minutes at 4 oC. The 
supernatant was collected and protein concentration was determined by Bradford 
assay. Protein content was brought to a working concentration (10 mg/mL) using lysis 
buffer before storage at -80 oC. 
2.4.21 Kinase-catalyzed biotinylation of Hela cell lysates  
APB (5 mM) or ATP-biotin (5 mM) was incubated with HeLa cell lysates (4 µg/µL) 
at 30°C for 2 hours. The final volume of the reaction was 20 µL. Heat-inactivated HeLa 
cell lysates were produced by heating at 95°C for 5 min before adding APB. NHS-biotin 
(0.5 mM) was incubated with cell lysates (4 µg/µL) as a positive biotinylation control 
reaction. As a control to cleave the phosphoramidate bond, TFA (50% final conc.) was 
added after reaction and incubated for 1 hour at 31°C with shaking at 800 rpm, followed 
by evaporation using speed vac, and neutralization by adding 1.5 M Tris base (pH=8.8, 
10 µL). The reaction mixtures were separated by SDS-PAGE (10%) and visualized by 
SYPRO® Ruby or transferred onto a polyvinylidene difluoride membrane (Immobilon-P, 
Milipore) and visualized with streptavidin-Cy5 (Life Technologies). Repetitive trials are 
shown in Figure 2.11 and A 2.20. 
2.4.22 Cell viability assay123 
Hela cells (100,000) were incubated in a 24 well plate and allowed to grow for 48 
h in F-12 growth media at 37°C in a 5% CO2 environment. APB (1, 5, 10, 15, 20, 30 
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mM) in growth media (200 uL) was added to cells and cells were incubated for an hour. 
The media was removed and cells were washed twice with DPBS (400uL), followed by 
trypsinization (section 2.4.18). Cells were collected by centrifugation at 4 oC at 1000 
rpm for 5 minutes, followed by washing twice with DPBS (100 uL). Cells were 
resuspended in an equal volume of cell suspension was mixed with trypan blue (0.4%) 
and counted using a hemocytometer. As a control, untreated cells were counted after 
subjecting them to the same washing conditions. Percentage viability was calculated by 
dividing the number of treated live cells by untreated ones. Kaleidagraph software 
(Synergy Software) was used to calculate EC50 of APB. The results are from three 
independent trials (Figure 2.12). 
2.4.23 Fluorescence microscopy assay. 
Hela cells (80,000) were grown on a cover slip in a 24 well plate overnight in F-
12 growth media (500 µL) at 37°C in a 5% CO2 environment until 80% confluency. The 
cells were then incubated in serum free media for 2 hours, followed by incubation with 
APB (5 mM) in serum free media (500 µL) for 1 hour. Cells were washed with DPBS 
(500µL) 3 times, followed by PBS (500 µL, 137mM NaCl, 27 KCl, 10 mM Na2HPO4, 2 
mM KH2PO4) three times. Cells were incubated with paraformaldehyde in water (4%, 
500 µL) for 20 minutes at room temperature, then washed with PBS (500 µL) three 
times. Triton-X100 (0.2 % in PBS) was added and incubated with cells for 5 minutes at 
room temperature, followed by washing with PBS (500 µL) 3 times each for 5 min.  
Blocking buffer (2% BSA, 2% normal goat serum, and 0.2 % gelatin in 1X PBS) was 
incubated with cells for 1 hour at room temperature.  Streptavidin-Cy5 (10 ug/mL) in 
blocking buffer (50 µL) was added and incubated with cells for 30 minutes.  Cells were 
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washed with 0.1% BSA in PBS (500µL) 3 times each for 5 minutes. Cells were 
incubated with DAPI (100 µg/mL) for 5 minutes, followed by washing with 1X PBS (500 
µL) 3 times each for 5 min. The cover slips were washed in water then installed on a 
glass slide containing Mowiol mounting solution (50 µL, Sigma Aldrich) saturated with 
DABCO (Sigma Aldrich). The slide was incubate at 31 oC for 30 minutes, and then kept 
at 4 oC until microscopy. Fluorescence photos were generated on an Olympus 
fluorescence microscope (BX 41) using laser wavelengths corresponding to DAPI (350 
nm) and Cy5 (650nm). DAPI photos were generated at 10 ms and Cy5 at 200 ms.   
Merged images were created using Adobe Photoshop.  Repetitive trials are shown in 
Figure 2.13 and A 2.21. 
2.4.24 Kinase-catalyzed biotinylation of live HeLa cells  
Hela cells (200,000 cells) were added to 12-well plates and allowed to grow for 
48 h in Ham’s F-12 growth media (F-12 media contains 10% FBS, penicillin (9 units), 
and streptomycin (9 units)) at 37°C in a 5% CO2 environment. The cells were then 
incubated with ATP-biotin (5 mM) or APB (5 mM) dissolved in F-12 growth media 
(400mL) for 1 hr under the same growth conditions as above. As a control, one well was 
preincubated with staurosporine (1 µM final concentration) in F-12 growth media for 1 
hour before adding media containing APB. The media was removed and cells were 
washed with DPBS (400 µL) two times, scraped, and collected by centrifugation at 1000 
rpm for 5 min at 0°C. Cell pellets were lysed in lysis buffer (31 µL) on ice for 30 minutes 
and then lysates were collected as in section VII. The lysate mixtures were separated by 
10 % SDS-PAGE and visualized by SYPRO® Ruby or transferred onto a polyvinylidene 
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difluoride membrane (Immobilon-P, Milipore) and visualized with streptavidin-Cy5 (Life 
Technologies). Repetitive trials are shown in Figure 2.14 and A 2.22. 
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CHAPTER 3 CHITOSAN-ASSISTED CELL PERMEABILIZATION OF ATP-BIOTIN 
FOR LIVE CELL KINASE-CATALYZED BIOTINYLATION 
3.1 Introduction 
In this chapter, a general method to permeabilize ATP analogs for kinase-
catalyzed labelling is discussed using an additive, which is an easier alternative method 
to the synthesis of a cell permeable ATP analog discussed in chapter 2. We chose ATP-
biotin as our model analog as ATP-biotin results in biotinylation of proteins, which can 
be easily analysed using various commercial streptavidin-conjugated reagents.92,99 We 
used deacetylated chitosan as an additive to permeabilize cells towards ATP-biotin. 
Deacetylated chitosan has an advantage of biocompatibility with cell media, which 
overcomes draw backs for previously reported ATP analogs permeabilizing additives. A 
summary of methods used to permeabilize cells towards ATP analogs using an external 
additives with comparison to our newly reported method, is also discussed in this 
chapter. 
3.1.1 Using additives to permeabilize cells toward ATP analogs 
ATP analogs have been used to study kinase-catalyzed phosphorylation. Due to 
the cell impermeability of ATP analogs, in cellulo application of ATP analogs must be 
coupled with the usage of cell permeabilizing agent. Several methods were used to 
permeabilize cells to access protein phosphorylation systems.100,124 Each method has 
its own advantages and limitations. In this chapter, we discuss these methods and 
compare it with our newly introduced procedure. 
One of the most frequently used permeabilizing agents is digitonin Figure 3.1). 
Digitonin has been used to permeabilize cells towards ATP analogs to identify kinase 
substrates in cellulo. Digitonin permeabilize cells by binding to cholesterol in cell 
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membrane forming tubular structure.100 Pores introduced by digitonin are big enough to 
allow large molecules such as polypeptides and ATP analogs to pass the cell 
membrane. The extent of permeabilization depends on the amount of cholesterol in the 
membrane.  Digitonin permeabilization can lead to damage of intracellular membranes, 
but this effect can attenuated by proper control of digitonin concentration and exposure 
time.100 Ionic strength and nature of growth should be considered with the application of 
digitonin in cell permeabilization. Many ions such as calcium can decrease the extent of 
cell permeabilization by resealing cell membrane. Also, glutamate in cell media 
increases phosphorylation rates when used with digitonin, affecting the physiological 
relevance of the experiment.100 Therefore, most experiments reported the usage of 
digitonin in phosphorylation buffer rather than in cell media,75,125 resulting in less 
physiologically relevant cell based experiment. 
 
 Figure 3. 1: Structue of digitonin  
Another cell permeabilizing additive used with ATP analogs is streptolysin-O 
protein.126 Streptolysin-O is a streptococcal hemolytic exotoxin that permeabilize cells 
by binding to cholesterol, similar to digitonin.100 Like digitonin, streptolysin-O can 
permeabilize cells to allow entry of large molecules, but the toxicity of the reagent 
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should be monitored. Cell permeabilization with streptolysin-O should be controlled as it 
can cause damaged to intracellular membranes.100 Unlike digitonin, streptolysin-O is 
unstable, which make it less favorable than digitonin. On the other hand, streptolysin-O 
can be used with cell growing media, without interference from media 
components.100,126 In addition to digitonin and streptolysin-O, more examples of cell 
permeabilizing agents are present, but less frequently applied to phosphorylation 
studies with ATP analogs such as alpha toxin and electroporation.100 
3.1.2 Deacetylated chitosan (DA) 
Recently, we reported the first cell permeable ATP analog, APB (Figure 2.4, 2), 
compatible with kinase-cosubstrate promiscuity (Chapter 1). APB can help in studying 
cellular phosphorylation. The cell permeability of APB is due to the replacement of PEG 
by a polyamine linker, which is positively charged under physiological conditions and 
neutralizes the negative charge of the triphosphates. This approach can be used in 
general to promote the cell permeability of -modified ATP analogs. Attaching a 
polyamine to ATP analogs requires synthesis of the analog, which may have its own 
synthetic challenge and may affect the activity of the ATP analog. In this chapter, we 
report the first usage of deacetylated chitosan (DC) (Figure 3.1) as a vehicle to deliver 
an ATP analog into cells for kinase-catalyzed biotinylation. DC allows us to perform all 
permeabilizing experiments in cell media, in contrast to other previously reported cell 
delivery methods.100 
Deacetylated chitosan (DC) is a polymer of deacetylated N-acetylglucosamine 
with a varying degree of deacetylation (Figure 3.1A). Due to the high proportion of free 
amines, DC was used recently in cell delivery of ATP and nucleotide drugs. DC deliver 
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ATP to cells through forming nanoparticles with the negatively charged nucleotides 
(Figure 3.1B).127 DC cell permeability depended on the ratio of positively charged 
nitrogens in DC to the negatively charged phosphates in ATP (N/P ratio). In addition, 
DC was used under normal cell growth conditions with media, reflecting more 
physiologically relevant experimental conditions. In this chapter, we introduce coupling 
DC cell permeabilization with in cellulo kinase-catalyzed labelling and phosphorylation 
studies. DC permeabilization offers a powerful alternative to synthesis of intrinsically 
permeable ATP analog or use of physiologically-compromised digitonin 
permeabilization. 
 
 
Figure 3. 2: A) Structure of deacetylated chitosan. B) Cell delivery of ATP or nucleotide 
drugs via deacetylated chitosan (DC) 
3.2 Results 
3.2.1 Cell permeability studies 
To test if DC can enhance the cell permeabilization of ATP-biotin, fluorescence 
microscopy was performed. ATP-biotin and DC were first preincubated to form the ATP-
biotin/DC complex. ATP-biotin/DC complex was incubated with HeLa cells in growth 
media under normal cell growth conditions (37 oC, 5% CO2, and humidity), followed by 
washing, fixing, permeabilizing, staining with streptavdin-Cy5 to detect biotin, and 
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followed by DAPI to detect nucleus. As controls, untreated cells or cells treated with 
ATP-biotin only or DC only were also considered. Indeed, only cells treated with ATP-
biotin/DC complex showed fluorescence signal (Figure 3.3 and A3.1). However, cells 
treated with ATP-biotin did not show fluorescence corresponding to biotin, which 
indicates the necessity of DC for cell permeabilization. Also, cells treated with DC only 
did not show any fluorescence, which rule out the possibility of auto-fluorescence from 
DC (Figure 3.3 and A3.1). These experiments indicated that DC promotes the cell 
permeability of ATP analogs.  
 
 
 
 
 
Figure 3.3: Fluorescence microscopy with DC. HeLa cells were incubated with ATP, 
ATP-biotin, DC, or the ATP-biotin/DC complex, followed by washing, fixing, and 
visualizing with Streptavidin Cy5 (Top) and DAPI (bottom). The images are 
representative of three independent trials. One trial is shown here and the rest of trials 
are in figure A3.1 
 
As a secondary method to confirm ATP-biotin cell delivery by DC, mass 
spectrometry analysis was used. HeLa cells were incubated with the ATP-biotin/DC 
complex, washed, and analyzed by MALDI-TOF (Mass assisted laser ionization-time of 
flight) MS. Only cells treated with ATP-biotin/DC complex showed a peak at m/z 934 
corresponding to ATP-biotin (Figure 3.4 and A3.2). Cells treated with ATP-biotin alone 
HeLa ATP ATP-biotin DC ATP-biotin/DC 
SA-
Cy5 
DAPI 
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did not show the presence of m/z 934 peak (Figure 3.4 and A3.2). The results confirm 
that DC promotes the cell permeability of ATP-biotin. 
 
Figure 3.4: MALDI in cellulo imaging of ATP-biotin. HeLa cells were incubated with 
ATP-biotin, DC, or the ATP-biotin/DC complex followed by washing and mixing with 
alpha picolinic acid in 50% acetonitrile. The mixture was spotted on Bruker MALDI plate 
for analysis. The data represents at least three independent trials. One trial is shown 
here and the rest of trials are in figure A3.2 
3.2.2 DC and cytotoxicity studies 
In preparation for cell labeling, we assessed the dose dependent cytotoxicity of 
increasing concentrations of ATP-biotin/DC in HeLa cells. Increasing concentrations of 
ATP-biotin/DC (while maintaining N/P ratio at 1:1) are incubated with HeLa cells. HeLa 
cells were washed, followed by resuspension in PBS buffer, and mixing with equal 
amount of trypan blue. Viable cells were counted and compared with the numbers 
obtained from untreated cells. The ATP-biotin/DC complex showed an EC50 of 7.38±0.5 
mg of DC (Figure 3.5). Importantly, HeLa cells exhibited cell viability of more than 80% 
for ATP-biotin/DC complex concentration (2mM/1.88 mg/mL) used in the cell imaging 
fluorescence assay. Cytotoxicity studies indicated that DC is not cytotoxic at cell 
permeability condition experiments. 
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ATP-biotin (mM) DC concentration (mg/mL) % viable cells 
1 0.9 95 ± 7.2 
2 1.88 85 ± 8.2 
4 3.75 79 ± 4.7 
8 7.5 52 ± 3.7 
10 9.4 37 ± 0.8 
 
Figure 3.5: A) Dose dependent cell viability of ATP-biotin/DC complex. B) DC 
concentrations used to draw the curve.  
3.2.3 Live cells kinase-catalyzed biotinylation 
Having confirmed the cell permeability and low toxicity of DC, kinase-catalyzed 
biotinylation in live cells was tested. HeLa cells in growth media under normal growth 
conditions were incubated with ATP-biotin/DC complex (4mM/3.75 mg/mL), followed by 
washing, harvesting, lysis, and separation of proteins by SDS-PAGE. Biotinylation was 
observed in cells treated with the ATP-biotin/DC complex, which is consistent with cell 
permeability (Figure 3.6A and A3.3A, lane 6). As a control, HeLa cells pretreated with 
the kinase inhibitor, staurosporine, showed reduced biotinylation (Figure 3.6A and 
B) 
A) 
(mg/mL) 
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A3.3A, lane 5), which confirms that biotinylation is kinase dependent. ATP-biotin alone 
did not show labeling (Figure 3.6A and A3.3A, lane 3), which indicates that DC is 
required for cell permeability. These live-cell labeling experiments show that DC-
permeabilization is compatible with live cells labeling at high efficiency.  
 
Figure 3.6: A) In cellulo kinase-catalyzed biotinylation of HeLa cells with ATP-biotin or 
ATP-biotin/DC complex. As a control, HeLa cells were preincubated with kinase inhibitor 
staurosporine (STSP) to prevent kinase catalysis (lane 5). B) In vitro kinase-catalyzed 
biotinylation of HeLa cell lysates with ATP-biotin. As a negative control, ATP-biotin was 
incubated with heat-denatured HeLa cell lysates (HDL). SDS-PAGE gel analysis was 
used to separate reaction mixtures and gels were visualized with streptavidin-Cy5 (SA-
Cy5, top gel) or SYPRO® Ruby total protein stain (bottom gels). The protein ladder 
contains proteins of the following sizes: 170, 130, 100, 72, 55, 43, 34, and 26 kDa. All 
images are representative of at least three independent trials. One trial is shown here 
and the two trials are shown in figure A3.3. 
                              A)                                                 B)                                         
1 2 3 4 5 6 7 8 9 10
Protein Ladder + +
Hela cells + + + + +
Lysates + +
HD Lysates +
ATP-biotin + + + + +
DC + + +
STSP +
Streptavdin
Cy5
Sypro Ruby
 
      
81 
 
 
We analyzed the quality of biotinylation of the in cellulo DC-assisted kinase-
catalyzed biotinylation (Figure 3.4A and A3.3A) to in vitro labeling (Figure 3.4B and 
A3.3B). The extent of biotinylation was different in lysates as comparative to live cells 
(Figure 3.4A and A3.3A, lane 6 versus Figure 3.4B and A3.3B, lane 10). The reactions 
with lysates showed different bands of protein biotinylation than in cellulo labeling 
(Figure 3.4B and A3.3B, lane 10). This difference may be due to compartmentalization 
in cells. Therefore, this difference suggests that in cellulo ATP-biotin labeling is a better 
reflection of phosphoproteomes than lysates.  
3.3  Conclusion and future directions 
In conclusion, DC can permeabilize ATP analog through neutralizing of negative 
charges on the triphosphates. DC was compatible with cell growth conditions and 
maintained low cytotoxicity. ATP-biotin/DC showed fluorescence in cells corresponding 
to biotin when used with live cells. The florescence indicates that DC permeablized cells 
towards ATP-biotin. Our results were confirmed by MALDI mass that detected ATP-
biotin in cells in presence of DC only. Importantly, using ATP-biotin/DC complex 
revealed biotinylation of protein substrates, which was detected by SDS-PAGE analysis. 
Unlike digitonin, DC can be used with cell growth media. Moreover, digitonin suffers 
from resealing of permeabilized cells when used with ATP analogs, in contrast to DC. 
Also, we compared between digitonin and DC permeabilization. Digitonin 
permeabilization was performed by my colleague Maheeka Embogama. The 
comparison experiments revealed that DC is a more efficient permeabilizing agent, 
which gave a better quality gels and fluorescence microscopy images.  Therefore, we 
recommend to use DC in future with ATP analogs to study kinases. 
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In addition to previously discussed advantages of DC, In cellulo kinase-catalyzed 
biotinylation using ATP-biotin/DC showed different biotinylated proteins than in vitro 
biotinylation, which may reflect compartmentalization inside cells. DC cell 
permeabilzation of ATP-biotin can be used to reveal a more physiologically relevant 
kinase enzyme signaling pathways. A paper describing this work is in final stage of 
writing. Indeed, ATP-biotin/DC provides an alternative method to the cell permeable 
ATP analogs (APB) discussed in chapter 1. DC provides an easier and cheaper method 
for in cellulo kinase-catalyzed studies using ATP analogs because there is no need to 
synthesize a new analog with DC. Also, DC is more feasible when synthesis of cell 
permeable ATP analog is not accessible. However, cell permeable ATP analog (APB) 
discussed in chapter 1 is less cytotoxic than DC. Therefore, the usage of either APB or 
ATP-biotin/DC should be selected depending on pros and cons of each method. 
In future, we are going to couple in cellulo kinase-catalyzed biotinylation with 
streptavidin columns to purify dynamically phosphorylated proteins. After purification, 
we will use Ms/Ms proteomic analysis to identify the purified proteins. Interestingly, DC 
can be used with other ATP analogs, such as ATP crosslinking analogs (discussed in 
chapter 4), to identify kinase-substrate pairs. The later method will provide a more 
physiologically data because kinase-substrate pairs identified from this method will 
reflect the compartmentalization inside the cells. 
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3.4 Experimental 
3.4.1 Materials 
 
ATP-biotin was synthesized as previously reported.80,128 Low molecular weight 
deacetylated chitosan (75-85% deacetylation), digitonin, 1,4-Diazabicyclo(2.2.2)octane 
(DABCO), and Mowiol® 4-88 were purchased from Sigma Aldrich. ATP was bought 
from MP Biomedicals.  1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDCI) and N,N,N',N'-Tetramethylethylenediamine for electrophoresis were purchased 
from Acros. Silica, DEAE sephadex A-25, and ammonium persulfate (APS) for 
electrophoresis were bought from Fisher Scientific. Dichloromethane (DCM), acetic 
acid, and hydrochloric acid were bought from EMD. 40% Bis-acrylamide (37.5:1) for gel 
electrophoresis was purchases from Biorad. F-12 media were bought from Invitrogen. 
Antibiotic and Dulbecco's Phosphate Buffered Saline (DPBS) for cell culture were 
purchased from HyClone. DAPI was purchased from Life-Technology. 
3.4.2 Instruments 
A Lyophilizer (VirTis BT 3.3 EL Benchtop) and Speed-vac (ThermoSAVANT, 
SPD131 DDA) were used during synthesis of ATP-biotin. The SDS-PAGE instrument 
were purchased from BioRad (Protean III). Mini-Transblot Electrophoretic Transfer Cell 
apparatus from BioRad was used in Protein transfer. Typhoon 9210 scanner 
(Amersham Biosciences) was used to visualize SDS gels and PVDF membranes. 
Olympus immunofluorescence microscope (Model BX 41) was used to visualize 
fluorescence images.  ATP-biotin mass was detected using MTP Plate (Bruker) and 
MALDI-TOF (Bruker ultraflex). 
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3.4.3 Synthesis of ATP-biotin 
ATP-biotin was synthesized as previously reported, as discussed in chapter 2 
(Section 2.11.5).80 
3.4.4 Preparation of 10 mg/mL deacetylated chitosan 
Deacetylated chitosan (75%, 500 mg) was triturated with 1.75% acetic acid in 
water (50 mL) till a homogenous. The mixture was stirred overnight at room 
temperature to produce homogenous solution. 
3.4.5 Preparation of ATP-biotin/chitosan mixture 
ATP-biotin (32 mM in water, 50 µL) was added portion wise to the deacetylated 
chitosan solution (10 mg/mL, 150 µL) with vortexing. The mixture was diluted with 
either water (4 µL) or staurosporine in water (4µL, 1 uM final) and volume was adjusted 
to 400 µL using media containing 10% FBS, penicillin (9 units), and streptomycin (9 
units) to yield ATP-biotin at a final concentration of 4mM and DC at a final 
concentration of 3.75 mg/mL. The concentrations was adjusted when using higher or 
lower concentrations of ATP-biotin. 
3.4.6 Fluorescence microscopy assay.1 
HeLa cells (160,000 cells) were grown on a cover slip in a 12 well plate 
overnight in F-12 media (500 µL) containing 10% FBS, penicillin (9 units), and 
streptomycin (9 units) at 37°C in a 5% CO2 environment. Cells were incubated in 
serum free media for 1 hour at 37°C in a 5% CO2 environment. Media was removed 
and cells were incubated with a mixture of ATP-biotin (2 mM)/ DC (1.9 mg/mL) complex 
(section 3.4.5) in media at 37C in a 5% CO2 environment for 2 hour. Cells were 
washed with DPBS (500µL) 3 times, followed by washing with PBS (500 µL) 3 times. 
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Paraformaldehyde (4% in water, 500 µL) was added and incubated for 20 minutes at 
room temperature to fix cells, followed  by washing with PBS (500 µL) three times. 
Cells were incubated with TritonX 100 (0.2 % in PBS, 500 µL) for 5 minutes at room 
temperature, followed by washing with PBS (500 µL) 3 times each for 5 min. Cells were 
incubated with blocking buffer (2% BSA, 2% normal goat serum, and 0.2 % gelatin in 
PBS) for 1 hour at room temperature, followed by incubation of cells with streptavidin-
Cy5 (10 µg/mL) in blocking buffer (50 µL) for 30 minutes.  Cells were washed with BSA 
(0.1% in 1X PBS, 500µL) 3 times, each for 5 minutes. DAPI (100 µg/mL in blocking 
buffer, 50 µL) was added to cells for 5 minutes, followed by washing with PBS (500 µL) 
3 times each for 5 min. Cover slips were immersed in water then fixed on a glass slide 
containing a Mowiol solution (6 µL) saturated with DABCO. The slide was incubate at 
31oC for 30 minutes, then kept at 4 oC. An Olympus fluorescence microscope was 
used to generate fluorescence photos using laser wavelengths corresponding to DAPI 
(Excitation/emission maximum 358/461 nm) and Cy5 (Excitation/emission maximum 
678/694 nm). DAPI photos were generated at 10 ms and Cy5 at 500 ms. Repeatitive 
trials are shown in Figure 3.3 and A3.1 
3.4.7 MALDI in cellulo imaging of ATP-biotin 
HeLa cells (20,000 cells) were suspended in F-12 growth media (50 L), then 
added to a 96 well plate. An equal volume (50 L) of ATP-biotin (4 mM), DC (3.75 
mg/mL) or ATP-biotin (4 mM)/DC (3.75 mg/mL) mixture was added to give a final 
concentration of 4 mM of ATP-biotin and 3.75 mg/mL of DC. Cells were incubated for 2 
hours at 37°C in a 5% CO2 environment. As a control, one well without ATP analog or 
DC was used as a reference. All reaction volumes were 100 L. Cells were collected 
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by centrifugation at 1000 rpm for 5 min at 4 oC, then washed twice with DPBS (100 L). 
Cell pellets were resuspended in water (20 L). The cell suspension (1L) was mixed 
with saturated solution of α-picolinic acid in 50% acetonitrile (1 L), and then applied to 
a MALDI plate (Bruker) for MS analysis using MALDI-TOF spectrometer (Bruker). MS 
spectrum was analyzed for the presence of ATP-biotin at m/z 934. Repetitive trials are 
shown in Figure 3.4 and A3.2. 
3.4.8 Cell viability assay for DC 
HeLa cells (100,000 cells) were grown in a 12 well plate for 48 h in F-12 media 
containing 10% FBS, penicillin (9 units), and streptomycin (9 units) at 37°C in a 5% 
CO2 environment. Increasing concentrations of ATP-biotin (1, 2, 4, 8, 10 mM)/DC (0.9. 
1.88, 3.75, 7.5, and 9.4 mg/mL) complex respectively, were mixed as in section III-3 
and the mixture was added to cells. Cells were incubated for 2 hours and then the 
media were removed. Cells were washed twice with DPBS (400 µL), followed by gentle 
scraping. Cells were collected by centrifugation at 4 oC, 1000 rpm for 5 minutes, 
followed by resuspension in DPBS (100 µL). Equal volume of cell suspension was 
mixed with trypan blue (0.4%) and cells were counted using Hemocytometer. As a 
control, untreated cells were grown and counted as described. Percentage cell viability 
was calculated by dividing the number of treated live cells by untreated ones and 
multiplying by 100. Kaleidagraph software (Synergy Software) was used to calculate 
EC50 of ATP-biotin/DC.  The results are from three independent trials (Figure A 3.1). 
3.4.9 Visualization of biotinylation 
Refer to Chapter 2 (section 2.4.10) 
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3.4.10 Sypro Ruby gel staining 
Refer to Chapter 2 (section 2.4.11) 
3.4.11 Starting a new cell culture 
Refer to Chapter 2 (section 2.4.16) 
3.4.12 DC-assisted kinase-catalyzed biotinylation of HeLa cells  
HeLa cells (200,000 cells) were grown in 12-well plates for 48 h in F-12 growth 
media at 37°C in a 5% CO2 environment. The cells were then incubated with ATP-
biotin (4 mM) alone or ATP-biotin (4 mM)/DC (3.75 mg/mL) complex in F-12 growth 
media for 2 hours under the same cell growing conditions. As a control, cells were 
preincubated with staurosporine (1 µM) in F-12 growth media at 37°C in a 5% CO2 
environment for 1 hour before adding the ATP-biotin/DC mixture in media containing 
staurosporine (1 µM). The media was removed and cells were washed with DPBS (400 
µL) two times, harvested by scraping, and collected by centrifugation at 1000 rpm for 5 
min at 0°C. Lysis buffer (21 µL, 50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Triton X-100, 
10% glycerol, and 1X protease inhibitor cocktail (GenDepot)) was added to cell pellets 
on ice for 30 minutes with rocking and then lysates were collected by removing cell 
debris through centrifugation at 13,200 rpm for 10 minutes at 4 oC. SDS-PAGE gel 
analysis (10%) was used to separate cell lysates and total proteins were visualized by 
SYPRO® Ruby. Biotinylation was detected with streptavidin-Cy5 (Life Technologies) 
(dilution 1:2000), after transferring the lysate mixture onto a polyvinylidene difluoride 
membrane (Immobilon-P, Milipore). Repetitive trials are shown in Figure 3.5A and 
A3.3A. 
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3.4.13 Kinase-catalyzed biotinylation of HeLa cell lysates.1 
HeLa cells (200,000 cells) were grown in 12-well plates for 48 h in F-12 media 
containing 10% FBS, penicillin (9 units), and streptomycin (9 units) at 37°C in a 5% 
CO2 environment. Cell were collected and lysates were prepared as in section 3.4.12 
and section 2.4.20. Lysates were incubated with ATP-biotin (4 mM) for 2 hours at 
37°C. As a control, ATP-biotin (4mM) was incubated with heat denatured cell lysates 
(heated at 95 oC for 1 min). SDS-PAGE (10%) analysis was used to separate reaction 
mixtures and total proteins were visualized by SYPRO® Ruby. Biotinylation was 
detected with streptavidin-Cy5 (Life Technologies), after transferring lysate mixture 
onto a polyvinylidene difluoride membrane (Immobilon-P, Milipore). Repetitive trials are 
shown in Figure 3.5A and A3.3A. 
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CHAPTER 4 DEVELOPMENT OF AN AFFINITY BASED ATP ANALOG FOR 
KINASE-CATALYZED CROSSLINKING 
4.1 Introduction 
Many cell signaling pathways are regulated through kinase-catalyzed 
phosphorylation biochemical reactions. Through phosphorylation, transcription of 
specific genes can be turned on followed by a specific response. Identifying kinase-
substrate pairs can reveal the details of signaling pathways that control cell function. In 
this chapter, different methods of kinase substrate identification are discussed. Also, 
we introduce the first affinity-based crosslinking ATP cosubstrates to identify substrates 
for cysteine-containing kinases. Akt1 was used as an example for those cysteine-
containing kinases. In addition, a brief discussion of various types of affinity-based 
crosslinking groups are discussed. 
4.1.1 Introduction to affinity based crosslinkers 
Cell signaling events are regulated through many biochemical reaction, such as 
phosphorylation, acetylation, methylation, etc.2 The biochemical reactions can govern 
protein-protein interactions, conformational changes, enzymatic function, etc. Many 
methods have been used to purify protein bound to enzymes to identify the substrates 
of the biochemical reactions, such as co-immunoprecipitation, bimolecular 
fluorescence complementation (BiFC), mass spectrometry, and tandem affinity 
purification.129 An alternative method to identify protein-protein interactions is the use of 
affinity-based crosslinkers (ABCL).129 In ABCL, a bifunctional cosubstrate or reagent 
bearing two reactive chemical group is introduced to cells or lysates. Physically 
interacting proteins react with the bifunctional reagent resulting in crosslinking of the 
interacting protein (Figure 4.1). The crosslinked protein complexes have a higher 
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molecular weight equal to the sum of the molecular weight of individual proteins. The 
crosslinked complex can be detected by SDS-PAGE gel analysis and western blotting 
with a corresponding antibody.130 
 
Figure 4. 1: Diagram deciphering affinity based crosslinking of two interacting proteins. 
RG is a reactive group. 
Many reactive chemical groups have been used to crosslink enzymes to their 
interacting substrates via a covalent bond (Table 4.1). The reactive groups can 
crosslink with specific amino acids in close proximity on the interacting proteins. An 
ideal crosslinker should be water soluble and should form stable covalent bond. A 
summary of the most important affinity based crosslinkers with their possible reacting 
amino acids is shown in table 4.1. 
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Table 4.1: Types of affinity based crosslinkers130 
Crosslinker 
reactive group 
Structure of 
crosslinker 
Functional group 
target on amino 
acid 
Reference 
NHS ester 
 
 
Amine 
(Primary or 
secondary) 
130 
Imidoester 
 
 
130 
Pentafluorophenyl 
esters (PFP) 
 
131 
Dichlorotriazine 
 
132 
Maleimide 
 
 
Sulfhydryl 
(Cysteine) 
130 
Acrylamides 
 
 
133 
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4.1.2 Photo affinity crosslinkers 
Another type of crosslinking reaction to identify interacting proteins is photo 
affinity labeling (PAL).130,136 In PAL, a photo-crosslinker, such as phenyl azide, 
benzophenone, or diazirine137-147 is installed on one protein. The modified protein can 
be used with lysates to crosslink with interacting proteins in presence of light (Figure 
4.2). A photo-crosslinker should possess four main criteria for successful PAL.147 First, 
it should be inert to absence of light. Second, the photo-crosslinker should be mildly 
activated without destructing the targeted biological system. Third, the life time of 
interacting proteins should be longer than the life time of activated photo-crosslinker. 
Lastly, the activated photo-crosslinker should be able to form stable covalent bond with 
proximal interacting proteins. A brief review of selected photo-crosslinkers is presented 
in next sections. 
 
Figure 4.2: Diagram deciphering protein-protein photo affinity crosslinking 
4.1.2.1 Aryl Azide 
Phenyl azides are well known photo-crosslinkers and are more stable than alkyl 
azides. Phenyl (aryl) azides can be excited using UV light to form a reactive nitrene 
(Figure 4.3).148,149 The nitrene intermediate inserts into different bonds, such as C-H, 
O-H, N-H, and S-H bonds of adjacent protein. Also, the nitrene can insert into the 
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phenyl ring to govern a ring expansion to form ketenimine. Ketemine can react with 
nearby nucleophiles on protein (Figure 4.3).150 The phenyl azide has an advantage of 
its broad reactivity with many functional groups. However, the high reactivity can lead 
to nonspecificity. 
 
Figure 4. 3: Reactivity of phenyl azides upon photolysis 
4.1.2.2 Diazirines 
Similar to aryl azides, diazirines form highly reactive carbene intermediates 
upon photolysis at λ 350 nm (Figure 4.4). The carbene can insert into different bonds, 
such as C-H, O-H, N-H, and S-H bonds of adjacent proteins.151,152 The formed carbene 
has the advantage of smaller size compared with the nitrene formed from aryl azides. 
The smaller size of carbene is more compatible with biomolecules. Unfortunately, 
carbenes suffer from the same nonspecific crosslinking as nitrenes. 
 
Figure 4. 4: Reactivity of diazirene upon photolysis 
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4.1.2.3 Benzophenones 
Benzophenones differ from azides and diazirenes by forming a diradical species 
upon photolysis at λ 350-360 nm (Figure 4.5). The diradical species can insert into 
different functional groups, as in case of azides or diazirenes. Unlike azides and 
diazirenes, benzophenones can relax to its original state if not inserted into another 
functional group (Figure 4.5).153 Benzophenones have many disadvantages, such as 
its bulky size, its preference to methionine,154 and requirement of long irradiation time 
155 when compared to azides and diazirenes. 
 
Figure 4. 5: Reactivity of benzophenone upon photolysis 
The Pflum lab has used modified ATP analogs with photo-crosslinkers on the -
phosphate for kinase-catalyzed substrate identification. A summary of kinase- 
substrate pairs identification methods are discussed later together with Pflum lab 
method. Also, the synthesis and applications of novel affinity based ATP analog 
crosslinkers are introduced later in this chapter. 
4.1.3 Current methods for identification of kinase-substrate pairs 
With increasing research reporting the involvement of kinases in several 
diseases, development of novel methods to identify kinase-substrate pairs is important 
to decipher molecular details of cell signaling. Depending on the crystal structures and 
the mechanisms of many kinases, many research groups have introduced various 
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techniques to identify kinase-substrate pairs. The techniques include in vitro 
phosphorylation, pull down assays, yeast two-hybrid systems, and chemical 
approaches, such as mechanism based crosslinkers and bifunctional 
photocrosslinkers. However, it is still challenging to determine kinase activities and its 
effectors in cell signaling pathways. Therefore, development of novel methods to 
identify kinase-substrate pairs in a kinase-catalyzed phosphorylation manner will allow 
a better deciphering of cell signaling events. In the next section, several existing 
kinase-substrate identification methods are discussed. Kinase-substrate identification 
methods fall in four main categories: in vitro phosphorylation, physical association, 
genetic approach, and chemical approach. 
4.1.3.1 In vitro phosphorylation 
4.1.3.1.1 (-32P) ATP 
In vitro phosphorylation is the most commonly used method to confirm kinase-
substrates. In early studies, radiolabeled (-32P) ATP was incubated with a particular 
kinase and substrate or cell lysates. The reaction mixture was then analyzed by SDS-
PAGE gel analysis.156 Later on, this technique was coupled to mass spectrometry to 
detect both kinase-substrates and phosphosites by quantifying the difference between 
(-32P) ATP treated and untreated lysates.  
4.1.3.1.2 As-kinase and kinase-substrate identification 
Shokat and his coworkers introduced the analog sensitive kinase (as-kinase) 
technique in late nineties to discover novel kinase substrates.60 In the as-kinase 
technique, a particular kinase was mutated in the ATP binding pocket at an certain 
amino acid called gate keeper to accommodate a bulkier N6-modified ATP to 
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phosphorylate protein substrates (Figure 4.6).157 The gate keeper mutation should 
follow certain criteria. First, the mutation at the ATP binding pocket should allow the 
kinase to accept the bulky ATP analog. Second, the mutation should not affect the 
activity of kinases. Lastly, it should preserve protein substrate specificity for the 
mutated kinase. Also, the bulky ATP analog should act as a cosubstrate to mutated 
kinase only, not the wild type.157 
 
Figure 4. 6: Schematic diagram of phosphorylation using as-kinases. N6-modified 
(32P) ATP analog was incubated with as-kinase and cell lysates. The as-kinase 
accepts the N6-modified (32P) ATP analog and phosphorylate its substrates, while 
wild (WT) kinases will not accept the N6-(32P) ATP analog and only accept normal 
ATP. Radiolabeled proteins can be separated by SDS-PAGE analysis and they 
constitutes the substrates for the as-kinase only.60 
 
In the as-kinase technique, the mutated kinase was incubated with cell lystates 
and (-32P) N-6-modified-ATP. The modified ATP was accepted by the as-kinase and 
phosphorylation of its substrates was detected by autoradiography (Figure 4.6). In case 
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of tyrosine kinases, non-radioactive N-6-modified-ATP were used and the 
phosphorylation was detected by phosphotyrosine antibody.158 Also, N-6-modified-ATP 
-S was used to identify kinase-substrates. The -S group can facilitate purification of 
phosphorylated substrates using iodoacetyl resin resulting in easier less tedious 
method (Figure 4.7).67,68 The as-kinase technique was used to identify substrates for 
several kinases such as v-Src, cSrc, ERK2, Cdk1-cyclinB, Cdk7, etc.159-164 
 
Figure 4.7: Schematic diagram of phosphorylation using as-kinases and N6-
modified ATP -S. N6-modified ATP -S was incubated with the as-kinase and cell 
lysate. The as-kinase accepts the ATP analog and thiophosphorylates its substrates, 
while wild (WT) kinases will accept only normal ATP. Thiophosphorylated substrates 
can be purified by thio-capture reagent such as iodoacetyl resins and they represent 
as-kinase substrates only without interference from other kinases. 
 
4.1.3.1.3 Yeast two hydrid (Y2H) 
Y2H is a technique used mainly to detect protein-protein interaction.165 A protein 
containing the active site of a kinase is fused to the DNA-binding domain of a 
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transcription factor, such as bacteria LexA is constructed. On the other hand, a group 
of substrates to an activation domain are assembled. Upon co-expression of the two 
fusion proteins, the binding of the kinase to its substrate activates the DNA-binding 
domain, which lead to formation of a signal, such as production of galactosidase or 
change in color (Figure 4.8). Y2H technique can be used with cells in the native 
conformation of kinase-substrate interaction. Many substrates were identified for 
several proteins using Y2H such as PKC.166-168 Y2H suffers from few disadvantages 
such as over expression of proteins and abnormal protein activities, which limits its 
usage in kinase substrate pair identification. 
 
Figure 4.8: Schematic diagram of yeast two hybrid assay. DNA binding domain of 
a transcription factor is fused to the catalytic subunit of certain kinase. On the other 
hand, an engineered activation domain is fused to kinase-substrate. Upon binding of 
the kinase to its substrate, the two domains interacts with each other and expression is 
turned on resulting in a signal, which can be change in color or production of 
galactosidase, etc.165 
 
4.1.3.1.4 Chemical genetic crosslinking of kinase-substrate pairs. 
Since kinase-substrate interaction is transient, a chemical method involved a 
kinase-substrate crosslinking via a covalent bond have been used. The crosslinking of 
kinase to its substrate lead to higher molecular weight complex that can be detected by 
SDS-PAGE, western blotting, or mass spectrometry (Section 4.1.1). A summary of 
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several chemical genetic kinase-substrate crosslinking approaches is discussed in the 
following section. 
4.1.3.1.4.1 Mechanism based crosslinking approach 
Shokat and his coworkers have reported a mechanism based approach to 
crosslink of kinases to their substrates.169 They used adenosine attached to o-
phthaldialdehyde through 5’-hydroxyl group (Figure 4.9A). Upon binding of the 
adenosine moiety to the ATP binding site of kinase, the nearby lysine residue in the 
active site reacts with the aldehyde group of o-phthaldialdehyde resuling into imine 
group (Figure 4.9A). Cysteine containing kinase-substrates reacts with the imine group 
via free sulfhydryl group (Figure 4.9B).169 Many biotinylated peptide substrates and 
their kinases were used to demonstrate this approach. Due to high reactivity of 
aldehyde groups, this approach suffers from non-specificity when used with lysates.  
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Figure 4.9: Schematic diagram of mechanism based crosslinking. Reaction of 
lysine side chain of kinase with o-phthaldialdehyde and sulfhydryl group on substrate 
results in crosslinking of the kinase to its substrate.169 
 
Second and third generation mechanism-based crosslinkers were developed to 
reduce the non-specificity associated with the approach (Figure 4.10). In the second 
generation, the o-phthaldialdehyde group was replaced with a naphthalene-2,3-
dialdehyde (NAD) (Figure 4.10A). The second generation of mechanism based 
crosslinkers were used in presence and absence of lysates with many kinases and 
fluorophore labeled peptide.170 In third generation of mechanism based crosslinkers, 3-
aminopyrazole, potent kinase inhibitor moiety, replaced the adenosine moiety (Figure 
4.10B). Also, the o-phthaldialdehyde was replace by thiophene-2,3-dialdehyde (Figure 
4.10C). The third generation crosslinker was able to crosslink Akt1 to fluorophore 
labeled peptide in lystates with lower non-specificity.171 
Figure 4.10: Structure of the A) second and B) and C) third generation of mechanism- 
based crosslinkers 
A fourth generation of mechanism based crosslinkers were introduced by 
Shokat and his coworker.133 An ATP analog with acrylic group attached directly to -
phosphate was created (Figure 4.11A). This compound binds to kinase through 
adenosine moiety, followed by the attack of lysine residue of the kinase onto acyl group 
on -phosphate of ATP (Figure 4.11A).  The cysteine containing substrate reacts with 
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the -carbon of the acrylic group via Michael reaction, resulting in crosslinking of kinase 
to substrate (Figure 4.11B).133 The fourth generation of crosslinkers are more specific 
than former generations when used with lysates. The mechanism-based crosslinking 
requires a substrate with amino acid mutated to cysteine.133 However, the fourth 
generation has not yet further adopted for kinase-substrate pair identification. 
 
Figure 4.11: Schematic diagram of the mechanism based crosslinking with fourth 
generation crosslinkers. Reaction of lysine side chain of kinase with acyl group, 
followed by Michael reaction of sulfhydryl group on substrate resulting in crosslinking of 
the kinase to its substrate.133 
4.1.3.1.4.2 Bifunctional crosslinker ATP analog 
An ATP analog with azide photocrosslinkers on both the adenine moiety and 
gamma phosphate was introduced (Figure 4.12).112 Upon photoactivation, the azide on 
the adenine ring can crosslink with the kinase, while the azide on the gamma 
phosphate can crosslink with substrate (Figure 4.12).112 This bifunctional crosslinker 
was used to crosslink Src kinase to Csk substrate. However, no further application has 
been reported beyond Src and Csk examples. 
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Figure 4.12: Schematic diagram of kinase-substrate crosslinking using bifunctional 
photo-crosslinking ATP analog112 
4.1.3.1.4.3 Phosphorylation dependent kinase-catalyzed crosslinking 
The kinase cosubstrate promiscuity introduced by Pflum lab (chapter 1) was 
developed into a kinase-substrate crosslinking tool. ATP analogs with -
photocrosslinkers were utilized as a phosphorylation-dependent crosslinkers of protein 
kinases with their substrates in presence of UV light.83,97 Examples of the 
photocrosslinking ATP analogs are ATP-ArN3 and ATP-BP (Figure 4.13).83,97 
Incubation of the photocrosslinking ATP analog with protein substrate and kinase leads 
to phosphorylation of their substrates. Simultaneously, UV radiation activates the 
photocrosslinking group to crosslink with the kinase (Figure 4.13). SDS-PAGE or 
western-blotting analysis of the reaction mixture shows the presence of a higher 
molecular weight band corresponding to the kinase-substrate crosslinked complex. 
Photocrosslinking of kinases to their substrates can provide a tool to discover either 
new kinases or kinase-substrate pairs in their native environment without any 
modification.  
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Figure 4.13: A) Schematic diagram of phosphorylation-dependent kinase-substrate 
crosslinking. B) Structure of the photocrosslinking ATP analogs developed by the Pflum 
lab. ATP-Ar-N3 (ATP-aryl-azide) and ATP-BP (ATP-benzophenone).83,97 
One limitation for phosphorylation-dependent photo-crosslinking method is that 
the photo-crosslinking exhibits non-specificity due to the conversion of the photo-
crosslinker to very reactive species (as discussed in section 4.2), which can crosslink 
with many proteins in the reaction medium. Therefore, developing phosphorylation-
dependent affinity based crosslinking ATP analog that can crosslink specifically to only 
amino acids in close proximity will be a valuable addition.  
4.2 Development of phosphorylation-dependent affinity based crosslinking ATP 
analog 
With over 500 protein kinases, developing a more specific tool to study certain 
kinases would provide a valuable contribution to study cell signaling. Genome 
sequencing reveled that about 200 kinases have cysteine residues within or near the 
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ATP binding pocket, which can be classified into 5 groups (Figure 4.14).172 Group one 
involves kinases with cysteines in the glycine rich loop or P-loop, such as Src. Group 
two contain kinases with cysteines located on the roof of the ATP-binding pocket, such 
as PLK1. Group 3 includes kinases with cysteines located in the hinge region and front 
pocket such as EGFR. Group 4 comprises kinases with cysteines adjacent to DFG-
motif, such as ERK1. Lastly, group 5 contains kinases with cysteine residues 
positioned in the activation loop, such as AKT1.172  
Considering that some kinases contain cysteines, we developed ATP-analogs 
that can specifically crosslink cysteine-containing kinases to their substrates to identify 
kinase-substrate pairs. Here, we created an ATP analogs with an acrylamide 
crosslinking group (ATP-acrylamides) (Figure 4.15) that can act as kinase cosubstrate. 
ATP-acrylamides can phosphorylate kinase substrates and react simultaneously with 
the cysteine residues in close proximity, resulting in crosslinking of kinase enzyme to 
its substrate (Figure 4.15). ATP-acrylamides were then used to crosslink Akt1 kinase to 
its substrates in HEK293 lysates. Crosslinked complexes were analyzed by SDS-
PAGE and western blotting, followed by tandem MS/MS proteomic analysis. Several 
known Akt1 substrates and physical interactors are identified. Interestingly, other 
proteins may comprise candidate Akt1 substrates. 
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Figure 4.14: Classification of human protein kinases family.12  Protein kinases fall into 
8 classes (CMGC, GYC, TK, TKL, STE, CL1, AGC, CAMK). Each class contains 
kinases with cysteine residues within or near kinase active site. Kinase containing 
cysteines fall into five classes and each class is assigned with different colour. Group 
1B (green), Group 2B (blue), Group 3F (black), Group 4 (red), and Group 5 (orange). 
Some kinases have cysteines from both group 2B and 4, which are assigned in 
purple.172 
 
106 
 
 
4.2.1 Results 
Here, we synthesized two analogs with different linkers between ATP and the 
acrylamide group; ATP-HEX-Acr 11 and ATP-PEG-Acr 12. These two compounds 
have an acrylamide, which can react with cysteine-containing kinases (Figure 4.15). 
The two linkers were chosen to examine the adequate length needed to position the 
acrylamide group near the cysteine residues of the kinase. ATP-HEX-Acr 11 has 8 
atoms linker to crosslink nearby cysteines, while ATP-PEG-Acr 12 has 15 atoms linker 
to crosslink far cysteines and provides flexibility for the molecule to bind to ATP binding 
site and simultaneously crosslink to cysteines. 
 
Figure 4.15: Schematic diagram of cross linking of kinase with protein substrate using 
ATP-acrylamide based crosslinker. 
4.2.2 Synthesis of ATP-acrylamides (11 and 12) 
Compound 11 and 12 were synthesized by reacting their corresponding amine 
(14 and 16 respectively) with methacrylic anhydride (13) (Scheme 4.1 A and B) to yield 
15 and 17 in 96 and 90% yield, respectively. Compound 15 and 17 were coupled with 
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ATP under pH controlled condition to yield compound 11 and 12 in 41 and 34%, 
respectively (Scheme 4.1 A and B). 
Scheme 4. 1: A) Synthesis of ATP-Hex-Acry (11). B) Synthesis of ATP-PEG-Acry (12). 
C) Synthesis of thiol containing fluorophore (17). 
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4.2.3 Detection of phosphorylation of mylein basic protein (MPB) with PKA and 
ATP-acrylamides using mercapto containing fluorophore (18) 
In order to test the reactivity of the ATP-acrylamides (11 and 12) as crosslinkers 
of cysteines through Michael reaction, we designed a model assay to simulate the 
crosslinking conditions. First, we synthesized a disulfide containing fluorophore (18) to 
act as a Michael donor fluorescein isothiocyanate (FITC) (19) and cystamine (20) 
(Scheme 4.1C). Second, we incubated 18 with ATP-acrylamides (11 and 12), PKA 
kinase, and MBP protein substrate under reducing conditions (Figure 4.16A and B). 
The expectation was that PKA would catalyze the phosphoacrylamide transfer from 
ATP-acrylamides (11 and 12) to MBP. Simultaneously, the fluorophore (18) would be 
reduced to a free thiol (21) (Figure 4.16 B) that would label the acrylamide group 
through a Michael reaction, resulting in fluorescence of MBP. As expected, MBP was 
fluorophore labeled in the presence of PKA and ATP-acrylamides (Figure 4.16 C, lane 
4 and 6). Reactions without PKA or in presence of staursporine, a kinase inhibitor, did 
not show labeling (Figure 4.16 C, lane 3, 5, 7, and 8), which indicates kinase 
dependency. Also, reactions without ATP-acrylamides (11 and 12) did not show any 
labeling (Figure 4.16 C, lane 2), which suggests that ATP-acrylamides are kinase 
cosubstrates. In summary, this experiment confirmed that ATP-acrylamides (11 and 
12) are kinase cosubstrates and can act as a Michael acceptor to cysteine containing 
proteins. 
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A) 
 
B) 
 
 
 
C)  
 
 
 
 
 
 
Figure 4.16: A) structure of DiFITCI-cystamine (20). B) Kinase-catalyzed labeling of 
MBP in presence of DIFITC-cystamine 18 and ATP-acrylamides (11 and 12). C) 
Detection of kinase-catalyzed phosphorylation of MPB with PKA and ATP-acrylamides 
in presence of DiFTC-cystamine (18). ATP-Hex-Acr 11 or ATP-PEG-Acr 12 were 
incubated with MBP, PKA, and DIFITC-cystamine (18). The reaction mixtures were 
separated by SDS-PAGE gel analysis. As a control, the reaction was performed in 
presence of staurosporine (STSP), kinase inhibitor. Top gel is visualized by typhoon 
scanning for in gel fluorescence (excitation/emission=495/519 nm) and bottom gel was 
visualized by SYPRO® Ruby total protein stain. These gel images is representative of 
at least three independent trials (Figure A4.18) 
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4.2.4 Exploring the efficiency of ATP-acrylamides (11 and 12) 
Having confirmed the cosubstrate properties of ATP-acrylamides, we studied 
the efficiency of such analogs as kinase-cosubstrates by quantifying the extent of 
phosphorylation. ATP, ATP-Hex-Acr 11, and ATP-PEG-Acr 12 were incubated with 
MPB and PKA, followed by cleavage of the acrylamide group with TFA. The reaction 
mixtures were analyzed by SDS-PAGE separation and staining with phosphoprotein 
stain ProQ diamond. Phosphorylation was quantified by ImageQuant 5.2 of the ProQ 
diamond stained gel. Compound 11 showed 60±9% conversion while ATP-PEG-Acr 12 
showed 68±9% compared to ATP (100%, Figure 4.17). This data suggests that both 
analogs have an acceptable similar efficiency but less than ATP. 
 
 
 
 
 
 
Figure 4.17: Quantitative analysis of MPB phosphorylation in the presence of PKA and 
incubated with either ATP (lane 2), ATP-Hex-Acr (lane 3), or ATP-PEG-Acr (lane 4), 
then treated with TFA. The reaction mixtures were analyzed by SDS-PAGE analysis, 
followed by staining with ProQ diamond phosphoprotein stain (top) or SYPRO® Ruby 
total protein stain (bottom).  The mean percentage of phosphorylation of MBP from four 
trials is shown on the top of the ProQ diamond gel. Full gel images and repetitive trials 
are shown in figure A4.19 
4.2.5 Kinase-catalyzed crosslinking of cysteine containing kinases to its 
substrates using affinity based crosslinking ATP-acrylamides (11 and 12) 
Having confirmed the ability of ATP-acrylamides (11 and 12) to act as both 
kinase cosubstrate and Michael acceptor, we moved to the next step by using these 
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analogs to crosslink cysteine-containing kinases to their substrates. We chose Akt1 as 
our model kinase. Akt1 has 7 cysteine residues.172 Of these residues Cys 296 and 310 
are within close proximity to ATP-binding pocket (Figure 4.18). Using our ATP-
acrylamide analogs 11 and 12 with Akt1 can provide a tool to identify Akt1 substrates 
by crosslinking the Akt1 through Cys 296 and Cys 310 to their corresponding 
substrates.  
Akt1 has a key role in PI3K/Akt1 pathway, which controls many cell functions, 
such as cell growth, apoptosis, etc (Chapter 1, section 1.2.3). Also, Akt1 is an 
interesting target because it is hyperactivated in many types of cancers, such as lung, 
colon, prostate, skin cancer, etc.24 For instance, in melanoma formation, Akt1 is 
overexpressed. Interstingly, 49% of melanomas contain pAkt1 that activates mTORC, 
which enhances tumor angiogenesis (Chapter 1, section 1.2.3).24 Therefore, Akt1 is an 
ideal kinase for this study.  
4.2.5.1 Docking of ATP-acrylamides into Akt1 kinase crystal structure 
To test the compatibility of ATP-acrylamides with Akt1, we docked ATP-
acrylamides into the crystal structure of Akt1 using Autodock. Both ATP-acrylamides 
showed binding to Akt1 similar to ATP with the adenine moiety binding into active site 
and the -phosphate protruding from the binding pocket (Figure 4.18). ATP-Hex-Acr 
(11) showed a distance of 18.6 and 14.8 Å from Cys 296 and 310, respectively (Figure 
4.18), while ATP-PEG-Acr (12) showed a distance of 18 and 19 Å from Cys 296 and 
310 (Figure 4.18), respectively. ATP-Hex-Acr has a short linker so the acrylamide 
group may not reach the cysteine residues, while ATP-PEG-Acr has a flexible long 
linker that may reach the cysteine residues and at same time phosphorylate Akt1 
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substrates. The docking studies suggests that ATP-acrylamides are kinase-
cosubstrates but ATP-PEG-Acr may be a better crosslinker due to its long linker. 
      
Figure 4.18: Crystal structure image of the catalytic active site of AKT1 kinase (pdb: 
4EKK) docked with compound 11(A) and 12 (B). Each atom of the ATP analogs is 
color-coded (C = green; H grey; N = blue; O = red; p = orange). ATP analogs were 
docked into the active site of Akt1 using AutoDock 4.2. Cysteine residues (C296 and 
C310) were shown in magenta red. The generated data was analyzed by both Auto 
dock tools 1.5.6 and PyMOL 1.5.0.5 (Schrodinger, LLC). 
 
4.2.5.2 In vitro Akt1 crosslinking to its substrates using ATP-acrylamides 
Since docking suggested that ATP-acrylamides can act as cosubstrates to Akt1, 
we tested the ability of ATP-acrylamides to crosslink Akt1 to its substrate in cell 
lysates. ATP-acrylamides were incubated with HEK293 cell lysates, followed by SDS-
PAGE gel separation, and analysis by Sypro Ruby total protein stain or an Akt1 
antibody after transferred to a PVDF membrane. As a control, the experiment was 
performed either without the ATP-acrylamides or with HEK293 lysates preincubated 
with staurosporine, a pan kinase inhibitor. Lysates treated with ATP-acrylamides 
showed high molecular weight complexes (Figure 4.19, lane 4 and 6), which may be 
due to crosslinking of Akt1 to its substrates. Staurosporine preincubated lysates 
showed reduced amount of the higher molecular weight complexes (Figure 4.19, lane 3 
A) B) 
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and 6), which confirm kinase dependence. Interestingly, ATP-PEG-Acr 12 showed a 
larger amount of higher molecular weight complexes (Figure 4.19, lane 6) when 
compared to ATP-Hex-Acr 11 (Figure 4.19, lane 4). The difference suggests that ATP-
acrylamide 12 may be a more efficient crosslinker due to its longer linker that can 
reach cysteine residues of AKT1. 
 
Figure 4.19: Kinase-catalyzed crosslinking of AKT with its substrates in HEK293 
lysates using ATP-acrylamides (11 and 12). HEK293 lysates were incubated with ATP-
acrylamides in presence of TCEP (tris(2-carboxyethyl)phosphine). TCEP was used to 
form necessary reducing conditions for cysteine reaction. As a control, the reaction was 
performed in presence of staurosporine (STSP), a kinase inhibitor. The reaction 
mixtures were separated by SDS-PAGE and transfered onto PVDF membrane as a 
western blotting. Top gel is visualized by treating with anti-AKT1 antibody followed by 
secondary HRP, while the bottom gel was visualized by SYPRO Ruby. These gel 
images is representative of at least three independent trials (Figure A4.20). 
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4.2.5.3 Akt1 substrate identification with ATP-acrylamides using K-CLIP (Kinase-
CrossLinking and ImmunoPrecipitation) 
With evidence that ATP-acrylamides can crosslink Akt1 to its substrates, we 
moved forward by evaluating and identifying the Akt1 crosslinked complexes. We 
developed an assay called Kinase-CrossLinking and ImmunoPrecipitation or K-CLIP, 
where crosslinking is coupled to immunoprecipitation (Figure 4.20 A). ATP-acrylamides 
(11 and 12) were incubated with HEK293 lysates, followed by immunoprecipitation of 
Akt1, SDS-PAGE gel analysis, and western blotting (Figure 4.20 A). The resulting 
higher molecular weight bands with 11 and 12 (Figure 4.20 B, lane 3 and 5) were 
excised from gel, trypsinized, and analyzed by MS/MS proteomics analysis. As a 
control, lanes from staursporine, a kinase inhibitor, treated lysates (Figure 4.20 B, lane 
2 and 4) and untreated lysates (Figure 4.20 B, lane 1) were also analyzed.  
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Figure 4.20: A) AKT1 substrate identification with ATP-acrylamides using K-CLIP 
(Kinase-CrossLinking and ImmunoPrecipitation. K=kinase or AKT1 and S=substrates. 
B) Kinase-catalyzed crosslinking of AKT with its substrates in HEK293 lysates using 
ATP-acrylamides (11 and 12). HEK293 lysates were incubated with ATP-acrylamides 
followed by immunoprecipitation with anti Akt1 antibody and agarose beads. As a 
control, the reaction was performed in presence of staurosporine (STSP), kinase 
inhibitor. The reaction mixtures were separated by SDS-PAGE electrophoresis and 
transferring onto PVDF membrane as a western blotting. Top gel is visualized by 
treating with anti-AKT1 antibody followed by secondary HRP, while the bottom gel was 
visualized by SYPRO Ruby. At least three independent trials were performed (Figure 
A4.21) but only two trials were used for in gel digestion and further Ms/Ms analysis. 
 
After analyzing the data, the number of unique peptides identified for each 
protein in the crosslinked Akt1 with ATP-Hex-Acr 11 (lane 3, Figure 4.20) or ATP-PEG-
Acr 12 (lane 5, Figure 4.20) were divided by number of unique peptides identified from 
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                                             1 2 3 4 5 
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corresponding staursporine treated HEK293 (lane 3 and 4 respectively, Figure 4.20) or 
non-crosslinked Akt1 (lane 1, Figure 4.20) to obtain peptide ratio of crosslinking 
reaction for both analogs. Only proteins with peptide ratio >1 for both untreated and 
staursporine experiments from two independent trials were considered for further 
analysis. The peptide ratio analysis revealed 116 proteins enriched from lysates 
treated with ATP-acrylamide 12 with peptide ratio >1 (Table A4.1), while only 17 
proteins were enriched in samples treated with ATP-acrylamide 11 with peptide ratio 
>1 (Table A4.2). The difference in detected proteins between the 2 samples may be 
due to the longer linker of ATP-acrylamide 12, which can led to access of cysteine 
residue of AKT1. The observed results from proteomic analysis is consistent with both 
the computational (Figure 4.18) and the gel analysis experiments (Figure 4.19, lane 6 
and lane 4). 
Since ATP-acrylamide 12 showing more effective crosslinking of Akt1 
substrates, we decided to continue our analysis only from compound 12 samples. A 
deeper analysis of ATP-acrylamide 12 proteomic data reveals that 11 out of the 116 
proteins are known interactors or substrates (Table 4.2 and Figure 4.21, inner circle 
blue color), which confirm the validity of the experiment. Interestingly, we found that 
many of the detected proteins are physical interactors to the 11 know 
interactors/substrates (indirect interactors) (Figure 4.21, Outer circles red, green, 
orange and yellow). The presence of AKT1 indirect interacting protein may be due to 
their interaction with AKT1 or its substrates when AKT1 signaling is active. In addition, 
sixty proteins are not known interacting/substrates with AKT1 or its known interactors. 
The detected proteins that are not AKT1 substrates represents prospective AKT1 
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substrate candidates or phosphorylation-dependent AKT1 interactors. As a future 
direction, several proteins will be selected for validation as AKT1 substrates. 
Table 4.2: Proteins identified from crosslinking of Akt1 with ATP-PEG-Acr in 
HEK293.  
No Protein identified Gene 
Accession 
number 
Mol. Wt 
(kDa) 
1.  
Stress-70 protein, 
mitochondrial 
HSPA9 GRP75 74  
2.  Vesicle-fusing ATPase NSF NSF 83  
3.  
Heat shock protein HSP 90-
alpha 
HSP90AA1 HS90A 85  
4.  
Heat shock protein HSP 90-
beta 
HSP90AB1 HS90B 83  
5.  
Heat shock cognate 71 kDa 
protein 
HSPA8 HSP7C 71  
6.  Creatine kinase B-type CKB KCRB 43  
7.  
L-lactate dehydrogenase A 
chain 
LDHA LDHA 37  
8.  
Transitional endoplasmic 
reticulum ATPase 
VCP TERA 89  
9.  
Pre-mRNA-processing factor 
19 
PRPF19 PRP19 55  
10.  
T-complex protein 1 subunit 
beta 
CCT2 TCPB 57  
11.  Zyxin ZYX ZYX 61  
After IP of Akt1 as in figure 4.20, Protein lists obtained from Ms/Ms analysis. Number of unique peptides 
identified for each protein in the crosslinked Akt1 with ATP-PEG-Acr lane (lane 5, Figure 4.20) were 
divided by number of unique peptides identified from staursporine treated HEK293 (lane 4, Figure 4.20) 
or non-crosslinked Akt1 (lane 1, Figure 4.20) to obtain peptide ratio of ATP-PEG-Acr. Only peptide ratio 
that is more than one and present in two independednt trials is considered to be solely phosphorylation 
dependent crosslinking and shown in the following table. Proteins from 1-7 are known Akt1 physical 
interactor (as reported in Biogrid database) and proteins from 8-11 are known Akt1 substrates (as 
reported in phosphosite database). The rest of proteins can be substrate candidates for Akt1 
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Figure 4.21: Proteomic analysis diagram showing the relation of 50% of 
AKT1-crosslinked proteins to AKT1. AKT1 is represented in black and direct 
interacting/substrate proteins are represented in blue (inner circle). Lines 
represent the presence of interactions between proteins. The analysis were 
performed by Genemania application in Cytoscape 3.3.0 program. AKT1 
substrates and direct interacting proteins were determined by Phosphosite 
Plus and Biogrid respectively. The diagram was generated by Cytoscape 
3.3.0.
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4.3 Conclusions and future directions 
In summary, we developed ATP-acrylamides that act as both kinase 
cosubstrates and affinity crosslinking ATP-analogs. We used a fluorescence gel 
analysis assay to show that ATP-acrylamides can act as kinase-cosubstrates and 
Michael acceptors. Importantly, ATP-acrylamides crosslink selectively cysteine 
containing kinases and their substrates that was demonstrated via Akt1 kinase. 
Coupling phosphorylation-dependent crosslinking using ATP-acylamides to 
immunoprecipitation followed by MS/MS analysis was able to separate and identify 
Akt1 substrates. ATP-PEG-Acr 12 with a long linker more efficiently crosslinked Akt1 to 
its substrates compared to ATP-Hex-Acr 11 with short linker. ATP-PEG-Acr 12 
crosslinked 116 proteins to Akt1 kinase, while ATP-Hex-Acrylamide 11 crosslinked 17 
proteins only. Out of the 116 crosslinked proteins via ATP-PEG-Acr 12, 11 proteins are 
known Akt1 interacting proteins or substrates. Interestingly, 44 proteins are indirectly 
interacting proteins to Akt1. The rest of the proteins can be either Akt1 substrates or 
interacting proteins. Lastly, coupling ATP-acrylamide crosslinking with 
immunoprecipitation created a new tool to discover new kinase substrates. In future, 
several of the crosslinked proteins will be chosen for validation as Akt1 substrates. In 
vitro phosphorylation experiments will represent the key studies to show Akt1 kinase 
relation to the selected proteins. 
Establishing affinity based crosslinking ATP analogs as a phosphorylation-
dependent kinase-substrate crosslinking tool will promote cell signaling studies. Also, 
having a cysteine specific crosslinker as ATP-acrylamides decrease the non-specificity 
and increase the confidence in the data obtained in the crosslinking. Furthermore, 
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developing other affinity based crosslinking ATP analogs with different crosslinker will 
be helpful and may reduce non-specificity with such experiments.  In contrast to other 
kinase-substrate crosslinking approaches, phosphorylation dependent kinase-substrate 
crosslinking requires the ATP analog to participate in phosphorylation as well as 
crosslinking. This methodology provides a powerful tool to identify kinases, their 
substrates, and phosphorylation-dependent interactions in cell signaling pathways 
when coupled to mass spectrometry. 
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4.4 Experimental 
4.4.1 Materials 
TCEP (tris(2-carboxyethyl)phosphine hydrochloride), iodoacetamide, proteomics 
grade trypsin, and ammonium bicarbonate were purchased from Sigma Aldrich. ATP 
was purchased from MP Biomedicals.  1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDCI), and N,N,N',N'-Tetramethylethylenediamine (TEMED) for 
electrophoresis were purchased from Acros. Methacrylic anhydride, hexane diamine, 
silica gel, DEAE sephadex A-25, and Ammonium persulfate (APS) for electrophoresis 
were bought from Fisher Scientific. Dichloromethane (DCM), acetic acid, hydrochloric 
acid, ammonium hydroxide, and HPLC grade acetonitrile were purchased from EMD. 
Ethanol was obtained from Decon lab. 40% Bis-acrylamide (37.5:1) for gel 
electrophoresis and Bradford reagent were purchases from Biorad. Myelin basic protein 
(MBP) and trypan blue were bought from Invitrogen. DMEM high glucose media was 
purchased from Gibco. PKA kinase was purchased from New England Biolabs. 
Antibiotic and Dulbecco's Phosphate Buffered Saline (DPBS) for cell culture were 
purchased from HyClone. AntiAkt1 and Goat Anti-Rabbit HRP Secondary antibodies 
were bought from cell signaling. HRP developer was purchased from Enzo life. 
4.4.2 Instruments 
1H NMR, 13C NMR, 31P NMR (Varian Mercury-400), and High resolution mass 
spectra (HRMS) (LCT Premier XT (Waters)) were used to characterize the final ATP 
analogs. CD3OD, D2O, and trimethylamine chemical shifts are shown in charts in 
Appendix 4. Absorbance of ATP analogs was measure by UV-Vis spectrophotometer 
(Shimadzu 2101 PC). A Lyophilizer (VirTis BT 3.3 EL Benchtop) and Speed-vac 
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(ThermoSAVANT, SPD131 DDA) were used during synthesis of ATP analogs. Bradford 
assay was done using a fluorimeter (GENios Plus Tecan). SDS-PAGE apparatus were 
bought from BioRad (Protean III). Protein transfer was performed using the Mini-
Transblot Electrophoretic Transfer Cell apparatus from BioRad. SDS gels and PVDF 
membranes were visualized by a Typhoon 9210 scanner (Amersham Biosciences).  
4.4.3 Synthesis of ATP-Hex-Acrylamide 
4.4.3.1 Synthesis of N-(aminohexyl)methacrylamide (15) 
 
Hexane diamine 14 (1.25 g, 10.75 mmol) was dissolved in DCM (300 mL) then 
glacial acetic acid (183 uL) was added. A solution of methacrylic anhydride 13 (0.48 
mL, 3.2 mmol) in DCM (50 mL) was added drop wise and stirred at room temperature 
for 3 hours. The solvent was removed in vacuo and the residue was dissolved in 
saturated solution of sodium carbonate (100 mL) until slightly basic. The aqueous 
solution was extracted with DCM (100 mL, three times) and the combined organic layer 
was dried over anhydrous sodium sulfate. The organic solvent was removed in vacuo 
and the residue was purified using silica column with a solvent mixture of ethanol: DCM 
in a 3:1 ratio containing ammonia (1%). Compound 15 was obtained as a white solid 
(0.56 g, 96%). 1HNMR (CD3OD, 400 Hz): δ 1.88-1.92 (4H, m), 2.05-2.11 (4H, m), 2.46 
(3H, s), 3.31 (2H, t), 3.76 (2H, t), 5.88 (1H, s), 6.19 (1H, s). 13CNMR (CD3OD, 100 Hz): 
17.39, 25.88, 26.15, 28.86, 29.34, 38.98, 39.96, 118.727, 140.06, 169.83.  ESI MS 
Calculated (M+H)+1 for C10H21N2O: 185.17; Observed 185.17. Data shown in figure 
A4.1-A4.3) 
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4.4.3.2 Synthesis of ATP-Hex-Acr (11) 
 
ATP disodium salt (32 mg, 0.059 mmol) was dissolved in water (5 mL) and the 
pH was adjusted to 7 using NaOH (0.5 M) and a pH meter. EDCI (452.5 mg, 2.36 
mmol) was added and the pH was adjusted to 5.6-5.8 using HCl (0.5 M). A solution of 
N-(aminohexyl)methacrylamide (15) (206 mg, 1.12 mmol) in water (2 mL) was added 
and the pH was readjusted to 5.6-5.8. The solution was stirred for 3 hours with control 
of pH and monitoring the progress of reaction by TLC (isopropanol:water:ammonia in 
3:1.5:0.5 ratio). The solution was brought to pH 8.5 using triethyl amine and the 
product was separated by anion exchange column (A-25 sephadex) with 0.1-1 M 
triethyl ammonium carbonate buffer (pH 8.5, section 2.4.6) as eluent. All liquids were 
lyophilized to dryness and solid compound was stored at -20 oC. ATP-Hex-Acr 11 was 
obtained as a white solid (14 mg, 41%). UV/Vis spectroscopy (H2O): 260 cm-1. 
1HNMR (CD3OD, 400 Hz): δ 1.02 (2H, m), 1.14 (6H, m), 1.74 (3H, m), 2.80 (2H, m), 
3.38 (2H, q), 4.09 (3H, d), 4.23 (1H,s), 4.59 (1H, s), 5.23 (1H, d), 5.45 (1H, d), 5.987 
(1H, d), 8.14 (1H, s), 8.43 (1H, s). 13CNMR (CD3OD, 100 Hz): 7.11, 17.62, 25.11-25.65 
(1C), 26.50, 27.99-28.087 (1C), 39.21-39.46 (1C), 58.56, 65.11, 70.34, 74.28, 84.11, 
86.89, 97.22, 120.52, 139.22, 140.36, 148.98, 151.52, 169.58, 198.80. 31PNMR (D2O): 
-3.41 (d), -11.32- -11.46 (d), -23.13 (t). ESI HRMs, (M-H)- for C20H33N7O13P3: calc. 
672.1349, found 672.1316. 
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4.4.4 Synthesis of ATP-PEG-Acrylamide (12) 
4.4.4.1 N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)methacrylamide (17) 
 
PEG diamine 16 (2.35 mL, 10.75 mmol) was dissolved in DCM (300 mL), 
followed by addition of acetic acid (183 uL). A solution of methacrylic anhydride 13 
(0.48 mL, 3.2 mmol) in DCM (50 mL) was added drop wise and stirred at room 
temperature for 3 hours. The solvent was removed in vacuo and the residue was 
dissolved in a saturated solution of sodium carbonate (100 mL) until slightly basic. The 
aqueous solution was extracted by DCM (100mL, three times) and the organic layer 
was dried over anhydrous sodium sulfate. The organic solvent was removed in vacuo 
and the residue was purified using silica column chromatography with a solvent mixture 
of ethanol: DCM (3:1) containing ammonia (1%). Compound 17 was obtained as yellow 
oil (0.83 g, 90%). 1HNMR (CD3OD, 400 Hz): δ 1.74-1.81 (4H, m), 1.93 (3H, s), 2.77-
2.81 (2H, m), 3.51-3.63 (14H, m), 5.35 (1H, s), 5.69 (1H, s). 13CNMR (CD3OD, 100 Hz): 
17.46, 29.00, 31.04, 36.93, 38.68, 68.80, 68.99, 69.77, 69.86, 70.07, 70.11, 118.95, 
139.96, 169.57. ESI pos. mass for C14H29N2O4 (M+H)+, calc. 289.21, found 289.21. 
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4.4.4.2 Synthesis of ATP-PEG-Acr (12) 
 
ATP (32 mg, 0.059 mmol) was dissolved in water (5 mL) and then the pH was 
adjusted to 7 using NaOH (0.5 M) and pH meter. EDCI (453 mg, 2.36 mmol) was 
added and the pH was adjusted to 5.6-5.8 using aqueous HCl (0.5 M). Compound (17) 
(288 mg, 1mmol) in water (2 mL) was added and the pH was readjusted to 5.6-5.8. The 
solution was stirred for 3 hours with control of pH and monitoring the progress of 
reaction by TLC (isopropanol:water:ammonia in 3:1.5:0.5 ratio). The solution was 
brought to a pH 8.5 using triethyl amine and the product was separated by anion 
exchange column (A-25 sephadex) with 0.1-1 M triethyl ammonium carbonate buffer 
(pH 8.5, section 2.4.6) as eluent. All fractions containing product were lyophilized to 
dryness and solid compound was stored at -80 oC. ATP-PEG-Acr 12 was obtained as a 
white solid (13.2 mg, 34%). UV/Vis spectroscopy (H2O): 260 cm-1. 1HNMR (D2O, 400 
Hz): δ 1.60 (4H, t), 2.08 (2H, m), 2.17 (3H, s), 3.57 (2H, t), 3.87 (13H, m), 4.52 (2H,s), 
4.67 (1H, s), 4.87 (1H, s), 5.69 (1H, s), 5.92 (1H, s), 6.41 (1H, d), 8.62 (1H, s), 8.87 
(1H, s). 13CNMR (D2O, 100 Hz): 7.05, 17.57, 26.41, 28.14, 36.63, 37.56, 58.46, 65.07, 
68.19, 68.51, 69.23-69.50 (2C), 70.27, 74.39, 84.08, 87.13, 120.72, 139.10 (2C), 
140.999 (2C), 148.69 (2C), 171.78. 31PNMR (D2O): -11.31- -10.91(d), -11.62- -11.49 
(d), -23.14 (t). ESI HRMs, (M-H)- for C24H41N7O16P3: calc. 776.1823, found 776.1822. 
126 
 
 
4.4.5 Scheme 4: Synthesis of 5,5'-((((disulfanediylbis(ethane-2,1-
diyl))bis(azanediyl))bis(carbonothioyl))bis(azanediyl))bis(2-(6-hydroxy-3-
oxo-3H-xanthen-9-yl)benzoic acid)= DiFITC-cystamine (18) 
 
FITC 19 (216.9 mg, 0.56 mmol) and cystamine 20 (54 mg, 0.24 mmol) were 
dissolved in DMF (15 mL). DIPEA (1.225 mL, 2.04 mM) was added and the solution 
was stirred overnight at room temperature. DMF was removed in vacuo and the 
residue was purified by silica column chromatography using DCM : Ethanol (1:3) to get 
compound 18 as red solid (178 mg, 80%). 1HNMR (CD3OD, 400 Hz):  3.06 (4H, t), 
3.96 (4H, t), 6.49-6.52 (4H, m), 6.64-6.65 (8H, m), 7.12-7.14 (2H, d), 7.72-7.75 (2H, 
dd), 8.15 (2H, d). 13CNMR (CD3OD, 100 Hz)  43.11, 62.99, 102.10, 110.08, 112.31, 
118.81, 124.45, 127.79, 128.96, 130.58, 140.74, 152.81, 160.16, 169.74, 181.48. ESI 
HRMs, (M+1)+ for C46H35N4O10S4, calc. 931.1236, found 931.1240.188 
4.4.6 Kinase-catalyzed in gel fluorescence of MBP using ATP-acrylamides and 
DIFITCI-cystamine 
Kinase-catalyzed labeling was performed by incubation of ATP-Hex-Acr or ATP-
PEG-Acr analogs (5 mM), PKA enzyme (5μg/mL, 500U), DIFITCI-cystamine (0.1 mM), 
TCEP (5.5 mg/mL, 22 mM) and myelin basic protein (MBP) (4 µg/ul) in the kinase 
reaction buffer (10 mM Tris, 1 mM MgCl2, pH 7.5). The final volume for the reaction 
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was 20 µL. The reaction mixture was incubated at 31oC for 3 hours at 31 oC with 
shaking (300 rpm), followed by incubation with iodoacetamide (15 mM, 2.8 mg/mL in 
0.13 M Tris buffer, pH=6.8) for 30 min at room temperature in dark to alkylate 
unreacted FITCI-cystamine. Acetone (80 µL) was added to reaction mixtures and 
incubated at -20 oC for 1 hour, followed by centrifugation at 13000 rpm for 10 min. The 
supernatant was removed and the residue was dissolved in Tris buffer (20 µL, 1M, 
pH=6.8), followed by precipitation by acetone (80 µL) and reincubation at -20oC for 1 
hour. The mixture were centrifuged at 13000 rpm for 10 minutes and the residue were 
dissolved in Tris buffer (10 µL, 1.5 M, pH=8.8). Reactions without MBP, PKA and/or 
ATP-Hex-acrylamide or ATP-PEG-acrylamide analogs were conducted as control 
experiments. Also, as a control, the reaction was run with PKA preincubated for 30 min 
with staursporine (1µM). The precipitated products were separated by SDS-PAGE 
(16% of acrylamide:Bis-acrylamide solution (37.5:1)) and gel image was produced by 
scanning the gel with Typhoon at  624, nm then visualized by SYPRO®Ruby (Figure 
4.16 and A4.18). 
4.4.7 In vitro quantification of ATP-acrylamides with PKA 
ATP, ATP-Hex-Acr or ATP-PEG-Acr (5 mM) were incubated with PKA enzyme 
(500U) and myelin basic protein (MBP) (1 µg/ml) in the buffer provided by the company 
(1X). The final volume of the reaction was 20 µl. The reaction mixtures were incubated 
at 31oC for 2 hours. TFA (50% final conc.) was added and incubated for 1 hour at 45 
oC with shaking at 700 rpm. TFA was evaporated using speed vac, followed by 
neutralization of the remaining TFA. The reaction mixtures were separated by SDS-
PAGE (16%) gel electrophoresis and visualized by SYPRO Ruby or Pro-Q diamond 
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stain. Quantification of phosphorylation of MBP was done by ImageQuant 5.2 on the 
gel stained by Pro-Q diamond stain by drawing a same-sized rectangle on MBP. MBP 
phosphorylation by ATP, ATP-Hex-Acr, and ATP-PEG-Acr was background corrected 
by subtracting the signal after kinase reaction to the signal of untreated MBP. The 
percentage of phosphorylation by ATP-Hex-Acr and ATP-PEG-Acr was calculated by 
dividing the signal for ATP-Hex-Acr and ATP-PEG-Acr reactions to the signal with ATP 
(100% phosphorylation) and multiplying by 100 (Figure 4.17 and A4.19). 
4.4.8 Docking of ATP-HEX-Acrylamide and ATP-PEG-Acrylamide 
The crystal structure of Akt1 was downloaded from RCSB Protein Data Bank 
(pdb ID: 4EKK). Pymol 1.5.0.5 (Schrodinger, LLC) was used to delete the co-
crystalized ligand and water. AutoDock Tools 1.5.6 was used to add all hydrogen 
atoms, Gasteiger charges and merging non polar hydrogen, followed by generation of 
pdbqt output file. The charge of Mn was changed from zero to +2 manually. A grid box 
with a spacing of 0.375 Å, size (90, 90, 60), and coordinates for the center of the grid 
box (63.202, 2.170, 24.916) were used. AutoGrid 4.2 was used to generate the grid 
maps file required for docking calculation. ATP, ATP-Hex-Acrylamide, and ATP-PEG-
Acrylamide were drawn in ChemBioDraw Ultra and MM2 energy minimization was 
done by Chem 3D Pro. AutoDock Tools 1.5.6 was used again to add hydrogens 
compute Gasteiger charges, merge nonpolar hydrogens, choose torsions, and 
generate a pdbqt file and all acyclic bonds were set rotatable except amide bonds. 
Docking calculations were generated by AutoDock 4.2 using genetic algorithm and a 
pdbqt file was generated. The pdbqt file for Akt1 was set as a rigid macromolecule, and 
the genetic algorithm search parameters were set to 100 GA runs with a population 
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size of 150, a maximum number of 2.5 × 105 energy evaluations, a maximum number 
of 2.7 × 104 generations, a mutation rate of 0.2, and a crossover rate of 0.8. Default 
docking parameters were used and the output DLG file was converted to pdbqt 
extension. PyMOL 1.5.0.5 (Schrodinger, LLC) was used to create images (Figure 
4.18). 
4.4.9 Kinase-catalyzed crosslinking of Akt1 to its substrates using affinity based 
crosslinking ATP-acrylamides  
Kinase-catalyzed crosslinking was performed by incubation of ATP-Hex-
acrylamide or ATP-PEG-acrylamide (5 mM), HEK293 lysates (150 ug) in kinase buffer 
(5 mM MOPS, 5 mM MgCl2, 1mM EGTA, 0.4 mM EDTA, pH 7.2) and TCEP (1.25 mM). 
The final volume for the reaction was 20 µL. The reaction mixture was incubated at 
31oC for 3 hours with shaking at 300 rpm. Reactions without ATP analogs or in 
presence of lysates preincubated with staursporine (1uM), a pan kinase inhibitor, for 30 
minutes were conducted as control experiments. The reaction mixtures were separated 
by SDS-PAGE (10% of acrylamide:Bis-acrylamide solution (37.5:1)) and visualized by 
SYPRO®Ruby total protein stain. Also, protein were transferred onto a polyvinylidene 
difluoride membrane (Immobilon-P, Milipore) and visualized with primary rabbit 
antiAKT followed by secondary antirabbit HRP (Figure 4.19 and A4.20). 
4.4.10 AKT1 substrate identification with ATP-acrylamides using K-CLIP (Kinase-
CrossLinking and ImmunoPrecipitation)  
Kinase-catalyzed crosslinking was performed by incubation of ATP-Hex-
acrylamide or ATP-PEG-acrylamide (5 mM), HEK293 lysates (500 µg) in the kinase 
buffer (5 mM MOPS, 5 mM MgCl2, 1mM EGTA, 0.4 mM EDTA, pH 7.2) and TCEP 
(1.25 mM). The final volume for the reaction was 30 µL. The reaction mixture was 
incubated at 31oC for 3 hours with shaking at 300 rpm. Reactions without ATP analogs 
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or in presence of lysates preincubated for 30 min with staursporine (1µM), kinase 
inhibitor, were conducted as control experiments. The reaction mixture was 
immunoprecipitated (IP) by incubation with Anti AKT (6 µL, 1:50 dilution, cell signaling) 
in Lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, 
and 1X protease inhibitor cocktail (GenDepot); 1 µL) up to final volume 300 uL, at 4 oC 
with rotation overnight. A/G PLUS-Agarose beads (20 µL slurry, Santa Cruz) were 
washed 3 times with lysis buffer (200 µL) and the lysates mixtures containing the 
antibody were incubated with the beads (20 µL slurry) with rotation for 4 hours at 4 oC. 
The reaction mixtures were centrifuged at 1 rcf/1min, washed 3 times with lysis buffer 
(200 µL), centrifuged to collect the beads (1 rcf for 1 min). The supernatant was 
removed, SDS loading dye (2x, 40 µL) was added, and the mixture was heated at 100 
oC for 5 min, followed by addition of β-mercaptoehtanol (BME, 4 µL), and heating for 
another 1 min. The reaction mixture was separated by SDS-PAGE (10% 
acrylamide:Bis-acrylamide solution (37.5:1)) and visualized by SYPRO®Ruby or 
transferred onto a polyvinylidene difluoride membrane (Immobilon-P, Milipore) and 
visualized with primary rabbit antiAKT followed by secondary antirabbit HRP (Figure 
4.20 and A4.21). 
4.4.11 Starting a new HEK293 cell culture and growing HEK293 cells 
Refer to chapter 2 (Section 2.4.16) but we used DMEM media for HEK293 cells (not F-
12). 
4.4.12 Lysis procedure of HEK293 cells 
Same as HeLa cells lysis procedure in chapter 2 (Section 2.11.12). 
4.4.13 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
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Refer to chapter 2 (Section 2.4.9). 
4.4.14 SyproRuby Staining 
Refer to chapter 2 (Section 2.4.11). 
4.4.15 Pro-Q diamond phosphoprotein staning 
Refer to chapter 2 (Section 2.4.13). 
4.4.16 Western Blotting 
To transfer proteins separated by SDS-PAGE, we used a polyvinylidene 
difluoride (PVDF) membrane (Immobilon P, Millipore). After wetting the PVDF 
membrane with methanol, a Mini-Transblot Electrophoretic Transfer Cell apparatus 
from BioRad was used to transfer the proteins in CAPS buffer (0.01 M CAPS (N-
cyclohexyl-3-aminopropanesulfonic acid) at pH 10.5, containing 10% methanol). The 
apparatus was set at constant voltage (90 V) for 120 minutes. The membrane was air 
dried after protein transfer and then re-wetted with methanol. The membrane was 
incubated for an hour in a blocking buffer (5% (w/v) BSA in TBST (150 mM NaCl, 50 
mM Tris chloride, pH 7.6 and 0.1% Tween-20). The membrane was rinsed with TBST 
twice (10 mL each) and then incubated overnight at 4oC in the recommended dilution of 
Anti Akt1 primary antibody (1: 1000, cell signaling) in blocking buffer. The membrane 
was washed with TBST twice (10 mL each) for 5 minutes to remove excess antibody. 
Rabbit HRP secondary antibody (Cell signaling) diluted in PBST (137 mM NaCl, 
2.7mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4 and 0.1% Tween-20) (1: 2000) 
was added and incubated for 1 hour, and then washed with TBST for 5 minutes twice 
(10 mL each). HRP substrate (1 mL, ThermoFischer) was used to develop the PVDF 
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membrane and proteins were visualized using the Typhoon 9400 scanner in 
chemiluminescence mode at 600 PTM.  
4.4.17 In gel tryptic digestion of Akt1 crosslinked substrates 
In gel tryptic digestion and sample preparation for proteomics was performed 
according to a protocol adapted from Bruker Daltonic and previously published 
reports.173 SYPRO®Ruby stained gel was kept overnight in destaining buffer (100 mL, 
10% methanol and 7% acetic acid in distilled water). Gel was washed twice with water 
(100 mL) for 10 minutes, followed by cutting of protein lanes above 55 KD into 1mm-
cubes. Gel pieces were transferred into 2 mL low binding protein tubes and then 
washed with a 1:1 mixture of NH4HCO3 (50 mM):acetonitrile (500 µL) for 15 minutes. 
The supernatant was removed and acetonitrile (500 µL) was added and left until gel 
pieces shrank. Acetonitrile was removed and gel pieces were rehydrated with 
NH4HCO3 (50 mM, 500 µL). After 5 minutes, an equal volume of acetonitrile (500 µL) 
was added to the gel pieces and incubated for 15 minutes, followed by removing of 
supernatant and incubation with acetonitrile (500 µL) till gel pieces dried. Acetonitrile 
were then removed and gel pieces were dried under vacuum. A solution of TCEP 
(tris(2-carboxyethyl)phosphine, 25 mM) in NH4HCO3 (50 mM, 500 µL) was added to gel 
pieces and incubated at room temperature for 15 minutes. The liquid was removed, 
replaced by a solution of iodoacetamide (55 mM) in NH4HCO3 (50 mM, 500 µL), and 
incubated 30 minutes in dark at room temperature. The iodoacetamide solution was 
removed and gel pieces were washed with 1:1 mixture of NH4HCO3 (50 mM) and 
acetonitrile (500 µL) for 15 minutes, followed by removal of liquid mixture and 
incubation with acetonitrile (500 µL) till gel pieces shrank. The acetonitrile was 
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removed and gel pieces were dried under vacuum. A solution of trypsin was freshly 
prepared by constituting one vial trypsin (Sigma Aldrich, 20 µg) in aqueous HCl (100 
µL, 1mM), followed by addition of a solution of NH4HCO3 (40 mM) in acetonitrile (9%) 
in water (900 µL). The final concentration of trypsin was 20 µg/mL. The trypsin solution 
(100µL) was added to gel pieces at 37 oC for 30 minutes.  A solution of NH4HCO3 (40 
mM) in acetonitrile (9%) in water was added to keep gel pieces wet if needed and then 
left overnight at 37 oC. The trypsinized peptide solution was transferred into low protein 
binding tubes and a solution of 0.1 % formic acid in 50% acetonitrile solution in water 
was added to gel pieces to extract any remaining peptides, followed by sonication for 
30 minutes. The extracting solution was removed and added to the tryptic-digestion 
solution, followed by addition of acetonitrile (500 µL) till gel pieces shrank. Acetonitrile 
was transferred to the tryptic-digestion solution and the mixture was dried under 
vacuum. The residue was analyzed by MS/MS tandem mass spectrometry to identify 
separated proteins.  
4.4.18 MS/MS tandem mass spectrometry 
MS/MS tandem mass spectrometry of trypsinized peptides was performed by Dr 
Joseph Caruso at Proteomics facility, Wayne State University, according to the 
following protocol. 
Trypsinized peptides were desalted with C18 tips (Pierce ThermoFischer), 
followed by separation on a nanoflow HPLC instrument (Easy-nLC 1000, Thermo 
Scientific) using reverse phase chromatography (Acclaim PepMap100 C18 pre-column, 
Acclaim PepMapRSLC C18 analytical column, Thermo Scientific). A linear gradient 
was used in HPLC. The gradient started with 95% buffer A (0.1% formic acid in water) 
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with 5% buffer B (acetonitrile) and continued for 2 minutes until it reached 90% buffer 
A. Then, the gradient changed to 68% buffer A over 30 minutes at a flow rate of 300 
nL/min for separation. Thermo Xcalibur 2.2 SP1.48 software (Thermo) was used to 
control pumps and instrument methods. After separation, peptides were ionized with a 
Nanospray Flex Ion Source (Proxeon Biosystems A/S), followed by spray into a Q 
Exactive mass spectrometer (Thermo Scientific) operated in positive mode and data 
was acquired using a data-dependent top 12 method. High energy collisional 
dissocation (HCD) was used to fragment the 12 most abundant ions from the full MS 
scan (375-1600 m/z). Dynamic exclusion was applied with the following parameters: 
12.0 s duration and precursor isolation width set to 3.0 m/z. Resolution of full MS and 
HCD scans  were as follow: 70,000 at 375 m/z and 17,500 at 200 m/z, respectively. 
Normalized collision energy for HCD spectra was set at 30 eV with aquiring data in 
profile mode. Lastly, we enabled isotope exclusion, singly charged and unrecognized 
charged ion exclusion. 
4.4.19 Peptide Spectrum Matching and Data Analysis 
Analysis of raw data was performed with Proteome Discoverer 1.4.0.288 
(Thermo) using the Mascot search algorithm (Matrix Science, London, UK; version 
1.4.1.14) and Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version 
1.4.1.14). Mascot was set up to search Uniprot human database assuming the 
digestion enzyme trypsin. Sequest was set up to search uniprot human also assuming 
trypsin. Mascot and Sequest were searched with a fragment ion mass tolerance of 
0.020 Da and a parent ion tolerance of 10.0 PPM. To calculate false discovery rates 
(FDR), the SwissProt database was utilized against human protein sequences and the 
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reverse decoy protein database. Carbamidomethyl of cysteine (+57) was specified in 
Mascot and Sequest as a fixed modification. Deamidated of asparagine and glutamine, 
oxidation of methionine (+16), acetyl of the n-terminus (+42), alkylation of cysteine with 
acrylamides (184 for ATP-Hex-Acr experiments and 288 for ATP-PEG-Acr), were 
specified in Mascot as variable modifications. Enzyme specificity was assigned for 
trypsin as c-terminal to lysine and arginine with 1 missed cleavage site allowed.  
Scaffold (version Scaffold_4.4.8, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 100.0% 
probability to achieve an FDR less than 1.0% by the Scaffold Local FDR algorithm. 
Protein identifications were accepted if they could be established at greater than 99.0% 
probability and contained at least 1 identified peptide.  Protein probabilities were 
assigned by the Protein Prophet algorithm.174 Proteins that contained similar peptides 
and could not be differentiated based on MS/MS analysis alone were grouped to 
satisfy the principles of parsimony. 
4.4.20 Proteomics MS/MS analysis procedure 
Protein lists were obtain for untreated lysates or lysates treated with ATP-
acrylamides in presence and absence of staursporine (kinase inhibitors). Peptide ratios 
for ATP-acrylamides were calculated by dividing peptide count obtained from lysates 
treated with ATP-acrylamides by either untreated lysates or lysates treated with both 
acrylamides and staursporine. Only proteins with peptides ratios greater than 1 were 
taken for further analysis in case of both untreated or staursporine treated lystaes. The 
interactome analysis was performed using the Genemania application in Cytoscape 
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3.3.0 program. AKT1 substrates and direct interacting proteins were determined by 
Phosphosite Plus and Biogrid, respectively. A diagram was generated by Cytoscape 
3.3.0 to show the relation of all isolated proteins to Akt1.  
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CHAPTER 5 SYNTHESIS AND STRUCTURAL ANALYSIS OF THE EFFECT OF 
DIFFERENT BOND LINKAGE ON THE -PHOSPHATE OF -MODIFIED ATP 
ANALOGS ON KINASE-COSUBSTRATE PROMISCUITY 
5.1 Introduction 
Several techniques have been developed to study kinase-catalyzed 
phosphorylation, such as 32P radio-labeling, covalent modification of phosphate, and gel 
based visualization of phosphoproteins.175-180 Most recently, the Pflum lab reported that 
-modified ATP analogs were promiscuously accepted by protein kinases. Several -
modified ATP analogs were developed to study enzymatic phosphorylation of proteins 
and peptides (Section 1.6, Chapter 1).79,85,86,92,128,181-184 Importantly, the modifications 
reported to date were installed on the -phosphate through a phosphoramidate bond.  In 
this chapter, we replace the nitrogen of the phosphoramidate bond with other atoms to 
study the ability of ATP analogs to act as kinase cosubstrates (Figure 5.1). Also, we 
discusse the structure activity relationship of -modified ATP analogs as kinase 
cosubstrates. 
5.1.1 Kinase-cosubstrate promiscuity 
any -modified ATP analogs, such as ATP--S and (32P)-ATP (Chapters 1 and 
4), are accepted promiscuously by protein kinases and participate in kinase-catalyzed 
phosphorylation reactions to furnish a modified phosphoproteins. Most recently, -
modified ATP analogs with a tag such as biotin,79,92,128,181,182 aryl-azide185 or ferrocene85 
were developed, and the modification has attached to the -phosphate via a 
phosphoramidate bond (Figure 1.6). The tag can allow visualization of protein 
substrates, purification of phosphorylated proteins (as in ATP-biotin, Section 1.6.2, 
Chapter 1), or crosslinking of protein substrates to their corresponding kinases (as in 
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ATP-Ar-azide, Section 1.6.4, Chapter 1).181,185 In this chapter, the structural analysis 
and requirements of the -modification to allow the promiscuity of kinase is explored.94 
Also, replacement of the phosphoramidate bond with other bonds, such as 
phosphodiester, is discussed. This work was performed in collaboration with my 
colleague Thilani Anthony. 
5.1.2 Structure analysis of -modified ATP analogs 
Many -modified ATP analogs are accepted by protein kinases depending on 
certain structure requirements. The functional group on the ATP molecule should be 
attached to -phosphate by a linker. The Pflum lab explored the structure requirements 
for the linker, as well as the function group.94 First, the nature and size of the functional 
group on -phosphate affect the efficiency of the ATP analog as a kinase cosubstrate. 
Small groups such as acetyl group (Entry a-c, Figure 5.1) furnished better activity than 
large groups such as aryl group (Entry d-k, Figure 5.1). Also the type of functional group 
affects the efficiency. For instance, higher conversion was detected when the terminal 
group had a sulfonamide functional group (Entry k versus Entry h, Figure 5.1), which 
indicates that a more polar functional group on ATP--modification is better for kinase 
activity. In addition, the length and nature of the linker affect the kinase activity. ATP 
analog with a longer linker (Entry i, Figure 5.1) were more efficient than an ATP analog 
with a shorter linker (Entry g, Figure 5.1), especially when the size of the functional 
group was big. Also, an ATP analog with a more hydrophilic linker such as 2,2’-
ethylenedioxybis-(ethylamine) (Entry j, Figure 5.1) has more efficiency as a kinase 
cosubstrate than those analogs with a more hydrophobic linker (Entry i, Figure 5.1).  
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Figure 5. 1: A) Kinase-catalyzed phosphorylation of proteins or peptides using ATP or 
ATP analogs B) Percentage phosphorylation of CK2 peptide using CK2 and different 
ATP analogs with different linker sizes and functional groups.94 
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5.1.3 Development of -modified ATP analogs with phosphodiester bond 
Mann and coworkers developed a new generation of  -modified ATP analogs 
containing a phosphodiester bond at the -phosphate. The developed ATP analogs had 
alkynes, azides, and alkenes as -modification (Figure 1.18), which are useful for 
subsequent click chemistry or Staudinger ligation (Chapter 1, Section1.66). Their 
analogs were accepted by cyclin E1/cdk2 kinase, as demonstrated using western 
blotting and phosphor specific antibodies. Unfortunately, the phosphodiester analogs 
were not well studied. They did not show the kinetics for their analogs or confirmed the 
phosphorylation of kinase substrate using mass spectrometry. A more detailed 
discussion of Mann work and the structure of their ATP analogs were discussed in 
chapter 1 (Section 1.66).86 
As a continuation of our previous studies, we studied the effect of directly 
attaching different atoms to the -phosphate on the ability of ATP analog to act as a 
kinase cosubstrate. We synthesized -modified ATP analogs with phosphoramidate, 
phosphodiester, and phosphonate bonds on the -phosphate (Figure 5.2 and Scheme 
5.1). We studied their kinase cosubstrate ability, including detailed kinetics and mass 
identification of phosphorylated products.  
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Figure 5. 2: ATP analogs (22-24) with different first atom linked to -phosphate. The 
figure shows ATP-C-heptyl with phosphonate bond, ATP-N-heptyl with 
phosphoramidate bond, and ATP-O-heptyl phosphodiesterbond 
5.2 Results 
5.2.1 Synthesis of ATP analogs 
ATP analogs with heptyl groups attached to the -phosphate through different 
atom linkage (C, N, O) were synthesized (compounds 22-24, Scheme 5.1). We selected 
heptyl group on -phosphate as it is a long and not bulky, which simulate our previously 
synthesized analogs and rules out any steric factors. The ATP-phosphonate (ATP-C-
heptyl, 22) was synthesized by my colleague, Thilani Anthony, (Scheme 5.1 A). The 
ATP-phosphoramidate analog (ATP-N-heptyl, 23) was synthesized by coupling ATP 
with heptyl amine (Scheme 5.1B). ATP-phosphodiester (ATP-O-heptyl, 24) was 
synthesized from ADP according to previously reported procedure.86 Heptyl alcohol 29 
was reacted with phosphorus oxychloride, followed by addition of triethylamine 
carbonate buffer (pH=7) (Scheme 5.1C). The resulting mixture was coupled without 
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purification with ADP tributyl ammonium salt 28 to give ATP-phosphodiester analog (24) 
(Scheme 5.1C).  
Scheme 5. 1: Synthesis of ATP analogs ATP-C-heptyl (22), ATP-N-heptyl (23), and 
ATP-O-heptyl (24). 
A)  
B) 
 
C) 
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5.2.2 Analysis of kinase cosubstrate promiscuity using ATP-C, N, and O-heptyl 
(22-24) 
Three -modified ATP analogs with same the heptyl group but different atoms of 
attachment on the -phosphate were synthesized. Since the connecting atom is the only 
difference in ATP analogs (22-24), it should be the only variable affecting the 
promiscuity of such ATP analogs. To investigate the effect of different bond connections 
on -modified ATP analog promiscuity, we used mass spectrometry to evaluate their 
ability to act as cosubstrates to kinases. The ATP analogs (22-24) were incubated with 
PKA kinase and kemptide peptide substrate and the resulting mixtures were analyzed 
by MALDI-TOF mass spectrometry. As a control, we analyzed the reaction mixture from 
the incubation of ATP, PKA, and kemptide (Ac-kemptide). The MALDI-TOF analysis of 
ATP revealed a peak at m/z 894.5, corresponding to [M+H] peak of phosphor-Ac-
Kemptide (Figure 5.3A), which confirmed the validity of the experiment for subsequent 
studies. The analysis of the reaction mixtures of ATP-C-heptyl 22, ATP-N-heptyl 23, and 
ATP-O-heptyl 24 analogs revealed an [M+H] peak at m/z 975.9, 991.4, and 992.9 
respectively, corresponding to modified phosphopeptide (Figure 5.3B, C, D, 
respectively). The data suggests that different atoms attached to -phosphate preserve 
the ability of ATP analog to act as a kinase cosubstrate but with different efficiencies.  
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Figure 5. 3: MALDI mass spectrometry spectra of modified phosphorylated of Ac-
kemptide using ATP analogs (22-24). ATP or ATP-analogs were incubated with 
kemptide and PKA followed by MALDI-TOF spectrometric analysis. A) ATP B) ATP-C-
heptyl (22) C) ATP-N-heptyl (23) D) ATP-O-heptyl (24). The expected masses of each 
peptide products are shown. The peak at m/z 814 is for unphosphorylated Ac-kemptide 
(calculated m/z 814.4894). Repetitve trials are shown in figure A5.13-A5.15. 
To confirm the kinase cosubstrate ability of each analog, we incubated ATP or 
the ATP analogs (22-24) with PKA and myelin basic protein (MBP) and the reaction 
mixture was analyzed by SDS-PAGE electrophoresis, followed by visualization of 
phosphoproteins using ProQ diamond stain or total proteins using Sypro Ruby stain. 
The reaction mixtures of ATP (Figure 5.4, lanes 2 and 9, top gel), ATP-N-heptyl (3) 
A) A) B) 
C) D) 
814.479 
814.481 814.482 
908.946 
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(Figure 5.4, lane 12, top gel), and ATP-C-heptyl (5) (Figure 5.4, lane 6, top gel) showed 
phosphorylation of MBP, while ATP-O-heptyl (4) (Figure 5.4, lane 4, top gel) did not 
show phosphorylation. The data from ATP, ATP-N-heptyl (3), and ATP-C-heptyl (5) 
confirmed the MALDI mass spectrometry data, while ATP-O-heptyl did not show 
phosphorylation. We specultate that the lack of ProQ signal of ATP-O-heptyl may be 
due to interference of modification with ProQ stain. 
 
Figure 5.4: Analysis of MPB phosphorylation in the presence of PKA and incubated with ATP 
(lane 2), ATP-O-heptyl (lane 4), ATP-C-heptyl (lane 6) or ATP-N-heptyl  (lane 12). The reaction 
mixtures were analyzed by SDS-PAGE analysis, followed by staining with ProQ diamond 
phosphoprotein stain (top) or SYPRO® Ruby total protein stain (bottom).  As a control ATP 
analogs were incubated with MBP in absence of PKA (lane 1, 3, 5, 11). Repetitive trials are 
shown in figure A5.17. 
5.2.3 Kinetic analysis of ATP analogs (22-24) 
Since gel analysis did not confirm the kinase cosubstrate ability of all ATP-
analogs (22-24), we performed kinetic analysis for all analogs and compared it with ATP 
using enzyme coupled assay.184 Kinetic analysis will confirm both the kinase 
cosubstrate property of all analogs and their efficiency. ATP or ATP analogs (3-6) were 
incubated with PKA and Ac-kemptide (Figure 5.5). The Km, Kcat, and Vmax were 
determined for each analog (Table 5.1). As a control, we performed the reaction in the 
absence of either PKA or Kemptide substrate. Kinetic analysis revealed the reactivity of 
ATP analogs only in presence of PKA and kemptide, while the absence of PKA or 
                       
                        
 1 2 3 4 5 6 7 8 9 10 11 12 
MPB  + + + + + + + + + + + + 
PKA  +  +  + +  + +  + 
ATP + +      + +    
ATP-O-heptyl   + +         
ATP-C-heptyl     + +       
ATP-N-heptyl           + + 
 
Pro-Q 
SYPRO 
Ruby 
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kemptide did not show any change in enzyme kinetics (Figure 5.5). The most efficient 
compound was the natural ATP (Kcat/Km=0.3). The least efficient analog was ATP-C-
heptyl 22 (Kcat/Km=0.03), which was 10 fold less efficient than ATP. ATP-N-heptyl and 
ATP-O-heptyl show similar efficiency (Kcat/Km=0.1), but three fold less than ATP. ATP-
C-heptyl be the less efficient due to less electronegativity compared to nitrogen and 
oxygen. The nitrogen and oxygen atoms of ATP analogs (23 and 24) has high 
electronegativity and may facilitate bond breakage between -phosphate and -
phosphate. In summary, the kinetic analysis confirmed that all analogs are kinase-
cosubstrates with different catalytic efficiencies. 
5.3 Conclusion and future directions 
In conclusion, kinase-cosubstrate promiscuity is affected by the atom attached to 
the -phosphate. Although all analogs are cosubstrates to kinases. ATP-N-heptyl (23) 
and ATP-O-heptyl (24) had similar efficiency, but three-fold less than to ATP. The ATP 
analog with carbon attached to the -phosphate (ATP-C-heptyl (22) was the least 
efficient ATP-analog. We note that the carbon linkage may be helpful in protein kinase 
studies due to its high stability.186 In the future, ATP analogs with carbon modifications 
on the -phosphate might be designed because they are stable in both acidic and basic 
media.186 ATP analogs with a carbon linker can phosphorylate kinase substrates and 
can withstand handling during purification of substrates in acidic and basic media. 
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Figure 5. 5: Michaels Menten plot of ATP analogs (22-24). ATP analogs (ATP (A), ATP-C-
heptyl 22 (B), ATP-N-heptyl 23 (C), ATP-O-heptyl 24 (D)) were incubated with kemptide and 
PKA and kinetic data was collected by coupling this reaction NADH enzyme coupled assay. As 
a control, the reactions were performed in the absence of either kemptide or PKA. 
Table 5. 1: Kinetic results of ATP analogs (22-24) 
 
kcat (s-1) Km (µM) Kcat/Km (s-1µM-1) 
ATP 3.9±0.7 11.6±1.72 0.3 
ATP-C-heptyl (5) 1.7±0.4 54±7.68 0.03  
ATP-N-heptyl (22) 3.9±1.9 35.7±13 0.1  
ATP-O-heptyl (4) 2.6±0.5 25±4.75 0.1  
 
A) B) 
C) D) 
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5.4 Experimental 
5.4.1 Materials 
ATP was purchased from MP Biomedicals.  1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDCI), phosphorus oxcychloride (POCl3), heptyl 
amine, heptyl alcohol, and N,N,N',N'-Tetramethylethylenediamine (TEMED) for 
electrophoresis were bought from Acros. Silica, DEAE sephadex A-25, and Ammonium 
persulfate (APS) for electrophoresis were purchased from Fisher Scientific. Diethyl 
ether and dimethyl formamide (DMF) were bought from EMD. 40% Bis-acrylamide 
(37.5:1) for gel electrophoresis was purchases from Biorad. Pyruvate kinase, lactate 
dehydrogenase, NADH, and phosphoenol pyruvic acid used for kinetics were purchased 
from Sigma Aldrich. Myelin basic protein (MBP) was bought from Invitrogen. PKA 
kinase was purchased from New England Biolabs. 3-Hydroxypicolinic acid was bought 
from Fluka. C18 (10 µL) desalting tips were bought from ThermosFischer. 
5.4.2 Instruments 
A Lyophilizer (VirTis BT 3.3 EL Benchtop) was used during synthesis of ATP 
analogs. SDS-PAGE instrument were bought from BioRad (Protean III) and gels were 
scanned via Typhoon 9210 scanner (Amersham Biosciences). 1H NMR, 13C NMR, 31P 
NMR (Varian Mercury-400), and High resolution mass spectra (HRMS) (LCT Premier 
XT (Waters)) were used to characterize synthesized analogs. Absorbance of ATP 
analogs was measure by UV-Vis spectrophotometer (Shimadzu 2101 PC). GENios Plus 
Fluorimeter (Tecan) was used to measure absorbance during kinetic studies. 
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5.4.3 Preparation of  ADP tributyl ammonium salt (28): 
5.4.3.1 Preparation of Dowex-8H+ column: 
Dowex-8H+ resin (5 gm) was incubated with aqueous HCl (0.1 M, 40 mL) 
overnight. The resin was packed into a glass column then washed with deionized water 
twice (20 mL each). 
5.4.3.2 Regeneration of Dowex-8H+: 
After use, Dowex-8H+ was regenerated by washing with aqueous HCl (0.1 M, 20 
mL, twice) until the elute was acidic followed by washing with deionized water until the 
elute was neutral. After regeneration, the resin was kept in a glass column at room 
temperature. 
5.4.3.3 Preparation of ADP tributyl ammonium salt (28) 
ADP. 2 Na (20 mg, 0.053 mmol) was dissolved in water (20 mL) and loaded to a 
Dowex-8H+ column (5 gm). The column was washed with deionized water twice (20 mL) 
and eluted in a solution of tributyl amine (26 µl, 0.106 mmol) in ethanol (200 µL) with 
stirring. The solution was lyophilized, and a white powder was obtained. The ADP 
tributyl ammonium salt (28) was used directly in the synthesis of ATP analogs. The 
quantities were scaled up as needed except the Dowex quantity. 
5.4.4 Synthesis of ATP-C-heptyl (22) 
Compound 22 was synthesized by my colleague, Dr. Thilani Anthony, according 
to the following procedure. 
5.4.4.1 Synthesis of diethyl heptylphosphonate 26 
In a 50 mL round bottom flask under nitrogen, equipped with a distillation setup, 
triethylphosphosphite (17.147 mL, 100 mmol) and 1-bromoheptane 25 (7.85 mL, 50 
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mmol) were mixed. The reaction mixture was heated at 140 oC for 4 hrs. The resulting 
byproduct bromoethane was distilled off (~3 mL). Then the reaction mixture was cooled 
to room temperature and distilled under vacuum (bp 175-180 oC in 11 mmHg) affording 
phosphonate 26 as colorless oil (8.97 g, 76%). Characterization of molecule is in Thilani 
Anthony’s thesis. 
5.4.4.2 Synthesis of heptylphosphonic acid 27 
TMSBr (1.0 mL, 7.8 mmol) was mixed with anhydrous dichloromethane. 
Compound 26 (1.3 mL, 1.3 mmol) was added at 0 oC and stirred at room temperature 
for 12 hrs. The solvent was evaporated under reduced pressure. Water (15 mL) was 
added and stirred for 10 hrs. The reaction was extracted with ethyl acetate, washed a 
brine and dried over MgSO4.  The solid was removed under vacuo to yield a white solid 
27 (0.157 g, 67%). Characterization of molecule is in Thilani Anthony’s thesis. 
5.4.4.3 Synthesis of ATP-C-heptyl 22 
Adenosine 5’- diphosphate tributyl ammonium salt 28 (0.066 mmol, 1.0 eq) was 
dissolved in molecular-sieve dried DMF (5 mL), followed by the addition of CDI (0.33 
mmol, 5 eq). The mixture was stirred for 10 hrs at room temperature. Methanol (0.3 mL) 
was added to the reaction and stirred for 1 hr, followed by addition of trimethylamine 
(0.2 mL). A solution of crude 27 (section 5.4.4.2) in DMF (0.5 mL) was added and 
stirred at room temperature for 8 hrs. The mixture was mixed with 5% of 1 M TEA 
carbonate buffer in water (5 mL, pH=8.5) and loaded onto anion exchange sephadex A-
25 (5 gm) column. 0.1-1 M triethyl ammonium carbonate buffer was used as eluent 
(section 2.4.6). The collected fractions were frozen and lyophilized to give white crystals 
of 22 (33%).1H NMR (400 MHz, D2O): δ 1.37 (3H, s), 1.57 (8H, m), 3.20 (2H, m), 3.82 
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(3, m), 4.50 (2H, s), 4.65 (1H, s), 4.80 (1H, s), 6.40 (1H, d), 8.60 (1H, s), 8.87 (1H, s). 
13C NMR (100 MHz, D2O): δ 13.32, 17.57, 21.90, 22.40, 26.41, 26.70, 27.99, 29.89, 
30.94, 65.02, 69.51, 70.26, 74.62, 84.42, 87.72, 120.72, 121.87, 126.84 (2C), 137.57. 
31P NMR (162 MHz, D2O): δ 21.57-21.73 (d), -11.70 -11.57 (d), -23.35 (t). UV/Vis 
spectroscopy (H2O): 260 nm. ESI HRMs, (M-H)- for C17H29N5O12P3: calc. 588.1026, 
found 588.1028. 
5.4.5 Synthesis of ATP-N-heptyl (23) 
The disodium salt of ATP (32 mg, 0.059 mmol) was dissolved in water (5 mL) 
and then the pH was adjusted to 7 using NaOH (0.5 M) and pH meter. EDCI (382 mg, 2 
mmol) was added and the pH was adjusted to 5.6-5.8 using aqueous HCl (0.5 M). A 
solution of heptyl amine (297 L, 2 mmol) in water (2 mL) was added and the pH was 
readjusted to 5.6-5.8. The solution was stirred for 3 hours and the progress of reaction 
was monitored by TLC (isopropanol:ammonia:water in 3:1.5:0.5 ratio). The pH was 
brought to 8.5 by triethyl amine and the product was separated by anion exchange 
column (A-25 sephadex, 5 gm) with 0.1-1 M triethyl ammonium carbonate buffer 
(pH=8.5) as eluent (section 2.4.6). The fractions containing product were lyophilized to 
dryness and the solid compound was stored at -80 oC. ATP-N-heptyl (23) was obtained 
as a white solid (10.4 mg, 45%). 1HNMR (400 MHz, D2O): δ 0.98 (3H, s), 1.19 (6H, m),  
2.79 (2H, m), 3.42 (5H, m) 4.09 (2H, s), 4.24 (1H, s), 4.39 (1H, s), 5.99 (1H, d), 8.20 
(1H, s), 8.47 (1H, s). 13C NMR (100 MHz, D2O): δ 7.06, 13.18, 21.80, 25.41, 26.60, 
27.76, 30.72, 58.48, 65.12, 70.30, 74.37, 87.17, 111.60, 114.11 (2C), 130.97, 156.89. 
31P NMR (162 MHz, D2O): δ -10.92 (d), -11.58 (d), -23.42 (t). UV/Vis spectroscopy 
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(H2O): 260 nm. ESI HRMs, (M-H)- for C17H30N6O12P3: calc. 603.1135, found 
603.1158. 
5.4.6 Synthesis of ATP-O-heptyl (24): 
5.4.6.1 Synthesis of heptyl phosphate (30) 
In 25 mL flask, a solution of phosphorus oxychloride (0.585 mmol, 55 uL) in 
diethyl ether (5 mL) was cooled to -78 oC. A solution of heptanol 29  (0.585 mmol, 85 
uL) and triethyl amine (0.585 mmol, 80 uL) in diethyl ether (5 mL) was added dropwise 
under Argon and then stirred at room temperature for 24 hours. The reaction was 
quenched using TEA carbonate buffer (0.1 M, 4 mL, pH=7). The solvent was 
evaporated in vacuo and used in the next step without purification. 
5.4.6.2 Synthesis of ATP-O-heptyl (24): 
ADP. 2Na (50 mg, 0.117 mmol) was converted to the tributyl ammonium salt as 
in section 5.4.3.3 and then dissolved with molecular sieve (4 Ao) dried DMF (3 mL), 
followed by addition of CDI (1.17 mmol, 190 mg, 10eq.). The reaction was stirred for 24 
hours under argon. Methanol (2.1 mmol, 85 uL, 18 eq.) was added and the reaction was 
stirred for 30 min. Unpurified heptyl phosphate (30) from section 5.4.6.1 in molecular 
sieve (4 Ao) dried DMF (3 mL) was added to the reaction mixture and the reaction was 
stirred for 36 hours under argon at room temperature. The mixture was mixed with 5% 
of 1 M TEA carbonate buffer in water (5 mL, pH=8.5) and loaded onto anion exchange 
sephadex A-25 (5 gm) column. 0.1-1 M triethyl ammonium carbonate buffer (pH=8.5) 
was used as eluent (section 2.4.6). The collected fractions were frozen and lyophilized 
to give white crystals (13.5 mg, 19%). 1H NMR (400 MHz, D2O): δ 1.20 (3H, s), 1.69 
(4H, m), 1.98 (2H, m), 3.40 (2H, m), 3.95 (2H, m), 4.26 (3H, m), 4.63 (2H, s), 4.76 (1H, 
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s), 4.92 (1H, s), 6.51 (1H, d), 8.78 (1H, s), 9.02 (1H, s). 13C NMR (100 MHz, D2O): δ 
13.33, 21.87, 24.77, 28.11, 29.77, 30.97, 42.16, 58.42, 66.97, 70.21, 74.69, 87.67, 
142.22 (2C), 145.44(2C), 148.25.. 31P NMR (162 MHz, D2O): δ -10.98 (d), -11.62 (d), -
23.38 (t). UV/Vis spectroscopy (H2O): 259 nm. ESI HRMs (M-H)- for C17H29N5O13P3: 
calc. 604.0975, found 604.0955.  
5.4.7 MALDI-TOF analysis of kinase-catalyzed reaction using ATP-C, N, and O-
heptyl analogs (22-24) 
Kinase-catalyzed reaction was performed by incubation of ATP or ATP analog (2 
mM), PKA enzyme (2 µg/mL, 52.6 nM) and kemptide (1 mM) in the kinase buffer 
provided by the manufacturer (50 mM Tris-HCl, 10 mM MgCl2, pH 7.5). The final volume 
for the reaction was 10 µL. The reaction mixture was incubated at 31oC for 2 hours 
followed by desalting using C18-Tips (Pierce). The desalted reaction (2 µL) was mixed 
with an equal volume of a saturated solution 3-hydroxypicolinic acid solution in 50% 
acetonitrile, followed by spotting on MALDI plate (Bruker). The resulted mass spectra 
were analyzed to detect either phospho-kemptide or modified phospho-kemptide. 
(Figure 5.3 and A5.13-A5.15) 
5.4.8 Procedure of desalting of kinase-catalyzed reaction before MALDI-TOF 
analysis adapted from Thermo-fischer scientific procedure 
C18 tips (10 µL, Thermo-fischer scientific) were wetted by aspiration using 50% 
acetonitrile in water (10µL). The tips were equilibrated by aspirating 0.1% TFA (10µL) 
twice. The sample to be desalted was diluted to 0.1% TFA using 2.5% TFA, followed by 
aspiration into the C18 tip three times.  The tip was rinsed by aspirating with 0.1% 
TFA/5% acetonitrile in water (10µL) twice. The sample was eluted using 0.1 % TFA in 
95% acetonitrile in water (10 µL). 
5.4.9 Pro-Q analysis of ATP-C, N, and O-heptyl analogs (22-24) 
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Kinase-catalyzed reaction was performed by incubation of ATP or ATP analog (3 
mM), PKA enzyme (2 µg/mL, 52.6 nM) and myelin basic protein (MBP) (1 µg/ul) in the 
kinase buffer provided by the manufacturer (50 mM Tris-HCl, 10 mM MgCl2, pH 7.5). 
The final volume for the reaction was 20 µL. The reaction mixture was incubated at 
31oC for 2 hours. Reactions without PKA were conducted as control experiments.  The 
reaction mixtures were separated by SDS-PAGE (16%) and visualized by SYPRO Ruby 
to detect total proteins or Pro-Q diamond stain to examine phosphorylation. 
5.4.10 Synthesis of N-acetylated kemptide (AcLRRASLG) 
See Chapter 2 (section 2.11.7) 
5.4.11 Kinetics of N, O, and C-heptyl ATP analogs (22-24) 
An NADH-dependent coupled assay was used to perform kinetic analysis, as 
previously described,184 with some exceptions. NADH (0.5 mM), pyruvate kinase (24 
units/mL), lactic acid dehydrogenase (36 units/mL), and kemptide (1.29 mM) were 
preincubated together for 30 min at 31 oC. ATP or ATP analogs at final concentrations 
of 1, 3, 10, 30 (ATP or 22) or 1, 3, 10, 30, 100 µM (23 or 24) were added and 
preincubated for another 5 minutes at 31 oC. The reaction was initiated by addition of 
PKA (2 µg/mL, 52.6 nM) in a final reaction volume of 25 L. The absorbance at 360 nm 
was taken every 30 second for 60 min using GENios Plus Fluorimeter (Tecan).  
Kaleidagraph software (Synergy Software) and non-linear regression analysis was used 
to obtain KM and Vmax values from the Michaelis-Mentor equation (v=Vmax*(S)/(KM + (S)), 
where v= rate of the reaction and (S)= substrate concentration). kcat was calculated by 
dividing Vmax by the concentration of PKA enzyme. 
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APPENDIX A: CHAPTER 1 
2.1 Compounds characterization 
 
Figure A 2.1: 1H NMR of di-tert-butyl ((butane-1,4-diylbis(azanediyl))bis(propane-3,1-
diyl))dicarbamate (4) in CDCl3 at 400 MHz 
 
Figure A 2.2: 13C NMR of di-tert-butyl ((butane-1,4-diylbis(azanediyl))bis(propane-3,1-
diyl))dicarbamate (4) in CDCl3 at 400 MHz. 
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Figure A 2.3: Electrospray ionization (ESI) postive mode low resolution mass spectrum 
of di-tert-butyl ((butane-1,4-diylbis(methylazanediyl))bis(propane-3,1-diyl))dicarbamate 
(5) in methanol/methylene chloride. (M+H)+ for C22H47N4O4: calc. 431.6, found 432.6 
 
Figure A 2.4: Electrospray ionization (ESI) postive mode low resolution mass spectrum 
of N1,N1'-(butane-1,4-diyl)bis(N1-methylpropane-1,3-diamine) (6) in 
methanol/methylene chloride. (M+H)+ for C12H31N4: calc. 231.4, found 231.5 
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Figure A 2.5: 1H NMR of polyamine biotin (7) in CD3OD at 400 MHz. 
 
Figure A 2.6: 13C NMR of polyamine biotin (7) in CD3OD at 100 MHz. 
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Figure A 2.7: 1H NMR of the triethyl amine salt of ATP-polyamine-biotin (ABP) recorded 
in D2O at 400 MHz. 
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Figure A 2.8: 13C NMR of the triethyl amine salt of ATP-polyamine-biotin (ABP) 
recorded in D2O at 100 MHz. 
 
Figure A 2.9: 31P NMR of the triethylamine salt of ATP-polyamine-biotin (ABP) recorded 
in D2O at 162 MHz. 
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Figure A 2.10: Electrospray ionization (ESI) negative mode high resolution mass 
spectrum (HRMS) of ATP-polyamine-biotin (ABP) recorded in acetonitrile. Calculated 
(M-H)-1 for C32H58N11O14P3S: 944.3098; Observed: 944.3046 
 
Figure A 2.11: UV-VIS spectrum of ATP-polyamine-biotin (ABP) recorded in water. The 
ABP absorbance appears at  260 nm 
 
 
 
 
 
 
 260 
161 
 
 
 
Figure A 2. 12: HPLC analysis of ATP-polyamine-biotin (ABP) purity. ATP-polyamine-
biotin appears at 27.511 minutes and is 95% pure. 
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Figure A 2. 13: 1HNMR of ATP-biotin (1) 
 
Figure A 2. 14: 31PNMR of ATP-biotin (1) 
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Figure A 2. 15: MALDI-TOF of ATP-biotin (1). (M-H)- for C30H51N9O17P3S: calc. 
934.234, found 934.523. 
 
 
Figure A 2. 16: MALDI-Tof positive mode of N-acetylated kemptide peptide 
(AcLRRASLG). Calculated (M+H)+1 for C34H63N13O10+: 814.4894; Observed: 814.372 
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2.2  Repetitive trials of MBP labeling with APB  
Trial 1 
 
Trial 2 
 
 
                                    
                                         
 1 2 3 4 5 7 8 9 
MBP + + + + + + + + 
PKA - + - + + - + + 
ATP - + - - - - - - 
APB - - + + + - + + 
50% TFA - - - - + - - - 
STSP - - - - - - - + 
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MBP + + + + + + + + 
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Trial 3 
 
Figure A 2.17: Full gel images of kinase-catalyzed biotinylation with MBP, PKA, and 
APB. MBP was incubated with APB and PKA in the manufacture provided buffer. As a 
control, TFA (50%) was added after biotinylation labeling to assure biotinylation via an 
acid-labile phosphoramidate bond (lane 5). A kinase inhibitor, staursporine (STSP) was 
preincubated with PKA to confirm biotinylation via a kinase-catalyzed reaction (lane 8). 
The labeled mixtures were separated by SDS-PAGE and visualized by SYPRO® Ruby 
to see total proteins (A) or streptavdin Cy-5 (SA-Cy5, Life Technologies) to detect 
biotinylation (B). The images are representative of at least three independent trials. 
 
 
 
 
 
 
 
 
                                 
                          
 1 2 3 4 5 6 7 8 
MBP + + + + + + + + 
PKA - + - + + - + + 
ATP - + - - - - - - 
APB - - + + + - + + 
50% TFA - - - - + - - - 
STSP - - - - - - - + 
 
Phosphobiotinylated 
MBP 
 
MBP 
A. 
SyproRuby 
B. 
SA-Cy5 
166 
 
 
2.3 Repetitive trials of Kemptide modification with APB 
Trial 2 
 
 
 
 
 
A. 
B. 
1332.490 1371.550 
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Trial 3 
 
 
Figure A 2.18: Repetitive trials of MALDI-TOF spectra of a kinase-catalyzed 
phosphobiotinylation reaction of N-acetylated kemptide with PKA in positive ion mode. 
A) Reaction in the presence of APB: ((M+H)+ for C56H107N19O14PS, Calculated: 
1332.7698; Observed: 1332.490 and 1332.495 respectively for repetitive independent 
trials ; (M+K) + for C56H106KN19O14PS, Calculated: 1371.7151; Observed: 1371.550 and 
1371.462 respectively for repetitive trials B) Reaction in the absence of APB showing no 
product peaks in the same m/z range. 
 
A. 
B. 
1332.495 
1371.462 
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2.4 Repetitive trials of quantification of phosphorylation of MBP using APB 
                       
 
 
Trials 1 and 2 
                      %  100 87  71            100  77  54 
                 
                      
 1 2 3 4 5 6 7 8 
MBP + + + + + + + + 
PKA + + + + + + + + 
ATP - + - - - + - - 
ATP-biotin - - + - - - + - 
APB - - - + - - - + 
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Figure A 2.19: Full gel images of quantitative analysis of MBP phosphorylation in 
presence of PKA with either ATP, ATP-biotin 1, or APB 2. The reaction mixtures were 
separated by SDS-PAGE and visualized by SYPRO® Ruby stain (top gel) to ensure 
homogeneity of protein loading in all lanes or ProQ diamond stain (bottom gel) to detect 
phosphorylation of MBP. MBP degree of phosphorylation was quantified from the ProQ 
diamond stained gel (bottom gel) and the percentage of phosphorylation was calculated 
by comparison with phosphorylation with ATP (100%). The quantitative analysis is a 
representation of at least three independent trials. 
 
 
 
 
 
 
 
 
 
Trials 3 and 4 
                                                    %100 69   45             100  55  50 
                    
                    
 1 2 3 4 5 6 7 8 
MBP + + + + + + + + 
PKA + + + + + + + + 
ATP - + - - - + - - 
ATP-biotin - - + - - - + - 
APB - - - + - - - + 
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2.5  Repetitive trials of biotinylation of HeLa cell lysates with APB and ATP-biotin 
Trial 2                                                                               Trial 3 
 
 
 
 
 
 
 
 
Figure A2.20: Kinase-catalyzed biotinylation of HeLa cell lysates (HCL) or heat-
inactivated HeLa cell lysates (HDL) with APB and ATP-biotin. Acid (50% trifluoroacetic 
acid final concentration) was added after biotin labeling to cleave the biotin tag (lane 5). 
NHS-biotin was used to assess nonspecific biotinylation. Reaction mixture were 
separated by SDS-PAGE and visualized with streptavidin-Cy5 (SA-Cy5, top gel) or 
SYPRO® Ruby total protein stain (bottom gels). The third independent trial is shown in 
Figure 2.11. 
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2.6 Repetitive trials of direct fluorescence imaging of APB in HeLa cells 
Trial 2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Untreated 
ATP 
ATP-biotin 
APB 
DAPI 
SA-Cy5 
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Trial 3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.21: Microscopy studies of ATP-biotin or APB cell permeability. HeLa cells 
were untreated or treated with ATP, ATP-biotin or APB before visualization with the 
nuclear stain DAPI or biotin stain streptavidin-Cy5 (SA-Cy5).  The third independent trial 
is shown in figure 2.13 
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2.7 Repetitive trials of in cellulo kinase-catalyzed biotinylation using APB  
Trial 2                                                                   Trial 3 
                 
Figure A 2.22: In cellulo kinase-catalyzed biotinylation with ATP-biotin or APB in HeLa 
cells. As a control, kinase inhibitor staurosporine (STSP) was pre-incubated with cells to 
prevent kinase catalysis (lane 3). Reaction mixtures (A and C) were separated by SDS-
PAGE and visualized with streptavidin-Cy5 (SA-Cy5, top gel) or SYPRO® Ruby total 
protein stain (bottom gels). The gels are representative of at least three independent 
trials. 
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2.8 Cell viability assay of APB 
 
 
Concentration (mM) % cell viability 
0.0 100% 
1.0 99 ± 3 % 
5.0 96 ± 1 % 
10 80 ± 4 % 
15 60 ± 6 % 
20 43 ± 3 % 
30 34 ± 2 % 
 
Figure A 2.23: Cell viability assays with varying concentrations of APB. A) Dose 
response curve of APB with 1, 5, 10, 15, 20, 30 mM final concentrations. The EC50 of 
APB is 19 ± 1. B) Table with the percentage viability data plotted in part A.  The 
concentration of APB used in kinase-catalyzed labeling of cells was 5 mM.   
 
 
 
 
 
 
A) 
B) 
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APPENDIX B: CHAPTER 2 
3.1  Repetitive trial of direct fluorescence imaging of ATP-biotin/DC complex 
Trial 2:  
 
 
 
 
 
 
 
 
Trial 3: 
 
 
 
 
 
 
 
 
Figure A 3. 1: Repetitive trials of Fluorescence microscopy of ATP-biotin/DC complex. 
HeLa cells were incubated with ATP, ATP-biotin, DC, or the ATP-biotin/DC complex, 
followed by washing, fixing, permeabilizing, and Cells visualization with Streptavidin Cy5 
(Top) and DAPI (bottom). 
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3.2 Repetitive trial of in cellulo MALDI-TOF analysis of ATP-biotin/DC complex 
Trial 2 
 
 
Trial 3 
 
Figure A 3. 2: Repetitive trials of MALDI in cellulo imaging of ATP-biotin. HeLa cells 
were incubated with ATP-biotin, DC, or the ATP-biotin/DC complex followed by washing 
and mixing with alpha picolinic acid in 50% acetonitrile. The mixture was spotted on 
Bruker MALDI plate for analysis. 
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3.3 Repetitive trial of In cellulo and in vitro biotinylation comparison 
Trial 2 
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Trial 3: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3. 3: Repetitive trials of in cellulo and in vitro biotinylation A) In cellulo kinase-
catalyzed biotinylation experiment of HeLa cells with ATP-biotin or ATP-biotin/DC 
complex. As a control, HeLa cells were preincubated with kinase inhibitor staurosporine 
(STSP) to prevent kinase catalysis (lane 5). B) In vitro kinase-catalyzed biotinylation 
using ATP-biotin with HeLa cell lysates (HCL). As a negative control, ATP-biotin was 
incubated with heat-denatured HeLa cell lysates (HDL). SDS-PAGE gel analysis was 
used to separate reaction mixtures and gels were visualized with streptavidin-Cy5 (top 
gel) or SYPRO® Ruby total protein stain (bottom gels). The protein ladder contains 
proteins of the following sizes: 170, 130, 100, 72, 55, 43, 34, and 26 kDa.  All images 
are representative of at least three independent trials. 
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APPENDIX C: CHAPTER 4 
4.1 Compounds characterization 
 
Figure A 4. 1: 1HNMR of N-(aminohexyl)methacrylamide (15) recorded in CD3OD. 
Peaks at and3.83 corresponds to CD3OD. 
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Figure A 4. 2: 13CNMR of N-(aminohexyl)methacrylamide (15) recorded in CD3OD. 
Peaks at 47.56 corresponds to CD3OD 
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Figure A 4. 3: Electrospray ionization positive mode mass spectrum of N-
(aminohexyl)methacrylamide (15). Calculated (M+1)+1 for C10H21N2O: 185.17; Observed 
185.17 
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Figure A 4. 4: 1HNMR of ATP-Hex-Acr triethylamine salt (11) recorded in D2O. Peaks at 
4.61 correspond to D2O and peaks at  3.04 and 1.10 correspond CH2 and CH3 of 
triethylamine respectively. 
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Figure A 4. 5: 13CNMR of ATP-Hex-Acr (11) recorded in D2O. Peaks at  46.58 and 
8.13 correspond CH2 and CH3 of triethylamine respectively. Multiplicity of C13 was 
observed to due to coupling with phosphorus as previously reported.187 
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Figure A 4. 6: 31PNMR of ATP-Hex-Acr (11) recorded in D2O.  
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Figure A 4. 7: Electrospray ionization (ESI) negative mode high resolution mass 
spectrum (HRMs) of ATP-Hex-Acr (11). Calculated (M-H)-1 for C20H33N7O13P3: 
672.1349; Observed 672.1316. 
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Figure A 4. 8: 1HNMR of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl) 
methacrylamide (17) recorded in CD3OD. Peaks at 3.32 and 4.85 corresponds to 
CD3OD 
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Figure A 4. 9: 13CNMR of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl) 
methacrylamide (17) recorded in CD3OD. Peaks at 47.84 corresponds to CD3OD 
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Figure A 4. 10: Electrospray ionization (ESI) positive mode mass spectrum of N-(3-(2-
(2-(3-aminopropoxy)ethoxy)ethoxy)propyl) methacrylamide (17). Calculated (M+H)+1 for 
C14H29N2O4: 289.21, observed 289.21. 
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Figure A 4. 11: 1HNMR of ATP-PEG-Acr (12) recorded in D2O. Peaks at 5.04 
correspond to D2O and peaks at  3.46 and 1.53 correspond CH2 and CH3 of 
triethylamine respectively.  
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Figure A 4. 12: 13CNMR of ATP-PEG-Acr (12) recorded in D2O. Peaks at  46.58 and 
8.13 correspond CH2 and CH3 of triethylamine respectively. Multiplicity of C13 was 
observed to due to coupling with phosphorus as previously reported.187 
 
 
Figure A 4. 13: 31PNMR of ATP-PEG-Acr (12) recorded in D2O.  
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Figure A 4. 14: Electrospray ionization (ESI) positive mode high resolution mass 
spectrum (HRMs) of ATP-PEG-Acr (12). Calculated (M-H)-1 for C24H41N7O16P3: 
776.1823, observed 776.1822. 
 
Figure A 4. 15: 1HNMR of DIFITC-cystamine (18) in CD3OD. Peaks at 3.30 and 4.87 
correspond to CD3OD 
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Figure A 4. 16: 13CNMR of DIFITC-cystamine (18) in CD3OD. Peaks at 47.56 
correspond to CD3OD 
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Figure A 4. 17: Electrospray ionization (ESI) positive mode high resolution mass 
spectrum (HRMs) of DIFITC-cystamine (18). Calculated (M+H)+1 for C46H35N4O10S4: 
931.1236, observed 931.1240. 
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4.2 Full gel images and repetitive trials of kinase-catalyzed in gel fluorescence of 
MBP using ATP-acrylamides and DIFITIC-cystamine  
 
Trial 1 
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Trial 2 
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Figure A 4.18: Repetitive trials of detection of kinase-catalyzed phosphorylation of MPB 
with PKA and ATP-acrylamides in presence of DiFTC-cystamine (18). ATP-Hex-Acr 11 
or ATP-PEG-Acr 12 were incubated with MBP, PKA, and DIFITC-cystamine (18). The 
reaction mixtures were separated by SDS-PAGE gel analysis. As a control, the reaction 
was performed in presence of staurosporine (STSP), kinase inhibitor. Top gel is 
visualized by typhoon scanning for in gel fluorescence (excitation/emission=495/519 
nm) and bottom gel was visualized by SYPRO® Ruby total protein stain. Trial 1 is also 
shown in figure 4.16C 
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4.3 Full gel images and repetitive trials of determining the efficiency of ATP-
acrylamides (11 and 12) 
Trial 1 and 2 
  
 
 
 
 
 
                                                      100% 69%  54%                  100% 38%   94% 
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ATP  - + - - - + - - 
11 - - +  - - +  
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Trial 3 and 4 
  
Figure A 4.19: Quantitative analysis of MPB phosphorylation in the presence of PKA 
and incubated with either ATP (lane 2 and 6), ATP-Hex-Acr (lane 3 and 7), or ATP-
PEG-Acr (lane 4 and 8), then treated with TFA. The reaction mixtures were analyzed by 
SDS-PAGE analysis, followed by staining with ProQ diamond phosphoprotein stain 
(top) or SYPRO® Ruby total protein stain (bottom).  MBP staining from ProQ diamond 
stained gel was quantified by Image quant, which corresponds to extent of 
phosphorylation. The mean percentage of phosphorylation of MBP from four trials is 
shown on the top of the ProQ diamond gel. 
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4.4 Full gel images and repetitive trials of In vitro Akt1 crosslinking to its 
substrates using ATP-acrylamides 
Trial 2: 
 
 
 
 
 
 
 
     
Higher molecular 
weight complex
Akt1
72
95
130
170
55
72
95
130
170
55
Anti 
Akt1
Sypro
Ruby
 
  1 2 3 4 5 
HEK293 Lysates + + + + + 
11   + +     
12       + + 
STSP   +   +   
TCEP + + + + + 
 
200 
 
 
Trial 3: 
 
Figure A 4.20: Kinase-catalyzed crosslinking of AKT with its substrates in HEK293 
lysates using ATP-acrylamides (11 and 12). HEK293 lysates were incubated with ATP-
acrylamides in presence of TCEP (tris(2-carboxyethyl)phosphine). TCEP was used to 
form necessary reducing conditions for cysteine reactivity. As a control, the reaction 
was performed in presence of staurosporine (STSP), kinase inhibitor. The reaction 
mixtures were separated by SDS-PAGE electrophoresis and transferring onto PVDF 
membrane as a western blotting. Top gel is visualized by treating with anti-AKT1 
antibody followed by secondary HRP, while the bottom gel was visualized by SYPRO 
Ruby. The third trial is shown in figure 4.19 
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4.5 Repetitive trials of Akt1 substrates identification with ATP-acrylamides using 
K-CLIP (Kinase-CrossLinking and ImmunoPrecipitation) 
Trial 1: 
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Trial 2: Shown in Chapter 4 (Figure 4.20) 
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Trial 3: 
 
Figure A 4.21: Kinase-catalyzed crosslinking of AKT with its substrates in HEK293 
lysates using ATP-acrylamides (11 and 12). HEK293 lysates were incubated with ATP-
acrylamides followed by immunoprecipitation with anti Akt1 antibody and agarose 
beads. As a control, the reaction was performed in presence of staurosporine (STSP), 
kinase inhibitor. The reaction mixtures were separated by SDS-PAGE electrophoresis 
and transferring onto PVDF membrane as a western blotting. Top gel is visualized by 
treating with anti-AKT1 antibody followed by secondary HRP, while the bottom gel was 
visualized by SYPRO Ruby. At least three independent trials were performed but only 
two trials were used for in gel digestion and further MS/MS analysis (Table A4.2 and 
A4.3) 
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4.6 Representation of the number of unique peptides identified from Akt1 
substrates identification experiment with ATP-acrylamides using K-CLIP.  
Table A.4.1: All proteins identified from crosslinking of Akt1 with ATP-PEG-Acr in 
HEK293 from 2 independent trials. 
After IP of Akt1 as in figure 4.20, Protein lists obtained from Ms/Ms analysis. Number of 
unique peptides identified for each protein in the crosslinked Akt1 with ATP-PEG-Acr 
lane (lane 5, Figure 4.20) were divided by number of unique peptides identified from 
staursporine treated HEK293 (lane 4, Figure 4.20) or non-crosslinked Akt1 (lane 1, 
Figure 4.20) to obtain peptide ratio of ATP-PEG-Acr. Only peptide ratio that is more 
than one and present in two independednt trials is considered to be solely 
phosphorylation dependent crosslinking and shown in the following table. Proteins from 
1-7 are known Akt1 physical interactor (as reported in Biogrid database) and proteins 
from 8-11 are known Akt1 substrates (as reported in phosphosite database). The rest 
of proteins can be substrate candidates for Akt1. This data represents proteins from 
two independent trials 
No Protein identified Gene 
Accession 
number 
Mol. Wt 
(kDa) 
Scansite 
motif 
1.  Stress-70 protein, mitochondrial HSPA9 GRP75 74  Yes 
2.  Vesicle-fusing ATPase NSF NSF 83  
Yes 
3.  Heat shock protein HSP 90-alpha 
HSP90AA
1 
HS90A 85  
Yes 
4.  Heat shock protein HSP 90-beta 
HSP90AB
1 
HS90B 83  
Yes 
5.  Heat shock cognate 71 kDa protein HSPA8 HSP7C 71  
Yes 
6.  Creatine kinase B-type CKB KCRB 43  
Yes 
7.  L-lactate dehydrogenase A chain LDHA LDHA 37  No 
8.  Transitional endoplasmic reticulum ATPase VCP TERA 89  
Yes 
9.  Pre-mRNA-processing factor 19 PRPF19 PRP19 55  
Yes 
10.  T-complex protein 1 subunit beta CCT2 TCPB 57  
Yes 
11.  Zyxin ZYX ZYX 61  
Yes 
12.  Aconitate hydratase, mitochondrial ACO2 ACON 85  
Yes 
13.  Alpha-actinin-4 ACTN4 ACTN4 105  
Yes 
14.  
Activator of 90 kDa heat shock protein 
ATPase homolog 1 
AHSA1 AHSA1 38  
Yes 
15.  Apoptosis-inducing factor 1, mitochondrial AIFM1 AIFM1 67  
Yes 
16.  Cytosol aminopeptidase LAP3 AMPL 56  
Yes 
17.  
ATPase family AAA domain-containing 
protein 3A 
ATAD3A ATD3A 71  
Yes 
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18.  Cytoskeleton-associated protein 4 CKAP4 CKAP4 66  
Yes 
19.  Cytosolic non-specific dipeptidase CNDP2 CNDP2 53  
Yes 
20.  Coatomer subunit gamma-1 COPG1 COPG1 98  
Yes 
21.  Cold shock domain-containing protein E1 CSDE1 CSDE1 89  
Yes 
22.  COP9 signalosome complex subunit 4 COPS4 CSN4 46  
Yes 
23.  Drebrin-like protein DBNL DBNL 48  
Yes 
24.  ATP-dependent RNA helicase DDX1 DDX1 DDX1 82  No 
25.  
Probable ATP-dependent RNA helicase 
DDX17 
DDX17 DDX17 80  
Yes 
26.  Peroxisomal multifunctional enzyme type 2 HSD17B4 DHB4 80  
Yes 
27.  Dynamin-1-like protein DNM1L DNM1L 82  
Yes 
28.  Dihydropyrimidinase-related protein 1 CRMP1 DPYL1 62  
Yes 
29.  
Developmentally-regulated GTP-binding 
protein 1 
DRG1 DRG1 41  
Yes 
30.  
Trifunctional enzyme subunit alpha, 
mitochondrial 
HADHA ECHA 83  
Yes 
31.  Elongation factor 2 EEF2 EF2 95  
Yes 
32.  
Eukaryotic translation initiation factor 3 
subunit D 
EIF3D EIF3D 64  
Yes 
33.  
Eukaryotic translation initiation factor 3 
subunit L 
EIF3L EIF3L 67  
Yes 
34.  Epiplakin EPPK1 EPIPL 556  
Yes 
35.  Exosome component 10 EXOSC10 EXOSX 101  
Yes 
36.  Ezrin EZR EZRI 69  
Yes 
37.  RNA-binding protein FUS FUS FUS 53  
Yes 
38.  Glucose-6-phosphate isomerase GPI G6PI 63  
Yes 
39.  Glucosidase 2 subunit beta PRKCSH GLU2B 59  
Yes 
40.  
Serine hydroxymethyltransferase, 
mitochondrial 
SHMT2 GLYM 56  
Yes 
41.  GMP synthase (glutamine-hydrolyzing) GMPS GUAA 77  
Yes 
42.  
Heterogeneous nuclear ribonucleoproteins 
C1/C2 
HNRNPC HNRPC 34  
Yes 
43.  Heterogeneous nuclear ribonucleoprotein F HNRNPF HNRPF 46  
Yes 
44.  Heterogeneous nuclear ribonucleoprotein K HNRNPK HNRPK 51  
Yes 
45.  Heterogeneous nuclear ribonucleoprotein M  HNRPM 78  
Yes 
46.  Heterogeneous nuclear ribonucleoprotein R HNRNPR HNRPR 71  
Yes 
47.  Hornerin HRNR HORN 282  
Yes 
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48.  Heat shock 70 kDa protein 1A HSPA1A HS71A 70  
Yes 
49.  Interferon regulatory factor 2-binding protein 1 IRF2BP1 I2BP1 62  
Yes 
50.  Importin subunit beta-1 KPNB1 IMB1 97  
Yes 
51.  Pyruvate kinase PKM PKM KPYM 58  
Yes 
52.  
LETM1 and EF-hand domain-containing 
protein 1, mitochondrial 
LETM1 LETM1 83  
Yes 
53.  Leukotriene A-4 hydrolase LTA4H LKHA4 69  
Yes 
54.  Leucine-rich repeat-containing protein 40 LRRC40 LRC40 68  
Yes 
55.  Melanoma-associated antigen D2 MAGED2 MAGD2 65  
Yes 
56.  DNA replication licensing factor MCM5 MCM5 MCM5 82  
Yes 
57.  MICOS complex subunit MIC60 IMMT MIC60 84  
Yes 
58.  
Mitochondrial-processing peptidase subunit 
alpha 
PMPCA MPPA 58  
Yes 
59.  Metastasis-associated protein MTA2 MTA2 MTA2 75  
Yes 
60.  Nuclear autoantigenic sperm protein NASP NASP 85  
Yes 
61.  
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial 
NDUFS1 NDUS1 79  
Yes 
62.  tRNA (cytosine(34)-C(5))-methyltransferase NSUN2 NSUN2 86  
Yes 
63.  
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex, mitochondrial 
DLAT ODP2 69  
Yes 
64.  Obg-like ATPase 1 OLA1 OLA1 45  
Yes 
65.  Transcriptional repressor p66-alpha 
GATAD2
A 
P66A 68  
Yes 
66.  Polyadenylate-binding protein 1 PABPC1 PABP1 71  
Yes 
67.  
Plasminogen activator inhibitor 1 RNA-
binding protein 
SERBP1 PAIRB 45  
Yes 
68.  Poly(rC)-binding protein 1 PCBP1 PCBP1 37  
Yes 
69.  Programmed cell death 6-interacting protein PDCD6IP PDC6I 96  
Yes 
70.  2',5'-phosphodiesterase 12 PDE12 PDE12 67  
Yes 
71.  Peptidyl-prolyl cis-trans isomerase D PPID PPID 41  No 
72.  U4/U6 small nuclear ribonucleoprotein Prp3 PRPF3 PRPF3 78  
Yes 
73.  26S protease regulatory subunit 10B PSMC6 PRS10 44  
Yes 
74.  
26S proteasome non-ATPase regulatory 
subunit 2 
PSMD2 PSMD2 100  
Yes 
75.  
26S proteasome non-ATPase regulatory 
subunit 3 
PSMD3 PSMD3 61  
Yes 
76.  
Bifunctional purine biosynthesis protein 
PURH 
ATIC PUR9 65  
Yes 
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77.  Glycogen phosphorylase, liver form PYGL PYGL 97  
Yes 
78.  CTP synthase 1 CTPS1 PYRG1 67  
Yes 
79.  Ran GTPase-activating protein 1 
RANGAP
1 
RAGP1 64  
Yes 
80.  Ribonucleoprotein PTB-binding 1 RAVER1 RAVR1 64  
Yes 
81.  Histone-binding protein RBBP4 RBBP4 RBBP4 48  No 
82.  RNA-binding protein 14 RBM14 RBM14 69  
Yes 
83.  RNA-binding protein 39 RBM39 RBM39 59  
Yes 
84.  Reticulocalbin-1 RCN1 RCN1 39  No 
85.  
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
RPN1 RPN1 69  Yes 
86.  Ubiquitin-40S ribosomal protein S27a RPS27A RS27A 18  No 
87.  40S ribosomal protein SA RPSA RSSA 33  No 
88.  Protein transport protein Sec31A SEC31A SC31A 133  
Yes 
89.  
Succinate dehydrogenase (ubiquinone) 
flavoprotein subunit, mitochondrial 
SDHA SDHA 73  
Yes 
90.  Septin-11 SEPT11 SEP11 49  
Yes 
91.  Serpin H1 
SERPINH
1 
SERPH 46  
Yes 
92.  Splicing factor 3A subunit 3 SF3A3 SF3A3 59  No 
93.  Splicing factor, proline- and glutamine-rich SFPQ SFPQ 76  
Yes 
94.  Signal recognition particle subunit SRP68 SRP68 SRP68 71  
Yes 
95.  
Signal recognition particle receptor subunit 
alpha 
SRPR SRPR 70  
Yes 
96.  Alanine--tRNA ligase, cytoplasmic AARS SYAC 107  
Yes 
97.  Phenylalanine--tRNA ligase beta subunit FARSB SYFB 66  
Yes 
98.  Glycine--tRNA ligase GARS SYG 83  
Yes 
99.  Arginine--tRNA ligase, cytoplasmic RARS SYRC 75  
Yes 
100. Tyrosine--tRNA ligase, cytoplasmic YARS SYYC 59  
Yes 
101. T-complex protein 1 subunit alpha TCP1 TCPA 60  
Yes 
102. T-complex protein 1 subunit delta CCT4 TCPD 58  
Yes 
103. T-complex protein 1 subunit epsilon CCT5 TCPE 60  
Yes 
104. T-complex protein 1 subunit gamma CCT3 TCPG 61  
Yes 
105. T-complex protein 1 subunit theta CCT8 TCPQ 60  
Yes 
106. Acetyl-CoA acetyltransferase, mitochondrial ACAT1 THIL 45  
Yes 
107. Mitochondrial import receptor subunit TOM70 
TOMM70
A 
TOM70 67  
Yes 
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108. Heat shock protein 75 kDa, mitochondrial TRAP1 TRAP1 80  
Yes 
109. Tetratricopeptide repeat protein 4 TTC4 TTC4 45  No 
110. Tubulin--tyrosine ligase-like protein 12  TTL12 74  
Yes 
111. Ubiquitin carboxyl-terminal hydrolase 5 USP5 UBP5 96  
Yes 
112. 
Synaptic vesicle membrane protein VAT-1 
homolog 
VAT1 VAT1 42  No 
113. V-type proton ATPase catalytic subunit A ATP6V1A VATA 68  
Yes 
114. 
Vacuolar protein sorting-associated protein 
35 
VPS35 VPS35 92  
Yes 
115. Exportin-T XPOT XPOT 110  
Yes 
116. X-ray repair cross-complementing protein 6 XRCC6 XRCC6 70  
Yes 
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Table A.4.2: Proteins identified from crosslinking of Akt1 with ATP-Hex-Acr in 
HEK293 from two independent trials 
After IP of Akt1 as in figure 4.20, Protein lists obtained from Ms/Ms analysis. Number of 
unique peptides identified for each protein in the crosslinked Akt1 with ATP-Hex-Acr 
lane (lane 3, Figure 4.20) were divided by number of unique peptides identified from 
staursporine treated HEK293 (lane 2, Figure 4.20) or non-crosslinked Akt1 (lane 1, 
Figure 4.20) to obtain peptide ratio of ATP-PEG-Acr. Only peptide ratio that is more 
than one is considered to be solely depended on phosphorylation dependednt 
crosslinking and shown in the following table. Proteins from 1-3 are known Akt1 physical 
interactor (as reported in Biogrid database). 
No Protein identification Gene 
Accession 
number 
Mol. Wt. 
(kDa) 
1.  Stress-70 protein, mitochondrial HSPA9 GRP75 74 
2.  Creatine kinase B-type CKB KCRB 43 
3.  L-lactate dehydrogenase A chain LDHA LDHA 37 
4.  
Apoptosis-inducing factor 1, 
mitochondrial 
AIFM1 AIFM1 67 
5.  Far upstream element-binding protein 3 FUBP3 FUBP3 62 
6.  RNA-binding protein FUS FUS FUS 53 
7.  
Heterogeneous nuclear 
ribonucleoprotein Q 
SYNCRIP HNRPQ 70 
8.  
KH domain-containing, RNA-binding, 
signal transduction-associated protein 1 
KHDRBS1 KHDR1 48 
9.  MICOS complex subunit MIC60 IMMT MIC60 84 
10.  Nucleolar protein 56 NOP56 NOP56 66 
11.  Nucleolar protein 58 NOP58 NOP58 60 
12.  Protein regulator of cytokinesis 1 PRC1 PRC1 72 
13.  RNA-binding protein 14 RBM14 RBM14 69 
14.  
Ribosomal L1 domain-containing protein 
1 
RSL1D1 RL1D1 55 
15.  V-type proton ATPase catalytic subunit A ATP6V1A VATA 68 
16.  
DNA repair protein XRCC1 OS=Homo 
sapiens 
XRCC1 XRCC1 69 
17.  YTH domain-containing family protein 2 YTHDF2 YTHD2 62 
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Table A. 4. 3: Representation of the number of unique peptides from Trial 1, figure 
A 4.21  
The table containing data for trypsinized proteins from SDS-PAGE gel of trial 1 
(Appendix C, section 4.5). The data of the table represents uncrosslinked lysated (lane 
1, Figure A 4.21), ATP-Hex-Acr crosslinked lysates in presence of staursporine (lane 2, 
Figure A 4.21), ATP-Hex-Acr crosslinked lysates (lane 3, Figure A 4.21), ATP-PEG-Acr 
crosslinked lysates in presence of staursporine (lane 4, Figure A 4.21), and ATP-Hex-
Acr crosslinked lysates (lane 5, Figure A 4.21). 
 
Protein identified 
Accession 
No. 
Mol. 
Wt. 
No. of unique peptides identified 
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 
Stress-70 protein, mitochondrial 
OS=Homo sapiens GN=HSPA9 
PE=1 SV=2 
GRP75 
74 
kDa 
5 1 8 4 6 
Creatine kinase B-type OS=Homo 
sapiens GN=CKB PE=1 SV=1 
KCRB 
43 
kDa 
0 1 5 5 10 
L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA PE=1 
SV=2 
LDHA 
37 
kDa 
0 0 1 0 1 
Heat shock protein HSP 90-alpha 
OS=Homo sapiens GN=HSP90AA1 
PE=1 SV=5 
HS90A 
85 
kDa 
31 5 13 20 35 
Heat shock protein HSP 90-beta 
OS=Homo sapiens GN=HSP90AB1 
PE=1 SV=4 
HS90B 
83 
kDa 
20 2 14 9 22 
Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 
PE=1 SV=1 
HSP7C 
71 
kDa 
13 0 4 10 18 
Vesicle-fusing ATPase OS=Homo 
sapiens GN=NSF PE=1 SV=3 
NSF 
83 
kDa 
0 0 0 0 1 
Transitional endoplasmic reticulum 
ATPase OS=Homo sapiens 
GN=VCP PE=1 SV=4 
TERA 
89 
kDa 
0 0 0 0 3 
Interleukin-1 receptor-associated 
kinase 1 OS=Homo sapiens 
GN=IRAK1 PE=1 SV=2 
IRAK1 
77 
kDa 
0 0 0 0 1 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
ACTB 
42 
kDa 
0 0 1 1 1 
Alpha-enolase OS=Homo sapiens 
GN=ENO1 PE=1 SV=2 
ENOA 
47 
kDa 
1 1 2 7 5 
Vimentin OS=Homo sapiens 
GN=VIM PE=1 SV=4 
VIME 
54 
kDa 
16 2 35 6 19 
Kinectin OS=Homo sapiens 
GN=KTN1 PE=1 SV=1 
KTN1 
156 
kDa 
0 0 0 0 1 
Proliferation-associated protein 2G4 
OS=Homo sapiens GN=PA2G4 
PE=1 SV=3 
PA2G4 
44 
kDa 
0 0 0 0 1 
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
gamma-1 OS=Homo sapiens 
GN=PLCG1 PE=1 SV=1 
PLCG1 
149 
kDa 
0 0 0 0 1 
DNA-dependent protein kinase 
catalytic subunit OS=Homo sapiens 
GN=PRKDC PE=1 SV=3 
PRKDC 
469 
kDa 
24 0 9 9 45 
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Dynactin subunit 1 OS=Homo 
sapiens GN=DCTN1 PE=1 SV=3 
DCTN1 
142 
kDa 
1 0 0 0 8 
DNA (cytosine-5)-methyltransferase 
1 OS=Homo sapiens GN=DNMT1 
PE=1 SV=2 
DNMT1 
183 
kDa 
1 0 0 0 4 
Probable ATP-dependent RNA 
helicase DDX5 OS=Homo sapiens 
GN=DDX5 PE=1 SV=1 
DDX5 
69 
kDa 
4 0 5 2 4 
Serine/threonine-protein 
phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform OS=Homo 
sapiens GN=PPP2R1A PE=1 SV=4 
2AAA 
65 
kDa 
4 0 4 1 9 
Sodium/potassium-transporting 
ATPase subunit alpha-1 OS=Homo 
sapiens GN=ATP1A1 PE=1 SV=1 
AT1A1 
113 
kDa 
4 0 2 0 13 
Clathrin heavy chain 1 OS=Homo 
sapiens GN=CLTC PE=1 SV=5 
CLH1 
192 
kDa 
22 1 4 4 33 
Elongation factor 1-gamma 
OS=Homo sapiens GN=EEF1G 
PE=1 SV=3 
EF1G 
50 
kDa 
7 1 6 4 11 
Heat shock 70 kDa protein 4 
OS=Homo sapiens GN=HSPA4 
PE=1 SV=4 
HSP74 
94 
kDa 
5 0 1 2 6 
Hexokinase-1 OS=Homo sapiens 
GN=HK1 PE=1 SV=3 
HXK1 
102 
kDa 
5 1 1 1 6 
Eukaryotic initiation factor 4A-I 
OS=Homo sapiens GN=EIF4A1 
PE=1 SV=1 
IF4A1 
46 
kDa 
14 1 10 7 17 
Ras GTPase-activating-like protein 
IQGAP1 OS=Homo sapiens 
GN=IQGAP1 PE=1 SV=1 
IQGA1 
189 
kDa 
0 0 0 0 7 
Actin, cytoplasmic 2 OS=Homo 
sapiens GN=ACTG1 PE=1 SV=1 
ACTG 
42 
kDa 
0 4 10 10 14 
6-phosphogluconate 
dehydrogenase, decarboxylating 
OS=Homo sapiens GN=PGD PE=1 
SV=3 
6PGD 
53 
kDa 
0 0 1 2 4 
Apoptosis-inducing factor 1, 
mitochondrial OS=Homo sapiens 
GN=AIFM1 PE=1 SV=1 
AIFM1 
67 
kDa 
0 0 1 0 1 
Cytosol aminopeptidase OS=Homo 
sapiens GN=LAP3 PE=1 SV=3 
AMPL 
56 
kDa 
0 0 1 0 3 
ATP synthase subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=ATP5A1 PE=1 SV=1 
ATPA 
60 
kDa 
10 0 11 8 12 
ATP synthase subunit beta, 
mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 
ATPB 
57 
kDa 
15 2 17 15 19 
Calreticulin OS=Homo sapiens 
GN=CALR PE=1 SV=1 
CALR 
48 
kDa 
1 0 2 2 6 
Protein DEK OS=Homo sapiens 
GN=DEK PE=1 SV=1 
DEK 
43 
kDa 
0 0 5 0 2 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 
DESP 
332 
kDa 
1 1 5 0 8 
DnaJ homolog subfamily A member 
1 OS=Homo sapiens GN=DNAJA1 
PE=1 SV=2 
DNJA1 
45 
kDa 
0 0 2 0 2 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
EFTU 
50 
kDa 
5 0 9 5 8 
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Eukaryotic translation initiation factor 
3 subunit D OS=Homo sapiens 
GN=EIF3D PE=1 SV=1 
EIF3D 
64 
kDa 
0 0 2 0 2 
Flap endonuclease 1 OS=Homo 
sapiens GN=FEN1 PE=1 SV=1 
FEN1 
43 
kDa 
0 0 1 1 2 
RNA-binding protein FUS OS=Homo 
sapiens GN=FUS PE=1 SV=1 
FUS 
53 
kDa 
0 0 3 0 2 
Ras GTPase-activating protein-
binding protein 1 OS=Homo sapiens 
GN=G3BP1 PE=1 SV=1 
G3BP1 
52 
kDa 
3 0 5 3 8 
Guanine nucleotide-binding protein-
like 3 OS=Homo sapiens GN=GNL3 
PE=1 SV=2 
GNL3 
62 
kDa 
1 0 2 0 3 
HEAT repeat-containing protein 1 
OS=Homo sapiens GN=HEATR1 
PE=1 SV=3 
HEAT1 
242 
kDa 
0 0 1 0 3 
Heterogeneous nuclear 
ribonucleoprotein D0 OS=Homo 
sapiens GN=HNRNPD PE=1 SV=1 
HNRPD 
38 
kDa 
0 0 1 0 1 
Heterogeneous nuclear 
ribonucleoprotein F OS=Homo 
sapiens GN=HNRNPF PE=1 SV=3 
HNRPF 
46 
kDa 
1 0 3 1 2 
Heterogeneous nuclear 
ribonucleoprotein M OS=Homo 
sapiens GN=HNRNPM PE=1 SV=3 
HNRPM 
78 
kDa 
13 1 17 6 15 
Heterogeneous nuclear 
ribonucleoprotein Q OS=Homo 
sapiens GN=SYNCRIP PE=1 SV=2 
HNRPQ 
70 
kDa 
0 0 1 0 1 
Eukaryotic translation initiation factor 
2 subunit 2 OS=Homo sapiens 
GN=EIF2S2 PE=1 SV=2 
IF2B 
38 
kDa 
0 0 2 0 1 
Eukaryotic translation initiation factor 
2 subunit 3 OS=Homo sapiens 
GN=EIF2S3 PE=1 SV=3 
IF2G 
51 
kDa 
4 1 6 3 5 
Eukaryotic translation initiation factor 
5B OS=Homo sapiens GN=EIF5B 
PE=1 SV=4 
IF2P 
139 
kDa 
0 0 1 0 4 
Eukaryotic translation initiation factor 
5 OS=Homo sapiens GN=EIF5 
PE=1 SV=2 
IF5 
49 
kDa 
1 0 3 0 3 
Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2 
IGHA1 
38 
kDa 
0 0 2 0 3 
Interleukin enhancer-binding factor 2 
OS=Homo sapiens GN=ILF2 PE=1 
SV=2 
ILF2 
43 
kDa 
1 0 4 2 4 
Importin subunit alpha-1 OS=Homo 
sapiens GN=KPNA2 PE=1 SV=1 
IMA1 
58 
kDa 
4 2 6 4 5 
Lamin-B1 OS=Homo sapiens 
GN=LMNB1 PE=1 SV=2 
LMNB1 
66 
kDa 
0 0 9 0 4 
Leucine-rich repeat-containing 
protein 47 OS=Homo sapiens 
GN=LRRC47 PE=1 SV=1 
LRC47 
63 
kDa 
0 0 1 0 5 
MICOS complex subunit MIC60 
OS=Homo sapiens GN=IMMT PE=1 
SV=1 
MIC60 
84 
kDa 
0 0 1 0 1 
Neurofilament light polypeptide 
OS=Homo sapiens GN=NEFL PE=1 
SV=3 
NFL 
62 
kDa 
2 0 8 0 4 
Neurofilament medium polypeptide 
OS=Homo sapiens GN=NEFM PE=1 
SV=3 
NFM 
102 
kDa 
6 1 9 0 7 
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Nucleosome assembly protein 1-like 
1 OS=Homo sapiens GN=NAP1L1 
PE=1 SV=1 
NP1L1 
45 
kDa 
2 0 4 3 5 
Nuclear pore complex protein 
Nup205 OS=Homo sapiens 
GN=NUP205 PE=1 SV=3 
NU205 
228 
kDa 
0 0 1 0 1 
Nuclear pore complex protein Nup93 
OS=Homo sapiens GN=NUP93 
PE=1 SV=2 
NUP93 
93 
kDa 
0 0 2 0 2 
Programmed cell death protein 4 
OS=Homo sapiens GN=PDCD4 
PE=1 SV=2 
PDCD4 
52 
kDa 
0 0 1 0 2 
Retrotransposon-derived protein 
PEG10 OS=Homo sapiens 
GN=PEG10 PE=1 SV=2 
PEG10 
80 
kDa 
0 0 1 0 1 
Protein regulator of cytokinesis 1 
OS=Homo sapiens GN=PRC1 PE=1 
SV=2 
PRC1 
72 
kDa 
0 0 3 0 1 
U4/U6 small nuclear 
ribonucleoprotein Prp31 OS=Homo 
sapiens GN=PRPF31 PE=1 SV=2 
PRP31 
55 
kDa 
0 0 1 0 1 
26S protease regulatory subunit 4 
OS=Homo sapiens GN=PSMC1 
PE=1 SV=1 
PRS4 
49 
kDa 
1 1 3 1 2 
26S protease regulatory subunit 8 
OS=Homo sapiens GN=PSMC5 
PE=1 SV=1 
PRS8 
46 
kDa 
1 0 3 2 5 
26S proteasome non-ATPase 
regulatory subunit 11 OS=Homo 
sapiens GN=PSMD11 PE=1 SV=3 
PSD11 
47 
kDa 
1 0 2 1 4 
RNA-binding protein 14 OS=Homo 
sapiens GN=RBM14 PE=1 SV=2 
RBM14 
69 
kDa 
2 0 7 1 4 
Ribosomal L1 domain-containing 
protein 1 OS=Homo sapiens 
GN=RSL1D1 PE=1 SV=3 
RL1D1 
55 
kDa 
0 0 1 0 2 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 
RSSA 
33 
kDa 
0 0 2 3 7 
tRNA-splicing ligase RtcB homolog 
OS=Homo sapiens GN=RTCB PE=1 
SV=1 
RTCB 
55 
kDa 
1 0 2 0 2 
Serpin H1 OS=Homo sapiens 
GN=SERPINH1 PE=1 SV=2 
SERPH 
46 
kDa 
0 0 1 2 3 
Sorting nexin-1 OS=Homo sapiens 
GN=SNX1 PE=1 SV=3 
SNX1 
59 
kDa 
0 0 1 0 1 
Phenylalanine--tRNA ligase beta 
subunit OS=Homo sapiens 
GN=FARSB PE=1 SV=3 
SYFB 
66 
kDa 
0 0 2 2 4 
T-complex protein 1 subunit delta 
OS=Homo sapiens GN=CCT4 PE=1 
SV=4 
TCPD 
58 
kDa 
6 0 8 7 12 
V-type proton ATPase catalytic 
subunit A OS=Homo sapiens 
GN=ATP6V1A PE=1 SV=2 
VATA 
68 
kDa 
1 0 2 1 2 
Serine/threonine-protein 
phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform OS=Homo 
sapiens GN=PPP2R2A PE=1 SV=1 
2ABA 
52 
kDa 
0 0 0 0 1 
Neutral amino acid transporter B(0) 
OS=Homo sapiens GN=SLC1A5 
PE=1 SV=2 
AAAT 
57 
kDa 
0 0 0 0 2 
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ATP-binding cassette sub-family E 
member 1 OS=Homo sapiens 
GN=ABCE1 PE=1 SV=1 
ABCE1 
67 
kDa 
0 0 0 0 1 
Acetyl-CoA carboxylase 1 
OS=Homo sapiens GN=ACACA 
PE=1 SV=2 
ACACA 
266 
kDa 
1 0 0 0 2 
Apoptotic chromatin condensation 
inducer in the nucleus OS=Homo 
sapiens GN=ACIN1 PE=1 SV=2 
ACINU 
152 
kDa 
0 0 0 0 1 
Actin-like protein 6A OS=Homo 
sapiens GN=ACTL6A PE=1 SV=1 
ACL6A 
47 
kDa 
0 0 0 0 1 
Aconitate hydratase, mitochondrial 
OS=Homo sapiens GN=ACO2 PE=1 
SV=2 
ACON 
85 
kDa 
2 1 1 1 3 
Alpha-actinin-1 OS=Homo sapiens 
GN=ACTN1 PE=1 SV=2 
ACTN1 
103 
kDa 
0 0 0 0 2 
Alpha-actinin-4 OS=Homo sapiens 
GN=ACTN4 PE=1 SV=2 
ACTN4 
105 
kDa 
3 1 0 0 8 
Alpha-centractin OS=Homo sapiens 
GN=ACTR1A PE=1 SV=1 
ACTZ 
43 
kDa 
0 0 0 0 2 
Proteasomal ubiquitin receptor 
ADRM1 OS=Homo sapiens 
GN=ADRM1 PE=1 SV=2 
ADRM1 
42 
kDa 
0 0 0 0 1 
NADPH:adrenodoxin 
oxidoreductase, mitochondrial 
OS=Homo sapiens GN=FDXR PE=1 
SV=3 
ADRO 
54 
kDa 
0 0 0 0 1 
ADP/ATP translocase 2 OS=Homo 
sapiens GN=SLC25A5 PE=1 SV=7 
ADT2 
33 
kDa 
0 0 0 0 1 
Afadin OS=Homo sapiens 
GN=MLLT4 PE=1 SV=3 
AFAD 
207 
kDa 
0 0 0 0 1 
Phosphoacetylglucosamine mutase 
OS=Homo sapiens GN=PGM3 PE=1 
SV=1 
AGM1 
60 
kDa 
1 0 1 1 2 
Activator of 90 kDa heat shock 
protein ATPase homolog 1 
OS=Homo sapiens GN=AHSA1 
PE=1 SV=1 
AHSA1 
38 
kDa 
0 0 0 0 3 
Aldehyde dehydrogenase X, 
mitochondrial OS=Homo sapiens 
GN=ALDH1B1 PE=1 SV=3 
AL1B1 
57 
kDa 
0 0 0 0 2 
Aminopeptidase B OS=Homo 
sapiens GN=RNPEP PE=1 SV=2 
AMPB 
73 
kDa 
0 0 0 0 1 
Rabankyrin-5 OS=Homo sapiens 
GN=ANKFY1 PE=1 SV=2 
ANFY1 
128 
kDa 
0 0 0 0 2 
Ankyrin-2 OS=Homo sapiens 
GN=ANK2 PE=1 SV=4 
ANK2 
434 
kDa 
0 0 0 0 1 
Ankyrin repeat and KH domain-
containing protein 1 OS=Homo 
sapiens GN=ANKHD1 PE=1 SV=1 
ANKH1 
269 
kDa 
0 0 0 0 1 
Protein arginine N-methyltransferase 
5 OS=Homo sapiens GN=PRMT5 
PE=1 SV=4 
ANM5 
73 
kDa 
0 0 0 0 1 
Annexin A6 OS=Homo sapiens 
GN=ANXA6 PE=1 SV=3 
ANXA6 
76 
kDa 
0 0 0 0 1 
AP-2 complex subunit mu OS=Homo 
sapiens GN=AP2M1 PE=1 SV=2 
AP2M1 
50 
kDa 
0 0 0 0 1 
AP-3 complex subunit delta-1 
OS=Homo sapiens GN=AP3D1 
PE=1 SV=1 
AP3D1 
130 
kDa 
0 0 0 0 2 
215 
 
 
Apoptosis inhibitor 5 OS=Homo 
sapiens GN=API5 PE=1 SV=3 
API5 
59 
kDa 
0 0 0 0 1 
Intron-binding protein aquarius 
OS=Homo sapiens GN=AQR PE=1 
SV=4 
AQR 
171 
kDa 
0 0 0 0 1 
Asparagine synthetase (glutamine-
hydrolyzing) OS=Homo sapiens 
GN=ASNS PE=1 SV=4 
ASNS 
64 
kDa 
5 0 4 2 9 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 OS=Homo 
sapiens GN=ATP2A2 PE=1 SV=1 
AT2A2 
115 
kDa 
1 0 0 0 8 
Plasma membrane calcium-
transporting ATPase 2 OS=Homo 
sapiens GN=ATP2B2 PE=1 SV=2 
AT2B2 
137 
kDa 
0 0 0 0 1 
ATPase family AAA domain-
containing protein 3A OS=Homo 
sapiens GN=ATAD3A PE=1 SV=2 
ATD3A 
71 
kDa 
0 0 0 0 1 
Transcriptional regulator ATRX 
OS=Homo sapiens GN=ATRX PE=1 
SV=5 
ATRX 
283 
kDa 
0 0 0 0 1 
Ataxin-10 OS=Homo sapiens 
GN=ATXN10 PE=1 SV=1 
ATX10 
53 
kDa 
0 0 0 0 1 
BRISC and BRCA1-A complex 
member 1 OS=Homo sapiens 
GN=BABAM1 PE=1 SV=1 
BABA1 
37 
kDa 
0 0 0 0 1 
Large proline-rich protein BAG6 
OS=Homo sapiens GN=BAG6 PE=1 
SV=2 
BAG6 
119 
kDa 
0 0 0 0 1 
BRCA2 and CDKN1A-interacting 
protein OS=Homo sapiens 
GN=BCCIP PE=1 SV=1 
BCCIP 
36 
kDa 
0 0 0 0 1 
Bleomycin hydrolase OS=Homo 
sapiens GN=BLMH PE=1 SV=1 
BLMH (+1) 
53 
kDa 
0 0 0 0 1 
E3 ubiquitin-protein ligase BRE1B 
OS=Homo sapiens GN=RNF40 
PE=1 SV=4 
BRE1B 
114 
kDa 
0 0 0 0 1 
Calnexin OS=Homo sapiens 
GN=CANX PE=1 SV=2 
CALX 
68 
kDa 
4 0 0 1 5 
Cullin-associated NEDD8-
dissociated protein 1 OS=Homo 
sapiens GN=CAND1 PE=1 SV=2 
CAND1 
136 
kDa 
7 0 2 0 11 
Histone-arginine methyltransferase 
CARM1 OS=Homo sapiens 
GN=CARM1 PE=1 SV=3 
CARM1 
66 
kDa 
0 0 0 0 1 
Cell division cycle and apoptosis 
regulator protein 1 OS=Homo 
sapiens GN=CCAR1 PE=1 SV=2 
CCAR1 
133 
kDa 
0 0 0 0 1 
Coiled-coil domain-containing 
protein 22 OS=Homo sapiens 
GN=CCDC22 PE=1 SV=1 
CCD22 
71 
kDa 
0 0 0 0 1 
Cell division cycle protein 20 
homolog OS=Homo sapiens 
GN=CDC20 PE=1 SV=2 
CDC20 
55 
kDa 
0 0 0 0 1 
60 kDa heat shock protein, 
mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 
CH60 
61 
kDa 
23 2 21 17 29 
Chromodomain-helicase-DNA-
binding protein 4 OS=Homo sapiens 
GN=CHD4 PE=1 SV=2 
CHD4 
218 
kDa 
3 0 1 0 5 
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Cytoskeleton-associated protein 4 
OS=Homo sapiens GN=CKAP4 
PE=1 SV=2 
CKAP4 
66 
kDa 
0 0 0 0 1 
Cytoskeleton-associated protein 5 
OS=Homo sapiens GN=CKAP5 
PE=1 SV=3 
CKAP5 
226 
kDa 
7 0 0 0 17 
Clustered mitochondria protein 
homolog OS=Homo sapiens 
GN=CLUH PE=1 SV=2 
CLU 
147 
kDa 
0 0 0 0 3 
Cytosolic non-specific dipeptidase 
OS=Homo sapiens GN=CNDP2 
PE=1 SV=2 
CNDP2 
53 
kDa 
0 0 0 0 2 
CCR4-NOT transcription complex 
subunit 1 OS=Homo sapiens 
GN=CNOT1 PE=1 SV=2 
CNOT1 
267 
kDa 
0 0 0 0 1 
Coatomer subunit alpha OS=Homo 
sapiens GN=COPA PE=1 SV=2 
COPA 
138 
kDa 
9 0 1 0 12 
Coatomer subunit gamma-1 
OS=Homo sapiens GN=COPG1 
PE=1 SV=1 
COPG1 
98 
kDa 
5 0 1 1 10 
Cold shock domain-containing 
protein E1 OS=Homo sapiens 
GN=CSDE1 PE=1 SV=2 
CSDE1 
89 
kDa 
4 0 1 1 5 
COP9 signalosome complex subunit 
3 OS=Homo sapiens GN=COPS3 
PE=1 SV=3 
CSN3 
48 
kDa 
0 0 0 0 2 
COP9 signalosome complex subunit 
4 OS=Homo sapiens GN=COPS4 
PE=1 SV=1 
CSN4 
46 
kDa 
0 0 0 0 2 
Catenin delta-1 OS=Homo sapiens 
GN=CTNND1 PE=1 SV=1 
CTND1 
108 
kDa 
0 0 0 0 1 
RNA polymerase-associated protein 
CTR9 homolog OS=Homo sapiens 
GN=CTR9 PE=1 SV=1 
CTR9 
134 
kDa 
0 0 0 0 1 
Cullin-2 OS=Homo sapiens 
GN=CUL2 PE=1 SV=2 
CUL2 
87 
kDa 
0 0 0 0 1 
Cytoplasmic FMR1-interacting 
protein 1 OS=Homo sapiens 
GN=CYFIP1 PE=1 SV=1 
CYFP1 
145 
kDa 
1 0 0 0 4 
Dynein assembly factor 5, axonemal 
OS=Homo sapiens GN=DNAAF5 
PE=1 SV=4 
DAAF5 
94 
kDa 
0 0 0 0 1 
Drebrin-like protein OS=Homo 
sapiens GN=DBNL PE=1 SV=1 
DBNL 
48 
kDa 
0 0 0 0 1 
ATP-dependent RNA helicase DDX1 
OS=Homo sapiens GN=DDX1 PE=1 
SV=2 
DDX1 
82 
kDa 
2 0 0 0 6 
Probable ATP-dependent RNA 
helicase DDX17 OS=Homo sapiens 
GN=DDX17 PE=1 SV=2 
DDX17 
80 
kDa 
9 0 7 4 10 
Probable ATP-dependent RNA 
helicase DDX20 OS=Homo sapiens 
GN=DDX20 PE=1 SV=2 
DDX20 
92 
kDa 
0 0 0 0 1 
ATP-dependent RNA helicase 
DDX50 OS=Homo sapiens 
GN=DDX50 PE=1 SV=1 
DDX50 
83 
kDa 
3 0 0 0 4 
ATP-dependent RNA helicase 
DDX54 OS=Homo sapiens 
GN=DDX54 PE=1 SV=2 
DDX54 
99 
kDa 
0 0 0 0 1 
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Peroxisomal multifunctional enzyme 
type 2 OS=Homo sapiens 
GN=HSD17B4 PE=1 SV=3 
DHB4 
80 
kDa 
0 0 0 1 3 
Putative pre-mRNA-splicing factor 
ATP-dependent RNA helicase 
DHX16 OS=Homo sapiens 
GN=DHX16 PE=1 SV=2 
DHX16 
119 
kDa 
0 0 0 0 1 
Protein diaphanous homolog 1 
OS=Homo sapiens GN=DIAPH1 
PE=1 SV=2 
DIAP1 
141 
kDa 
1 0 0 0 2 
DnaJ homolog subfamily C member 
10 OS=Homo sapiens 
GN=DNAJC10 PE=1 SV=2 
DJC10 
91 
kDa 
0 0 0 0 1 
DnaJ homolog subfamily C member 
7 OS=Homo sapiens GN=DNAJC7 
PE=1 SV=2 
DNJC7 
56 
kDa 
0 0 0 0 1 
Dynamin-1-like protein OS=Homo 
sapiens GN=DNM1L PE=1 SV=2 
DNM1L 
82 
kDa 
1 0 0 0 2 
Dedicator of cytokinesis protein 7 
OS=Homo sapiens GN=DOCK7 
PE=1 SV=4 
DOCK7 
243 
kDa 
0 0 0 0 1 
DNA polymerase delta catalytic 
subunit OS=Homo sapiens 
GN=POLD1 PE=1 SV=2 
DPOD1 
124 
kDa 
1 0 0 0 3 
DNA polymerase alpha catalytic 
subunit OS=Homo sapiens 
GN=POLA1 PE=1 SV=2 
DPOLA 
166 
kDa 
0 0 0 0 2 
Dipeptidyl peptidase 3 OS=Homo 
sapiens GN=DPP3 PE=1 SV=2 
DPP3 
83 
kDa 
0 0 0 0 1 
Dihydropyrimidinase-related protein 
1 OS=Homo sapiens GN=CRMP1 
PE=1 SV=1 
DPYL1 
62 
kDa 
0 0 0 0 1 
Developmentally-regulated GTP-
binding protein 1 OS=Homo sapiens 
GN=DRG1 PE=1 SV=1 
DRG1 
41 
kDa 
0 0 0 0 2 
Double-stranded RNA-specific 
adenosine deaminase OS=Homo 
sapiens GN=ADAR PE=1 SV=4 
DSRAD 
136 
kDa 
0 0 0 0 1 
ATP-dependent RNA helicase 
DDX39A OS=Homo sapiens 
GN=DDX39A PE=1 SV=2 
DX39A 
49 
kDa 
3 0 1 1 5 
Spliceosome RNA helicase DDX39B 
OS=Homo sapiens GN=DDX39B 
PE=1 SV=1 
DX39B 
49 
kDa 
0 0 0 0 3 
Cytoplasmic dynein 1 heavy chain 1 
OS=Homo sapiens GN=DYNC1H1 
PE=1 SV=5 
DYHC1 
532 
kDa 
16 0 5 2 29 
Trifunctional enzyme subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=HADHA PE=1 SV=2 
ECHA 
83 
kDa 
3 0 2 1 4 
Proteasome-associated protein 
ECM29 homolog OS=Homo sapiens 
GN=ECM29 PE=1 SV=2 
ECM29 
204 
kDa 
0 0 0 0 6 
Enhancer of mRNA-decapping 
protein 4 OS=Homo sapiens 
GN=EDC4 PE=1 SV=1 
EDC4 
152 
kDa 
0 0 0 0 1 
Early endosome antigen 1 
OS=Homo sapiens GN=EEA1 PE=1 
SV=2 
EEA1 
162 
kDa 
0 0 0 0 2 
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Elongation factor 1-alpha 1 
OS=Homo sapiens GN=EEF1A1 
PE=1 SV=1 
EF1A1 
50 
kDa 
17 3 14 10 19 
Elongation factor 2 OS=Homo 
sapiens GN=EEF2 PE=1 SV=4 
EF2 
95 
kDa 
35 5 24 24 38 
Eukaryotic translation initiation factor 
2D OS=Homo sapiens GN=EIF2D 
PE=1 SV=3 
EIF2D 
65 
kDa 
0 0 0 0 1 
Eukaryotic translation initiation factor 
3 subunit B OS=Homo sapiens 
GN=EIF3B PE=1 SV=3 
EIF3B 
92 
kDa 
6 0 3 1 7 
Eukaryotic translation initiation factor 
3 subunit F OS=Homo sapiens 
GN=EIF3F PE=1 SV=1 
EIF3F 
38 
kDa 
4 0 1 3 5 
Eukaryotic translation initiation factor 
3 subunit L OS=Homo sapiens 
GN=EIF3L PE=1 SV=1 
EIF3L 
67 
kDa 
2 0 1 0 5 
Epiplakin OS=Homo sapiens 
GN=EPPK1 PE=1 SV=2 
EPIPL 
556 
kDa 
3 0 0 0 4 
Clathrin interactor 1 OS=Homo 
sapiens GN=CLINT1 PE=1 SV=1 
EPN4 
68 
kDa 
0 0 0 0 1 
ERC protein 2 OS=Homo sapiens 
GN=ERC2 PE=1 SV=3 
ERC2 
111 
kDa 
0 0 0 0 1 
Eukaryotic peptide chain release 
factor subunit 1 OS=Homo sapiens 
GN=ETF1 PE=1 SV=3 
ERF1 
49 
kDa 
0 0 0 0 1 
Extended synaptotagmin-1 
OS=Homo sapiens GN=ESYT1 
PE=1 SV=1 
ESYT1 
123 
kDa 
2 0 0 0 4 
Exosome component 10 OS=Homo 
sapiens GN=EXOSC10 PE=1 SV=2 
EXOSX 
101 
kDa 
0 0 0 0 1 
Ezrin OS=Homo sapiens GN=EZR 
PE=1 SV=4 
EZRI 
69 
kDa 
2 0 0 3 5 
Hsc70-interacting protein OS=Homo 
sapiens GN=ST13 PE=1 SV=2 
F10A1 
41 
kDa 
0 0 0 0 1 
Constitutive coactivator of PPAR-
gamma-like protein 1 OS=Homo 
sapiens GN=FAM120A PE=1 SV=2 
F120A 
122 
kDa 
1 0 0 0 2 
Fanconi anemia group I protein 
OS=Homo sapiens GN=FANCI 
PE=1 SV=4 
FANCI 
149 
kDa 
0 0 0 0 1 
Fatty acid synthase OS=Homo 
sapiens GN=FASN PE=1 SV=3 
FAS 
273 
kDa 
19 0 7 3 48 
FK506-binding protein 15 OS=Homo 
sapiens GN=FKBP15 PE=1 SV=2 
FKB15 
134 
kDa 
0 0 0 0 1 
Peptidyl-prolyl cis-trans isomerase 
FKBP4 OS=Homo sapiens 
GN=FKBP4 PE=1 SV=3 
FKBP4 
52 
kDa 
1 0 0 2 4 
Protein flightless-1 homolog 
OS=Homo sapiens GN=FLII PE=1 
SV=2 
FLII 
145 
kDa 
0 0 0 0 2 
Filamin-A OS=Homo sapiens 
GN=FLNA PE=1 SV=4 
FLNA 
281 
kDa 
8 0 5 1 37 
Filamin-B OS=Homo sapiens 
GN=FLNB PE=1 SV=2 
FLNB 
278 
kDa 
0 0 0 0 8 
Filamin-C OS=Homo sapiens 
GN=FLNC PE=1 SV=3 
FLNC 
291 
kDa 
0 1 0 0 1 
Fascin OS=Homo sapiens 
GN=FSCN1 PE=1 SV=3 
FSCN1 
55 
kDa 
1 0 1 4 5 
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Fumarate hydratase, mitochondrial 
OS=Homo sapiens GN=FH PE=1 
SV=3 
FUMH 
55 
kDa 
1 0 1 0 2 
Fragile X mental retardation 
syndrome-related protein 1 
OS=Homo sapiens GN=FXR1 PE=1 
SV=3 
FXR1 
70 
kDa 
1 0 1 0 2 
Glucose-6-phosphate isomerase 
OS=Homo sapiens GN=GPI PE=1 
SV=4 
G6PI 
63 
kDa 
4 0 3 4 8 
Neutral alpha-glucosidase AB 
OS=Homo sapiens GN=GANAB 
PE=1 SV=3 
GANAB 
107 
kDa 
4 0 1 0 15 
Translational activator GCN1 
OS=Homo sapiens GN=GCN1L1 
PE=1 SV=6 
GCN1L 
293 
kDa 
5 0 0 0 16 
Rab GDP dissociation inhibitor beta 
OS=Homo sapiens GN=GDI2 PE=1 
SV=2 
GDIB 
51 
kDa 
0 0 0 2 3 
Gem-associated protein 4 
OS=Homo sapiens GN=GEMIN4 
PE=1 SV=2 
GEMI4 
120 
kDa 
0 0 0 0 1 
Glomulin OS=Homo sapiens 
GN=GLMN PE=1 SV=2 
GLMN 
68 
kDa 
0 0 0 0 1 
Glucosidase 2 subunit beta 
OS=Homo sapiens GN=PRKCSH 
PE=1 SV=2 
GLU2B 
59 
kDa 
0 0 0 0 1 
Serine hydroxymethyltransferase, 
mitochondrial OS=Homo sapiens 
GN=SHMT2 PE=1 SV=3 
GLYM 
56 
kDa 
8 0 6 5 9 
Guanine nucleotide-binding protein-
like 1 OS=Homo sapiens GN=GNL1 
PE=1 SV=2 
GNL1 
69 
kDa 
0 0 0 0 1 
Golgin subfamily A member 2 
OS=Homo sapiens GN=GOLGA2 
PE=1 SV=3 
GOGA2 
113 
kDa 
0 0 0 0 1 
Procollagen galactosyltransferase 1 
OS=Homo sapiens GN=COLGALT1 
PE=1 SV=1 
GT251 
72 
kDa 
0 0 0 0 1 
GMP synthase (glutamine-
hydrolyzing) OS=Homo sapiens 
GN=GMPS PE=1 SV=1 
GUAA 
77 
kDa 
0 0 0 0 1 
Histone acetyltransferase type B 
catalytic subunit OS=Homo sapiens 
GN=HAT1 PE=1 SV=1 
HAT1 
50 
kDa 
1 0 1 1 3 
Histone deacetylase 1 OS=Homo 
sapiens GN=HDAC1 PE=1 SV=1 
HDAC1 
55 
kDa 
0 0 0 0 1 
Histone deacetylase 2 OS=Homo 
sapiens GN=HDAC2 PE=1 SV=2 
HDAC2 
55 
kDa 
1 0 1 0 3 
E3 ubiquitin-protein ligase HECTD1 
OS=Homo sapiens GN=HECTD1 
PE=1 SV=3 
HECD1 
289 
kDa 
0 0 0 0 1 
Heterogeneous nuclear 
ribonucleoprotein H2 OS=Homo 
sapiens GN=HNRNPH2 PE=1 SV=1 
HNRH2 
49 
kDa 
1 0 1 0 2 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 OS=Homo 
sapiens GN=HNRNPC PE=1 SV=4 
HNRPC 
34 
kDa 
0 0 0 0 1 
Heterogeneous nuclear 
ribonucleoprotein K OS=Homo 
sapiens GN=HNRNPK PE=1 SV=1 
HNRPK 
51 
kDa 
9 0 7 8 14 
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Heterogeneous nuclear 
ribonucleoprotein L OS=Homo 
sapiens GN=HNRNPL PE=1 SV=2 
HNRPL 
64 
kDa 
0 0 0 0 2 
Heterogeneous nuclear 
ribonucleoprotein R OS=Homo 
sapiens GN=HNRNPR PE=1 SV=1 
HNRPR 
71 
kDa 
3 0 1 1 6 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 
HORN 
282 
kDa 
1 3 1 1 4 
Heat shock protein 105 kDa 
OS=Homo sapiens GN=HSPH1 
PE=1 SV=1 
HS105 
97 
kDa 
3 0 0 2 5 
Heat shock 70 kDa protein 1A 
OS=Homo sapiens GN=HSPA1A 
PE=1 SV=1 
HS71A 
70 
kDa 
22 10 18 18 29 
E3 ubiquitin-protein ligase HUWE1 
OS=Homo sapiens GN=HUWE1 
PE=1 SV=3 
HUWE1 
482 
kDa 
3 0 0 0 5 
Hypoxia up-regulated protein 1 
OS=Homo sapiens GN=HYOU1 
PE=1 SV=1 
HYOU1 
111 
kDa 
0 0 0 0 5 
Interferon regulatory factor 2-binding 
protein 1 OS=Homo sapiens 
GN=IRF2BP1 PE=1 SV=1 
I2BP1 
62 
kDa 
0 0 0 0 1 
Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 
IGKC 
12 
kDa 
0 0 0 0 1 
Acetolactate synthase-like protein 
OS=Homo sapiens GN=ILVBL PE=1 
SV=2 
ILVBL 
68 
kDa 
0 0 0 0 1 
Importin subunit alpha-7 OS=Homo 
sapiens GN=KPNA6 PE=1 SV=1 
IMA7 
60 
kDa 
1 0 1 0 2 
Importin subunit beta-1 OS=Homo 
sapiens GN=KPNB1 PE=1 SV=2 
IMB1 
97 
kDa 
7 1 2 1 8 
Importin-11 OS=Homo sapiens 
GN=IPO11 PE=1 SV=1 
IPO11 
113 
kDa 
0 0 0 0 1 
Importin-4 OS=Homo sapiens 
GN=IPO4 PE=1 SV=2 
IPO4 
119 
kDa 
6 0 1 0 10 
Importin-5 OS=Homo sapiens 
GN=IPO5 PE=1 SV=4 
IPO5 
124 
kDa 
10 0 1 0 11 
Importin-7 OS=Homo sapiens 
GN=IPO7 PE=1 SV=1 
IPO7 
120 
kDa 
5 0 0 0 6 
C-Jun-amino-terminal kinase-
interacting protein 4 OS=Homo 
sapiens GN=SPAG9 PE=1 SV=4 
JIP4 
146 
kDa 
0 0 0 0 1 
Keratin, type II cytoskeletal 6C 
OS=Homo sapiens GN=KRT6C 
PE=1 SV=3 
K2C6C 
60 
kDa 
0 3 2 0 1 
cAMP-dependent protein kinase type 
II-alpha regulatory subunit 
OS=Homo sapiens GN=PRKAR2A 
PE=1 SV=2 
KAP2 
46 
kDa 
0 0 0 0 1 
cAMP-dependent protein kinase 
catalytic subunit alpha OS=Homo 
sapiens GN=PRKACA PE=1 SV=2 
KAPCA 
41 
kDa 
0 0 0 0 1 
KIF1-binding protein OS=Homo 
sapiens GN=KIF1BP PE=1 SV=1 
KBP 
72 
kDa 
0 0 0 0 1 
Calcium/calmodulin-dependent 
protein kinase type II subunit delta 
OS=Homo sapiens GN=CAMK2D 
PE=1 SV=3 
KCC2D 
56 
kDa 
0 0 0 0 1 
Creatine kinase M-type OS=Homo 
sapiens GN=CKM PE=1 SV=2 
KCRM 
43 
kDa 
0 2 0 0 1 
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Creatine kinase U-type, 
mitochondrial OS=Homo sapiens 
GN=CKMT1A PE=1 SV=1 
KCRU 
47 
kDa 
0 0 0 0 1 
Kinesin-like protein KIF11 OS=Homo 
sapiens GN=KIF11 PE=1 SV=2 
KIF11 
119 
kDa 
0 0 0 0 2 
Kinesin-like protein KIFC1 
OS=Homo sapiens GN=KIFC1 PE=1 
SV=2 
KIFC1 
74 
kDa 
0 0 0 0 1 
Kinesin-1 heavy chain OS=Homo 
sapiens GN=KIF5B PE=1 SV=1 
KINH 
110 
kDa 
2 0 0 0 4 
Protein kinase C delta type 
OS=Homo sapiens GN=PRKCD 
PE=1 SV=2 
KPCD 
78 
kDa 
0 0 0 0 1 
Pyruvate kinase PKM OS=Homo 
sapiens GN=PKM PE=1 SV=4 
KPYM 
58 
kDa 
8 2 5 10 22 
Lethal(2) giant larvae protein 
homolog 1 OS=Homo sapiens 
GN=LLGL1 PE=1 SV=3 
L2GL1 
115 
kDa 
0 0 0 0 1 
Lupus La protein OS=Homo sapiens 
GN=SSB PE=1 SV=2 
LA 
47 
kDa 
0 0 0 1 2 
La-related protein 4 OS=Homo 
sapiens GN=LARP4 PE=1 SV=3 
LARP4 
81 
kDa 
0 0 0 0 1 
Putative lipocalin 1-like protein 1 
OS=Homo sapiens GN=LCN1P1 
PE=5 SV=1 
LC1L1 (+1) 
18 
kDa 
0 0 0 0 1 
Luc7-like protein 3 OS=Homo 
sapiens GN=LUC7L3 PE=1 SV=2 
LC7L3 
51 
kDa 
0 0 0 0 1 
LETM1 and EF-hand domain-
containing protein 1, mitochondrial 
OS=Homo sapiens GN=LETM1 
PE=1 SV=1 
LETM1 
83 
kDa 
0 0 0 0 3 
Leukotriene A-4 hydrolase 
OS=Homo sapiens GN=LTA4H 
PE=1 SV=2 
LKHA4 
69 
kDa 
2 0 0 1 6 
Lon protease homolog, 
mitochondrial OS=Homo sapiens 
GN=LONP1 PE=1 SV=2 
LONM 
106 
kDa 
5 0 0 1 7 
Lipopolysaccharide-responsive and 
beige-like anchor protein OS=Homo 
sapiens GN=LRBA PE=1 SV=4 
LRBA 
319 
kDa 
0 0 0 0 2 
Leucine-rich repeat-containing 
protein 40 OS=Homo sapiens 
GN=LRRC40 PE=1 SV=1 
LRC40 
68 
kDa 
0 0 0 0 1 
Protein LTV1 homolog OS=Homo 
sapiens GN=LTV1 PE=1 SV=1 
LTV1 
55 
kDa 
0 0 0 0 1 
Lysozyme C OS=Homo sapiens 
GN=LYZ PE=1 SV=1 
LYSC 
17 
kDa 
0 0 0 0 1 
Microtubule-actin cross-linking factor 
1, isoforms 1/2/3/5 OS=Homo 
sapiens GN=MACF1 PE=1 SV=4 
MACF1 
838 
kDa 
0 0 0 0 1 
Melanoma-associated antigen D2 
OS=Homo sapiens GN=MAGED2 
PE=1 SV=2 
MAGD2 
65 
kDa 
0 0 0 0 1 
Microtubule-associated protein 1B 
OS=Homo sapiens GN=MAP1B 
PE=1 SV=2 
MAP1B 
271 
kDa 
0 0 0 0 3 
Microtubule-associated protein 4 
OS=Homo sapiens GN=MAP4 PE=1 
SV=3 
MAP4 
121 
kDa 
0 0 0 0 1 
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DNA replication licensing factor 
MCM2 OS=Homo sapiens 
GN=MCM2 PE=1 SV=4 
MCM2 
102 
kDa 
11 0 2 2 12 
DNA replication licensing factor 
MCM3 OS=Homo sapiens 
GN=MCM3 PE=1 SV=3 
MCM3 
91 
kDa 
6 0 2 2 8 
DNA replication licensing factor 
MCM5 OS=Homo sapiens 
GN=MCM5 PE=1 SV=5 
MCM5 
82 
kDa 
7 0 3 0 8 
DNA replication licensing factor 
MCM6 OS=Homo sapiens 
GN=MCM6 PE=1 SV=1 
MCM6 
93 
kDa 
5 2 4 4 9 
7SK snRNA methylphosphate 
capping enzyme OS=Homo sapiens 
GN=MEPCE PE=1 SV=1 
MEPCE 
74 
kDa 
0 0 0 0 1 
Methionine synthase OS=Homo 
sapiens GN=MTR PE=1 SV=2 
METH 
141 
kDa 
0 0 0 0 1 
Moesin OS=Homo sapiens 
GN=MSN PE=1 SV=3 
MOES 
68 
kDa 
0 0 0 0 2 
Mannosyl-oligosaccharide 
glucosidase OS=Homo sapiens 
GN=MOGS PE=1 SV=5 
MOGS 
92 
kDa 
0 0 0 0 1 
Dual specificity mitogen-activated 
protein kinase kinase 2 OS=Homo 
sapiens GN=MAP2K2 PE=1 SV=1 
MP2K2 
44 
kDa 
0 0 0 0 1 
Mitochondrial-processing peptidase 
subunit alpha OS=Homo sapiens 
GN=PMPCA PE=1 SV=2 
MPPA 
58 
kDa 
0 0 0 0 1 
Cation-independent mannose-6-
phosphate receptor OS=Homo 
sapiens GN=IGF2R PE=1 SV=3 
MPRI 
274 
kDa 
0 0 0 0 2 
DNA mismatch repair protein Msh3 
OS=Homo sapiens GN=MSH3 PE=1 
SV=4 
MSH3 
127 
kDa 
0 0 0 0 1 
Metastasis-associated protein MTA2 
OS=Homo sapiens GN=MTA2 PE=1 
SV=1 
MTA2 
75 
kDa 
2 0 0 0 3 
Myosin-9 OS=Homo sapiens 
GN=MYH9 PE=1 SV=4 
MYH9 
227 
kDa 
16 0 1 1 21 
Unconventional myosin-VI 
OS=Homo sapiens GN=MYO6 PE=1 
SV=4 
MYO6 
150 
kDa 
0 0 0 0 1 
N-alpha-acetyltransferase 15, NatA 
auxiliary subunit OS=Homo sapiens 
GN=NAA15 PE=1 SV=1 
NAA15 
101 
kDa 
6 0 2 0 7 
Nicotinamide 
phosphoribosyltransferase 
OS=Homo sapiens GN=NAMPT 
PE=1 SV=1 
NAMPT 
56 
kDa 
1 0 0 1 2 
Nuclear autoantigenic sperm protein 
OS=Homo sapiens GN=NASP PE=1 
SV=2 
NASP 
85 
kDa 
0 0 0 0 5 
Nck-associated protein 1 OS=Homo 
sapiens GN=NCKAP1 PE=1 SV=1 
NCKP1 
129 
kDa 
0 0 0 0 1 
NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial 
OS=Homo sapiens GN=NDUFS1 
PE=1 SV=3 
NDUS1 
79 
kDa 
0 0 0 0 2 
Serine/threonine-protein kinase 
Nek9 OS=Homo sapiens GN=NEK9 
PE=1 SV=2 
NEK9 
107 
kDa 
0 0 0 0 1 
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Negative elongation factor B 
OS=Homo sapiens GN=NELFB 
PE=1 SV=1 
NELFB 
66 
kDa 
0 0 0 0 1 
Nucleolar protein 11 OS=Homo 
sapiens GN=NOL11 PE=1 SV=1 
NOL11 
81 
kDa 
0 0 0 0 1 
Nodal modulator 1 OS=Homo 
sapiens GN=NOMO1 PE=1 SV=5 
NOMO1 
134 
kDa 
1 0 0 0 3 
Probable 28S rRNA (cytosine(4447)-
C(5))-methyltransferase OS=Homo 
sapiens GN=NOP2 PE=1 SV=2 
NOP2 
89 
kDa 
0 0 0 0 1 
Nucleolar protein 9 OS=Homo 
sapiens GN=NOP9 PE=1 SV=1 
NOP9 
69 
kDa 
0 0 0 0 1 
tRNA (cytosine(34)-C(5))-
methyltransferase OS=Homo 
sapiens GN=NSUN2 PE=1 SV=2 
NSUN2 
86 
kDa 
3 0 1 0 4 
Nuclear pore complex protein 
Nup155 OS=Homo sapiens 
GN=NUP155 PE=1 SV=1 
NU155 
155 
kDa 
3 0 1 0 4 
Nucleoporin NUP188 homolog 
OS=Homo sapiens GN=NUP188 
PE=1 SV=1 
NU188 
196 
kDa 
0 0 0 0 1 
Nucleolin OS=Homo sapiens 
GN=NCL PE=1 SV=3 
NUCL 
77 
kDa 
11 0 7 1 12 
Nuclear migration protein nudC 
OS=Homo sapiens GN=NUDC 
PE=1 SV=1 
NUDC 
38 
kDa 
0 0 0 0 1 
Nuclear mitotic apparatus protein 1 
OS=Homo sapiens GN=NUMA1 
PE=1 SV=2 
NUMA1 
238 
kDa 
2 0 2 0 8 
Nuclear pore complex protein Nup88 
OS=Homo sapiens GN=NUP88 
PE=1 SV=2 
NUP88 
84 
kDa 
0 0 0 0 1 
Lipoamide acyltransferase 
component of branched-chain alpha-
keto acid dehydrogenase complex, 
mitochondrial OS=Homo sapiens 
GN=DBT PE=1 SV=3 
ODB2 
53 
kDa 
0 0 0 0 2 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial OS=Homo sapiens 
GN=DLAT PE=1 SV=3 
ODP2 
69 
kDa 
0 0 0 0 2 
Protein O-GlcNAcase OS=Homo 
sapiens GN=MGEA5 PE=1 SV=2 
OGA 
103 
kDa 
0 0 0 0 2 
UDP-N-acetylglucosamine--peptide 
N-acetylglucosaminyltransferase 110 
kDa subunit OS=Homo sapiens 
GN=OGT PE=1 SV=3 
OGT1 
117 
kDa 
0 0 0 0 1 
Obg-like ATPase 1 OS=Homo 
sapiens GN=OLA1 PE=1 SV=2 
OLA1 
45 
kDa 
0 0 0 0 2 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit OS=Homo sapiens 
GN=DDOST PE=1 SV=4 
OST48 
51 
kDa 
2 0 0 0 3 
Serine/threonine-protein 
phosphatase 4 regulatory subunit 3A 
OS=Homo sapiens GN=SMEK1 
PE=1 SV=1 
P4R3A 
95 
kDa 
0 0 0 0 1 
Transcriptional repressor p66-alpha 
OS=Homo sapiens GN=GATAD2A 
PE=1 SV=1 
P66A 
68 
kDa 
0 0 0 0 1 
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Polyadenylate-binding protein 1 
OS=Homo sapiens GN=PABPC1 
PE=1 SV=2 
PABP1 
71 
kDa 
4 1 2 3 8 
Polyadenylate-binding protein 4 
OS=Homo sapiens GN=PABPC4 
PE=1 SV=1 
PABP4 
71 
kDa 
1 0 0 0 4 
Plasminogen activator inhibitor 1 
RNA-binding protein OS=Homo 
sapiens GN=SERBP1 PE=1 SV=2 
PAIRB 
45 
kDa 
2 1 2 2 3 
Lysophosphatidylcholine 
acyltransferase 1 OS=Homo sapiens 
GN=LPCAT1 PE=1 SV=2 
PCAT1 
59 
kDa 
0 0 0 0 1 
Poly(rC)-binding protein 1 OS=Homo 
sapiens GN=PCBP1 PE=1 SV=2 
PCBP1 
37 
kDa 
0 0 0 0 3 
Poly(rC)-binding protein 2 OS=Homo 
sapiens GN=PCBP2 PE=1 SV=1 
PCBP2 
39 
kDa 
0 0 0 0 1 
Programmed cell death 6-interacting 
protein OS=Homo sapiens 
GN=PDCD6IP PE=1 SV=1 
PDC6I 
96 
kDa 
3 0 0 0 7 
2',5'-phosphodiesterase 12 
OS=Homo sapiens GN=PDE12 
PE=1 SV=2 
PDE12 
67 
kDa 
0 0 0 0 1 
Protein disulfide-isomerase 
OS=Homo sapiens GN=P4HB PE=1 
SV=3 
PDIA1 
57 
kDa 
0 0 0 0 1 
Protein disulfide-isomerase A3 
OS=Homo sapiens GN=PDIA3 
PE=1 SV=4 
PDIA3 
57 
kDa 
8 2 8 9 15 
Sister chromatid cohesion protein 
PDS5 homolog A OS=Homo sapiens 
GN=PDS5A PE=1 SV=1 
PDS5A 
151 
kDa 
1 0 0 0 2 
Proline-, glutamic acid- and leucine-
rich protein 1 OS=Homo sapiens 
GN=PELP1 PE=1 SV=2 
PELP1 
120 
kDa 
1 0 0 0 3 
PERQ amino acid-rich with GYF 
domain-containing protein 2 
OS=Homo sapiens GN=GIGYF2 
PE=1 SV=1 
PERQ2 
150 
kDa 
0 0 0 0 1 
Phosphoglucomutase-2 OS=Homo 
sapiens GN=PGM2 PE=1 SV=4 
PGM2 
68 
kDa 
0 0 0 0 1 
GPI transamidase component PIG-S 
OS=Homo sapiens GN=PIGS PE=1 
SV=3 
PIGS 
62 
kDa 
0 0 0 0 1 
Plectin OS=Homo sapiens 
GN=PLEC PE=1 SV=3 
PLEC 
532 
kDa 
0 0 0 0 2 
Peptidyl-prolyl cis-trans isomerase D 
OS=Homo sapiens GN=PPID PE=1 
SV=3 
PPID 
41 
kDa 
0 0 0 0 2 
Pre-mRNA-processing factor 19 
OS=Homo sapiens GN=PRPF19 
PE=1 SV=1 
PRP19 
55 
kDa 
0 0 0 0 1 
Pre-mRNA-processing-splicing 
factor 8 OS=Homo sapiens 
GN=PRPF8 PE=1 SV=2 
PRP8 
274 
kDa 
2 0 0 0 13 
U4/U6 small nuclear 
ribonucleoprotein Prp3 OS=Homo 
sapiens GN=PRPF3 PE=1 SV=2 
PRPF3 
78 
kDa 
0 0 0 0 1 
26S protease regulatory subunit 10B 
OS=Homo sapiens GN=PSMC6 
PE=1 SV=1 
PRS10 
44 
kDa 
0 0 0 1 3 
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26S protease regulatory subunit 6A 
OS=Homo sapiens GN=PSMC3 
PE=1 SV=3 
PRS6A 
49 
kDa 
3 0 1 0 5 
26S protease regulatory subunit 6B 
OS=Homo sapiens GN=PSMC4 
PE=1 SV=2 
PRS6B 
47 
kDa 
4 0 2 1 5 
26S proteasome non-ATPase 
regulatory subunit 2 OS=Homo 
sapiens GN=PSMD2 PE=1 SV=3 
PSMD2 
100 
kDa 
12 1 2 3 13 
26S proteasome non-ATPase 
regulatory subunit 3 OS=Homo 
sapiens GN=PSMD3 PE=1 SV=2 
PSMD3 
61 
kDa 
3 0 2 2 4 
26S proteasome non-ATPase 
regulatory subunit 6 OS=Homo 
sapiens GN=PSMD6 PE=1 SV=1 
PSMD6 
46 
kDa 
0 0 0 0 1 
Polypyrimidine tract-binding protein 
1 OS=Homo sapiens GN=PTBP1 
PE=1 SV=1 
PTBP1 
57 
kDa 
7 0 5 8 9 
Trifunctional purine biosynthetic 
protein adenosine-3 OS=Homo 
sapiens GN=GART PE=1 SV=1 
PUR2 
108 
kDa 
5 1 2 1 17 
Adenylosuccinate lyase OS=Homo 
sapiens GN=ADSL PE=1 SV=2 
PUR8 
55 
kDa 
1 0 0 2 3 
Bifunctional purine biosynthesis 
protein PURH OS=Homo sapiens 
GN=ATIC PE=1 SV=3 
PUR9 
65 
kDa 
4 1 4 5 12 
Periodic tryptophan protein 2 
homolog OS=Homo sapiens 
GN=PWP2 PE=1 SV=2 
PWP2 
102 
kDa 
0 0 0 0 1 
Glycogen phosphorylase, liver form 
OS=Homo sapiens GN=PYGL PE=1 
SV=4 
PYGL 
97 
kDa 
4 0 1 1 6 
CAD protein OS=Homo sapiens 
GN=CAD PE=1 SV=3 
PYR1 
243 
kDa 
4 0 3 2 18 
CTP synthase 1 OS=Homo sapiens 
GN=CTPS1 PE=1 SV=2 
PYRG1 
67 
kDa 
0 0 0 1 7 
CTP synthase 2 OS=Homo sapiens 
GN=CTPS2 PE=1 SV=1 
PYRG2 
66 
kDa 
0 0 0 0 1 
DNA repair protein RAD50 
OS=Homo sapiens GN=RAD50 
PE=1 SV=1 
RAD50 
154 
kDa 
0 0 0 0 3 
Ran GTPase-activating protein 1 
OS=Homo sapiens GN=RANGAP1 
PE=1 SV=1 
RAGP1 
64 
kDa 
2 0 0 0 7 
Ribonucleoprotein PTB-binding 1 
OS=Homo sapiens GN=RAVER1 
PE=1 SV=1 
RAVR1 
64 
kDa 
0 0 0 0 1 
Histone-binding protein RBBP4 
OS=Homo sapiens GN=RBBP4 
PE=1 SV=3 
RBBP4 
48 
kDa 
2 0 1 0 3 
Rab GTPase-activating protein 1 
OS=Homo sapiens GN=RABGAP1 
PE=1 SV=3 
RBGP1 
122 
kDa 
0 0 0 0 1 
Rab3 GTPase-activating protein 
non-catalytic subunit OS=Homo 
sapiens GN=RAB3GAP2 PE=1 
SV=1 
RBGPR 
156 
kDa 
0 0 0 0 2 
RNA-binding protein 12 OS=Homo 
sapiens GN=RBM12 PE=1 SV=1 
RBM12 
97 
kDa 
0 0 0 0 1 
RNA-binding protein 39 OS=Homo 
sapiens GN=RBM39 PE=1 SV=2 
RBM39 
59 
kDa 
1 0 1 0 2 
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E3 SUMO-protein ligase RanBP2 
OS=Homo sapiens GN=RANBP2 
PE=1 SV=2 
RBP2 
358 
kDa 
0 0 0 0 1 
Reticulocalbin-1 OS=Homo sapiens 
GN=RCN1 PE=1 SV=1 
RCN1 
39 
kDa 
0 0 0 0 1 
UV excision repair protein RAD23 
homolog B OS=Homo sapiens 
GN=RAD23B PE=1 SV=1 
RD23B 
43 
kDa 
0 0 0 0 1 
ATP-dependent DNA helicase Q1 
OS=Homo sapiens GN=RECQL 
PE=1 SV=3 
RECQ1 
73 
kDa 
0 0 0 0 1 
Replication initiator 1 OS=Homo 
sapiens GN=REPIN1 PE=1 SV=1 
REPI1 
64 
kDa 
0 0 0 0 1 
Ribonuclease inhibitor OS=Homo 
sapiens GN=RNH1 PE=1 SV=2 
RINI 
50 
kDa 
0 0 0 0 1 
60S ribosomal protein L27a 
OS=Homo sapiens GN=RPL27A 
PE=1 SV=2 
RL27A 
17 
kDa 
0 0 0 0 1 
60S ribosomal protein L3 OS=Homo 
sapiens GN=RPL3 PE=1 SV=2 
RL3 
46 
kDa 
5 0 4 0 7 
60S ribosomal protein L6 OS=Homo 
sapiens GN=RPL6 PE=1 SV=3 
RL6 
33 
kDa 
1 0 1 1 4 
60 kDa SS-A/Ro ribonucleoprotein 
OS=Homo sapiens GN=TROVE2 
PE=1 SV=2 
RO60 
61 
kDa 
1 0 0 0 2 
Rho-associated protein kinase 2 
OS=Homo sapiens GN=ROCK2 
PE=1 SV=4 
ROCK2 
161 
kDa 
0 0 0 0 1 
DNA-directed RNA polymerase II 
subunit RPB1 OS=Homo sapiens 
GN=POLR2A PE=1 SV=2 
RPB1 
217 
kDa 
0 0 0 0 2 
DNA-directed RNA polymerase II 
subunit RPB2 OS=Homo sapiens 
GN=POLR2B PE=1 SV=1 
RPB2 
134 
kDa 
0 0 0 0 1 
DNA-directed RNA polymerase III 
subunit RPC3 OS=Homo sapiens 
GN=POLR3C PE=1 SV=1 
RPC3 
61 
kDa 
0 0 0 0 1 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
OS=Homo sapiens GN=RPN1 PE=1 
SV=1 
RPN1 
69 
kDa 
2 0 2 1 5 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2 
OS=Homo sapiens GN=RPN2 PE=1 
SV=3 
RPN2 
69 
kDa 
0 0 0 0 2 
RRP12-like protein OS=Homo 
sapiens GN=RRP12 PE=1 SV=2 
RRP12 
144 
kDa 
0 0 0 0 2 
Protein RRP5 homolog OS=Homo 
sapiens GN=PDCD11 PE=1 SV=3 
RRP5 
209 
kDa 
0 0 0 0 1 
Ubiquitin-40S ribosomal protein 
S27a OS=Homo sapiens 
GN=RPS27A PE=1 SV=2 
RS27A 
18 
kDa 
3 0 1 2 4 
RNA 3'-terminal phosphate cyclase 
OS=Homo sapiens GN=RTCA PE=1 
SV=1 
RTCA 
39 
kDa 
0 0 0 0 1 
U1 small nuclear ribonucleoprotein 
70 kDa OS=Homo sapiens 
GN=SNRNP70 PE=1 SV=2 
RU17 
52 
kDa 
0 0 0 0 1 
RuvB-like 2 OS=Homo sapiens 
GN=RUVBL2 PE=1 SV=3 
RUVB2 
51 
kDa 
11 2 10 6 12 
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Solute carrier family 12 member 2 
OS=Homo sapiens GN=SLC12A2 
PE=1 SV=1 
S12A2 
131 
kDa 
0 0 0 0 1 
Protein transport protein Sec16A 
OS=Homo sapiens GN=SEC16A 
PE=1 SV=3 
SC16A 
234 
kDa 
0 0 0 0 2 
Protein transport protein Sec31A 
OS=Homo sapiens GN=SEC31A 
PE=1 SV=3 
SC31A 
133 
kDa 
1 0 0 0 3 
Succinate dehydrogenase 
(ubiquinone) flavoprotein subunit, 
mitochondrial OS=Homo sapiens 
GN=SDHA PE=1 SV=2 
SDHA 
73 
kDa 
1 0 0 0 3 
Translocation protein SEC63 
homolog OS=Homo sapiens 
GN=SEC63 PE=1 SV=2 
SEC63 
88 
kDa 
0 0 0 0 1 
Septin-11 OS=Homo sapiens 
GN=SEPT11 PE=1 SV=3 
SEP11 
49 
kDa 
0 0 0 0 1 
Septin-2 OS=Homo sapiens 
GN=SEPT2 PE=1 SV=1 
SEPT2 
41 
kDa 
0 0 0 0 2 
Splicing factor 3A subunit 1 
OS=Homo sapiens GN=SF3A1 
PE=1 SV=1 
SF3A1 
89 
kDa 
1 0 1 0 3 
Splicing factor 3A subunit 3 
OS=Homo sapiens GN=SF3A3 
PE=1 SV=1 
SF3A3 
59 
kDa 
1 0 0 0 2 
Splicing factor 3B subunit 1 
OS=Homo sapiens GN=SF3B1 
PE=1 SV=3 
SF3B1 
146 
kDa 
6 0 0 0 10 
Splicing factor 3B subunit 3 
OS=Homo sapiens GN=SF3B3 
PE=1 SV=4 
SF3B3 
136 
kDa 
0 0 0 0 5 
Splicing factor, proline- and 
glutamine-rich OS=Homo sapiens 
GN=SFPQ PE=1 SV=2 
SFPQ 
76 
kDa 
4 1 0 4 9 
Superkiller viralicidic activity 2-like 2 
OS=Homo sapiens GN=SKIV2L2 
PE=1 SV=3 
SK2L2 
118 
kDa 
0 0 0 0 1 
STE20-like serine/threonine-protein 
kinase OS=Homo sapiens GN=SLK 
PE=1 SV=1 
SLK 
143 
kDa 
0 0 0 0 1 
Structural maintenance of 
chromosomes protein 2 OS=Homo 
sapiens GN=SMC2 PE=1 SV=2 
SMC2 
136 
kDa 
4 0 0 0 6 
Structural maintenance of 
chromosomes protein 3 OS=Homo 
sapiens GN=SMC3 PE=1 SV=2 
SMC3 
142 
kDa 
6 0 3 1 8 
Transcription activator BRG1 
OS=Homo sapiens GN=SMARCA4 
PE=1 SV=2 
SMCA4 
185 
kDa 
0 0 0 0 6 
Structural maintenance of 
chromosomes flexible hinge domain-
containing protein 1 OS=Homo 
sapiens GN=SMCHD1 PE=1 SV=2 
SMHD1 
226 
kDa 
0 0 0 0 2 
SWI/SNF-related matrix-associated 
actin-dependent regulator of 
chromatin subfamily D member 2 
OS=Homo sapiens GN=SMARCD2 
PE=1 SV=3 
SMRD2 
59 
kDa 
0 0 0 0 1 
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Staphylococcal nuclease domain-
containing protein 1 OS=Homo 
sapiens GN=SND1 PE=1 SV=1 
SND1 
102 
kDa 
2 0 0 2 3 
U4/U6.U5 tri-snRNP-associated 
protein 2 OS=Homo sapiens 
GN=USP39 PE=1 SV=2 
SNUT2 
65 
kDa 
0 0 0 0 1 
FACT complex subunit SPT16 
OS=Homo sapiens GN=SUPT16H 
PE=1 SV=1 
SP16H 
120 
kDa 
10 0 6 0 11 
Transcription elongation factor SPT6 
OS=Homo sapiens GN=SUPT6H 
PE=1 SV=2 
SPT6H 
199 
kDa 
0 0 0 0 1 
Spectrin beta chain, non-erythrocytic 
1 OS=Homo sapiens GN=SPTBN1 
PE=1 SV=2 
SPTB2 
275 
kDa 
0 0 0 0 2 
Spectrin alpha chain, non-
erythrocytic 1 OS=Homo sapiens 
GN=SPTAN1 PE=1 SV=3 
SPTN1 
285 
kDa 
0 0 0 0 2 
Signal recognition particle subunit 
SRP68 OS=Homo sapiens 
GN=SRP68 PE=1 SV=2 
SRP68 
71 
kDa 
1 0 1 1 6 
Signal recognition particle subunit 
SRP72 OS=Homo sapiens 
GN=SRP72 PE=1 SV=3 
SRP72 
75 
kDa 
0 0 0 1 3 
Signal recognition particle receptor 
subunit alpha OS=Homo sapiens 
GN=SRPR PE=1 SV=2 
SRPR 
70 
kDa 
0 0 0 0 2 
Serine/arginine-rich splicing factor 
11 OS=Homo sapiens GN=SRSF11 
PE=1 SV=1 
SRS11 
54 
kDa 
0 0 0 0 1 
Signal transducer and activator of 
transcription 1-alpha/beta OS=Homo 
sapiens GN=STAT1 PE=1 SV=2 
STAT1 
87 
kDa 
0 0 0 0 2 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3A OS=Homo sapiens 
GN=STT3A PE=1 SV=2 
STT3A 
81 
kDa 
0 0 0 0 1 
SURP and G-patch domain-
containing protein 2 OS=Homo 
sapiens GN=SUGP2 PE=1 SV=2 
SUGP2 
120 
kDa 
0 0 0 0 1 
Alanine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=AARS PE=1 
SV=2 
SYAC 
107 
kDa 
1 0 0 1 7 
Aspartate--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=DARS PE=1 
SV=2 
SYDC 
57 
kDa 
6 0 5 1 8 
Aspartate--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=DARS2 PE=1 SV=1 
SYDM 
74 
kDa 
0 0 0 0 1 
Glycine--tRNA ligase OS=Homo 
sapiens GN=GARS PE=1 SV=3 
SYG 
83 
kDa 
0 0 0 0 1 
Isoleucine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=IARS PE=1 
SV=2 
SYIC 
145 
kDa 
10 0 1 0 15 
Lysine--tRNA ligase OS=Homo 
sapiens GN=KARS PE=1 SV=3 
SYK 
68 
kDa 
2 0 1 0 3 
Leucine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=LARS PE=1 
SV=2 
SYLC 
134 
kDa 
10 0 1 2 12 
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Arginine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=RARS PE=1 
SV=2 
SYRC 
75 
kDa 
4 0 1 2 11 
Valine--tRNA ligase OS=Homo 
sapiens GN=VARS PE=1 SV=4 
SYVC 
140 
kDa 
5 0 2 1 6 
Tyrosine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=YARS PE=1 
SV=4 
SYYC 
59 
kDa 
0 0 0 1 4 
Tyrosine--tRNA ligase, mitochondrial 
OS=Homo sapiens GN=YARS2 
PE=1 SV=2 
SYYM 
53 
kDa 
0 0 0 0 1 
Transforming acidic coiled-coil-
containing protein 3 OS=Homo 
sapiens GN=TACC3 PE=1 SV=1 
TACC3 
90 
kDa 
0 0 0 0 1 
TBC1 domain family member 15 
OS=Homo sapiens GN=TBC1D15 
PE=1 SV=2 
TBC15 
79 
kDa 
0 0 0 0 1 
Transducin beta-like protein 2 
OS=Homo sapiens GN=TBL2 PE=1 
SV=1 
TBL2 
50 
kDa 
0 0 0 0 2 
T-complex protein 1 subunit alpha 
OS=Homo sapiens GN=TCP1 PE=1 
SV=1 
TCPA 
60 
kDa 
9 1 4 4 14 
T-complex protein 1 subunit beta 
OS=Homo sapiens GN=CCT2 PE=1 
SV=4 
TCPB 
57 
kDa 
9 2 6 6 16 
T-complex protein 1 subunit epsilon 
OS=Homo sapiens GN=CCT5 PE=1 
SV=1 
TCPE 
60 
kDa 
3 1 1 1 11 
T-complex protein 1 subunit gamma 
OS=Homo sapiens GN=CCT3 PE=1 
SV=4 
TCPG 
61 
kDa 
9 0 6 6 15 
T-complex protein 1 subunit eta 
OS=Homo sapiens GN=CCT7 PE=1 
SV=2 
TCPH 
59 
kDa 
6 0 6 5 12 
T-complex protein 1 subunit theta 
OS=Homo sapiens GN=CCT8 PE=1 
SV=4 
TCPQ 
60 
kDa 
6 1 5 4 12 
T-complex protein 1 subunit zeta 
OS=Homo sapiens GN=CCT6A 
PE=1 SV=3 
TCPZ 
58 
kDa 
6 0 2 2 7 
Transcription elongation regulator 1 
OS=Homo sapiens GN=TCERG1 
PE=1 SV=2 
TCRG1 
124 
kDa 
1 0 0 0 3 
General transcription factor 3C 
polypeptide 1 OS=Homo sapiens 
GN=GTF3C1 PE=1 SV=4 
TF3C1 
239 
kDa 
0 0 0 0 2 
General transcription factor 3C 
polypeptide 2 OS=Homo sapiens 
GN=GTF3C2 PE=1 SV=2 
TF3C2 
101 
kDa 
0 0 0 0 1 
General transcription factor 3C 
polypeptide 5 OS=Homo sapiens 
GN=GTF3C5 PE=1 SV=2 
TF3C5 
60 
kDa 
0 0 0 0 1 
Acetyl-CoA acetyltransferase, 
mitochondrial OS=Homo sapiens 
GN=ACAT1 PE=1 SV=1 
THIL 
45 
kDa 
0 0 0 0 3 
THO complex subunit 5 homolog 
OS=Homo sapiens GN=THOC5 
PE=1 SV=2 
THOC5 
79 
kDa 
0 0 0 0 1 
Transketolase OS=Homo sapiens 
GN=TKT PE=1 SV=3 
TKT 
68 
kDa 
3 0 1 3 9 
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Talin-1 OS=Homo sapiens 
GN=TLN1 PE=1 SV=3 
TLN1 
270 
kDa 
0 0 0 0 6 
Mitochondrial import receptor 
subunit TOM70 OS=Homo sapiens 
GN=TOMM70A PE=1 SV=1 
TOM70 
67 
kDa 
0 0 0 0 1 
DNA topoisomerase 2-alpha 
OS=Homo sapiens GN=TOP2A 
PE=1 SV=3 
TOP2A 
174 
kDa 
11 0 5 0 15 
DNA topoisomerase 2-beta 
OS=Homo sapiens GN=TOP2B 
PE=1 SV=3 
TOP2B 
183 
kDa 
0 0 0 0 5 
Tripeptidyl-peptidase 2 OS=Homo 
sapiens GN=TPP2 PE=1 SV=4 
TPP2 
138 
kDa 
0 0 0 0 3 
Nucleoprotein TPR OS=Homo 
sapiens GN=TPR PE=1 SV=3 
TPR 
267 
kDa 
0 0 0 0 5 
Heat shock protein 75 kDa, 
mitochondrial OS=Homo sapiens 
GN=TRAP1 PE=1 SV=3 
TRAP1 
80 
kDa 
4 0 2 6 11 
tRNA (guanine(26)-N(2))-
dimethyltransferase OS=Homo 
sapiens GN=TRMT1 PE=1 SV=1 
TRM1 
72 
kDa 
0 0 0 0 1 
TRMT1-like protein OS=Homo 
sapiens GN=TRMT1L PE=1 SV=2 
TRM1L 
82 
kDa 
0 0 0 0 1 
Pre-rRNA-processing protein TSR1 
homolog OS=Homo sapiens 
GN=TSR1 PE=1 SV=1 
TSR1 
92 
kDa 
0 0 0 0 1 
Tetratricopeptide repeat protein 37 
OS=Homo sapiens GN=TTC37 
PE=1 SV=1 
TTC37 
175 
kDa 
0 0 0 0 1 
Tetratricopeptide repeat protein 4 
OS=Homo sapiens GN=TTC4 PE=1 
SV=3 
TTC4 
45 
kDa 
0 0 0 0 1 
Tubulin--tyrosine ligase-like protein 
12 OS=Homo sapiens GN=TTLL12 
PE=1 SV=2 
TTL12 
74 
kDa 
3 0 0 1 5 
Alpha-taxilin OS=Homo sapiens 
GN=TXLNA PE=1 SV=3 
TXLNA 
62 
kDa 
0 0 0 0 1 
Thioredoxin domain-containing 
protein 5 OS=Homo sapiens 
GN=TXNDC5 PE=1 SV=2 
TXND5 
48 
kDa 
1 0 0 1 2 
U5 small nuclear ribonucleoprotein 
200 kDa helicase OS=Homo sapiens 
GN=SNRNP200 PE=1 SV=2 
U520 
245 
kDa 
6 0 4 0 14 
116 kDa U5 small nuclear 
ribonucleoprotein component 
OS=Homo sapiens GN=EFTUD2 
PE=1 SV=1 
U5S1 
109 
kDa 
3 0 0 0 7 
Ubiquitin-like modifier-activating 
enzyme 1 OS=Homo sapiens 
GN=UBA1 PE=1 SV=3 
UBA1 
118 
kDa 
10 2 2 6 20 
Ubiquitin conjugation factor E4 A 
OS=Homo sapiens GN=UBE4A 
PE=1 SV=2 
UBE4A 
123 
kDa 
0 0 0 0 1 
Ubiquitin carboxyl-terminal hydrolase 
10 OS=Homo sapiens GN=USP10 
PE=1 SV=2 
UBP10 
87 
kDa 
0 0 0 0 1 
Ubiquitin carboxyl-terminal hydrolase 
14 OS=Homo sapiens GN=USP14 
PE=1 SV=3 
UBP14 
56 
kDa 
1 0 1 1 2 
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Ubiquitin carboxyl-terminal hydrolase 
19 OS=Homo sapiens GN=USP19 
PE=1 SV=2 
UBP19 
146 
kDa 
0 0 0 0 1 
Ubiquitin carboxyl-terminal hydrolase 
24 OS=Homo sapiens GN=USP24 
PE=1 SV=3 
UBP24 
294 
kDa 
0 0 0 0 2 
Ubiquitin carboxyl-terminal hydrolase 
5 OS=Homo sapiens GN=USP5 
PE=1 SV=2 
UBP5 
96 
kDa 
4 0 0 0 5 
Ubiquitin carboxyl-terminal hydrolase 
7 OS=Homo sapiens GN=USP7 
PE=1 SV=2 
UBP7 
128 
kDa 
0 0 0 0 1 
UDP-glucose:glycoprotein 
glucosyltransferase 1 OS=Homo 
sapiens GN=UGGT1 PE=1 SV=3 
UGGG1 
177 
kDa 
0 0 0 0 2 
Uridine 5'-monophosphate synthase 
OS=Homo sapiens GN=UMPS 
PE=1 SV=1 
UMPS 
52 
kDa 
1 0 0 1 2 
General vesicular transport factor 
p115 OS=Homo sapiens GN=USO1 
PE=1 SV=2 
USO1 
108 
kDa 
4 0 0 0 5 
Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X OS=Homo sapiens 
GN=USP9X PE=1 SV=3 
USP9X 
292 
kDa 
1 0 0 0 4 
Synaptic vesicle membrane protein 
VAT-1 homolog OS=Homo sapiens 
GN=VAT1 PE=1 SV=2 
VAT1 
42 
kDa 
0 0 0 0 2 
Vigilin OS=Homo sapiens 
GN=HDLBP PE=1 SV=2 
VIGLN 
141 
kDa 
7 0 3 0 12 
Vacuolar protein sorting-associated 
protein 35 OS=Homo sapiens 
GN=VPS35 PE=1 SV=2 
VPS35 
92 
kDa 
4 0 1 2 5 
Vacuolar protein-sorting-associated 
protein 36 OS=Homo sapiens 
GN=VPS36 PE=1 SV=1 
VPS36 
44 
kDa 
0 0 0 0 1 
WASH complex subunit 7 OS=Homo 
sapiens GN=KIAA1033 PE=1 SV=2 
WASH7 
136 
kDa 
0 0 0 0 1 
WD and tetratricopeptide repeats 
protein 1 OS=Homo sapiens 
GN=WDTC1 PE=1 SV=2 
WDTC1 
76 
kDa 
0 0 0 0 1 
Exportin-1 OS=Homo sapiens 
GN=XPO1 PE=1 SV=1 
XPO1 
123 
kDa 
8 0 0 0 9 
Exportin-2 OS=Homo sapiens 
GN=CSE1L PE=1 SV=3 
XPO2 
110 
kDa 
7 0 2 0 8 
Exportin-5 OS=Homo sapiens 
GN=XPO5 PE=1 SV=1 
XPO5 
136 
kDa 
2 0 1 0 5 
Exportin-T OS=Homo sapiens 
GN=XPOT PE=1 SV=2 
XPOT 
110 
kDa 
1 0 0 0 2 
X-ray repair cross-complementing 
protein 6 OS=Homo sapiens 
GN=XRCC6 PE=1 SV=2 
XRCC6 
70 
kDa 
16 0 12 3 20 
Zinc finger CCCH domain-containing 
protein 11A OS=Homo sapiens 
GN=ZC3H11A PE=1 SV=3 
ZC11A 
89 
kDa 
0 0 0 0 1 
Zinc finger CCCH domain-containing 
protein 18 OS=Homo sapiens 
GN=ZC3H18 PE=1 SV=2 
ZCH18 
106 
kDa 
0 0 0 0 1 
Zinc finger protein ZPR1 OS=Homo 
sapiens GN=ZPR1 PE=1 SV=1 
ZPR1 
51 
kDa 
0 0 0 0 1 
232 
 
 
Centromere/kinetochore protein 
zw10 homolog OS=Homo sapiens 
GN=ZW10 PE=1 SV=3 
ZW10 
89 
kDa 
0 0 0 0 1 
Zyxin OS=Homo sapiens GN=ZYX 
PE=1 SV=1 
ZYX 
61 
kDa 
0 0 0 0 2 
AP-1 complex subunit mu-1 
OS=Homo sapiens GN=AP1M1 
PE=1 SV=3 
AP1M1 
49 
kDa 
0 0 1 0 0 
Cathepsin L2 OS=Homo sapiens 
GN=CTSV PE=1 SV=2 
CATL2 
37 
kDa 
0 0 1 0 0 
Cytoskeleton-associated protein 2 
OS=Homo sapiens GN=CKAP2 
PE=1 SV=1 
CKAP2 
77 
kDa 
0 0 1 0 0 
Probable ATP-dependent RNA 
helicase DDX47 OS=Homo sapiens 
GN=DDX47 PE=1 SV=1 
DDX47 
51 
kDa 
0 0 1 0 0 
Translation initiation factor eIF-2B 
subunit gamma OS=Homo sapiens 
GN=EIF2B3 PE=1 SV=1 
EI2BG 
50 
kDa 
0 0 1 0 0 
Eukaryotic translation initiation factor 
3 subunit E OS=Homo sapiens 
GN=EIF3E PE=1 SV=1 
EIF3E 
52 
kDa 
3 0 4 2 2 
Eukaryotic translation initiation factor 
3 subunit G OS=Homo sapiens 
GN=EIF3G PE=1 SV=2 
EIF3G 
36 
kDa 
0 0 1 1 0 
Filaggrin-2 OS=Homo sapiens 
GN=FLG2 PE=1 SV=1 
FILA2 
248 
kDa 
0 0 1 0 0 
Far upstream element-binding 
protein 3 OS=Homo sapiens 
GN=FUBP3 PE=1 SV=2 
FUBP3 
62 
kDa 
0 0 1 0 0 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
GSTP1 
23 
kDa 
0 0 2 0 0 
Histone H1.2 OS=Homo sapiens 
GN=HIST1H1C PE=1 SV=2 
H12 
21 
kDa 
2 0 3 0 1 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
H4 
11 
kDa 
0 0 2 0 0 
Hepatoma-derived growth factor-
related protein 2 OS=Homo sapiens 
GN=HDGFRP2 PE=1 SV=1 
HDGR2 
74 
kDa 
0 0 1 0 0 
Heterogeneous nuclear 
ribonucleoprotein H OS=Homo 
sapiens GN=HNRNPH1 PE=1 SV=4 
HNRH1 
49 
kDa 
5 0 8 4 5 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
OS=Homo sapiens GN=HNRNPUL2 
PE=1 SV=1 
HNRL2 
85 
kDa 
0 0 1 0 0 
Insulin-like growth factor 2 mRNA-
binding protein 2 OS=Homo sapiens 
GN=IGF2BP2 PE=1 SV=2 
IF2B2 
66 
kDa 
3 0 5 0 3 
Eukaryotic initiation factor 4A-III 
OS=Homo sapiens GN=EIF4A3 
PE=1 SV=4 
IF4A3 
47 
kDa 
2 1 3 3 2 
Eukaryotic translation initiation factor 
4 gamma 2 OS=Homo sapiens 
GN=EIF4G2 PE=1 SV=1 
IF4G2 
102 
kDa 
0 0 2 0 0 
Keratin, type II cytoskeletal 75 
OS=Homo sapiens GN=KRT75 
PE=1 SV=2 
K2C75 
60 
kDa 
0 0 2 0 0 
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Keratin, type II cytoskeletal 8 
OS=Homo sapiens GN=KRT8 PE=1 
SV=7 
K2C8 
54 
kDa 
0 0 1 0 0 
KH domain-containing, RNA-binding, 
signal transduction-associated 
protein 1 OS=Homo sapiens 
GN=KHDRBS1 PE=1 SV=1 
KHDR1 
48 
kDa 
2 0 3 1 2 
Keratin, type II cuticular Hb4 
OS=Homo sapiens GN=KRT84 
PE=2 SV=2 
KRT84 
65 
kDa 
0 0 6 0 0 
Putative RNA-binding protein Luc7-
like 2 OS=Homo sapiens 
GN=LUC7L2 PE=1 SV=2 
LC7L2 
47 
kDa 
1 0 2 0 0 
Prelamin-A/C OS=Homo sapiens 
GN=LMNA PE=1 SV=1 
LMNA 
74 
kDa 
0 0 4 0 0 
Lamin-B2 OS=Homo sapiens 
GN=LMNB2 PE=1 SV=3 
LMNB2 
68 
kDa 
0 0 3 0 0 
Non-POU domain-containing 
octamer-binding protein OS=Homo 
sapiens GN=NONO PE=1 SV=4 
NONO 
54 
kDa 
7 2 8 7 7 
Nucleolar protein 56 OS=Homo 
sapiens GN=NOP56 PE=1 SV=4 
NOP56 
66 
kDa 
1 0 3 0 1 
Nucleolar protein 58 OS=Homo 
sapiens GN=NOP58 PE=1 SV=1 
NOP58 
60 
kDa 
0 0 3 0 0 
Nucleosome assembly protein 1-like 
4 OS=Homo sapiens GN=NAP1L4 
PE=1 SV=1 
NP1L4 
43 
kDa 
0 0 1 1 1 
Plakophilin-1 OS=Homo sapiens 
GN=PKP1 PE=1 SV=2 
PKP1 
83 
kDa 
0 0 1 0 0 
U4/U6 small nuclear 
ribonucleoprotein Prp4 OS=Homo 
sapiens GN=PRPF4 PE=1 SV=2 
PRP4 
58 
kDa 
0 0 1 0 0 
26S protease regulatory subunit 7 
OS=Homo sapiens GN=PSMC2 
PE=1 SV=3 
PRS7 
49 
kDa 
3 0 5 2 3 
Pumilio homolog 2 OS=Homo 
sapiens GN=PUM2 PE=1 SV=2 
PUM2 
114 
kDa 
0 0 1 0 0 
RNA-binding motif protein, X 
chromosome OS=Homo sapiens 
GN=RBMX PE=1 SV=3 
RBMX 
42 
kDa 
0 0 8 2 1 
Regulator of chromosome 
condensation OS=Homo sapiens 
GN=RCC1 PE=1 SV=1 
RCC1 
45 
kDa 
1 0 2 2 2 
Protein Red OS=Homo sapiens 
GN=IK PE=1 SV=3 
RED 
66 
kDa 
0 0 1 0 0 
Ribosome biogenesis regulatory 
protein homolog OS=Homo sapiens 
GN=RRS1 PE=1 SV=2 
RRS1 
41 
kDa 
0 0 2 0 0 
WD40 repeat-containing protein 
SMU1 OS=Homo sapiens 
GN=SMU1 PE=1 SV=2 
SMU1 
58 
kDa 
0 0 1 0 0 
Sorting nexin-2 OS=Homo sapiens 
GN=SNX2 PE=1 SV=2 
SNX2 
58 
kDa 
0 0 1 1 0 
Serine/threonine-protein kinase 26 
OS=Homo sapiens GN=STK26 
PE=1 SV=2 
STK26 
47 
kDa 
0 0 1 1 1 
TAR DNA-binding protein 43 
OS=Homo sapiens GN=TARDBP 
PE=1 SV=1 
TADBP 
45 
kDa 
0 0 1 1 1 
Tubulin alpha-1A chain OS=Homo 
sapiens GN=TUBA1A PE=1 SV=1 
TBA1A 
50 
kDa 
0 0 1 1 0 
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Tubulin beta-2A chain OS=Homo 
sapiens GN=TUBB2A PE=1 SV=1 
TBB2A 
50 
kDa 
1 0 2 1 1 
Deoxynucleotidyltransferase 
terminal-interacting protein 2 
OS=Homo sapiens GN=DNTTIP2 
PE=1 SV=2 
TDIF2 
84 
kDa 
0 0 1 0 0 
Nucleolar transcription factor 1 
OS=Homo sapiens GN=UBTF PE=1 
SV=1 
UBF1 
89 
kDa 
0 0 1 0 0 
E3 UFM1-protein ligase 1 OS=Homo 
sapiens GN=UFL1 PE=1 SV=2 
UFL1 
90 
kDa 
0 0 1 0 0 
U3 small nucleolar RNA-associated 
protein 18 homolog OS=Homo 
sapiens GN=UTP18 PE=1 SV=3 
UTP18 
62 
kDa 
1 0 2 0 1 
DNA repair protein XRCC1 
OS=Homo sapiens GN=XRCC1 
PE=1 SV=2 
XRCC1 
69 
kDa 
0 0 1 0 0 
5'-3' exoribonuclease 2 OS=Homo 
sapiens GN=XRN2 PE=1 SV=1 
XRN2 
109 
kDa 
0 0 1 1 0 
YTH domain-containing family 
protein 2 OS=Homo sapiens 
GN=YTHDF2 PE=1 SV=2 
YTHD2 
62 
kDa 
0 0 1 1 1 
Zinc finger CCCH domain-containing 
protein 15 OS=Homo sapiens 
GN=ZC3H15 PE=1 SV=1 
ZC3HF 
49 
kDa 
0 0 1 0 0 
Zinc finger CCCH-type antiviral 
protein 1 OS=Homo sapiens 
GN=ZC3HAV1 PE=1 SV=3 
ZCCHV 
101 
kDa 
0 0 1 0 0 
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Table A. 4. 4: Representation of the number of unique peptides from Trial 2, figure 
A 4.21: The table containing data for trypsinized proteins from SDS-PAGE gel of trial 2 
(Appendix C, section 4.5). The data of the table represents uncrosslinked lysated (lane 
1, Figure A 4.21), ATP-Hex-Acr crosslinked lysates in presence of staursporine (lane 2, 
Figure A 4.21), ATP-Hex-Acr crosslinked lysates (lane 3, Figure A 4.21), ATP-PEG-Acr 
crosslinked lysates in presence of staursporine (lane 4, Figure A 4.21), and ATP-Hex-
Acr crosslinked lysates (lane 5, Figure A 4.21) 
 
Identified Protein 
Accession 
Number 
Mol. Wt. 
the number of unique peptides 
Lane 1 Lane  2 Lane  3 Lane  4 Lane  5 
Stress-70 protein, 
mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 
SV=2 
GRP75 74 kDa 3 4 12 0 8 
Vesicle-fusing ATPase 
OS=Homo sapiens GN=NSF 
PE=1 SV=3 
NSF 83 kDa 0 0 1 0 2 
Heat shock protein HSP 90-
alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 
HS90A 85 kDa 19 13 19 1 30 
Heat shock protein HSP 90-
beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 
HS90B 83 kDa 14 5 11 0 16 
Heat shock cognate 71 kDa 
protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 
HSP7C 71 kDa 6 9 4 0 10 
Creatine kinase B-type 
OS=Homo sapiens GN=CKB 
PE=1 SV=1 
KCRB 43 kDa 6 4 4 1 7 
L-lactate dehydrogenase A 
chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 
LDHA 37 kDa 0 0 0 0 1 
Transitional endoplasmic 
reticulum ATPase OS=Homo 
sapiens GN=VCP PE=1 SV=4 
TERA 89 kDa 0 0 0 0 1 
Alpha-enolase OS=Homo 
sapiens GN=ENO1 PE=1 
SV=2 
ENOA 47 kDa 2 2 0 0 4 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
ACTB 42 kDa 0 0 0 0 1 
Interleukin-1 receptor-
associated kinase 1 OS=Homo 
sapiens GN=IRAK1 PE=1 
SV=2 
IRAK1 77 kDa 0 0 1 0 0 
Integrin-linked protein kinase 
OS=Homo sapiens GN=ILK 
PE=1 SV=2 
ILK 51 kDa 0 0 0 0 1 
4F2 cell-surface antigen heavy 
chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 
4F2 68 kDa 0 0 1 0 1 
Aconitate hydratase, 
mitochondrial OS=Homo 
sapiens GN=ACO2 PE=1 
SV=2 
ACON 85 kDa 0 0 1 0 1 
Activator of 90 kDa heat shock 
protein ATPase homolog 1 
OS=Homo sapiens 
GN=AHSA1 PE=1 SV=1 
AHSA1 38 kDa 0 0 1 0 2 
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Apoptosis-inducing factor 1, 
mitochondrial OS=Homo 
sapiens GN=AIFM1 PE=1 
SV=1 
AIFM1 67 kDa 0 0 1 0 1 
ATPase family AAA domain-
containing protein 3A 
OS=Homo sapiens 
GN=ATAD3A PE=1 SV=2 
ATD3A 71 kDa 3 0 6 0 5 
Cytoskeleton-associated 
protein 4 OS=Homo sapiens 
GN=CKAP4 PE=1 SV=2 
CKAP4 66 kDa 0 0 1 0 2 
Cold shock domain-containing 
protein E1 OS=Homo sapiens 
GN=CSDE1 PE=1 SV=2 
CSDE1 89 kDa 0 0 1 0 1 
Cytoplasmic dynein 1 
intermediate chain 2 OS=Homo 
sapiens GN=DYNC1I2 PE=1 
SV=3 
DC1I2 71 kDa 1 0 4 0 3 
Probable ATP-dependent RNA 
helicase DDX17 OS=Homo 
sapiens GN=DDX17 PE=1 
SV=2 
DDX17 80 kDa 6 4 7 0 8 
DnaJ homolog subfamily C 
member 2 OS=Homo sapiens 
GN=DNAJC2 PE=1 SV=4 
DNJC2 72 kDa 0 0 2 0 1 
Developmentally-regulated 
GTP-binding protein 1 
OS=Homo sapiens GN=DRG1 
PE=1 SV=1 
DRG1 41 kDa 0 0 1 0 1 
Eukaryotic translation initiation 
factor 3 subunit D OS=Homo 
sapiens GN=EIF3D PE=1 
SV=1 
EIF3D 64 kDa 0 0 1 0 2 
Eukaryotic translation initiation 
factor 3 subunit L OS=Homo 
sapiens GN=EIF3L PE=1 SV=1 
EIF3L 67 kDa 4 0 5 0 5 
Pre-mRNA 3'-end-processing 
factor FIP1 OS=Homo sapiens 
GN=FIP1L1 PE=1 SV=1 
FIP1 67 kDa 0 0 1 0 1 
RNA-binding protein FUS 
OS=Homo sapiens GN=FUS 
PE=1 SV=1 
FUS 53 kDa 0 0 2 0 1 
Glucosidase 2 subunit beta 
OS=Homo sapiens 
GN=PRKCSH PE=1 SV=2 
GLU2B 59 kDa 0 0 1 0 1 
Histone H2B type 1-C/E/F/G/I 
OS=Homo sapiens 
GN=HIST1H2BC PE=1 SV=4 
H2B1C (+8) 14 kDa 0 0 1 0 1 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
OS=Homo sapiens 
GN=HNRNPC PE=1 SV=4 
HNRPC 34 kDa 0 0 1 0 3 
Insulin-like growth factor 2 
mRNA-binding protein 1 
OS=Homo sapiens 
GN=IGF2BP1 PE=1 SV=2 
IF2B1 63 kDa 3 2 12 0 13 
Insulin-like growth factor 2 
mRNA-binding protein 3 
OS=Homo sapiens 
GN=IGF2BP3 PE=1 SV=2 
IF2B3 64 kDa 3 1 7 0 6 
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Interleukin enhancer-binding 
factor 3 OS=Homo sapiens 
GN=ILF3 PE=1 SV=3 
ILF3 95 kDa 0 0 1 0 1 
Importin subunit alpha-5 
OS=Homo sapiens 
GN=KPNA1 PE=1 SV=3 
IMA5 60 kDa 0 0 1 0 1 
KH domain-containing, RNA-
binding, signal transduction-
associated protein 1 OS=Homo 
sapiens GN=KHDRBS1 PE=1 
SV=1 
KHDR1 48 kDa 1 1 3 0 3 
Lamina-associated polypeptide 
2, isoform alpha OS=Homo 
sapiens GN=TMPO PE=1 
SV=2 
LAP2A 75 kDa 3 0 5 0 6 
LETM1 and EF-hand domain-
containing protein 1, 
mitochondrial OS=Homo 
sapiens GN=LETM1 PE=1 
SV=1 
LETM1 83 kDa 0 0 1 0 3 
Leukotriene A-4 hydrolase 
OS=Homo sapiens GN=LTA4H 
PE=1 SV=2 
LKHA4 69 kDa 0 0 1 0 2 
Protein ERGIC-53 OS=Homo 
sapiens GN=LMAN1 PE=1 
SV=2 
LMAN1 58 kDa 0 0 1 0 1 
Melanoma-associated antigen 
D2 OS=Homo sapiens 
GN=MAGED2 PE=1 SV=2 
MAGD2 65 kDa 0 0 1 0 1 
MICOS complex subunit 
MIC60 OS=Homo sapiens 
GN=IMMT PE=1 SV=1 
MIC60 84 kDa 1 0 2 0 3 
Nuclear cap-binding protein 
subunit 1 OS=Homo sapiens 
GN=NCBP1 PE=1 SV=1 
NCBP1 92 kDa 1 0 2 0 2 
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit, mitochondrial 
OS=Homo sapiens 
GN=NDUFS1 PE=1 SV=3 
NDUS1 79 kDa 0 0 2 0 2 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase 
complex, mitochondrial 
OS=Homo sapiens GN=DLAT 
PE=1 SV=3 
ODP2 69 kDa 0 0 1 0 1 
Dynamin-like 120 kDa protein, 
mitochondrial OS=Homo 
sapiens GN=OPA1 PE=1 SV=3 
OPA1 112 kDa 1 0 2 0 2 
Transcriptional repressor p66-
alpha OS=Homo sapiens 
GN=GATAD2A PE=1 SV=1 
P66A 68 kDa 0 0 1 0 1 
Transcriptional repressor p66-
beta OS=Homo sapiens 
GN=GATAD2B PE=1 SV=1 
P66B 65 kDa 0 0 2 0 1 
Plasminogen activator inhibitor 
1 RNA-binding protein 
OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 
PAIRB 45 kDa 1 0 4 0 3 
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Poly(rC)-binding protein 1 
OS=Homo sapiens 
GN=PCBP1 PE=1 SV=2 
PCBP1 37 kDa 0 0 1 0 4 
Phosphoenolpyruvate 
carboxykinase (GTP), 
mitochondrial OS=Homo 
sapiens GN=PCK2 PE=1 SV=3 
PCKGM 71 kDa 1 0 3 0 4 
U4/U6 small nuclear 
ribonucleoprotein Prp3 
OS=Homo sapiens 
GN=PRPF3 PE=1 SV=2 
PRPF3 78 kDa 0 0 1 0 1 
26S proteasome non-ATPase 
regulatory subunit 3 OS=Homo 
sapiens GN=PSMD3 PE=1 
SV=2 
PSMD3 61 kDa 2 0 3 0 3 
26S proteasome non-ATPase 
regulatory subunit 4 OS=Homo 
sapiens GN=PSMD4 PE=1 
SV=1 
PSMD4 41 kDa 0 0 1 0 2 
Cytochrome b-c1 complex 
subunit 1, mitochondrial 
OS=Homo sapiens 
GN=UQCRC1 PE=1 SV=3 
QCR1 53 kDa 0 0 1 0 1 
Cytochrome b-c1 complex 
subunit 2, mitochondrial 
OS=Homo sapiens 
GN=UQCRC2 PE=1 SV=3 
QCR2 48 kDa 0 0 1 0 3 
Ran GTPase-activating protein 
1 OS=Homo sapiens 
GN=RANGAP1 PE=1 SV=1 
RAGP1 64 kDa 2 0 3 0 5 
RNA-binding protein 14 
OS=Homo sapiens 
GN=RBM14 PE=1 SV=2 
RBM14 69 kDa 0 0 5 0 2 
DNA-directed RNA 
polymerases I and III subunit 
RPAC1 OS=Homo sapiens 
GN=POLR1C PE=1 SV=1 
RPAC1 39 kDa 0 0 1 0 1 
Protein RUFY3 OS=Homo 
sapiens GN=RUFY3 PE=1 
SV=1 
RUFY3 53 kDa 0 0 1 0 1 
Signal recognition particle 
subunit SRP68 OS=Homo 
sapiens GN=SRP68 PE=1 
SV=2 
SRP68 71 kDa 1 0 3 0 3 
Stomatin-like protein 2, 
mitochondrial OS=Homo 
sapiens GN=STOML2 PE=1 
SV=1 
STML2 39 kDa 0 0 1 0 1 
Lysine--tRNA ligase OS=Homo 
sapiens GN=KARS PE=1 
SV=3 
SYK 68 kDa 1 0 2 0 3 
Arginine--tRNA ligase, 
cytoplasmic OS=Homo sapiens 
GN=RARS PE=1 SV=2 
SYRC 75 kDa 1 0 4 0 7 
Tubulin beta-4B chain 
OS=Homo sapiens 
GN=TUBB4B PE=1 SV=1 
TBB4B 50 kDa 2 2 3 1 3 
Acetyl-CoA acetyltransferase, 
mitochondrial OS=Homo 
sapiens GN=ACAT1 PE=1 
SV=1 
THIL 45 kDa 0 0 2 0 6 
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Heat shock protein 75 kDa, 
mitochondrial OS=Homo 
sapiens GN=TRAP1 PE=1 
SV=3 
TRAP1 80 kDa 5 1 6 0 13 
V-type proton ATPase catalytic 
subunit A OS=Homo sapiens 
GN=ATP6V1A PE=1 SV=2 
VATA 68 kDa 0 0 1 0 3 
Vacuolar protein sorting-
associated protein 35 
OS=Homo sapiens GN=VPS35 
PE=1 SV=2 
VPS35 92 kDa 1 0 2 0 4 
X-ray repair cross-
complementing protein 5 
OS=Homo sapiens 
GN=XRCC5 PE=1 SV=3 
XRCC5 83 kDa 1 1 7 0 13 
X-ray repair cross-
complementing protein 6 
OS=Homo sapiens 
GN=XRCC6 PE=1 SV=2 
XRCC6 70 kDa 7 2 10 0 15 
YTH domain-containing family 
protein 2 OS=Homo sapiens 
GN=YTHDF2 PE=1 SV=2 
YTHD2 62 kDa 1 0 4 0 2 
Zyxin OS=Homo sapiens 
GN=ZYX PE=1 SV=1 
ZYX 61 kDa 1 0 2 0 2 
Serine/threonine-protein 
phosphatase 2A 56 kDa 
regulatory subunit delta isoform 
OS=Homo sapiens 
GN=PPP2R5D PE=1 SV=1 
2A5D 70 kDa 0 0 0 0 1 
Aldehyde dehydrogenase 
family 16 member A1 
OS=Homo sapiens 
GN=ALDH16A1 PE=1 SV=2 
A16A1 85 kDa 0 0 0 0 1 
Alpha-actinin-4 OS=Homo 
sapiens GN=ACTN4 PE=1 
SV=2 
ACTN4 105 kDa 1 1 0 0 6 
ADP/ATP translocase 2 
OS=Homo sapiens 
GN=SLC25A5 PE=1 SV=7 
ADT2 33 kDa 0 0 0 0 2 
AFG3-like protein 2 OS=Homo 
sapiens GN=AFG3L2 PE=1 
SV=2 
AFG32 89 kDa 0 0 0 0 1 
Acylglycerol kinase, 
mitochondrial OS=Homo 
sapiens GN=AGK PE=1 SV=2 
AGK 47 kDa 0 0 0 0 1 
Cytosol aminopeptidase 
OS=Homo sapiens GN=LAP3 
PE=1 SV=3 
AMPL 56 kDa 2 0 1 0 4 
Annexin A2 OS=Homo sapiens 
GN=ANXA2 PE=1 SV=2 
ANXA2 39 kDa 0 0 0 0 1 
AP-1 complex subunit beta-1 
OS=Homo sapiens GN=AP1B1 
PE=1 SV=2 
AP1B1 105 kDa 0 0 0 0 1 
ADP-ribosylation factor 
GTPase-activating protein 1 
OS=Homo sapiens 
GN=ARFGAP1 PE=1 SV=2 
ARFG1 45 kDa 0 0 0 0 1 
ADP-ribosylation factor 
GTPase-activating protein 2 
OS=Homo sapiens 
GN=ARFGAP2 PE=1 SV=1 
ARFG2 57 kDa 0 0 0 0 1 
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N-acetylserotonin O-
methyltransferase-like protein 
OS=Homo sapiens 
GN=ASMTL PE=1 SV=3 
ASML 69 kDa 0 0 0 0 1 
ATPase family AAA domain-
containing protein 3B 
OS=Homo sapiens 
GN=ATAD3B PE=1 SV=1 
ATD3B 73 kDa 0 0 0 0 1 
Calcium-binding mitochondrial 
carrier protein Aralar2 
OS=Homo sapiens 
GN=SLC25A13 PE=1 SV=2 
CMC2 74 kDa 1 0 0 0 3 
Cytosolic non-specific 
dipeptidase OS=Homo sapiens 
GN=CNDP2 PE=1 SV=2 
CNDP2 53 kDa 0 0 0 0 1 
Coatomer subunit beta 
OS=Homo sapiens 
GN=COPB1 PE=1 SV=3 
COPB 107 kDa 2 0 0 0 3 
Coatomer subunit beta' 
OS=Homo sapiens 
GN=COPB2 PE=1 SV=2 
COPB2 102 kDa 1 0 0 0 3 
Coatomer subunit gamma-1 
OS=Homo sapiens 
GN=COPG1 PE=1 SV=1 
COPG1 98 kDa 3 0 0 0 4 
Cleavage and polyadenylation 
specificity factor subunit 6 
OS=Homo sapiens 
GN=CPSF6 PE=1 SV=2 
CPSF6 59 kDa 0 0 0 0 1 
COP9 signalosome complex 
subunit 4 OS=Homo sapiens 
GN=COPS4 PE=1 SV=1 
CSN4 46 kDa 0 0 0 0 2 
Drebrin-like protein OS=Homo 
sapiens GN=DBNL PE=1 SV=1 
DBNL 48 kDa 0 0 0 0 2 
ATP-dependent RNA helicase 
DDX1 OS=Homo sapiens 
GN=DDX1 PE=1 SV=2 
DDX1 82 kDa 1 0 1 0 3 
Probable ATP-dependent RNA 
helicase DDX23 OS=Homo 
sapiens GN=DDX23 PE=1 
SV=3 
DDX23 96 kDa 0 0 0 0 2 
Probable ATP-dependent RNA 
helicase DDX5 OS=Homo 
sapiens GN=DDX5 PE=1 SV=1 
DDX5 69 kDa 2 0 0 0 3 
Peroxisomal multifunctional 
enzyme type 2 OS=Homo 
sapiens GN=HSD17B4 PE=1 
SV=3 
DHB4 80 kDa 0 0 0 0 3 
Dynamin-1-like protein 
OS=Homo sapiens 
GN=DNM1L PE=1 SV=2 
DNM1L 82 kDa 0 0 0 0 1 
Dihydropyrimidinase-related 
protein 1 OS=Homo sapiens 
GN=CRMP1 PE=1 SV=1 
DPYL1 62 kDa 0 0 0 0 1 
Trifunctional enzyme subunit 
alpha, mitochondrial OS=Homo 
sapiens GN=HADHA PE=1 
SV=2 
ECHA 83 kDa 1 0 1 0 3 
Elongation factor 2 OS=Homo 
sapiens GN=EEF2 PE=1 SV=4 
EF2 95 kDa 9 9 5 0 25 
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Eukaryotic translation initiation 
factor 3 subunit E OS=Homo 
sapiens GN=EIF3E PE=1 
SV=1 
EIF3E 52 kDa 2 0 1 0 3 
Eukaryotic translation initiation 
factor 3 subunit G OS=Homo 
sapiens GN=EIF3G PE=1 
SV=2 
EIF3G 36 kDa 0 1 1 0 2 
Endoplasmin OS=Homo 
sapiens GN=HSP90B1 PE=1 
SV=1 
ENPL 92 kDa 9 2 0 1 16 
Eukaryotic peptide chain 
release factor GTP-binding 
subunit ERF3A OS=Homo 
sapiens GN=GSPT1 PE=1 
SV=1 
ERF3A 56 kDa 0 1 0 0 1 
Exosome component 10 
OS=Homo sapiens 
GN=EXOSC10 PE=1 SV=2 
EXOSX 101 kDa 0 0 0 0 1 
Ezrin OS=Homo sapiens 
GN=EZR PE=1 SV=4 
EZRI 69 kDa 0 0 0 0 2 
Protein FAM98B OS=Homo 
sapiens GN=FAM98B PE=1 
SV=1 
FA98B 37 kDa 0 0 0 0 1 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo 
sapiens GN=GAPDH PE=1 
SV=3 
G3P 36 kDa 0 1 0 0 1 
Glucose-6-phosphate 1-
dehydrogenase OS=Homo 
sapiens GN=G6PD PE=1 
SV=4 
G6PD 59 kDa 0 0 0 0 1 
Glucose-6-phosphate 
isomerase OS=Homo sapiens 
GN=GPI PE=1 SV=4 
G6PI 63 kDa 3 1 0 0 5 
Golgi resident protein GCP60 
OS=Homo sapiens 
GN=ACBD3 PE=1 SV=4 
GCP60 61 kDa 0 0 0 0 1 
Glutamine--fructose-6-
phosphate aminotransferase 
(isomerizing) 1 OS=Homo 
sapiens GN=GFPT1 PE=1 
SV=3 
GFPT1 79 kDa 0 0 0 0 1 
Serine 
hydroxymethyltransferase, 
mitochondrial OS=Homo 
sapiens GN=SHMT2 PE=1 
SV=3 
GLYM 56 kDa 6 2 2 0 7 
Mannose-1-phosphate 
guanyltransferase alpha 
OS=Homo sapiens 
GN=GMPPA PE=1 SV=1 
GMPPA 46 kDa 0 0 0 0 1 
Golgi-associated PDZ and 
coiled-coil motif-containing 
protein OS=Homo sapiens 
GN=GOPC PE=1 SV=1 
GOPC 51 kDa 0 0 0 0 1 
78 kDa glucose-regulated 
protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 
GRP78 72 kDa 3 5 4 0 5 
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Glutathione reductase, 
mitochondrial OS=Homo 
sapiens GN=GSR PE=1 SV=2 
GSHR 56 kDa 1 0 0 0 2 
GMP synthase (glutamine-
hydrolyzing) OS=Homo 
sapiens GN=GMPS PE=1 
SV=1 
GUAA 77 kDa 0 0 0 0 1 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
H4 11 kDa 0 0 0 0 1 
Heterogeneous nuclear 
ribonucleoprotein F OS=Homo 
sapiens GN=HNRNPF PE=1 
SV=3 
HNRPF 46 kDa 1 0 0 0 3 
Heterogeneous nuclear 
ribonucleoprotein K OS=Homo 
sapiens GN=HNRNPK PE=1 
SV=1 
HNRPK 51 kDa 6 2 6 0 9 
Heterogeneous nuclear 
ribonucleoprotein M OS=Homo 
sapiens GN=HNRNPM PE=1 
SV=3 
HNRPM 78 kDa 12 2 12 0 13 
Heterogeneous nuclear 
ribonucleoprotein R OS=Homo 
sapiens GN=HNRNPR PE=1 
SV=1 
HNRPR 71 kDa 2 0 2 0 3 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 
HORN 282 kDa 0 0 0 0 1 
Heat shock 70 kDa protein 1A 
OS=Homo sapiens 
GN=HSPA1A PE=1 SV=1 
HS71A 70 kDa 19 23 22 9 22 
Heat shock protein HSP 90-
alpha A2 OS=Homo sapiens 
GN=HSP90AA2P PE=1 SV=2 
HS902 39 kDa 0 0 0 0 1 
Interferon regulatory factor 2-
binding protein 1 OS=Homo 
sapiens GN=IRF2BP1 PE=1 
SV=1 
I2BP1 62 kDa 0 0 0 0 1 
Isocitrate dehydrogenase 
(NAD) subunit beta, 
mitochondrial OS=Homo 
sapiens GN=IDH3B PE=1 
SV=2 
IDH3B 42 kDa 0 0 0 0 1 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
IGHG1 36 kDa 0 2 0 0 1 
Importin subunit alpha-3 
OS=Homo sapiens 
GN=KPNA4 PE=1 SV=1 
IMA3 58 kDa 0 0 0 0 1 
Importin subunit beta-1 
OS=Homo sapiens 
GN=KPNB1 PE=1 SV=2 
IMB1 97 kDa 4 1 4 0 6 
Inositol-3-phosphate synthase 
1 OS=Homo sapiens 
GN=ISYNA1 PE=1 SV=1 
INO1 61 kDa 0 0 0 0 1 
Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 
PE=1 SV=6 
K1C10 59 kDa 19 27 20 9 21 
Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 
PE=1 SV=4 
K1C14 52 kDa 2 6 2 1 4 
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Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 
PE=1 SV=4 
K1C16 51 kDa 0 0 0 0 5 
Keratin, type I cytoskeletal 17 
OS=Homo sapiens GN=KRT17 
PE=1 SV=2 
K1C17 48 kDa 0 0 0 0 3 
Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 
PE=1 SV=3 
K1C9 62 kDa 10 15 10 10 15 
Keratin, type I cuticular Ha1 
OS=Homo sapiens GN=KRT31 
PE=1 SV=3 
K1H1 47 kDa 0 0 0 0 16 
Keratin, type I cuticular Ha2 
OS=Homo sapiens GN=KRT32 
PE=2 SV=3 
K1H2 50 kDa 0 0 0 0 9 
Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
K22E 65 kDa 12 30 19 11 19 
Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 
PE=1 SV=6 
K2C1 66 kDa 22 28 28 22 28 
Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 
PE=1 SV=3 
K2C5 62 kDa 1 9 2 1 7 
Keratin, type II cytoskeletal 6A 
OS=Homo sapiens 
GN=KRT6A PE=1 SV=3 
K2C6A 60 kDa 1 2 0 1 9 
Keratin, type II cytoskeletal 6C 
OS=Homo sapiens 
GN=KRT6C PE=1 SV=3 
K2C6C 60 kDa 0 1 0 0 1 
Pyruvate kinase PKM 
OS=Homo sapiens GN=PKM 
PE=1 SV=4 
KPYM 58 kDa 5 4 3 1 9 
Keratin-associated protein 11-1 
OS=Homo sapiens 
GN=KRTAP11-1 PE=2 SV=1 
KR111 17 kDa 0 0 0 0 3 
Keratin-associated protein 19-5 
OS=Homo sapiens 
GN=KRTAP19-5 PE=1 SV=1 
KR195 8 kDa 0 0 0 0 2 
Keratin-associated protein 19-7 
OS=Homo sapiens 
GN=KRTAP19-7 PE=1 SV=1 
KR197 7 kDa 0 0 0 0 1 
Keratin-associated protein 24-1 
OS=Homo sapiens 
GN=KRTAP24-1 PE=2 SV=1 
KR241 28 kDa 0 0 0 0 1 
Keratin-associated protein 2-1 
OS=Homo sapiens 
GN=KRTAP2-1 PE=2 SV=2 
KRA21  14 kDa 0 0 0 0 1 
Keratin-associated protein 3-1 
OS=Homo sapiens 
GN=KRTAP3-1 PE=1 SV=1 
KRA31 11 kDa 0 0 0 0 1 
Keratin-associated protein 6-1 
OS=Homo sapiens 
GN=KRTAP6-1 PE=3 SV=1 
KRA61 7 kDa 0 0 0 0 1 
Keratin-associated protein 9-1 
OS=Homo sapiens 
GN=KRTAP9-1 PE=3 SV=1 
KRA91 26 kDa 0 0 0 0 1 
Keratin, type I cuticular Ha4 
OS=Homo sapiens GN=KRT34 
PE=2 SV=2 
KRT34 49 kDa 0 0 0 0 5 
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Keratin, type I cuticular Ha5 
OS=Homo sapiens GN=KRT35 
PE=2 SV=5 
KRT35 50 kDa 0 0 0 0 2 
Keratin, type II cuticular Hb2 
OS=Homo sapiens GN=KRT82 
PE=3 SV=3 
KRT82 57 kDa 0 0 0 0 8 
Keratin, type II cuticular Hb5 
OS=Homo sapiens GN=KRT85 
PE=1 SV=1 
KRT85 56 kDa 0 0 0 0 6 
Keratin, type II cuticular Hb6 
OS=Homo sapiens GN=KRT86 
PE=1 SV=1 
KRT86 53 kDa 0 1 0 0 15 
Ribosomal protein S6 kinase 
alpha-3 OS=Homo sapiens 
GN=RPS6KA3 PE=1 SV=1 
KS6A3 84 kDa 1 0 0 0 2 
Keratin, type I cuticular Ha3-I 
OS=Homo sapiens 
GN=KRT33A PE=2 SV=2 
KT33A 46 kDa 0 0 0 0 3 
Keratin, type I cuticular Ha3-II 
OS=Homo sapiens 
GN=KRT33B PE=1 SV=3 
KT33B 46 kDa 0 0 0 0 3 
La-related protein 6 OS=Homo 
sapiens GN=LARP6 PE=1 
SV=1 
LARP6 55 kDa 0 0 0 0 1 
L-lactate dehydrogenase B 
chain OS=Homo sapiens 
GN=LDHB PE=1 SV=2 
LDHB 37 kDa 0 0 0 0 2 
Leucine-rich repeat-containing 
protein 40 OS=Homo sapiens 
GN=LRRC40 PE=1 SV=1 
LRC40 68 kDa 0 0 0 0 1 
DNA replication licensing factor 
MCM4 OS=Homo sapiens 
GN=MCM4 PE=1 SV=5 
MCM4 97 kDa 1 0 1 0 3 
DNA replication licensing factor 
MCM5 OS=Homo sapiens 
GN=MCM5 PE=1 SV=5 
MCM5 82 kDa 3 0 3 0 4 
DNA replication licensing factor 
MCM7 OS=Homo sapiens 
GN=MCM7 PE=1 SV=4 
MCM7 81 kDa 5 0 5 0 9 
Mitogen-activated protein 
kinase 3 OS=Homo sapiens 
GN=MAPK3 PE=1 SV=4 
MK03 43 kDa 0 0 0 0 1 
Mitochondrial-processing 
peptidase subunit alpha 
OS=Homo sapiens 
GN=PMPCA PE=1 SV=2 
MPPA 58 kDa 0 0 0 0 1 
Mitochondrial ribonuclease P 
protein 1 OS=Homo sapiens 
GN=TRMT10C PE=1 SV=2 
MRRP1 47 kDa 0 0 0 0 1 
Metastasis-associated protein 
MTA2 OS=Homo sapiens 
GN=MTA2 PE=1 SV=1 
MTA2 75 kDa 0 0 0 0 1 
N-alpha-acetyltransferase 15, 
NatA auxiliary subunit 
OS=Homo sapiens GN=NAA15 
PE=1 SV=1 
NAA15 101 kDa 0 0 0 0 2 
Nuclear autoantigenic sperm 
protein OS=Homo sapiens 
GN=NASP PE=1 SV=2 
NASP 85 kDa 0 0 0 0 2 
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Non-POU domain-containing 
octamer-binding protein 
OS=Homo sapiens GN=NONO 
PE=1 SV=4 
NONO 54 kDa 7 6 3 0 8 
tRNA (cytosine(34)-C(5))-
methyltransferase OS=Homo 
sapiens GN=NSUN2 PE=1 
SV=2 
NSUN2 86 kDa 1 0 0 0 3 
5'-nucleotidase domain-
containing protein 1 OS=Homo 
sapiens GN=NT5DC1 PE=1 
SV=1 
NT5D1 52 kDa 0 0 0 0 1 
Nucleoside diphosphate-linked 
moiety X motif 19, 
mitochondrial OS=Homo 
sapiens GN=NUDT19 PE=1 
SV=1 
NUD19 42 kDa 0 0 0 0 1 
NudC domain-containing 
protein 1 OS=Homo sapiens 
GN=NUDCD1 PE=1 SV=2 
NUDC1 67 kDa 0 0 0 0 1 
Obg-like ATPase 1 OS=Homo 
sapiens GN=OLA1 PE=1 SV=2 
OLA1 45 kDa 0 0 0 0 1 
Delta-1-pyrroline-5-carboxylate 
synthase OS=Homo sapiens 
GN=ALDH18A1 PE=1 SV=2 
P5CS 87 kDa 2 0 2 0 5 
Polyadenylate-binding protein 
1 OS=Homo sapiens 
GN=PABPC1 PE=1 SV=2 
PABP1 71 kDa 5 1 4 0 7 
Pantothenate kinase 4 
OS=Homo sapiens 
GN=PANK4 PE=1 SV=1 
PANK4 86 kDa 0 0 0 0 1 
Programmed cell death 6-
interacting protein OS=Homo 
sapiens GN=PDCD6IP PE=1 
SV=1 
PDC6I 96 kDa 0 0 0 0 1 
2',5'-phosphodiesterase 12 
OS=Homo sapiens GN=PDE12 
PE=1 SV=2 
PDE12 67 kDa 0 0 0 0 1 
Junction plakoglobin 
OS=Homo sapiens GN=JUP 
PE=1 SV=3 
PLAK 82 kDa 0 1 1 0 3 
Polyribonucleotide 
nucleotidyltransferase 1, 
mitochondrial OS=Homo 
sapiens GN=PNPT1 PE=1 
SV=2 
PNPT1 86 kDa 0 0 0 0 1 
Peptidyl-prolyl cis-trans 
isomerase D OS=Homo 
sapiens GN=PPID PE=1 SV=3 
PPID 41 kDa 0 0 0 0 1 
Pre-mRNA-processing factor 
19 OS=Homo sapiens 
GN=PRPF19 PE=1 SV=1 
PRP19 55 kDa 0 0 0 0 1 
26S protease regulatory 
subunit 10B OS=Homo sapiens 
GN=PSMC6 PE=1 SV=1 
PRS10 44 kDa 0 0 0 0 2 
Puromycin-sensitive 
aminopeptidase OS=Homo 
sapiens GN=NPEPPS PE=1 
SV=2 
PSA 103 kDa 3 0 0 0 5 
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26S proteasome non-ATPase 
regulatory subunit 12 
OS=Homo sapiens 
GN=PSMD12 PE=1 SV=3 
PSD12 53 kDa 0 0 0 0 1 
26S proteasome non-ATPase 
regulatory subunit 2 OS=Homo 
sapiens GN=PSMD2 PE=1 
SV=3 
PSMD2 100 kDa 3 0 2 0 6 
Paraspeckle component 1 
OS=Homo sapiens 
GN=PSPC1 PE=1 SV=1 
PSPC1 59 kDa 0 0 0 0 1 
Poly(U)-binding-splicing factor 
PUF60 OS=Homo sapiens 
GN=PUF60 PE=1 SV=1 
PUF60 60 kDa 0 0 0 0 1 
Bifunctional purine 
biosynthesis protein PURH 
OS=Homo sapiens GN=ATIC 
PE=1 SV=3 
PUR9 65 kDa 4 2 4 0 10 
Glycogen phosphorylase, liver 
form OS=Homo sapiens 
GN=PYGL PE=1 SV=4 
PYGL 97 kDa 0 0 0 0 4 
CTP synthase 1 OS=Homo 
sapiens GN=CTPS1 PE=1 
SV=2 
PYRG1 67 kDa 1 0 1 0 5 
Ribonucleoprotein PTB-binding 
1 OS=Homo sapiens 
GN=RAVER1 PE=1 SV=1 
RAVR1 64 kDa 0 0 0 0 1 
Histone-binding protein RBBP4 
OS=Homo sapiens 
GN=RBBP4 PE=1 SV=3 
RBBP4 48 kDa 1 0 1 0 2 
Histone-binding protein RBBP7 
OS=Homo sapiens 
GN=RBBP7 PE=1 SV=1 
RBBP7 48 kDa 1 0 1 0 2 
RNA-binding protein 39 
OS=Homo sapiens 
GN=RBM39 PE=1 SV=2 
RBM39 59 kDa 1 0 0 0 3 
Reticulocalbin-1 OS=Homo 
sapiens GN=RCN1 PE=1 
SV=1 
RCN1 39 kDa 0 0 0 0 1 
60S ribosomal protein L24 
OS=Homo sapiens GN=RPL24 
PE=1 SV=1 
RL24 18 kDa 0 0 0 0 1 
60S ribosomal protein L29 
OS=Homo sapiens GN=RPL29 
PE=1 SV=2 
RL29 18 kDa 0 0 0 0 1 
Heterogeneous nuclear 
ribonucleoprotein A/B 
OS=Homo sapiens 
GN=HNRNPAB PE=1 SV=2 
ROAA 36 kDa 0 0 0 0 1 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1 OS=Homo sapiens 
GN=RPN1 PE=1 SV=1 
RPN1 69 kDa 3 0 3 0 6 
Ubiquitin-40S ribosomal protein 
S27a OS=Homo sapiens 
GN=RPS27A PE=1 SV=2 
RS27A 18 kDa 3 0 3 0 4 
40S ribosomal protein SA 
OS=Homo sapiens GN=RPSA 
PE=1 SV=4 
RSSA 33 kDa 3 1 2 0 5 
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Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 
S10A8 11 kDa 0 0 0 0 1 
Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 
SV=1 
S10A9 13 kDa 0 0 0 0 1 
SUMO-activating enzyme 
subunit 1 OS=Homo sapiens 
GN=SAE1 PE=1 SV=1 
SAE1 38 kDa 0 0 0 0 1 
SUMO-activating enzyme 
subunit 2 OS=Homo sapiens 
GN=UBA2 PE=1 SV=2 
SAE2 71 kDa 2 1 2 0 3 
Adenosylhomocysteinase 
OS=Homo sapiens GN=AHCY 
PE=1 SV=4 
SAHH 48 kDa 0 0 0 0 1 
Suprabasin OS=Homo sapiens 
GN=SBSN PE=1 SV=2 
SBSN 61 kDa 0 0 0 0 1 
Protein transport protein 
Sec23A OS=Homo sapiens 
GN=SEC23A PE=1 SV=2 
SC23A 86 kDa 1 0 1 0 3 
Protein transport protein 
Sec31A OS=Homo sapiens 
GN=SEC31A PE=1 SV=3 
SC31A 133 kDa 0 0 0 0 1 
Succinate dehydrogenase 
(ubiquinone) flavoprotein 
subunit, mitochondrial 
OS=Homo sapiens GN=SDHA 
PE=1 SV=2 
SDHA 73 kDa 0 0 0 0 1 
Septin-11 OS=Homo sapiens 
GN=SEPT11 PE=1 SV=3 
SEP11 49 kDa 0 0 0 0 1 
D-3-phosphoglycerate 
dehydrogenase OS=Homo 
sapiens GN=PHGDH PE=1 
SV=4 
SERA 57 kDa 12 2 6 0 14 
Phosphoserine 
aminotransferase OS=Homo 
sapiens GN=PSAT1 PE=1 
SV=2 
SERC 40 kDa 0 0 0 0 4 
Serpin H1 OS=Homo sapiens 
GN=SERPINH1 PE=1 SV=2 
SERPH 46 kDa 2 1 1 0 4 
Splicing factor 3A subunit 3 
OS=Homo sapiens GN=SF3A3 
PE=1 SV=1 
SF3A3 59 kDa 0 0 0 0 1 
Splicing factor, proline- and 
glutamine-rich OS=Homo 
sapiens GN=SFPQ PE=1 
SV=2 
SFPQ 76 kDa 1 1 0 0 6 
Shootin-1 OS=Homo sapiens 
GN=KIAA1598 PE=1 SV=4 
SHOT1 72 kDa 0 0 0 0 1 
Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 
SPB3 45 kDa 0 0 0 0 1 
Signal recognition particle 54 
kDa protein OS=Homo sapiens 
GN=SRP54 PE=1 SV=1 
SRP54 56 kDa 0 0 0 0 1 
Signal recognition particle 
receptor subunit alpha 
OS=Homo sapiens GN=SRPR 
PE=1 SV=2 
SRPR 70 kDa 0 0 0 0 3 
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Succinyl-CoA ligase (ADP-
forming) subunit beta, 
mitochondrial OS=Homo 
sapiens GN=SUCLA2 PE=1 
SV=3 
SUCB1 50 kDa 0 0 0 0 1 
Succinyl-CoA ligase (GDP-
forming) subunit beta, 
mitochondrial OS=Homo 
sapiens GN=SUCLG2 PE=1 
SV=2 
SUCB2 47 kDa 0 0 0 0 1 
ATP-dependent RNA helicase 
SUPV3L1, mitochondrial 
OS=Homo sapiens 
GN=SUPV3L1 PE=1 SV=1 
SUV3 88 kDa 0 0 0 0 1 
Alanine--tRNA ligase, 
cytoplasmic OS=Homo sapiens 
GN=AARS PE=1 SV=2 
SYAC 107 kDa 0 0 0 0 1 
Phenylalanine--tRNA ligase 
beta subunit OS=Homo 
sapiens GN=FARSB PE=1 
SV=3 
SYFB 66 kDa 0 0 0 0 3 
Glycine--tRNA ligase 
OS=Homo sapiens GN=GARS 
PE=1 SV=3 
SYG 83 kDa 0 0 0 0 1 
Methionine--tRNA ligase, 
cytoplasmic OS=Homo sapiens 
GN=MARS PE=1 SV=2 
SYMC 101 kDa 4 0 0 0 8 
Glutamine--tRNA ligase 
OS=Homo sapiens GN=QARS 
PE=1 SV=1 
SYQ 88 kDa 1 0 1 0 3 
Tyrosine--tRNA ligase, 
cytoplasmic OS=Homo sapiens 
GN=YARS PE=1 SV=4 
SYYC 59 kDa 2 1 1 0 3 
T-complex protein 1 subunit 
alpha OS=Homo sapiens 
GN=TCP1 PE=1 SV=1 
TCPA 60 kDa 3 1 2 0 8 
T-complex protein 1 subunit 
beta OS=Homo sapiens 
GN=CCT2 PE=1 SV=4 
TCPB 57 kDa 6 4 2 1 7 
T-complex protein 1 subunit 
delta OS=Homo sapiens 
GN=CCT4 PE=1 SV=4 
TCPD 58 kDa 3 3 0 0 7 
T-complex protein 1 subunit 
epsilon OS=Homo sapiens 
GN=CCT5 PE=1 SV=1 
TCPE 60 kDa 2 1 1 0 3 
T-complex protein 1 subunit 
gamma OS=Homo sapiens 
GN=CCT3 PE=1 SV=4 
TCPG 61 kDa 4 2 4 1 6 
T-complex protein 1 subunit 
theta OS=Homo sapiens 
GN=CCT8 PE=1 SV=4 
TCPQ 60 kDa 4 2 3 0 7 
Transcription factor p65 
OS=Homo sapiens GN=RELA 
PE=1 SV=2 
TF65 60 kDa 0 0 0 0 1 
Thimet oligopeptidase 
OS=Homo sapiens 
GN=THOP1 PE=1 SV=2 
THOP1 79 kDa 0 0 0 0 1 
Mitochondrial import inner 
membrane translocase subunit 
TIM44 OS=Homo sapiens 
GN=TIMM44 PE=1 SV=2 
TIM44 51 kDa 0 0 0 0 2 
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Mitochondrial import receptor 
subunit TOM70 OS=Homo 
sapiens GN=TOMM70A PE=1 
SV=1 
TOM70 67 kDa 0 0 0 0 1 
Trypsin-2 OS=Homo sapiens 
GN=PRSS2 PE=1 SV=1 
TRY2 26 kDa 0 0 0 0 1 
Tetratricopeptide repeat protein 
4 OS=Homo sapiens 
GN=TTC4 PE=1 SV=3 
TTC4 45 kDa 0 0 0 0 1 
Tubulin--tyrosine ligase-like 
protein 12 OS=Homo sapiens 
GN=TTLL12 PE=1 SV=2 
TTL12 74 kDa 1 0 1 0 4 
Ubiquitin carboxyl-terminal 
hydrolase 5 OS=Homo sapiens 
GN=USP5 PE=1 SV=2 
UBP5 96 kDa 0 0 0 0 2 
Protein unc-45 homolog A 
OS=Homo sapiens 
GN=UNC45A PE=1 SV=1 
UN45A 103 kDa 0 0 0 0 1 
Synaptic vesicle membrane 
protein VAT-1 homolog 
OS=Homo sapiens GN=VAT1 
PE=1 SV=2 
VAT1 42 kDa 2 0 0 0 3 
V-set and immunoglobulin 
domain-containing protein 8 
OS=Homo sapiens GN=VSIG8 
PE=2 SV=1 
VSIG8 44 kDa 0 0 0 0 2 
WD repeat-containing protein 1 
OS=Homo sapiens GN=WDR1 
PE=1 SV=4 
WDR1 66 kDa 0 0 0 0 1 
Exportin-T OS=Homo sapiens 
GN=XPOT PE=1 SV=2 
XPOT 110 kDa 1 0 0 0 2 
Neutral amino acid transporter 
B(0) OS=Homo sapiens 
GN=SLC1A5 PE=1 SV=2 
AAAT 57 kDa 0 0 2 0 0 
ADP/ATP translocase 3 
OS=Homo sapiens 
GN=SLC25A6 PE=1 SV=4 
ADT3 33 kDa 0 0 1 0 0 
Phosphoacetylglucosamine 
mutase OS=Homo sapiens 
GN=PGM3 PE=1 SV=1 
AGM1 60 kDa 0 0 1 0 0 
AP-2 complex subunit mu 
OS=Homo sapiens 
GN=AP2M1 PE=1 SV=2 
AP2M1-
DECOY 
? 0 0 1 0 0 
Rho guanine nucleotide 
exchange factor 7 OS=Homo 
sapiens GN=ARHGEF7 PE=1 
SV=2 
ARHG7 90 kDa 0 0 1 0 0 
E3 ubiquitin-protein ligase 
ARIH1 OS=Homo sapiens 
GN=ARIH1 PE=1 SV=2 
ARI1 64 kDa 0 0 1 0 0 
Bone morphogenetic protein 1 
OS=Homo sapiens GN=BMP1 
PE=1 SV=2 
BMP1-
DECOY 
? 0 0 1 0 0 
Basic leucine zipper and W2 
domain-containing protein 1 
OS=Homo sapiens GN=BZW1 
PE=1 SV=1 
BZW1 48 kDa 0 0 1 0 0 
Coatomer subunit delta 
OS=Homo sapiens 
GN=ARCN1 PE=1 SV=1 
COPD 57 kDa 1 1 2 0 1 
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Cullin-4B OS=Homo sapiens 
GN=CUL4B PE=1 SV=4 
CUL4B 104 kDa 0 0 1 0 0 
Nucleolar RNA helicase 2 
OS=Homo sapiens 
GN=DDX21 PE=1 SV=5 
DDX21 87 kDa 5 0 7 0 5 
ATP-dependent RNA helicase 
DDX50 OS=Homo sapiens 
GN=DDX50 PE=1 SV=1 
DDX50 83 kDa 0 0 2 0 0 
Dynein heavy chain 14, 
axonemal OS=Homo sapiens 
GN=DNAH14 PE=2 SV=3 
DYH14 400 kDa 0 0 1 0 0 
Eukaryotic translation initiation 
factor 2D OS=Homo sapiens 
GN=EIF2D PE=1 SV=3 
EIF2D 65 kDa 0 0 1 0 0 
RNA-binding protein EWS 
OS=Homo sapiens 
GN=EWSR1 PE=1 SV=1 
EWS 68 kDa 0 0 1 0 0 
Exocyst complex component 3 
OS=Homo sapiens 
GN=EXOC3 PE=1 SV=2 
EXOC3 87 kDa 0 0 1 0 0 
Far upstream element-binding 
protein 3 OS=Homo sapiens 
GN=FUBP3 PE=1 SV=2 
FUBP3 62 kDa 1 0 2 0 1 
Fragile X mental retardation 
syndrome-related protein 1 
OS=Homo sapiens GN=FXR1 
PE=1 SV=3 
FXR1 70 kDa 0 0 2 0 0 
Guanine nucleotide-binding 
protein subunit beta-like protein 
1 OS=Homo sapiens 
GN=GNB1L PE=1 SV=2 
GNB1L 36 kDa 0 0 1 0 0 
Heterogeneous nuclear 
ribonucleoprotein Q OS=Homo 
sapiens GN=SYNCRIP PE=1 
SV=2 
HNRPQ 70 kDa 1 0 2 0 1 
Insulin-like growth factor 2 
mRNA-binding protein 2 
OS=Homo sapiens 
GN=IGF2BP2 PE=1 SV=2 
IF2B2 66 kDa 4 0 7 0 4 
La-related protein 7 OS=Homo 
sapiens GN=LARP7 PE=1 
SV=1 
LARP7 67 kDa 1 0 2 0 1 
Prolow-density lipoprotein 
receptor-related protein 1 
OS=Homo sapiens GN=LRP1 
PE=1 SV=2 
LRP1-
DECOY 
? 0 0 1 0 0 
Myristoylated alanine-rich C-
kinase substrate OS=Homo 
sapiens GN=MARCKS PE=1 
SV=4 
MARCS 32 kDa 0 0 1 0 0 
Mitotic spindle assembly 
checkpoint protein MAD1 
OS=Homo sapiens 
GN=MAD1L1 PE=1 SV=2 
MD1L1 83 kDa 0 0 2 0 0 
7SK snRNA methylphosphate 
capping enzyme OS=Homo 
sapiens GN=MEPCE PE=1 
SV=1 
MEPCE 74 kDa 0 0 1 0 0 
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Double-strand break repair 
protein MRE11A OS=Homo 
sapiens GN=MRE11A PE=1 
SV=3 
MRE11 81 kDa 0 0 1 0 0 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex subunit 2 
OS=Homo sapiens 
GN=NDUFA2 PE=1 SV=3 
NDUA2 11 kDa 0 0 1 0 0 
Nucleolar protein 56 OS=Homo 
sapiens GN=NOP56 PE=1 
SV=4 
NOP56 66 kDa 1 0 3 0 1 
Nucleolar protein 58 OS=Homo 
sapiens GN=NOP58 PE=1 
SV=1 
NOP58 60 kDa 1 0 2 0 0 
Nucleophosmin OS=Homo 
sapiens GN=NPM1 PE=1 
SV=2 
NPM 33 kDa 0 0 1 0 0 
PiggyBac transposable 
element-derived protein 1 
OS=Homo sapiens 
GN=PGBD1 PE=1 SV=1 
PGBD1 93 kDa 0 0 1 0 0 
Protein regulator of cytokinesis 
1 OS=Homo sapiens 
GN=PRC1 PE=1 SV=2 
PRC1 72 kDa 0 0 3 0 0 
CAD protein OS=Homo 
sapiens GN=CAD PE=1 SV=3 
PYR1 243 kDa 4 1 5 0 0 
60S ribosomal protein L15 
OS=Homo sapiens GN=RPL15 
PE=1 SV=2 
RL15 24 kDa 0 0 1 0 0 
Ribosomal L1 domain-
containing protein 1 OS=Homo 
sapiens GN=RSL1D1 PE=1 
SV=3 
RL1D1 55 kDa 1 0 2 0 1 
60S ribosomal protein L8 
OS=Homo sapiens GN=RPL8 
PE=1 SV=2 
RL8 28 kDa 0 0 1 0 0 
RING finger protein 214 
OS=Homo sapiens 
GN=RNF214 PE=1 SV=2 
RN214 78 kDa 0 0 1 0 0 
Septin-9 OS=Homo sapiens 
GN=SEPT9 PE=1 SV=2 
SEPT9 65 kDa 0 0 1 0 0 
Suppressor of SWI4 1 homolog 
OS=Homo sapiens GN=PPAN 
PE=1 SV=1 
SSF1 53 kDa 0 0 1 0 0 
Pre-mRNA-splicing factor 
SYF1 OS=Homo sapiens 
GN=XAB2 PE=1 SV=2 
SYF1 100 kDa 0 0 1 0 0 
Tubulin beta-6 chain 
OS=Homo sapiens 
GN=TUBB6 PE=1 SV=1 
TBB6 50 kDa 0 0 1 0 0 
Testis-expressed sequence 10 
protein OS=Homo sapiens 
GN=TEX10 PE=1 SV=2 
TEX10 106 kDa 0 0 1 0 0 
General transcription factor 3C 
polypeptide 5 OS=Homo 
sapiens GN=GTF3C5 PE=1 
SV=2 
TF3C5 60 kDa 0 0 2 0 0 
TRMT1-like protein OS=Homo 
sapiens GN=TRMT1L PE=1 
SV=2 
TRM1L 82 kDa 0 0 1 0 0 
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DNA repair protein XRCC1 
OS=Homo sapiens 
GN=XRCC1 PE=1 SV=2 
XRCC1 69 kDa 0 0 1 0 0 
YTH domain-containing family 
protein 1 OS=Homo sapiens 
GN=YTHDF1 PE=1 SV=1 
YTHD1 61 kDa 0 0 1 0 0 
Zinc finger CCCH domain-
containing protein 14 
OS=Homo sapiens 
GN=ZC3H14 PE=1 SV=1 
ZC3HE 83 kDa 0 0 1 0 0 
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Table A. 4. 5: Representation of the protein identification probability 
(Identification confidence) of proteins with peptide ratio more than 1, from Trial 1 
and Trial 2, figure A 4.21 
The table containing data for trypsinized proteins from SDS-PAGE gel of trial 1 and trial 
2 (Appendix C, section 4.5). The data of the table represents uncrosslinked lysated 
(lane 1, Figure A 4.21), ATP-Hex-Acr crosslinked lysates in presence of staursporine 
(lane 2, Figure A 4.21), ATP-Hex-Acr crosslinked lysates (lane 3, Figure A 4.21), ATP-
PEG-Acr crosslinked lysates in presence of staursporine (lane 4, Figure A 4.21), and 
ATP-Hex-Acr crosslinked lysates (lane 5, Figure A 4.21) 
Identified Proteins (900) 
Mol. 
Wt 
Protein identification probability  
Trial 1 Trial 2 
1 2 3 4 5 1 2 3 4 5 
Aconitate hydratase, 
mitochondrial OS=Homo 
sapiens GN=ACO2 PE=1 
SV=2 
85  
100
% 
100
% 
99% 
100
% 
100
% 
0 93% 99% 0 
100
% 
Alpha-actinin-4 OS=Homo 
sapiens GN=ACTN4 PE=1 
SV=2 
105  
100
% 
100
% 
0 
100
% 
100
% 
100
% 
100
% 
0 0 
100
% 
Activator of 90  heat shock 
protein ATPase homolog 1 
OS=Homo sapiens 
GN=AHSA1 PE=1 SV=1 
38  0 0 0 
100
% 
100
% 
0 94% 99% 0 
100
% 
Apoptosis-inducing factor 1, 
mitochondrial OS=Homo 
sapiens GN=AIFM1 PE=1 
SV=1 
67  0 0 
100
% 
6% 
100
% 
0 0 99% 0 
100
% 
Cytosol aminopeptidase 
OS=Homo sapiens 
GN=LAP3 PE=1 SV=3 
56  0 0 99% 0 
100
% 
100
% 
0 
100
% 
0 
100
% 
ATPase family AAA 
domain-containing protein 
3A OS=Homo sapiens 
GN=ATAD3A PE=1 SV=2 
71  
100
% 
0 21% 
100
% 
100
% 
100
% 
89% 
100
% 
0 
100
% 
Cytoskeleton-associated 
protein 4 OS=Homo 
sapiens GN=CKAP4 PE=1 
SV=2 
66  99% 99% 0 0 
100
% 
83% 0 
100
% 
0 
100
% 
Cytosolic non-specific 
dipeptidase OS=Homo 
sapiens GN=CNDP2 PE=1 
SV=2 
53  0 66% 0 0 
100
% 
0 0 0 20% 99% 
Coatomer subunit gamma-1 
OS=Homo sapiens 
GN=COPG1 PE=1 SV=1 
98  
100
% 
65% 99% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Cold shock domain-
containing protein E1 
OS=Homo sapiens 
GN=CSDE1 PE=1 SV=2 
89  
100
% 
100
% 
100
% 
100
% 
100
% 
99% 
100
% 
100
% 
0 
100
% 
COP9 signalosome 
complex subunit 4 
OS=Homo sapiens 
GN=COPS4 PE=1 SV=1 
46  0 0 0 
100
% 
100
% 
0 0 0 0 
100
% 
Drebrin-like protein 
OS=Homo sapiens 
GN=DBNL PE=1 SV=1 
48  0 0 0 0 99% 0 0 0 0 
100
% 
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ATP-dependent RNA 
helicase DDX1 OS=Homo 
sapiens GN=DDX1 PE=1 
SV=2 
82  
100
% 
54% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Probable ATP-dependent 
RNA helicase DDX17 
OS=Homo sapiens 
GN=DDX17 PE=1 SV=2 
80  
100
% 
67% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Peroxisomal multifunctional 
enzyme type 2 OS=Homo 
sapiens GN=HSD17B4 
PE=1 SV=3 
80  0 57% 0 
100
% 
100
% 
0 0 92% 0 
100
% 
Dynamin-1-like protein 
OS=Homo sapiens 
GN=DNM1L PE=1 SV=2 
82  
100
% 
0 99% 0 
100
% 
80% 0 
100
% 
0 
100
% 
Dihydropyrimidinase-related 
protein 1 OS=Homo 
sapiens GN=CRMP1 PE=1 
SV=1 
62  0 0 0 98% 99% 0 0 0 84% 99% 
Developmentally-regulated 
GTP-binding protein 1 
OS=Homo sapiens 
GN=DRG1 PE=1 SV=1 
41  0 0 0 0 
100
% 
0 0 99% 0 
100
% 
Trifunctional enzyme 
subunit alpha, mitochondrial 
OS=Homo sapiens 
GN=HADHA PE=1 SV=2 
83  
100
% 
0 
100
% 
100
% 
100
% 
99% 0 
100
% 
0 
100
% 
Elongation factor 2 
OS=Homo sapiens 
GN=EEF2 PE=1 SV=4 
95  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Eukaryotic translation 
initiation factor 3 subunit D 
OS=Homo sapiens 
GN=EIF3D PE=1 SV=1 
64  
100
% 
73% 
100
% 
0 
100
% 
100
% 
57% 
100
% 
0 
100
% 
Eukaryotic translation 
initiation factor 3 subunit L 
OS=Homo sapiens 
GN=EIF3L PE=1 SV=1 
67  
100
% 
0 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Epiplakin OS=Homo 
sapiens GN=EPPK1 PE=1 
SV=2 
556  
100
% 
0 
100
% 
100
% 
100
% 
100
% 
0 71% 
100
% 
0 
Exosome component 10 
OS=Homo sapiens 
GN=EXOSC10 PE=1 SV=2 
101  0 0 0 99% 99% 0 0 0 0 99% 
Ezrin OS=Homo sapiens 
GN=EZR PE=1 SV=4 
69  
100
% 
0 0 
100
% 
100
% 
53% 
100
% 
100
% 
0 
100
% 
RNA-binding protein FUS 
OS=Homo sapiens 
GN=FUS PE=1 SV=1 
53  99% 0 
100
% 
0 
100
% 
100
% 
70% 
100
% 
0 
100
% 
Glucose-6-phosphate 
isomerase OS=Homo 
sapiens GN=GPI PE=1 
SV=4 
63  
100
% 
99% 
100
% 
100
% 
100
% 
100
% 
100
% 
96% 0 
100
% 
Glucosidase 2 subunit beta 
OS=Homo sapiens 
GN=PRKCSH PE=1 SV=2 
59  96% 49% 84% 0 
100
% 
72% 97% 
100
% 
0 99% 
Serine 
hydroxymethyltransferase, 
mitochondrial OS=Homo 
sapiens GN=SHMT2 PE=1 
SV=3 
56  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
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Stress-70 protein, 
mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 
SV=2 
74  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
GMP synthase [glutamine-
hydrolyzing] OS=Homo 
sapiens GN=GMPS PE=1 
SV=1 
77  0 0 0 
100
% 
99% 0 0 0 0 99% 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
OS=Homo sapiens 
GN=HNRNPC PE=1 SV=4 
34  0 0 0 0 99% 0 0 
100
% 
0 
100
% 
Heterogeneous nuclear 
ribonucleoprotein M 
OS=Homo sapiens 
GN=HNRNPM PE=1 SV=3 
78  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
96% 
100
% 
Heterogeneous nuclear 
ribonucleoprotein R 
OS=Homo sapiens 
GN=HNRNPR PE=1 SV=1 
71  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 
282  
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
100
% 
0 
100
% 
Heat shock 70  protein 1A 
OS=Homo sapiens 
GN=HSPA1A PE=1 SV=1 
70  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
Heat shock protein HSP 90-
alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 
SV=5 
85  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
Heat shock protein HSP 90-
beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 
SV=4 
83  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
79% 
100
% 
Heat shock cognate 71  
protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 
71  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
99% 
100
% 
Interferon regulatory factor 
2-binding protein 1 
OS=Homo sapiens 
GN=IRF2BP1 PE=1 SV=1 
62  0 0 0 0 99% 0 0 0 0 
100
% 
Importin subunit beta-1 
OS=Homo sapiens 
GN=KPNB1 PE=1 SV=2 
97  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Creatine kinase B-type 
OS=Homo sapiens 
GN=CKB PE=1 SV=1 
43  0 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
Pyruvate kinase PKM 
OS=Homo sapiens 
GN=PKM PE=1 SV=4 
58  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
L-lactate dehydrogenase A 
chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 
37  0 0 
100
% 
100
% 
100
% 
0 99% 0 0 
100
% 
LETM1 and EF-hand 
domain-containing protein 
1, mitochondrial OS=Homo 
sapiens GN=LETM1 PE=1 
SV=1 
83  77% 0 0 0 
100
% 
0 0 
100
% 
0 
100
% 
Leukotriene A-4 hydrolase 
OS=Homo sapiens 
GN=LTA4H PE=1 SV=2 
69  
100
% 
0 
100
% 
100
% 
100
% 
93% 96% 99% 0 
100
% 
Leucine-rich repeat- 68  0 0 0 0 99% 0 0 0 0 99% 
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containing protein 40 
OS=Homo sapiens 
GN=LRRC40 PE=1 SV=1 
Melanoma-associated 
antigen D2 OS=Homo 
sapiens GN=MAGED2 
PE=1 SV=2 
65  
100
% 
74% 56% 
100
% 
100
% 
0 58% 
100
% 
40% 
100
% 
DNA replication licensing 
factor MCM5 OS=Homo 
sapiens GN=MCM5 PE=1 
SV=5 
82  
100
% 
0 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
MICOS complex subunit 
MIC60 OS=Homo sapiens 
GN=IMMT PE=1 SV=1 
84  83% 0 
100
% 
0 99% 
100
% 
0 
100
% 
0 
100
% 
Mitochondrial-processing 
peptidase subunit alpha 
OS=Homo sapiens 
GN=PMPCA PE=1 SV=2 
58  0 0 0 0 99% 90% 0 31% 0 99% 
Metastasis-associated 
protein MTA2 OS=Homo 
sapiens GN=MTA2 PE=1 
SV=1 
75  
100
% 
0 96% 0 
100
% 
99% 0 
100
% 
0 
100
% 
Nuclear autoantigenic 
sperm protein OS=Homo 
sapiens GN=NASP PE=1 
SV=2 
85  0 0 0 99% 
100
% 
100
% 
0 99% 0 
100
% 
NADH-ubiquinone 
oxidoreductase 75  subunit, 
mitochondrial OS=Homo 
sapiens GN=NDUFS1 
PE=1 SV=3 
79  0 32% 99% 0 
100
% 
87% 0 
100
% 
0 
100
% 
Vesicle-fusing ATPase 
OS=Homo sapiens 
GN=NSF PE=1 SV=3 
83  
100
% 
73% 0 0 
100
% 
100
% 
0 
100
% 
62% 
100
% 
tRNA (cytosine(34)-C(5))-
methyltransferase 
OS=Homo sapiens 
GN=NSUN2 PE=1 SV=2 
86  
100
% 
0 
100
% 
0 
100
% 
100
% 
0 0 0 
100
% 
Dihydrolipoyllysine-residue 
acetyltransferase 
component of pyruvate 
dehydrogenase complex, 
mitochondrial OS=Homo 
sapiens GN=DLAT PE=1 
SV=3 
69  0 0 0 0 
100
% 
0 41% 99% 0 
100
% 
Obg-like ATPase 1 
OS=Homo sapiens 
GN=OLA1 PE=1 SV=2 
45  0 0 0 0 
100
% 
100
% 
97% 0 0 99% 
Transcriptional repressor 
p66-alpha OS=Homo 
sapiens GN=GATAD2A 
PE=1 SV=1 
68  99% 0 0 
100
% 
99% 99% 0 99% 0 99% 
Polyadenylate-binding 
protein 1 OS=Homo 
sapiens GN=PABPC1 PE=1 
SV=2 
71  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 
45  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
94% 
100
% 
0 
100
% 
Poly(rC)-binding protein 1 37  0 0 0 99% 100 0 0 100 0 100
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OS=Homo sapiens 
GN=PCBP1 PE=1 SV=2 
% % % 
Programmed cell death 6-
interacting protein 
OS=Homo sapiens 
GN=PDCD6IP PE=1 SV=1 
96  
100
% 
89% 0 
100
% 
100
% 
98% 57% 0 0 
100
% 
2',5'-phosphodiesterase 12 
OS=Homo sapiens 
GN=PDE12 PE=1 SV=2 
67  0 0 0 0 99% 0 0 0 0 99% 
Peptidyl-prolyl cis-trans 
isomerase D OS=Homo 
sapiens GN=PPID PE=1 
SV=3 
41  0 0 0 
100
% 
100
% 
0 0 0 26% 99% 
Pre-mRNA-processing 
factor 19 OS=Homo 
sapiens GN=PRPF19 PE=1 
SV=1 
55  99% 0 
100
% 
100
% 
100
% 
100
% 
0 99% 0 
100
% 
U4/U6 small nuclear 
ribonucleoprotein Prp3 
OS=Homo sapiens 
GN=PRPF3 PE=1 SV=2 
78  62% 84% 
100
% 
0 99% 0 0 
100
% 
0 
100
% 
26S protease regulatory 
subunit 10B OS=Homo 
sapiens GN=PSMC6 PE=1 
SV=1 
44  0 0 0 
100
% 
100
% 
0 0 0 0 
100
% 
26S proteasome non-
ATPase regulatory subunit 
2 OS=Homo sapiens 
GN=PSMD2 PE=1 SV=3 
100  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
96% 
100
% 
0 
100
% 
26S proteasome non-
ATPase regulatory subunit 
3 OS=Homo sapiens 
GN=PSMD3 PE=1 SV=2 
61  
100
% 
97% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Bifunctional purine 
biosynthesis protein PURH 
OS=Homo sapiens 
GN=ATIC PE=1 SV=3 
65  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Glycogen phosphorylase, 
liver form OS=Homo 
sapiens GN=PYGL PE=1 
SV=4 
97  
100
% 
100
% 
100
% 
100
% 
100
% 
99% 95% 0 0 
100
% 
CTP synthase 1 OS=Homo 
sapiens GN=CTPS1 PE=1 
SV=2 
67  0 0 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Ran GTPase-activating 
protein 1 OS=Homo 
sapiens GN=RANGAP1 
PE=1 SV=1 
64  
100
% 
0 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Ribonucleoprotein PTB-
binding 1 OS=Homo 
sapiens GN=RAVER1 
PE=1 SV=1 
64  0 0 0 0 99% 82% 77% 98% 0 
100
% 
Histone-binding protein 
RBBP4 OS=Homo sapiens 
GN=RBBP4 PE=1 SV=3 
48  
100
% 
0 
100
% 
99% 
100
% 
100
% 
0 99% 0 
100
% 
RNA-binding protein 14 
OS=Homo sapiens 
GN=RBM14 PE=1 SV=2 
69  
100
% 
0 
100
% 
100
% 
100
% 
32% 0 
100
% 
0 
100
% 
RNA-binding protein 39 
OS=Homo sapiens 
GN=RBM39 PE=1 SV=2 
59  
100
% 
0 
100
% 
0 
100
% 
100
% 
0 88% 0 
100
% 
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Reticulocalbin-1 OS=Homo 
sapiens GN=RCN1 PE=1 
SV=1 
39  0 0 0 76% 99% 99% 0 99% 0 
100
% 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1 OS=Homo 
sapiens GN=RPN1 PE=1 
SV=1 
69  
100
% 
0 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Ubiquitin-40S ribosomal 
protein S27a OS=Homo 
sapiens GN=RPS27A PE=1 
SV=2 
18  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
41% 
100
% 
40S ribosomal protein SA 
OS=Homo sapiens 
GN=RPSA PE=1 SV=4 
33  0 0 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
90% 
100
% 
Protein transport protein 
Sec31A OS=Homo sapiens 
GN=SEC31A PE=1 SV=3 
133  
100
% 
0 99% 0 
100
% 
100
% 
0 0 0 
100
% 
Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
OS=Homo sapiens 
GN=SDHA PE=1 SV=2 
73  99% 0 95% 0 
100
% 
0 0 0 0 
100
% 
Septin-2 OS=Homo sapiens 
GN=SEPT2 PE=1 SV=1 
49 0 0 0 0 
100
% 
0 0 0 0 99% 
Serpin H1 OS=Homo 
sapiens GN=SERPINH1 
PE=1 SV=2 
46  0 0 99% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Splicing factor 3A subunit 3 
OS=Homo sapiens 
GN=SF3A3 PE=1 SV=1 
59  99% 0 96% 99% 
100
% 
100
% 
0 99% 0 
100
% 
Splicing factor, proline- and 
glutamine-rich OS=Homo 
sapiens GN=SFPQ PE=1 
SV=2 
76  
100
% 
100
% 
99% 
100
% 
100
% 
100
% 
100
% 
0 0 
100
% 
Signal recognition particle 
subunit SRP68 OS=Homo 
sapiens GN=SRP68 PE=1 
SV=2 
71  
100
% 
0 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Signal recognition particle 
receptor subunit alpha 
OS=Homo sapiens 
GN=SRPR PE=1 SV=2 
70  0 0 0 0 
100
% 
72% 0 0 0 
100
% 
Alanine--tRNA ligase, 
cytoplasmic OS=Homo 
sapiens GN=AARS PE=1 
SV=2 
107  
100
% 
100
% 
0 
100
% 
100
% 
93% 0 0 0 
100
% 
Phenylalanine--tRNA ligase 
beta subunit OS=Homo 
sapiens GN=FARSB PE=1 
SV=3 
66  
100
% 
83% 
100
% 
100
% 
100
% 
100
% 
90% 
100
% 
48% 
100
% 
Glycine--tRNA ligase 
OS=Homo sapiens 
GN=GARS PE=1 SV=3 
83  0 0 0 0 
100
% 
0 0 0 0 99% 
Arginine--tRNA ligase, 
cytoplasmic OS=Homo 
sapiens GN=RARS PE=1 
SV=2 
75  
100
% 
39% 
100
% 
100
% 
100
% 
100
% 
95% 
100
% 
0 
100
% 
Tyrosine--tRNA ligase, 
cytoplasmic OS=Homo 
59  0 0 0 
100
% 
100
% 
100
% 
100
% 
99% 0 
100
% 
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sapiens GN=YARS PE=1 
SV=4 
T-complex protein 1 subunit 
alpha OS=Homo sapiens 
GN=TCP1 PE=1 SV=1 
60  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
68% 
100
% 
T-complex protein 1 subunit 
beta OS=Homo sapiens 
GN=CCT2 PE=1 SV=4 
57  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
T-complex protein 1 subunit 
delta OS=Homo sapiens 
GN=CCT4 PE=1 SV=4 
58  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
T-complex protein 1 subunit 
epsilon OS=Homo sapiens 
GN=CCT5 PE=1 SV=1 
60  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
T-complex protein 1 subunit 
gamma OS=Homo sapiens 
GN=CCT3 PE=1 SV=4 
61  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
T-complex protein 1 subunit 
theta OS=Homo sapiens 
GN=CCT8 PE=1 SV=4 
60  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
53% 
100
% 
Transitional endoplasmic 
reticulum ATPase 
OS=Homo sapiens 
GN=VCP PE=1 SV=4 
89  
100
% 
0 0 97% 
100
% 
95% 0 0 0 
100
% 
Acetyl-CoA 
acetyltransferase, 
mitochondrial OS=Homo 
sapiens GN=ACAT1 PE=1 
SV=1 
45  0 0 0 
100
% 
100
% 
0 0 
100
% 
0 
100
% 
Mitochondrial import 
receptor subunit TOM70 
OS=Homo sapiens 
GN=TOMM70A PE=1 SV=1 
67  0 0 0 0 99% 0 0 0 0 
100
% 
Heat shock protein 75 , 
mitochondrial OS=Homo 
sapiens GN=TRAP1 PE=1 
SV=3 
80  
100
% 
52% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Tetratricopeptide repeat 
protein 4 OS=Homo 
sapiens GN=TTC4 PE=1 
SV=3 
45  0 0 0 0 99% 
100
% 
0 0 0 99% 
Tubulin--tyrosine ligase-like 
protein 12 OS=Homo 
sapiens GN=TTLL12 PE=1 
SV=2 
74  
100
% 
37% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
Ubiquitin carboxyl-terminal 
hydrolase 5 OS=Homo 
sapiens GN=USP5 PE=1 
SV=2 
96  
100
% 
69% 99% 92% 
100
% 
100
% 
0 70% 0 
100
% 
Synaptic vesicle membrane 
protein VAT-1 homolog 
OS=Homo sapiens 
GN=VAT1 PE=1 SV=2 
42  0 0 0 0 
100
% 
100
% 
0 0 0 
100
% 
V-type proton ATPase 
catalytic subunit A 
OS=Homo sapiens 
GN=ATP6V1A PE=1 SV=2 
68  
100
% 
0 
100
% 
100
% 
100
% 
54% 0 
100
% 
0 
100
% 
Vacuolar protein sorting-
associated protein 35 
OS=Homo sapiens 
GN=VPS35 PE=1 SV=2 
92  
100
% 
78% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
0 
100
% 
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Exportin-T OS=Homo 
sapiens GN=XPOT PE=1 
SV=2 
110  
100
% 
0 6% 71% 
100
% 
100
% 
0 11% 0 
100
% 
X-ray repair cross-
complementing protein 6 
OS=Homo sapiens 
GN=XRCC6 PE=1 SV=2 
70  
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
100
% 
0 
100
% 
Zyxin OS=Homo sapiens 
GN=ZYX PE=1 SV=1 
61  0 0 29% 0 
100
% 
100
% 
0 
100
% 
0 
100
% 
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APPENDIX D: CHAPTER 5 
5.1 Compound characterization 
  
Figure A 5. 1: 1HNMR of ATP-C-heptyl (5) recorded in D2O. Peaks at 5.03 
correspond to D2O and peaks at  3.43 and 1.52 correspond CH2 and CH3 of 
triethylamine respectively. 
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Figure A 5. 2: 13CNMR of ATP-C-heptyl (5) recorded in D2O. Peaks at  46.59 and 8.14 
correspond CH2 and CH3 of triethylamine respectively. Multiplicity of C13 was observed 
to due to coupling with phosphorus as previously reported.187 
 
 
 Figure A 5. 3: 31PNMR of ATP-C-heptyl (5) recorded in D2O. 
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Figure A 5. 4: Electrospray ionization (ESI) negative mode high resolution mass 
spectrum (HRMs) of ATP-C-heptyl (5). Calculated (M-H)-1 for C17H29N5O12P3: calc. 
588.1026, found 588.1028 
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Figure A 5. 5: 1HNMR of ATP-N-heptyl (23) recorded in D2O. Peaks at 4.65 
correspond to D2O and peaks at  3.03 and 1.11 correspond CH2 and CH3 of 
triethylamine respectively. 
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Figure A 5. 6:13CNMR of ATP-N-heptyl (23) recorded in D2O. Peaks at  46.58 and 
8.11 correspond CH2 and CH3 of triethylamine respectively. Multiplicity of C13 was 
observed to due to coupling with phosphorus as previously reported.187 
 
Figure A 5. 7: 31PNMR of ATP-N-heptyl (23) recorded in D2O. 
266 
 
 
 
Figure A 5. 8: Electrospray ionization (ESI) positive mode high resolution mass 
spectrum (HRMs) of ATP-N-heptyl (23). Calculated (M-H)-1 for C17H30N6O12P3: 
603.1135, observed 603.1158. 
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Figure A 5. 9: 1HNMR of ATP-O-heptyl (24) recorded in D2O. Peaks at 5.12 
correspond to D2O and peaks at  3.54 and 1.61 correspond CH2 and CH3 of 
triethylamine respectively. 
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Figure A 5. 10:13CNMR of ATP-O-heptyl (24) recorded in D2O. Peaks at  46.59 and 
8.14 correspond CH2 and CH3 of triethylamine respectively. Multiplicity of C13 was 
observed to due to coupling with phosphorus as previously reported.187 
 
Figure A 5. 11: 31PNMR of ATP-O-heptyl (24) recorded in D2O. 
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Figure A 5. 12: Electrospray ionization (ESI) positive mode high resolution mass 
spectrum (HRMs) of ATP-O-heptyl (24). Calculated (M-H)-1 for C17H29N5O13P3: 
604.975, observed 604.0955. 
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5.2 Repetitive trials of MALDI-TOF analysis of kinase-catalyzed reaction using 
ATP-C, N, and O-heptyl analogs (22-24) 
 
a) Kemptide phosphorylation using ATP  
Trial 2 
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Trial 3 
 
 
Figure A 5. 13: MALDI mass spectrometry spectra of modified phosphorylation of Ac-
kemptide using ATP. ATP was incubated with kemptide and PKA followed by MALDI-
TOF spectrometric analysis. Two trials are shown here, with the third trial in Figure 
5.3A. 
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b) Kemptide phosphorylation using ATP-C-heptyl (22) 
Trial 2 
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Trial 3 
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Trial 4 
 
Figure A 5. 14: MALDI mass spectrometry spectra of modified phosphorylation of Ac-
kemptide using ATP-C-heptyl (22). ATP was incubated with kemptide and PKA followed 
by MALDI-TOF spectrometric analysis. Two trials are shown here, with the third trial in 
Figure 5.3B. 
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c) Kemptide phosphorylation using ATP-N-heptyl (23) 
Trial 2 
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Trial 3 
 
Figure A 5.15: MALDI mass spectrometry spectra of modified phosphorylation of Ac-
kemptide using ATP-N-heptyl. ATP-N-heptyl was incubated with kemptide and PKA 
followed by MALDI-TOF spectrometric analysis. Two trials are shown here, with the 
third trial in Figure 5.3C 
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d) Kemptide phosphorylation using ATP-O-heptyl (24) 
Trial 2: 
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Trial 3: 
 
Figure A 5.16: MALDI mass spectrometry spectra of modified phosphorylation of Ac-
kemptide using ATP-O-heptyl. ATP-O-heptyl was incubated with kemptide and PKA 
followed by MALDI-TOF spectrometric analysis. . Two trials are shown here, with the 
third trial in Figure 5.3D 
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5.3 Full gel images and repetitive trial of Pro-Q analysis of ATP-C, N, and O-heptyl 
analogs (22-24) 
 
Trial 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
                        
 1 2 3 4 5 6 7 8 9 10 11 12 
MPB  + + + + + + + + + + + + 
PKA  +  +  + +  + +  + 
ATP + +      + +    
ATP-O-heptyl   + +         
ATP-C-heptyl     + +       
ATP-N-heptyl           + + 
 
Pro-Q 
SYPRO 
Ruby 
MBP 
MBP 
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Trial 2 
    
   
 1 2 3 4 5 6 7 11 12 
MPB  + + + + + + + + + 
PKA  +  +  + +  + 
ATP + +        
ATP-O-heptyl   + +      
ATP-C-heptyl     + +    
ATP-N-heptyl        + + 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pro-Q 
SYPRO 
Ruby 
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Trial 3 
      
 
 1 2 3 4 5 6 7 
MPB  + + + + + + + 
PKA  +  +  + + 
ATP + +      
ATP-O-heptyl   + +    
ATP-C-heptyl     + +  
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Trial 4 
                     
                      
 1 2 3 4 5 6 7 8 
MBP + + + + + + + + 
PKA  +  + + +  - - 
ATP-O-heptyl - - + - - + - - 
ATP-N-heptyl - - - + -  + - 
ATP-C-heptyl  - - - - + - - + 
 
 
Figure A 5.17: Analysis of MPB phosphorylation in the presence of PKA and 
incubated with either ATP, ATP-O-heptyl, ATP-C-heptyl or ATP-N-heptyl. The 
reaction mixtures were analyzed by SDS-PAGE analysis, followed by staining with 
ProQ diamond phosphoprotein stain (top) or SYPRO® Ruby total protein stain 
(bottom).  As a control ATP analogs were incubated with MBP in absence of PKA. 
Four trials are shown here, with the full gel image of the trial in Figure 5.4 shown as 
trial 1. 
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5.4 Michaelis-Menton plots of ATP, ATP-C-heptyl, ATP-N-heptyl, and ATP-O-heptyl 
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B) ATP-C-heptyl 
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C) ATP-N-heptyl 
0
2
4
6
8
10
12
14
0 20 40 60 80 100 120
M
ea
n
A
v=Vmax*S/Km+S
ErrorValue
1.879212.501Vmax
13.16635.731Km
NA1.4403Chisq
NA0.98702R
Concentrations ( M)
R
at
e 
(
M
/m
in
)
 
D) ATP-O-heptyl                                                   
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Figure A 5.18: Michaelis-Menton curve fits for reaction containing ATP, ATP-C-heptyl, 
ATP-N-heptyl, and ATP-O-heptyl.  
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ABSTRACT 
DEVELOPMENT OF -MODIFIED ATP ANALOGS TO STUDY KINASE-
CATALYZED PHOSPHORYLATIONS 
 
by 
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Degree: Doctor of Philosophy 
 Kinase-catalyzed protein phosphorylation is one of the most important post-
translational modifications that controls cascades of biochemical reactions. 
Irregularities in phosphorylation result in many diseases, such as diabetes mellitus, 
Parkinsons, and cancer. The development of new methods to monitor kinase-catalyzed 
phosphorylation is needed to decipher details of normal and diseased cell signaling. 
The Pflum lab recently developed several -modified ATP analogs to study kinase 
catalyzed phosphorylation reactions. The -modified ATP analogs have different tags, 
such as biotin for substrate labeling or aryl-azide for kinase substrates identification. 
Unfortunately, use of -modified ATP analogs was limited to in vitro studies due to the 
cell impermeability of ATP analogs. Here, we report the first cell permeable ATP 
analog compatible with kinase-catalyzed labeling. Cell permeable ATP-biotin showed 
in vitro protein labeling similar to the previously reported ATP-biotin. Importantly, biotin 
labeling of kinase substrates in living cells was also observed. Also, we report an 
alternative method to permeabilize ATP analogs in cases where synthesis of cell 
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permeable ATP analog is not feasible. Permeabilizing ATP analogs will aid in 
monitoring kinase-catalyzed phosphorylation in living cells, which will enhance studies 
on cell signaling cascades and disease formation. Furthermore, we developed new 
crosslinking ATP analogs to identify substrates to kinases. We report affinity-based 
crosslinking ATP analogs, ATP-acrylamides. ATP-acrylamides crosslinked cysteine 
containing kinases to their substrates through specific proximal cysteine residues on 
kinases. ATP-acrylamides will solve problems accompanied with the previously 
reported ATP-Ar-azide that suffer from nonspecific crosslinking due to the very reactive 
crosslinking azide group. ATP-acrylamides will provide the details of cell signaling of 
specific kinases, which is supporting biomedical studies. Lastly, we are studying the 
effect of different bonds between the -phosphate and the attached group on kinase 
cosubstrate promiscuity phenomenon. This study revealed the electronic effect of 
several atoms on the ability of ATP-analogs to act as kinase-cosubstrates. 
Understanding the factors governing the ability of ATP analogs to act as cosubstrate 
will lead to development of more suitable ATP analogs for kinase catalyzed 
phosphorylation studies. 
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